

## **INFORMATION TO USERS**

This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer.

**The quality of this reproduction is dependent upon the quality of the copy submitted.** Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction.

In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.

Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps.

Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order.

ProQuest Information and Learning  
300 North Zeeb Road, Ann Arbor, MI 48106-1346 USA  
800-521-0600

**UMI<sup>®</sup>**



**University of Alberta**

**Dietary Linolenic and Docosahexaenoic Acid Influence the Docosahexaenoic Acid  
Content of Brain Membrane Lipids and Function in Developing Rats**

**By**

**Raffick Amid Razzakk Bowen**



**A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment  
of the requirements for the degree of Doctor of Philosophy**

**in**

**Nutrition and Metabolism**

**Department of Agricultural, Food and Nutritional Sciences**

**Edmonton, Alberta**

**Fall 2001**



**National Library  
of Canada**

**Acquisitions and  
Bibliographic Services**

**395 Wellington Street  
Ottawa ON K1A 0N4  
Canada**

**Bibliothèque nationale  
du Canada**

**Acquisitions et  
services bibliographiques**

**395, rue Wellington  
Ottawa ON K1A 0N4  
Canada**

*Your file* *Votre référence*

*Our file* *Notre référence*

**The author has granted a non-exclusive licence allowing the National Library of Canada to reproduce, loan, distribute or sell copies of this thesis in microform, paper or electronic formats.**

**The author retains ownership of the copyright in this thesis. Neither the thesis nor substantial extracts from it may be printed or otherwise reproduced without the author's permission.**

**L'auteur a accordé une licence non exclusive permettant à la Bibliothèque nationale du Canada de reproduire, prêter, distribuer ou vendre des copies de cette thèse sous la forme de microfiche/film, de reproduction sur papier ou sur format électronique.**

**L'auteur conserve la propriété du droit d'auteur qui protège cette thèse. Ni la thèse ni des extraits substantiels de celle-ci ne doivent être imprimés ou autrement reproduits sans son autorisation.**

0-612-68913-1

**Canada**

**University of Alberta**

**Library Release Form**

**Name of Author:** Raffick Amid Razzakk Bowen

**Title of Thesis:** Dietary Linolenic and Docosahexaenoic Acid Influence the Docosahexaenoic Acid Content of Brain Membrane Lipids and Function in Developing Rats

**Degree:** Doctor of Philosophy

**Year this Degree Granted:** 2001

Permission is hereby granted to the University of Alberta Library to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific purposes only.

The author reserves all other publication and other rights in association with the copyright in the thesis, and except herein before provided neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatever without the author's prior written permission.



#37, 12158-82 Ave.,

Surrey, British Columbia

Canada, V3W 3E3

April, 2001

*It is only through hard work that I can give an impression of ease and simplicity.  
I must strive to erase all traces of effort and to reach clarity and purity.*

*-Henri Matisse*

*Always choose the unknown and go headlong.  
Even if you suffer, it is worth it – it always pays.  
You always come out of it more grown up, more mature, more intelligent.*

*-Osho*

**University of Alberta**

**Faculty of Graduate Studies and Research**

The undersigned certify that they have read, and recommend to the Faculty of Graduate Studies and Research for acceptance, a thesis entitled **Dietary Linolenic and Docosahexaenoic Acid Influence the Docosahexaenoic Acid Content of Brain Membrane Lipids and Function in Developing Rats** submitted by **Raffick Amid Razzakk Bowen** in partial fulfillment of the requirements for the degree of **Doctor of Philosophy in Nutrition and Metabolism**.




M. T. Clandinin (Supervisor)



C. J. Field



L. J. McCargar



J. Van Aerde



B. Holub

Date... *May 4, 2001*

*This thesis is respectfully dedicated to the health of all children and to the men and women who have spent their lives understanding and improving maternal and child health through nutrition.*

## **ABSTRACT**

One of the debates in infant nutrition concerns whether or not dietary C18:3n-3 can provide for accretion of C22:6n-3 in neonatal tissues. The functional significance of C22:6n-3 in brain has not been fully elucidated. The objectives of this study were to investigate if: (1) increasing maternal dietary linolenic acid (C18:3n-3) increases the docosahexaenoic acid (C22:6n-3) content in neuronal cell phospholipids in two-week-old rat pups; (2) increasing maternal dietary C18:3n-3 increases the C18:3n-3 and C22:6n-3 content of different tissues of two-week-old rat pups; (3) maternal dietary C22:6n-3 is more effective than high C18:3n-3 at increasing the C22:6n-3 content in neuronal and glial cell phospholipids in rat pups at two weeks of age; (4) maternal dietary C20:4n-6 and C22:6n-3 increases synaptic plasma membrane (SPM) phospholipid and cholesterol content, SPM phospholipid C20:4n-6 and C22:6n-3 content, and SPM sodium-potassium adenosine triphosphatase (Na, K-ATPase) activity in rat pups at two and five weeks of age; (5) C20:4n-6 and C22:6n-3 are present in gangliosides of SPM; (6) C20:4n-6 and C22:6n-3 content in SPM gangliosides can be altered by diet fat; and (7) alkaline ceramidase (CDase) activity is present in the SPM in two-week-old rat pups. The stomach fatty acid composition of the rat pups reflected the diets of their respective dams. Objective (1) established that phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS) of neuronal cells showed no significant increase in C22:6n-3 content with high levels of C18:3n-3 in maternal diet; objective (2) showed that C18:3n-3 content in the whole body, brain, liver, skin, epididymal fat pads, and muscles was significantly greater in rat pups fed high compared to low C18:3n-3 diet but the C22:6n-3 content in these tissues was not quantitatively different; objective (3) showed that the

C22:6n-3 content in PE and PS of both neuronal and glial cell was higher when rat pups were fed C22:6n-3 compared C18:3n-3 diet ( $p < 0.05$ ); and objective (4) demonstrated that rats fed a maternal diet with C20:4n-6 and C22:6n-3 from two to five weeks of age: a) does not increase SPM cholesterol and phospholipid content, b) increases the C20:4n-6 (mainly PS) and C22:6n-3 content of SPM phospholipids, c) increases the SPM Na, K-ATPase Vmax (activity) (~2-fold) but not Km compared to a low C18:3n-3 diet; objective (5) showed by gas-liquid chromatography (GC) and GC-mass spectrometry that C20:4n-6 and C22:6n-3 are present in gangliosides of SPM of two-week-old rats; objective (6) suggest that the C20:4n-6 and C22:6n-3 content of SPM gangliosides of two-week-old rats can be altered by diet fat; and objective (7) showed that alkaline CDase activity is present in the rat SPM and is approximately 15-fold greater than brain homogenate.

It is concluded that dietary C22:6n-3 but not C18:3n-3 supports accretion of C22:6n-3 in neonatal tissues and that increasing the C22:6n-3 content of brain membrane phospholipid increases the activity of SPM Na, K-ATPase. It is also concluded that the presence of alkaline CDase activity in the SPM with the changes in C20:4n-6 and C22:6n-3 content of SPM gangliosides by diet fat may alter the activity of SPM alkaline CDase. Thus, dietary C18:3n-3 and C22:6n-3 can influence the structure and function of brain membrane lipids. This study supports the rationale for providing C20:4n-6 and C22:6n-3 in infant formulas.

## **ACKNOWLEDGEMENTS**

I would like to thank God for his/her many blessings, it is because of him/her that I am.

I would like to thank my mother, Philma Bowen, for her love, encouragement, and endless discussions. You are truly a remarkable lady.

I would like to thank my father, Dr. Harold Bowen, for always allowing me to speak my mind and providing an environment to think, analyze, and discuss the ambiguities of life.

To my brother (Shaffick) and sisters (Joan, Denise, Ade, and Keba) , thanks for the constant reminder that everything eventually comes to an end.

To my niece, Natasha, never lose your curiosity for life.

To Esmie Taylor, Enaches', and Buni, thanks for your generosity.

I am very grateful for all the assistance, guidance, and wisdom from the individuals in the laboratory. I would like to especially thank the coffee (therapy) group: Dr. French, Dr. Suh, David, Jacqueline, Eek, and Tony for the opportunity to discuss (vent) the trials and tribulations of science and life. I am deeply honored to have spent time with all of you.

To Dr. Goh, thanks for those "colorful" discussions, you are one of a kind...never lose your spirit.

To Elizabeth and Laurie, I really appreciate both of you for helping me with those Western blots and any last minute equipment or chemicals.

I would like to thank my committee members who were very good to me and allowed me to complete my program within the "normal" time period.

To my supervisor, Dr. Clandinin, it is an honor to have been part of your research group and I greatly appreciate you giving me the support, guidance, and opportunity to pursue my dream....you are a great mentor!!!

To all my friends, especially Gordon, Andrew, Derek, Michelle, Ted, and Ziya : Thank you for all your love and support...and, yes, I am done!!!

Lastly, I would like to thank Winnie (Wing-Kei) Yung, words can not express all you have done for me. I enjoy you being a part of my life.

## TABLE OF CONTENTS

<b>CHAPTER I.</b>	<b>LITERATURE REVIEW</b>	<b>1</b>
<b>A.</b>	<b>INTRODUCTION</b>	<b>2</b>
<b>B.</b>	<b>BRAIN</b>	<b>2</b>
1.	Neuronal and Glial Cell Structure and Function	2
a)	Neuronal Cells	2
i)	Classification Based on Number of Processes	3
ii)	Classification Based on Axon Length	3
b)	Glial Cells	3
2.	Development	4
a)	Neuronal Induction	5
b)	Neurogenesis	6
c)	Gliogenesis	6
d)	Neuronal Cell Migration	7
e)	Neuronal Cell Aggregation	7
f)	Axon and Dendrite Outgrowth	8
g)	Synaptogenesis	8
h)	Myelination	9
3.	Critical Periods	10
<b>C.</b>	<b>SODIUM-POTASSIUM ADENOSINE TRIPHOSPHATASE</b>	<b>10</b>
1.	Biological Functions	10
2.	Structure	11
3.	Cellular Localization	13
4.	Transport Cycle	14
5.	Significance in Brain	15

<b>D. PHOSPHOLIPIDS</b>	<b>16</b>
1. Structure	16
2. Role in Cell Membranes	17
3. Synthesis in Brain	18
a) Phosphatidylcholine	18
i) CDP-Choline Pathway	18
ii) Phosphatidylethanolamine Methyltransferase	19
b) Phosphatidylethanolamine	20
i) CDP-Ethanolamine Pathway	20
ii) Decarboxylation of Phosphatidylserine	21
c) Phosphatidylinositol	21
d) Interconversion or Base Exchange: Phosphatidylcholine, Phosphatidylethanolamine, and Phosphatidylserine Synthesis	22
4. Composition of Phospholipids and Developmental Changes	24
a) Whole Brain	24
b) Neuronal and Glial Cells	25
c) Synaptic Plasma Membrane	25
5. Effect on Sodium-Potassium Adenosine Triphosphatase	26
<b>E. SPHINGOLIPIDS</b>	<b>27</b>
1. Sphingomyelin	27
a) Serine Palmitoyl Transferase	27
b) 3-Ketosphinganine Reductase	28
c) Sphinganine N-Acyl Transferase	28
d) Dihydroceramide Desaturase	30
e) Sphingomyelin Synthase	30
2. Gangliosides	31
a) Nomenclature	31
b) Chemical Structure and Composition	31
c) Cellular Localization	33

d)	Distribution in Central and Peripheral Nervous System	34
e)	Composition in Neuronal Membranes	35
f)	Physiochemical Properties	35
g)	Metabolism	36
i)	Biosynthesis	36
ii)	Biodegradation	38
(1)	Glycosidase	38
(2)	Ceramidase	39
(3)	Sphingosine Kinase	40
(4)	Sphingosine-1-Phosphate Lyase	40
iii)	Recycling	41
h)	Composition and Developmental Changes in Brain	41
i)	Biological Functions	42
j)	Sphingolipid Metabolites as Modulators of Cellular Processes	43
i)	Sphingomyelinase Cycle	43
ii)	Ceramide	43
(1)	Role in Growth Suppression	43
(2)	Role in Cell-Cycle Arrest	44
(3)	Role in Cell Differentiation	45
(4)	Role in Apoptosis	45
iii)	Sphingosine	46

**F. CHOLESTEROL** 47

**G. N-6 AND N-3 FATTY ACIDS** 48

1.	Classification	48
2.	Metabolism	49
a)	Delta-6-Desaturase	51
b)	Delta-5-Desaturase	51
c)	Elongase	51

3.	Very Long Chain N-6 and N-3 Fatty Acids	52
	a) Structure and Tissue Distribution	52
	b) Biosynthesis	53
	c) Biological Function	56
4.	Composition and Developmental Changes in Brain	56
	a) Total Phospholipids	56
	b) Individual Phospholipids	57
	i) Phosphatidylcholine	57
	ii) Phosphatidylethanolamine	57
	iii) Phosphatidylserine	57
	iv) Phosphatidylinositol	57
	c) Sphingolipids	57
5.	Accretion in Brain	58
6.	Endogenous Sources for Fetal Brain	59
	a) Placenta	59
	b) Intestine	60
	c) Liver	61
	d) Metabolism in Brain Cells	61
7.	Exogenous Sources for Neonatal Brain	63
	a) Human Milk	63
	b) Infant Formulas	64

## **H. FACTORS AFFECTING NEURAL TISSUE N-6 AND N-3 FATTY ACID COMPOSITION AND FUNCTION**

1.	Diet	66
2.	Gene Expression of Desaturases and Elongases	68
3.	Phenylketonuria	68
	a) Phenylketonuria Causes Loss of Brain Myelin	69
	b) Phenylketonuria Causes Loss of Brain Fatty Acids	70
	i) Monounsaturated Fatty Acids	70

ii) Polyunsaturated Fatty Acids	70
<b>I. CHAPTER SUMMARY</b>	71
<b>J. REFERENCES</b>	72
<b>CHAPTER II. RESEARCH PLAN</b>	117
<b>A. RATIONALE</b>	117
<b>B. HYPOTHESES</b>	119
<b>C. CHAPTER FORMAT</b>	120
<b>D. REFERENCES</b>	124
<b>CHAPTER III. DOES INCREASING DIETARY C18:3N-3 CONTENT INCREASE THE C22:6N-3 CONTENT OF PHOSPHOLIPIDS IN NEURONAL CELLS OF NEONATAL RATS?</b>	125
<b>A. INTRODUCTION</b>	125
<b>B. MATERIALS AND METHODS</b>	127
1. Animal Care	127
2. Diets	127
3. Isolation of Neuronal cells	129
4. Lipid Analysis	130
5. Fatty Acid Analysis	130
6. Statistical Analysis	131

<b>C. RESULTS</b>	131
1. Growth Characteristics	131
2. Purity of Neuronal cell Preparations	131
3. Fatty Acid Composition of Stomach Contents	132
4. Neuronal Cells Phospholipid Fatty Acid Composition	133
a) Phosphatidylcholine and Phosphatidylethanolamine	133
b) Phosphatidylserine and Phosphatidylinositol	134
<b>D. DISCUSSION</b>	136
<b>E. REFERENCES</b>	139
<b>CHAPTER IV. HIGH DIETARY C18:3N-3 INCREASES THE C18:3N-3 BUT NOT THE C22:6N-3 CONTENT IN THE WHOLE BODY, BRAIN, SKIN, EPIDIDYMAL FAT PADS, AND MUSCLES OF SUCKLING RAT PUPS</b>	143
<b>A. INTRODUCTION</b>	143
<b>B. MATERIALS AND METHODS</b>	144
1. Animal and Diets	144
2. Lipid Extraction and Fatty Acid Analysis	145
3. Statistical Analysis	146
<b>C. RESULTS</b>	147
1. Fatty Acid Composition of Stomach Contents	147
2. Whole Body and Tissue Weights and Lipid Content	147
a) Brain	148
b) Liver	149
c) Skin (Epidermis, Dermis, and Subcutaneous Tissue)	151
d) Epididymal Fat Pads	151
e) Muscles (Front and Back Legs)	151

f)	Tissue C18:3n-3 Content in Whole Body	152
<b>D.</b>	<b>DISCUSSION</b>	153
<b>E.</b>	<b>REFERENCES</b>	156
<b>CHAPTER V.</b>	<b>DIETARY C22:6N-3 IS MORE EFFECTIVE THAN HIGHER LEVELS OF C18:3N-3 IN INCREASING THE C22:6N-3 CONTENT IN PHOSPHOLIPIDS OF NEURONAL AND GLIAL CELLS FROM WHOLE BRAIN IN NEONATAL RAT</b>	160
<b>A.</b>	<b>INTRODUCTION</b>	160
<b>B.</b>	<b>MATERIALS AND METHODS</b>	161
1.	Animal and Diets	162
2.	Isolation of Neuronal and Glial cells from Whole Brain	163
3.	Lipid Extraction and Fatty Acid Analysis	164
4.	Statistical Analysis	164
<b>C.</b>	<b>RESULTS</b>	165
1.	Whole Body and Brain Weights	165
2.	Purity of Neuronal and Glial Cell Preparations from Whole Brain	165
3.	Fatty Acid Composition of Stomach Contents	166
4.	Neuronal and Glial Cell Phospholipid Fatty Acid Composition	168
a)	Phosphatidylethanolamine	168
b)	Phosphatidylserine	169
c)	Phosphatidylcholine and Phosphatidylinositol	171
<b>D.</b>	<b>DISCUSSION</b>	174

<b>E. REFERENCES</b>	177
<b>CHAPTER VI. DIETARY LINOLENIC AND DOCOSAHEXAENOIC ACID ALTERS SYNAPTIC PLASMA MEMBRANE PHOSPHOLIPID FATTY ACID COMPOSITION, AND SODIUM-POTASSIUM ADENOSINE TRIPHOSPHATASE KINETICS IN DEVELOPING RATS</b>	183
<b>A. INTRODUCTION</b>	183
<b>B. MATERIALS AND METHODS</b>	184
1. Animal Care	184
2. Diets	185
3. Isolation of Synaptic Plasma Membrane	185
4. Lipid Analysis	186
5. Fatty Acid Analysis	187
6. Na, K-ATPase Assay	187
7. Synaptic Plasma Membrane PAGE and Immunoblotting	188
8. Statistical Analysis	189
<b>C. RESULTS</b>	189
1. Growth Characteristics	189
2. Fatty Acid Composition of Stomach Contents	189
3. Purity of Synaptic Plasma Membrane Preparations	192
4. Synaptic Plasma Membrane Protein Electrophoresis and Immunoblotting	192
5. Synaptic Plasma Membrane Phospholipid and Cholesterol Content	192
6. Fatty Acid Composition of Synaptic Plasma Membrane Phospholipids	194
a) Total Phospholipids	194
b) Phosphatidylcholine	196
c) Ethanolamine Glycerophospholipid	196

d) Phosphatidylserine	199
e) Phosphatidylinositol	199
7. Na, K-ATPase Kinetics	202
<b>D. DISCUSSION</b>	204
<b>E. REFERENCES</b>	209
<b>CHAPTER VII. DIETARY N-6 AND N-3 FATTY ACIDS ALTERS SYNAPTIC PLASMA MEMBRANE GANGLIOSIDE FATTY ACID COMPOSITION OF RATS AT TWO WEEKS OF AGE</b>	216
<b>A. INTRODUCTION</b>	216
<b>B. MATERIALS AND METHODS</b>	217
1. Animal Care	217
2. Diets	218
3. Isolation of Synaptic Plasma Membrane	218
4. Lipid Analysis	218
5. Fatty Acid Analysis	219
6. Gas-Chromatography Mass Spectrometry	219
<b>C. RESULTS</b>	219
1. Growth Characteristics	219
2. Fatty Acid Composition of Stomach Contents	220
3. Purity of Synaptic Plasma Membrane Preparations	220
4. Gas-Chromatography Mass Spectrometry Analysis	220

5. Dietary Fat Changes in Synaptic Plasma Membrane Ganglioside Fatty Acid Content	220
<b>D. DISCUSSION</b>	226
<b>E. REFERENCES</b>	228
<b>CHAPTER VIII. THE PRESENCE OF ALKALINE CERAMIDASE IN THE SYNAPTIC PLASMA MEMBRANE OF TWO-WEEK-OLD RAT PUPS</b>	231
<b>A. INTRODUCTION</b>	231
<b>B. MATERIALS AND METHODS</b>	232
1. Animal Care	232
2. Diet	232
3. Synaptic Plasma Membrane Isolation	232
4. Ceramide Synthesis	232
5. Ceramidase Assay	233
<b>C. RESULTS</b>	234
1. Purity of Synaptic Plasma Membrane Preparation	234
2. Purity of <sup>3</sup> H-Palmitoyl Ceramide	234
<b>D. DISCUSSION</b>	236
<b>E. REFERENCES</b>	238

<b>CHAPTER IX. GENERAL SUMMARY, CONCLUSIONS, LIMITATIONS, IMPLICATIONS, AND FUTURE RESEARCH</b>	<b>240</b>
<b>A. GENERAL SUMMARY</b>	<b>240</b>
<b>B. CONCLUSIONS</b>	<b>242</b>
<b>C. LIMITATIONS</b>	<b>243</b>
<b>D. IMPLICATIONS OF THESIS</b>	<b>243</b>
<b>E. FUTURE RESEARCH</b>	<b>244</b>
<b>F. REFERENCES</b>	<b>248</b>
<b>APPENDICES</b>	<b>249</b>

## LIST OF TABLES

Table 3.1	Fatty Acid Composition of Experimental Diets Fed to Lactating Dams at Two Weeks of Age	129
Table 3.2	The Content of Fatty Acids in the Stomach of Rat Pups at Two Weeks of Age	132
Table 3.3	Effect of Varying C18:2n-6 to C18:3n-3 Ratio on the Fatty Acid Composition of Neuronal Phosphatidylserine	135
Table 3.4	Effect of Varying C18:2n-6 to C18:3n-3 Ratio on the Fatty Acid Composition of Neuronal Phosphatidylinositol	136
Table 4.1	Fatty Acid Composition of Experimental Diets Fed to Lactating Dams and Stomach Content of Rat Pups of Two Weeks of Age	146
Table 4.2	Whole Body, Tissue Weights, Lipid Content of Rat Pups at Two Weeks of Age	148
Table 4.3	Effect of Low and High C18:3n-3 Diet on the Essential Fatty Acid Composition of Whole Body and Tissue Lipids	150
Table 5.1	Fatty Acid Composition of Experimental Diets Fed to Lactating Dams at Two Weeks of Age	163
Table 5.2	The Content of Fatty Acids in the Stomach of Rat Pups at Two-Weeks of Age	167
Table 5.3	Effect of Low to High C18:3n-3 vs. Preformed C22:6n-3 on the Fatty Acid Composition of Neuronal and Glial Cell Phosphatidylcholine	172

<b>Table 5.4</b>	<b>Effect of Low to High C18:3n-3 vs. Preformed C22:6n-3 on the Fatty Acid Composition of Neuronal and Glial Cell Phosphatidylinositol</b>	<b>173</b>
<b>Table 6.1</b>	<b>Fatty Acid Composition of Experimental Diets</b>	<b>186</b>
<b>Table 6.2</b>	<b>Content of Fatty Acids in the Stomach of Rats at Two and Five Weeks of Age</b>	<b>191</b>
<b>Table 6.3</b>	<b>Total and Individual Phospholipids and Cholesterol Content in Synaptic Plasma Membrane from Rats Fed Different Fat Diets at Two and Five Weeks of Age</b>	<b>193</b>
<b>Table 6.4</b>	<b>Fatty Acid Composition of Total Phospholipids in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet</b>	<b>195</b>
<b>Table 6.5</b>	<b>Fatty Acid Composition of Phosphatidylcholine in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet</b>	<b>197</b>
<b>Table 6.6</b>	<b>Fatty Acid Composition of Phosphatidylethanolamine in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet</b>	<b>198</b>
<b>Table 6.7</b>	<b>Fatty Acid Composition of Phosphatidylserine in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet</b>	<b>200</b>
<b>Table 6.8</b>	<b>Fatty Acid Composition of Phosphatidylinositol in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet</b>	<b>201</b>

<b>Table 7.1</b>	<b>Fatty Acid Composition of GM1a in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet at Two Weeks of Age</b>	<b>222</b>
<b>Table 7.2</b>	<b>Fatty Acid Composition of GD1a in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet at Two Weeks of Age</b>	<b>223</b>
<b>Table 7.3</b>	<b>Fatty Acid Composition of GD1b in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet at Two Weeks of Age</b>	<b>224</b>
<b>Table 7.4</b>	<b>Fatty Acid Composition of GT1b in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet at Two Weeks of Age</b>	<b>225</b>
<b>Table 8.1</b>	<b>Alkaline CDase Activity of Rat Pups on a Control Diet at Two Weeks of Age</b>	<b>236</b>

## **LIST OF FIGURES**

<b>Figure 1.1</b>	<b>Structure of Neuronal Cell</b>	<b>2</b>
<b>Figure 1.2</b>	<b>Structure of Glial Cell</b>	<b>4</b>
<b>Figure 1.3</b>	<b>Structure of Na, K-ATPase</b>	<b>12</b>
<b>Figure 1.4</b>	<b>Na, K-ATPase Transport Cycle</b>	<b>15</b>
<b>Figure 1.5</b>	<b>Structure of Phospholipids</b>	<b>17</b>
<b>Figure 1.6</b>	<b>Schematic of Phospholipid Synthesis</b>	<b>23</b>
<b>Figure 1.7</b>	<b>Structure of Sphingomyelin</b>	<b>27</b>
<b>Figure 1.8</b>	<b>Biosynthesis of Sphingomyelin</b>	<b>29</b>
<b>Figure 1.9</b>	<b>Structure of a Ganglioside</b>	<b>32</b>
<b>Figure 1.10</b>	<b>Gangliosides GM1a, GD1a, GD1b, and GT1b</b>	<b>33</b>
<b>Figure 1.11</b>	<b>Gangliosides in Cell Membrane</b>	<b>34</b>
<b>Figure 1.12</b>	<b>Biosynthesis of Ganglioside</b>	<b>37</b>
<b>Figure 1.13</b>	<b>Structure of Cholesterol</b>	<b>48</b>
<b>Figure 1.14</b>	<b>N-6 and N-3 Fatty Acid Structures</b>	<b>49</b>
<b>Figure 1.15</b>	<b>Polyunsaturated Fatty Acid Biosynthesis</b>	<b>50</b>
<b>Figure 1.16</b>	<b>Very Long Chain N-6 and N-3 Fatty Acid Biosynthesis</b>	<b>55</b>
<b>Figure 2.1</b>	<b>Brain Growth as a Function of Age in Different Species</b>	<b>117</b>
<b>Figure 3.1</b>	<b>C20:4n-6 and C22:6n-3 Content in Neuronal Cell Phosphatidylcholine and Phosphatidylethanolamine</b>	<b>133</b>

<b>Figure 5.1</b>	<b>Fatty Acid Composition of Neuronal and Glial Cell Phosphatidylethanolamine</b>	<b>169</b>
<b>Figure 5.2</b>	<b>Fatty Acid Composition of Neuronal and Glial Cell Phosphatidylserine</b>	<b>170</b>
<b>Figure 6.1</b>	<b>Synaptic Plasma Membrane Na, K-ATPase Kinetics of Rats Fed Low LNA, Control, or AA + DHA Diet at Two and Five Weeks of Age</b>	<b>203</b>
<b>Figure 7.1</b>	<b>Total Ion Chromatogram of C20:4n-6 and C22:6n-3 methyl esters from GM1a in Synaptic Plasma Membrane of Rats at Two Weeks of Age</b>	<b>220</b>
<b>Figure 8.1</b>	<b>Separation of Synthesized <sup>3</sup>H-Palmitoyl Ceramide on Thin-Layer Chromatography Plate</b>	<b>235</b>

## **ABBREVIATIONS**

<b>AA</b>	<b>Arachidonic acid</b>
<b>ANOVA</b>	<b>Analysis of variance</b>
<b>ATP</b>	<b>Adenosine triphosphate</b>
<b>ATPase</b>	<b>Adenosine triphosphatase</b>
<b>BBM</b>	<b>Brush border membrane</b>
<b>C2</b>	<b>Two carbons</b>
<b>C6</b>	<b>Six carbons</b>
<b>CAPK</b>	<b>Ceramide activated protein kinase</b>
<b>CAPP</b>	<b>Ceramide activated protein phosphatase</b>
<b>CDase</b>	<b>Ceramidase</b>
<b>cDNA</b>	<b>Complementary deoxyribonucleic acid</b>
<b>Cer</b>	<b>Ceramide</b>
<b>CDP</b>	<b>Cytidine diphosphate</b>
<b>CMP</b>	<b>Cytidine monophosphate</b>
<b>CoA</b>	<b>Coenzyme A</b>
<b>CTP</b>	<b>Cytidine triphosphate</b>
<b>Da</b>	<b>Dalton</b>
<b>DHA</b>	<b>Docosaheanoic acid</b>
<b>EDTA</b>	<b>Ethylenediaminetetraacetic acid</b>
<b>EPG</b>	<b>Ethanolamine glycerophospholipid</b>
<b>ERK</b>	<b>Extracellular-regulated kinase</b>
<b>g</b>	<b>Gram</b>
<b>Gal</b>	<b>Galactose</b>
<b>GalNac</b>	<b>N-acetylgalactosamine</b>
<b>GD1a</b>	<b>Ganglioside (disialic acid; "a" sialo-isomer)</b>
<b>GD1b</b>	<b>Ganglioside (disialic acid; "b" sialo-isomer)</b>
<b>GLC</b>	<b>Gas-liquid chromatography</b>
<b>GM1a</b>	<b>Ganglioside (monosialic acid; "a" sialo-isomer)</b>

<b>GT1b</b>	<b>Ganglioside (trisialic acid; "b" sialo-isomer)</b>
<b>hr</b>	<b>Hour</b>
<b>HDL</b>	<b>High density lipoprotein</b>
<b>HMG-CoA</b>	<b><math>\beta</math>-hydroxy-<math>\beta</math>-methyl-glutaryl-CoA</b>
<b>HPH</b>	<b>Hyperphenylalanemic</b>
<b>HPTLC</b>	<b>High performance thin-layer chromatography</b>
<b>IFN</b>	<b>Interferon</b>
<b>IL</b>	<b>Interleukin</b>
<b>K</b>	<b>Potassium</b>
<b>kb</b>	<b>kilobase</b>
<b>kDa</b>	<b>Kilo-Dalton</b>
<b>K<sub>m</sub></b>	<b>Michaelis constant</b>
<b>LA</b>	<b>Linoleic acid</b>
<b>LCP</b>	<b>Long-chain polyenes (20-22 carbon atoms)</b>
<b>LCPUFA</b>	<b>Long-chain polyunsaturated fatty acid (20-22 carbon atoms)</b>
<b>LDL</b>	<b>Low density lipoprotein</b>
<b>LNA</b>	<b>Linolenic acid</b>
<b>M</b>	<b>Molar concentration</b>
<b>MAPK</b>	<b>Mitogen-activated protein kinase</b>
<b>MEK</b>	<b>Mitogen-activated extracellular-regulated kinase-activating kinase</b>
<b>mg</b>	<b>Milligram, 10<sup>-3</sup> gram</b>
<b>min</b>	<b>Minute</b>
<b>mL</b>	<b>Milliliter, 10<sup>-3</sup> litre</b>
<b>mM</b>	<b>Millimolar concentration</b>
<b>mmol</b>	<b>Millimole</b>
<b>mRNA</b>	<b>Messenger ribonucleic acid</b>
<b>MUFA</b>	<b>Monounsaturated fatty acid</b>
<b>N-3</b>	<b>Omega-3</b>

<b>N-6</b>	<b>Omega-6</b>
<b>Na</b>	<b>Sodium</b>
<b>NADPH</b>	<b>Nicotinamide adenine dinucleotide phosphate</b>
<b>NANA</b>	<b>N-acetylneuraminic acid</b>
<b>NeuAc</b>	<b>Neuraminic acid</b>
<b>PAH</b>	<b>phenylalanine hydroxylase</b>
<b>PA</b>	<b>Phosphatidic acid</b>
<b>PAGE</b>	<b>Polyacrylamide gel electrophoresis</b>
<b>PC</b>	<b>Phosphatidylcholine</b>
<b>PE</b>	<b>Phosphatidylethanolamine</b>
<b>PEMT</b>	<b>Phosphatidylethanolamine methyl transferase</b>
<b>pH</b>	<b>measure of acidity; = <math>-\log [H^+]</math></b>
<b>PHE</b>	<b>phenylalanine</b>
<b>PI</b>	<b>Phosphatidylinositol</b>
<b>PKU</b>	<b>Phenylketonuria</b>
<b>PKC</b>	<b>Protein kinase C</b>
<b>PL</b>	<b>Phospholipids</b>
<b>PLD</b>	<b>Phospholipase D</b>
<b>PS</b>	<b>Phosphatidylserine</b>
<b>PUFA</b>	<b>Polyunsaturated fatty acids</b>
<b>SAP</b>	<b>Sphingolipid activator proteins</b>
<b>SAT</b>	<b>Sialic acid transferase</b>
<b>SDS</b>	<b>Sodium dodecyl sulfate</b>
<b>SM</b>	<b>Sphingomyelin</b>
<b>SPM</b>	<b>Synaptic plasma membrane</b>
<b>SPP</b>	<b>Sphingosine-1-phosphate</b>
<b>SPT</b>	<b>Serine palmitoyl transferase</b>
<b>TLC</b>	<b>Thin-layer chromatography</b>
<b>TNF</b>	<b>Tumor necrosis factor</b>
<b>TPL</b>	<b>Total phospholipids</b>

<b>UDP</b>	<b>Uridine diphosphate</b>
<b>UV</b>	<b>Ultraviolet</b>
<b>VLCFA</b>	<b>Very long-chain fatty acid (&gt; 24 carbon atoms)</b>
<b>V<sub>max</sub></b>	<b>Maximal velocity</b>
<b>μg</b>	<b>Microgram, 10<sup>-6</sup> gram</b>
<b>μL</b>	<b>Microlitre, 10<sup>-6</sup> litre</b>
<b>μmol</b>	<b>Micromole, 10<sup>-6</sup> μmol</b>

## **CHAPTER I. LITERATURE REVIEW**

### **A. INTRODUCTION**

Lipids provide most of the dietary energy and constitute the major energy store in infants and children. Research over the past three decades has shown that there is interest in the quality of dietary lipids supplied during fetal and neonatal periods when there is rapid development of the nervous system.

Dietary fatty acid, particularly, linoleic (C18:2n-6) and linolenic (C18:3n-3) acid have received most of the attention in studies of the effects of dietary lipids on the central nervous system. The reason is that C18:2n-6 and C18:3n-3 cannot be synthesized by mammals but must be supplied in the diet. These two fatty acids are precursors of two series of long-chain polyunsaturated fatty acids (PUFAs), arachidonic (C20:4n-6) and docosahexaenoic (C22:6n-3) acid which constitute a large portion of the fatty acids in brain. Insufficient C20:4n-6 and/or C22:6n-3 delays growth and development of the brain and this may result in reversible and/or irreversible damage to the structure and function of the central nervous system.

In infant nutrition, human breast milk is the gold standard. It is clear that infant formulas do not meet all the qualities of mother's milk. Beside the psychological advantages of "bonding" through continuous breast-feeding or immunological factors, it is evident that the nutritional aspects of formulas do not contain all components of human milk such as enzymes, immune compounds, hormones, or growth factors. Improvements in the separation of fatty acids by gas-liquid chromatography (ie. capillary vs. packed columns) over the last 20 years have allowed scientists to study in greater detail the fatty acid composition of human milk and develop new infant formulas.

In North America, infant formulas generally derive their lipid composition from vegetable and animal oils and thus do not contain C20:4n-6 and C22:6n-3 as found in human milk. The absence of C20:4n-6 and C22:6n-3 in infant formulas compared to human milk has been shown over time to decrease brain membrane phospholipid C20:4n-6 and C22:6n-3 content (Farquarson et al., 1992; Makrides et al., 1994). This suggests that C18:2n-6 and C18:3n-3 present in infant formulas is inadequate for optimal nutrition

in early life. In fact, the *in vivo* biosynthesis of C20:4n-6 and C22:6n-3 may be limited in newborns (Clandinin et al., 1980a; Salem et al. 1996; reviewed by Innis et al. 1999).


This chapter will review literature on the importance of brain growth and development: brain membrane lipids, in particular, phospholipids and gangliosides; and the effects of dietary n-6 and n-3 fatty acids on brain membrane structure and function. This information will be needed to support the rationale to be developed in subsequent chapters of this thesis.

## **B. BRAIN**

### **1. Neuronal and Glial Cell Structure and Function**

#### **a) Neuronal Cells**

The neuronal cell is the unit of structure and function of the nervous system, composed of a cell body and one or more processes (Figure 1.1). Neuronal cells are classified on a morphologic basis according to the number of their processes or upon the length of the axon (reviewed by Siegel et al., 1981).



**Figure 1.1 Structure of Neuronal Cell**

(Adapted from Siegel et al. 1981)

i) **Classification Based on Number of Processes**

Neuronal cells may be unipolar, bipolar, or multipolar. Neuronal cells that have one, two, and more than two processes are called unipolar, bipolar, and multipolar neurons, respectively. Unipolar neuronal cells (sensory) are found almost exclusively in the peripheral nervous system (reviewed by Siegel et al., 1981). Bipolar neuronal cells have a dendrite and an axon attached to opposite ends of the cell body (reviewed by Siegel et al., 1981). Bipolar neuronal cells are found in the retina, in cochlea and vestibular ganglion, and some places in the central nervous system (reviewed by Siegel et al., 1981). Multipolar neuronal cells have only one axon, but several dendrites, each of which may give rise to secondary branches (reviewed by Siegel et al., 1981). Multipolar neuronal cells comprise the bulk of the neuronal cells whose cell bodies lie within the central nervous system (reviewed by Siegel et al., 1981).

ii) **Classification Based on Axon Length**


Morphologically, these neuronal cells are all of the multipolar type. Golgi type I neuronal cells have long axons, most of which leave the central nervous system via ventral root of spinal nerves (reviewed by Siegel et al., 1981). Golgi type II neuronal cells have short axons, all of which stay in the central nervous system (reviewed by Siegel et al., 1981). The majority of interneurons are of this type (reviewed by Siegel et al., 1981).

*The major function of the neuronal cell is to help in the processing of incoming information so that appropriate motor responses can occur (reviewed by Siegel et al., 1981). The neuronal cell uses dendrites and axons to achieve these responses (reviewed by Siegel et al., 1981). Dendrites receive messages from the sense organs or other neuronal cell and carry them to the cell body (reviewed by Siegel et al., 1981). Axons, in turn, carry the resultant messages from the cell body to the other neuronal cells until an effector organ is reached (reviewed by Siegel et al., 1981). Hence, dendrites, cell body, and axons are crucial for neuronal cells to process and establish an appropriate response.*

b) **Glial Cells**

In the nervous system, glial cells support neuronal cell function. There are four types of glial cells: astrocytes, oligodendrocytes, ependymal, and microglia (Figure 1.2:

reviewed by Siegel et al., 1981). Astrocytes are found throughout the central nervous system (reviewed by Siegel et al., 1981). Astrocytes are responsible for the blood-brain barrier, which prevents certain substances to pass from blood to the brain and neuronal cell tissue repair after brain injury (reviewed by Siegel et al., 1981). Oligodendrocytes are found in gray and white matter of the central nervous system (Siegel et al., 1981). Oligodendrocytes appear to hold gray matter together, whereas, in white matter, they are responsible for the myelin sheath around the axons (reviewed by Siegel et al., 1981). Ependymal cells line inner surface of the brain, in the ventricles (reviewed by Siegel et al., 1981). No physiological role has been assigned to these cells, however, the cilia present on the surface of these cells may be involved in propulsion of cerebrospinal fluid within the ventricles (reviewed by Siegel et al., 1981). Microglia, unlike astrocytes and oligodendrocytes are highly mobile (reviewed by Siegel et al., 1981). Microglia serve as macrophages to remove debris from the nervous system (reviewed by Siegel et al., 1981).



**Figure 1.2 Structure of Glial Cells**

(Adapted from Thompson et al., 1993)

## 2. Development

The human brain follows a general pattern of development, beginning as a neural tube and gradually acquiring the features of the adult brain (reviewed by Cowan, 1979). Eight major stages can be identified in the development of any part of the brain. In order of appearance, they are: (1) the induction of the neural plate, (2) the proliferation of cells, (3) the migration of cells from the region in which they are generated to the place where

they finally reside. (4) the aggregation of cells to form identifiable parts of the brain. (5) the formation of connection with other neuronal cells (synaptogenesis). (6) the selective death of certain cells. (7) the elimination of some connections that were initially formed and the stabilization of others. (8) the myelination of axons by oligodendrocytes entering the brain.

**a) Neuronal Induction**

During embryogenesis, the basic structure of the nervous system develops by formation of the primitive streak during blastula stage (reviewed by Balinsky, 1975). This primitive streak separates the mesoderm from the ectoderm and endoderm (reviewed by Balinsky, 1975). The transformation of the ectoderm into neural plate is induced by the underlying mesoderm (Spemann, 1938). The inductive process may vary in different regions of the neural plate because brain stem and spinal cord arise under the chordal mesoderm whereas the forebrain arises under the influence of prechordal mesoderm (Nieuwkoop, 1952; Sidman & Rakic, 1982; Eyal-Giladi, 1984). The neural tube is formed by folding of the neural plate along the rostral-caudal axis, a process known as neuralation (O'Rahilly & Gardner, 1979). This process begins toward the end of the third embryonic week in humans (reviewed by Lou, 1982) and in rats (reviewed by Herschkowitz, 1989) between the first and second day of gestation. As neuralation progresses, the sequential association of the mesoderm and ectoderm results in induction of brain regions (forebrain, midbrain, and hindbrain) and spinal cord structures (reviewed by Lou, 1982).

At the time of neural tube closure, cells at the edge of the neural plate separate from neuroepithelium and migrate into the extracellular matrix to become neural crest cells (Angevine & Sidman, 1961). Following migration of neural crest cells to their final locations, these neural crest cells differentiate into neuronal and glial cells of dorsal roots and autonomic ganglia; neural crest cells provide the gastrointestinal tract and sensory ganglia of the cranial nerves and melanocytes (Brown et al., 1991). The neuroepithelium, or ventricular zone, that contains pseudostratified columnar epithelial cells that line the wall of the neural tube are actively proliferating (Sauer, 1935). As the cells within the neuroepithelium become postmitotic (never divide again) and migrate outward and

differentiate, the neural tube becomes thicker from the outer surface and the ventricular zone becomes defined (Sidman et al., 1959; Watterson, 1965). The cells of the neuroepithelium differentiate into two cell types of the nervous system: the neurons, which form the functional unit of the nervous system, and the glia cells which provides various types of support functions to neuronal cells and are important in myelin function (Sidman & Rakic, 1982).

#### **b) Neurogenesis**

Neuronal cell proliferation occurs within the neuroepithelium lining the ventricular zone of the neural tube (Sauer & Chittenden, 1959; Sidman et al., 1959; Fujita, 1962). Neuronal proliferation begins around fourteenth week of gestation and is completed by the twenty-fifth week when an adult number of neuronal cells is present (Dobbing & Sands, 1970; reviewed by Lou, 1982). In rats, the developmental events occur at eighteen days of gestation and is completed by twenty days gestation (reviewed by Lou, 1982). The period of neuronal cell proliferation may well be extended over longer periods of time. In rats, it has been shown that the number of neuronal cells in the hippocampus increase until one year of age (Bayer et al., 1985). These results suggest that also in humans the number of neuronal cells in some regions may increase postnatally.

#### **c) Gliogenesis**

Glial cells tend to originate after neuronal cells in any particular region of the brain (Ichikawa & Hirata, 1982). Glial cells differ from neural cell formation. Firstly, cells that produce glia lie outside the neuroepithelium, at or near the site where they will be located in adults (Bayer, 1985). Secondly, glial cell production continues throughout life (Jacobson, 1970). Gliogenesis is a postnatal event after term gestation (Das, 1977), but in some brain regions it has been detected before birth (Das, 1977; Rodier, 1980). Early gliogenesis is completed by the fifteenth week of gestation in human and the sixteenth day in rats (reviewed by Morgane et. al., 1993), and thirdly, damage to glial cells is not permanent. Glial cells can recover from low level of irradiation and brain injury (Bayer & Altman, 1975).

**d) Neuronal Cell Migration**

Since neuronal cells of the central nervous system are generated close to or at the neuroepithelium of the neural tube, they must subsequently undergo migration past other cells before reaching their definitive locations where they will reside for life (Sidman & Rakic, 1973). The peak time for this occurrence in humans is the third to fifth month of gestation, although it has been detected in certain brain regions as early as the second month and slightly after the fifth month (Sidman & Rakic, 1973). In the 1970s, it became clear that neuronal cells migrate radially outward from the ventricular layers along surface of radial glial cells (Rakic, 1977). Evidence for this relationship between neuronal cells from radial glial cells came from the *Weaver* mouse (Rakic & Sidman, 1973). In this mouse model, Bergmann glial cells in the cerebellar cortex degenerated at an early stage and failed to migrate granule cells from external to the internal granule layer (Rakic & Sidman, 1973). These findings suggested that granule cells failed to migrate due to the lack of glial cell guidance (Rakic & Sidman, 1973). In a comprehensive series of experiments, Rakic (1971a and 1971b) studied the development of the cerebral cortex, hippocampus, and cerebellum in monkeys and humans (reviewed by Rakic 1988a, 1988b, 1990, 1995). The formation of the various cell types and their migration to their final destinations have been followed by light and electron microscopy and by labeling of the glial cells with specific antibodies (Rakic, 1971a and 1971b). Similar experiments in mice (Luskin, 1988) were performed with recombinant retroviruses encoding a marker gene to infect early neuronal and glial cell progenitors (reviewed by Luskin, 1994; Goldman & Luskin, 1998; and Pavlath & Luskin, 1999). The results of these studies demonstrated that neuronal cells moved along the glial cell processes during development (Rakic, 1971a and 1971b; Luskin et al., 1988; reviewed by Rakic 1988a, 1988b, 1990, and 1995). Thus, glial cells are needed for neuronal cell migration.

**e) Neuronal Cell Aggregation**

Neuronal cell migration ceases in brain when the cells reach their destination and selectively aggregate to form a group or a cortical layer (Sidman & Rakic, 1973). The underlying mechanism of aggregation is not yet known but it has been suggested that adhesion molecules may play a major role in the aggregation process (reviewed by

Nybrue & Bock, 1989). Cell adhesion molecules are proteins that mediate cellular interaction in the embryo. Cell adhesion molecules function in the pattern formation and morphogenesis of tissues (reviewed by Edelman, 1989). Neuronal cell adhesion molecules, which are expressed by all major cell types in the nervous system could be responsible for neuronal cell migration (reviewed by Edelman, 1989).

#### **f) Axon and Dendrite Outgrowth**

As neuronal cells migrate along radial glia, many neuronal cells extend processes that are recognizable as axons (reviewed by Bray & Hollenbeck, 1988). The tips of each process are composed of a specialized motile structure, a growth cone (reviewed by Bray & Hollenbeck, 1988 and Jacobson, 1991). Growth cones are constantly moving by local extension and retractions (reviewed by Jacobson, 1991). When in contact with appropriate substrate, growth cones crawl forward and leave behind the elongating axon (reviewed by Bray & Hollenbeck, 1988). Axon outgrowth is a prenatal and a postnatal event in both the human and rats (reviewed by Herschkowitz, 1989). The mechanism involved in the growth and guidance of axons appear to be specific and non-specific (reviewed by Herschkowitz, 1989).

The migrating neuronal cells begin to sprout dendrites as soon as they arrive at the cortical plate (Juraska & Fifikova, 1979). The apical and basilar dendrites are formed first which is followed by oblique branches off the apical dendrites (Juraska & Fifikova, 1979). Golgi-Cox studies of cortical neuronal cells show that the complexity of dendrites continues to increase for at least twenty-four months postnatally (Conel, 1939). There are regional differences in rate of dendritic growth (Purpura, 1975; Goldman & Rakic, 1983).

#### **g) Synaptogenesis**

Synaptogenesis is the contact between axons and target cells. Synaptogenesis starts before neurogenesis is completed (reviewed by Jacobson, 1978). Synaptic formation differs appreciably among brain regions in the human brain (reviewed by Jacobson, 1978). Synapses appear in the human cerebral cortex as early as the third month of gestation (Molliver et al., 1973). The number of synapses increases coincident with the elaboration of dendritic spines, which are the primary sites onto which synaptic

contacts are made (Paldino & Purpura, 1979a and 1979b). Quantitative determination by electron microscopy have demonstrated that the number of synapses increases until eight months postnatally in the striate cortex and until twenty-four months after birth in the frontal cortex (Huttenlocher, 1979; Huttenlocher et al., 1982; Huttenlocher & de Courten, 1987). After reaching these peak values, a slight reduction in number occurs over the course of many months (Huttenlocher & de Courten, 1987). Although patterns of neuronal cell connection are initiated by directed axon outgrowth, ultimate cortical organization is effected by specific neuronal cell interaction (Sperry, 1963; reviewed by Edelman, 1983). These interactions appear to be mediated by molecules on the surface of neuronal cells and neuronal cell processes that result in the selective linking of axons to certain neurons by specific chemical affinity (Sperry, 1963). Neuronal cell adhesion molecules have been shown to promote cell-to-cell interactions among neuronal cells (reviewed by Edelman, 1983) but the final pattern of synaptic connectivity appears to be shaped by events such as competition for trophic factors and modulators that affect neuronal cell activity or target cells (Purves & Lichtman, 1985; Purves, 1988).

Following synaptogenesis, a period of synaptic refinement occurs which is fundamental for normal neuronal cell function. Synaptic refinement decreases the number of inputs per cell by eliminating weaker connections by apoptosis (programmed cell death) and strengthening of the remaining connection through successful competition for trophic substances (Lichtman & Purves, 1980; Purves & Lichtman, 1980). Therefore, apoptosis and synapse refinement thus follows as the final stage of brain morphogenesis (Bayer, 1985).

#### **h) Myelination**

Undifferentiated oligodendrocytes arise within the ventricular zone and migrate in the cerebral wall (Oksche, 1968; reviewed by Colello & Pott, 1997). As these precursors migrate in the brain, they respond to local influences of other neuronal and glial cells by proliferation and differentiation (Noble, 1986). The oligodendrocytes then align along axons and elaborate cell processes that ultimately form myelin sheath (Peters, 1969; reviewed by Colello & Pott, 1997). In the central nervous system, oligodendrocytes may produce myelin for up to forty parallel axon segments (Peters, 1964). Myelination

exhibits pronounced regional variation (Yakovlev & Leaours, 1967; reviewed by Colello & Pott, 1997). In human, myelination begins in the prenatal period and continues into adult life (reviewed by Herschkowitz, 1988 and Colello & Pott, 1997).

### **3. Critical Periods**

The cells, regions, and various structures of the brain do not develop uniformly as in other tissues and organs (Dobbing & Sands, 1979; Dobbing, 1990). There are characteristic, well-defined stages of growth that occur anatomically and biochemically (Gottlieb et al., 1977; Albers, 1985) and result in significant growth spurts or critical periods in fetal and neonatal life. Critical periods are defined as specific times of increased metabolic activity during which a particular developmental process predominates (Dobbing & Sands, 1979). In view of the complexity of the brain, it is conceivable that normal brain development could be disrupted by any number of events, particularly during the critical periods of brain growth and development. Influences of exogenous factors, such as, the amount or type of dietary n-6 and n-3 fatty acids on brain membrane lipid composition during development could possibly alter brain structure and function (e.g. sodium-potassium adenosine triphosphatase transport activities) (Foot et al., 1982; reviewed by Hargreaves & Clandinin, 1990; Clandinin et al., 1997; Clandinin, 1999).

## **C. SODIUM-POTASSIUM ADENOSINE TRIPHOSPHATASE**

### **1. Biological Functions**

The sodium-potassium adenosine triphosphatase (Na, K-ATPase), or sodium pump, is a membrane bound protein that establishes and maintains the high internal potassium ion and low internal sodium ion concentration typical of most animal cells (reviewed by Wallick, 1979). The Na, K-ATPase transfers chemical energy of hydrolysis of adenosine triphosphate (ATP) to potential energy of electrochemical ion gradients found by sodium ions and potassium ions across the cell membrane (reviewed by Wallick, 1979). Na, K-ATPase transports three sodium ions out in exchange for two potassium ions that are taken into the cell (reviewed by Wallick, 1979). The


electrochemical gradient that Na, K-ATPase generates is for a large number of basic and specialized cellular functions like regulation of cell volume, the resting membrane potential of tissues, and excitable properties of muscle and nerve cells (reviewed by Jorgensen, 1990). A variety of secondary active systems that transport ions (calcium, hydrogen, chloride, sulphate, and phosphate) or nutrients (glucose and amino acids) across the cell membrane are driven by the inwardly directed electrochemical gradient for sodium ions (reviewed by Skou & Esmann, 1992 and Glynn, 1993).

## 2. Structure

Na, K-ATPase is an oligomeric integral membrane protein that is composed of stoichiometric amounts of two major polypeptides, the alpha and beta subunits (reviewed by Jorgensen & Anderson, 1988 and Lingrel, 1992). The alpha-subunit is a multi-spanning membrane protein with a molecular mass of about 112 kDa (reviewed by Jorgensen & Anderson, 1988 and Lingrel, 1992). This subunit is responsible for both catalytic and transport functions of the enzyme (reviewed by Jorgensen & Anderson, 1988 and Lingrel, 1992). The alpha subunit comprises of a binding site for cations, adenosine triphosphate, and cardiac glycosides (i.e. ouabain, digoxin, or digitoxin; reviewed by Jorgensen & Anderson, 1988 and Lingrel, 1992). Three isoforms of the alpha-subunit ( $\alpha_1$ ,  $\alpha_2$ , and  $\alpha_3$ ) appear to be expressed in rodent brains (Shull et al., 1986). The three isoforms from cDNA clones show about 85% sequence homology, with the most substantial differences occurring in the N-terminal region (Shull et al., 1986). The regions including the catalytic phosphorylation site are identical for a length of 85 amino acid residues, and there are major hydrophobic domains with 94-96% homology between the three isoforms (Shull et al., 1986). The three alpha-subunit isoforms are expressed to varying extents at different stages of development (Shull et al., 1986). There is evidence that at least five different genes encode for the alpha-subunit (Shull et al., 1986). Transcriptions of the  $\alpha_1$ -subunit genes were detected in all tissues, whereas  $\alpha_2$  and  $\alpha_3$  subunits mRNA were expressed predominately in brain (Emanuel et al., 1987).

The smaller constituent, beta subunit mainly  $\beta_1$  and  $\beta_2$ , is a polypeptide that crosses the membrane once and, depending on the degree of glycosylation in different tissues, has a molecular weight between 40 and 60 kDa (Blanco et al., 1994). The subunit

was for a long time believed not to participate directly in the catalytic cycle or binding of cardiac glycosides. Recently, it was demonstrated that assembly of a (alpha-beta) heterodimer is necessary for a stable and functionally competent configuration of the pump (Figure 1.3); in particular, the beta subunit is needed for the alpha subunit to exit from the endoplasmic reticulum and to acquire the correct configuration (Geering et al., 1989; Kawamura & Noguchi, 1991). The beta subunit appears to be involved in the occlusion of potassium ion and the modulation of the potassium and sodium ion affinity of the enzyme (Lutsenko & Kaplan, 1993). The amino acid sequence of the beta subunits has been detected from cDNA clones and the tissue distribution of the beta isoforms and the corresponding mRNA has been examined (Shull et al., 1986; Mercer et al., 1986; Young et al., 1987; Martin-Vasallo et al., 1989; Levensen, 1994). The  $\beta_1$ -subunit was composed of 304 amino acid residues, whereas the  $\beta_2$ -subunit had 290 residues (Levensen, 1994). The two beta-subunits had approximately 58% amino acid sequence homology (Levensen, 1994). The  $\beta$ -subunit gene encodes mRNA ranging in size from approximately 1.9 to 3.9 Kb (Levensen, 1994). Previous studies has shown that multiple beta subunits mRNAs are derived by alternative splicing and encodes a single  $\beta$ -subunit polypeptide (Young et al., 1987). The pattern of expression of beta-subunit mRNA is complex and tissue-specific (Mercer et al., 1986; Emanuel et al., 1987), but is distinct from the alpha-subunit mRNA (Mercer et al., 1986; Emanuel et al., 1987).



**Figure 1.3 Structure of Na, K-ATPase**

(Adapted from Mercer, 1999)

A third protein termed the gamma-subunit with a molecular mass between 8 to 14 kDa has been detected as part of the native enzyme in purified separations (Reeves et al., 1980). The gamma subunit is expressed primarily in renal tissues (Therien et al., 1997). Expression studies have shown that the gamma subunit is not required for normal Na, K-ATPase activity (Hardwicke & Freytag, 1981; Detomasso et al., 1993). However, recently it was shown that the gamma subunit can modify the voltage dependence of potassium ion activation when expressed in *Xenopus* oocytes (Beguin et al., 1997). It appears that the gamma subunit can stabilize the E1 conformation of the enzyme (Therien et al., 1997). Although there is increasing evidence that the gamma subunit can modify Na, K-ATPase function, the exact role of the subunit in Na, K-ATPase function awaits further investigation. Further studies have shown that the gamma-subunit of Na, K-ATPase consists of 58 amino acids with a molecular mass of approximately 6.5-7.0 kDa (Mercer et al., 1993). cDNAs for the human (Kim et al., 1997) and *X. laevis* (Beguin et al., 1997) gamma subunits have been cloned and sequenced. Amino acid sequence comparisons shown strong homology (~75%) among different species, which is further increased to 93% when only mammalian sequences are compared (Kuster et al., 2000).

### **3. Cellular Localization**


In the nervous system, Na, K-ATPase has been found to be associated with both neuronal and glial cells (Cummins & Hyden, 1962). Na, K-ATPase is found to be particularly most active in the gray matter of the nervous tissue (Bonting et al., 1962). The gray matter exhibits approximately fivefold more enzyme activity than the white matter (Bonting et al., 1962). Hosie (1965) and Albers et al. (1965) have shown that an enriched preparation of Na, K-ATPase can be obtained from nerve endings fraction of brain (synaptic plasma membrane; SPM). Kurokawa et al. (1965) confirmed by sucrose gradient technique that there was indeed high specific activity of Na, K-ATPase in nerve fraction of brain.

#### **4. Transport Cycle**

Na, K-ATPase belongs to a class of P-type ATPase that are responsible for active transport of a variety of cation across cell membranes (Sachsand & Munson, 1991; Apell, 1997; Holmgren et al., 2000). The P-type description refers to the unique characteristic of ATPase in forming a transient, phosphorylated aspartyl residue during the catalytic cycle (Sachsand & Munson, 1991; Apell, 1997; Holmgren et al., 2000). Accompanying the phosphorylation-dephosphorylation process, the P-type ATPase bind, occlude, and transport ions by cycling between two different cation-dependent conformations, called E1 and E2 (Repke & Schon, 1992; Apell, 1997; Holmgren et al., 2000). The precise molecular mechanisms that couple the hydrolysis of adenosine triphosphate to the conformational changes and the translocation of ions remain unknown.

The description of the Na, K-ATPase transport is based on the hypothesis proposed by Albers (1967) and Post et al. (1969) (Figure 1.4). The Na, K-ATPase undergoes a sequence of transition between the E1 conformation with inward facing cation binding sites and high affinity for sodium ion and the E2 conformation with outward facing cation binding sites and high affinity for potassium ion (Albers, 1967; Post et al., 1969). Transitions between these two conformations are induced by the phosphorylation (E1-P and E2-P; Figure 1.4) -dephosphorylation (E1 and E2; Figure 1.4) reactions (Albers, 1967; Post et al., 1969). In the E1 Na, K-ATPase form, three intracellular sodium ions become bound (Albers, 1967; Post et al., 1969). Hydrolysis of adenosine triphosphate and phosphorylation of the protein (E1-P; Figure 1.4) leads to occlusion of the three sodium ions followed by a transition to the E2-P form (Albers, 1967; Post et al., 1969). Sodium ion is now released externally, and instead two potassium ions become bound; this leads to spontaneous dephosphorylation and occlusion of the potassium ions (E2; Figure 1.4; Albers, 1967; Post et al., 1969). Stimulated by adenosine triphosphate, a conformational change back to E1 form is induced, potassium is fed into the cytoplasm and the transport cycle is completed (Albers, 1967; Post et al., 1969).

The role of membrane lipids on the function of Na, K-ATPase is discussed on page 26.



The top is extracellular.  
The bottom is intracellular.

**Figure 1.4 Na, K-ATPase Transport Cycle**  
(Adapted from Dalton, 1999)

## 5. Significance in Brain


In brain, at least 40% of the energy released by respiration is required by the Na, K-ATPase in order to maintain the ionic gradients of sodium and potassium across cell membranes, even under resting conditions (Whittam, 1962; Ritchie, 1980; Astrop et al., 1981; Yarowsky & Ingvar, 1981; Hansen, 1985). The Na, K-ATPase has a critical role in the functioning of the brain. The activity of Na, K-ATPase is present in high concentrations in both neuronal and glial cells (reviewed by Sweadner & Goldin, 1980). In addition, to maintaining the ion gradients required for nerve impulses, the enzyme is

implicated in the indirect modulation of synaptic action (reviewed by Sweadner & Goldin, 1980). When the enzyme is very active, it hyperpolarizes the nerve membrane altering the threshold for synaptic action (reviewed by Albers, 1967). When Na, K-ATPase activity is low, sodium ions accumulate in the nerve terminals and are exchanged for extracellular calcium by sodium / calcium exchange system (Goddard & Robinson, 1976; Akerman & Nicholls, 1981; DiPolo & Beauge, 1983). The elevated intraterminal calcium concentration then facilitates the release of neurotransmitters during subsequent impulses, since the release of neurotransmitter is calcium dependant (reviewed by Lees, 1991). These processes may operate to different extents in the presynaptic and postsynaptic cells (reviewed by Lees, 1991). Also, it has been reported that the activity of Na, K-ATPase is increased by certain neurotransmitters (reviewed by Lees, 1991). In glial cells, the Na, K-ATPase plays a critical part by taking up the potassium released by neurons during periods of intense activity, when potassium reaches extracellular concentrations high enough to depolarize the nerve membrane (reviewed by Lees, 1991). The failure of this process can result in epileptic seizure (Hertz, 1978).

## **D. PHOSPHOLIPIDS**

### **1. Structure**

Phospholipids contain both fatty acids and phosphoric acid esterified to an alcohol (reviewed by Ramsey & Nicholas, 1972; Strickland, 1973; Porcellati et al., 1976). Polar head groups such as choline, ethanolamine, serine, and inositol may be esterified with the second acid group on the phosphate (Figure 1.5). Further diversity in phospholipids is provided by the variation in the fatty acids present with palmitic (C16:0), stearic (C18:0), oleic (C18:1n-9), C18:2n-6, C20:4n-6, and C22:6n-3 being most common. In general, the hydroxyl group at position-1 of the glycerol moiety of a PA is esterified with a saturated fatty acid and that at position-2 is esterified with an unsaturated fatty acid reflecting the specificity of the enzymes involved in the synthesis (Strickland, 1973; Porcellati et al., 1976). Regardless of structure, all phospholipids are markedly polar, possessing both a hydrophobic tail (two hydrocarbon chains) and a hydrophilic head (containing the phosphate group and the second alcohol which rotate away from the tail).



**Figure 1.5 Structure of Phospholipids**

## 2. Role in Cell Membranes

Phospholipids along with cholesterol are the primary lipid constituents of membranes. The two opposing lipid leaflets make up the membrane bilayer which serves as a permeability barrier imparting cellular compartmentalization and support matrix for membrane-bound proteins (Singer & Nicholson, 1972). Biological membranes are fluid in nature which permits lateral diffusion of lipid and protein in the plane of the membrane (Coleman, 1973; Sun et al., 1983). The hydrophilic head group and hydrophobic fatty acyl tails make phospholipids amphipathic. In the membrane bilayer, phospholipids orient in such a way that their hydrophilic head groups face outward contacting the

aqueous phase while the hydrophobic fatty acyl tails aggregate and exclude water (Singer & Nicholson, 1972).

### **3. Synthesis in Brain**

Before the 1940's, it was generally assumed that once phospholipids are synthesized in the nervous system of mammals during growth and development they were static entities (Ansell & Spanner, 1961). The introduction of isotopes into research, especially [<sup>32</sup>P] inorganic phosphate dispelled this assumption when it was shown that once [<sup>32</sup>P] inorganic phosphate were available to the intracellular pool, they become rapidly incorporated into membrane phospholipids (Ansell & Spanner, 1967).

The pathways of phospholipid biosynthesis are similar among different tissues and organs (Ansell & Spanner, 1967). However, the central mechanism regulating the changing levels and composition of phospholipids during brain development are not well understood. Precursor availability and/or the levels and modulators of enzyme activity could be mechanisms that regulate phospholipid synthesis (Ansell & Spanner, 1967).

#### **a) Phosphatidylcholine**

Two pathways exist for the de novo synthesis of phosphatidylcholine (PC): (1) the cytidine diphosphate (CDP)-choline pathway which synthesizes PC from CDP-choline and diacylglycerol (DAG), and (2) the phosphatidylethanolamine methyl transferase (PEMT) pathway which converts phosphatidylethanolamine (PE) to PC.

##### **i) CDP-Choline Pathway**

When labeled choline was injected intracerebrally into the adult rat and the specific radioactivity and time sequence of phosphorylcholine, CDP-choline, and PC were determined, it became apparent the cytidine route was the principal pathway for de novo biosynthesis of PC (Ansell & Spanner, 1968) (Figure 1.6). Choline derived mostly from diet or by synthesis in liver can enter the brain and be rapidly phosphorylated by choline kinase to form phosphorylcholine (McCaman, 1962). The structural gene for choline kinase has been cloned from yeast (Hosaka et al., 1989) and the cDNA from rat liver (Uchida & Yamashita, 1992). The conversion of phosphocholine into CDP-choline

requires a cytidylyltransferase enzyme (Porcellati & Arienti, 1970). To date, cDNAs for cytidylyltransferase have been cloned from several mammals (humans, mouse, and chinese hamster) (Rutherford et al., 1993; Kalmar et al., 1994; Sweitzer & Kent, 1994). The deduced protein sequence of these enzymes is 95-99% identical to each other. The enzyme has a subunit molecular weight of 42 kDa, and the purified forms exists as a dimer (Cornell, 1989; Weinhold et al., 1989). The CDP-choline can then be transferred to DAG by CDP-choline:1,2-DAG choline transferase to form PC (McCaman & Cook, 1966). CDP-choline:1,2-DAG choline transferase has been cloned from yeast (Hjelmstad & Bell, 1990) but only partial purification of this enzyme from liver has been achieved so far (O & Choy, 1990). CDP-choline:1,2-DAG choline transferase from yeast has 407 amino acids with a predicted molecular weight of approximately 46 kDa (Hjelmstad and Bell, 1990). This enzyme has been shown to display its highest activity in vitro preparation of neonatal tissue and neuronal rich gray matter (McCaman & Cook, 1966). Thus, demonstrating the importance of this enzyme in neonatal neuronal PC biosynthesis.

ii) Phosphatidylethanolamine Methyltransferase

The transfer of methyl groups from S-adenosylmethionine to PE by methyltransferase is an alternative route for the formation of PC (Figure 1.6; Bremer et al., 1960). This methylation pathway is quantitatively significant only in liver where it may account for about 20-40% of the synthesis of PC (Sundler & Akesson, 1975). In all other tissues, including brain, the activity of the methylation enzyme(s) is very low (Sundler & Akesson, 1975). Sastry et al. (1985) suggested that two enzymes function in animal tissues for the methylation reaction, one transferring the first methyl group to PE, and a second enzyme catalyzing the second and third methylation. Pajares et al. (1984) purified methyltransferase from rat liver and found that this enzyme catalyzes all three methylation steps of PE synthesis. However, in *Saccharomyces* (Greenberg et al., 1983) and in *Neurospora* (Scarborough & Nyc, 1967), it appears that at least two enzymes are involved in the stepwise methylation sequence. Thus, it is possible that different tissue express different number of methyltransferase in the PEMT pathway. Recently, the murine gene that codes for PEMT was cloned and characterized (Walkey et al., 1996).

This gene predicts a 199 amino acid protein with a molecular weight of 22.5 kDa and has greater than 92% homology with rat PEMT cDNA (Walkey et al., 1996).

Diets containing different ratios of soybean and sunflower oil were mixed to produce a range of dietary n-6 to n-3 fatty acids ratios (Hargreaves & Clandinin, 1989). Resulting levels of C22:5n-6 found in microsomal membrane PE correlated with production of phosphatidylmethylethanolamine via the PEMT pathway, but was negatively correlated with CDP-choline pathway (Hargreaves & Clandinin, 1989). Thus, PC synthesis via PEMT and CDP-choline pathways responds to change in diet fat.

## **b) Phosphatidylethanolamine**

### **i) CDP-Ethanolamine Pathway**

The de novo synthesis of PE occurs via the CDP-ethanolamine pathway (Figure 1.6). The phosphorylation of ethanolamine by kinase is different from that of choline as seen by different requirements of kinase for magnesium and adenosine triphosphate (Spanner & Ansell, 1979). This suggests that two separate enzymes may be involved in choline or ethanolamine phosphorylation. The formation of CDP-ethanolamine by cytidine triphosphate (CTP):ethanolamine phosphate cytidyltransferase seems to be the rate-limiting enzyme in the formation of PE (Porcellati et al., 1971). Nakashima et al (1997) reported the cloning of a human cDNA for CTP:ethanolamine phosphate cytidyltransferase by complementation *in vivo* of a yeast mutant of which the CTP:ethanolamine phosphate cytidyltransferase gene was disrupted. The deduced protein encoded by the cDNA consists of 389 amino acids with a calculated molecular mass of approximately 43.8 kDa (Nakashima et al., 1997). The combining of CDP-ethanolamine and DAG by CDP-ethanolamine:1,2-DAG ethanolamine phosphotransferase is the final step in PE formation (Ansell & Metcalfe, 1971). The DAG species containing PUFAs rather than monenoic, dienoic, or trienoic species seems to be the preferred substrates for PE synthesis (Holub, 1978). Complementation of *S. cerevisiae* mutants defective in CDP-ethanolamine:1,2-DAG ethanolamine phosphotransferase has resulted in the isolation of a gene encoding CDP-ethanolamine:1,2-DAG ethanolamine phosphotransferase activity (Hjelmstad & Bell, 1991). The derived amino acid sequence for the *S. cerevisiae* CDP-ethanolamine:1,2-

DAG ethanolamine phosphotransferase gene predicts a protein of 44.5 kDa containing seven membrane-spanning domains (Hjelmstad & Bell, 1991). Recently, CDP-ethanolamine:1,2-DAG ethanolamine phosphotransferase has been purified from bovine liver microsomes (Mancini et al., 1999). The isolated protein has a molecular mass of about 38 kDa (Mancini et al., 1999). Future research should provide amino acid sequence and gene cloning for this enzyme.

ii) **Decarboxylation of Phosphatidylserine**

PE formation occurs by decarboxylation of phosphatidylserine (PS; Figure 1.6). Bremer et al (1960), using radiolabeled L-[3-<sup>14</sup>C] serine showed *in vivo* labeling of PE in liver. Wilson et al. (1995) who incubated labeled serine with liver mitochondria and brain homogenates also showed the appearance of the label in the ethanolamine moiety of PE. Dennis & Kennedy (1972) clearly demonstrated the decarboxylation of PS by a mitochondrial enzyme in liver, PS decarboxylase (Dennis & Kennedy, 1972). Experiments by Yavin & Ziegler (1977) established that about 13% of PE were formed via this route in differentiating cells of the cerebral hemisphere. The cDNA for the mammalian PS decarboxylase was cloned in somatic cell mutants (Kuge et al., 1991; Kuge et al., 1996). The full-length cDNA for PS decarboxylase was isolated by polymerase chain reaction methods and it encodes for a protein of 409 amino acids (Kuge et al., 1991; Kuge et al., 1996).


c) **Phosphatidylinositol**

Studies by Agranoff et al. (1958) and Paules & Kennedy (1958) lead to the discovery of CDP-DAG:myoinositol phosphatidyltransferase that catalyzes the synthesis of phosphatidylinositol (PI; Figure 1.6). CDP-DAG-myoinositol phosphatidyltransferase catalyzes the reaction of CDP-DAG with myoinositol (Agranoff et al., 1958; Paules & Kennedy, 1958). This enzyme appears to be located in the microsomal fraction of liver (Takenawa & Egawa, 1977) and brain (Ghalayini & Eichberg, 1985). The enzyme shows high selectivity for myoinositol (Benjamins & Agranoff, 1969). Unfortunately, no amino acid sequence information has yet been obtained for the mammalian enzyme. However,

recently Tanaka et al (1996) has cloned the rat CDP-DAG:myoinositol phosphatidyltransferase cDNA by functional complementation of a *S. cerevisiae* CDP-DAG:myoinositol phosphatidyltransferase mutant, deficient in CDP-DAG:myoinositol phosphatidyltransferase activity. The cloned cDNA encodes a protein of 213 amino acids with a calculated molecular mass of approximately 24 kDa (Tanaka et al., 1996).

**d) Interconversion or Base Exchange: Phosphatidylcholine, Phosphatidylethanolamine, and Phosphatidylserine Synthesis**

It is known that base-exchange enzymes of the nervous system exist that are responsible for the energy-independent incorporation of choline, ethanolamine, and serine into membrane phospholipid with the formation of PC, PE, and PS, respectively (Figure 1.6; Porcellati et al., 1971; Kanfer, 1972). These enzymes are membrane-bound to the microsomal fraction (Porcellati et al., 1971; Kanfer, 1972) and have a strict requirement for calcium (Buchanan & Kanfer, 1980). The serine-base exchange enzymes (PS synthase) seem to be the sole route for PS production in brain as well as other tissues and PE seems to be the preferred substrate for exchange (Yavin & Zeigler, 1977). PS synthase cDNA has been isolated from Chinese hamster ovaries (Kuge et al., 1991). It has been shown by immunoprecipitation that the PS synthase has an apparent molecular mass of 42 kDa (Kuge et al., 1991). Recently, partial human cDNA encoding PS synthase has been found (Kuge et al., 1997). The gene sequence is indicative of a protein of approximately 474 amino acids (Kuge et al., 1997).



**Figure 1.6 Schematic of Phospholipid Synthesis**

#### **4. Composition of Phospholipids and Developmental Changes**

Past research has examined the changes in whole brain phospholipid composition with development and aging. However, analysis of whole brain does not consider the differences in brain region, cell type, or subcellular fractions as well as the timing of maturation (Sun & Horrocks, 1970). It is well established that the content of each lipid class and their fatty acyl constituents change continuously from fetal life to old age (Rouser & Yamamoto, 1968).

##### **a) Whole Brain**

In the human fetus, phospholipid content changes from about 13-17% of the brain dry weight to about 50% in term infants (Svennerholm, 1964). Among the individual phospholipids, PC comprises about half of the phospholipid in fetal brain (Svennerholm, 1964). Rouser & Yamamoto (1968) examined the phospholipids of male human brain from birth to 98 years. It was found that the phospholipid composition changes continuously throughout aging (Rouser & Yamamoto, 1968). Most of the brain phospholipids increase up to age thirty and then start to decline (Rouser & Yamamoto, 1968). Generally, it was found that the greatest increase in brain phospholipids occurred during the first year of life, which was five to fourteen times greater than any other year (Rouser & Yamamoto, 1968).

In rodents, the total brain phospholipids increase markedly from birth to 50 days of age with about a two-fold increase by ten days of age (Cuzner & Davidson, 1968). After ten days, the level of phospholipids in brain starts to plateau (Erickson & Lands, 1959). Wells & Dittmer (1967) examined the morphological changes in rat brain with deposition of lipid classes. Among the phospholipids, the study revealed that during active myelination (10-20 days), there was a rapid increase (2-4 fold) in sphingomyelin (SM) and PA content (Wells & Dittmer, 1967). The other phospholipids, in contrast to SM and PA, showed marked elevations prior to myelination. Therefore, SM and PA may be associated with changes in myelin membrane structures while PC, PE, PS, and PI (about 49-60% of adult brain levels) are associated with non-myelin structures during development (Wells & Dittmer, 1967). In rat brain, when phospholipids are considered as a percentage of the total lipids, there is a fall from 74-56% during maturation (Norton &

Poduslo, 1973). Individual phospholipids expressed relative to total lipid, PE and PS remain constant during development at about 25% and 6%, respectively, whereas PC decreases from 30-18% (Galli & Cecconi, 1967; Norton & Poduslo, 1973). SM increases from 1% to 3-4% by 37 days (Ansell & Spanner, 1961; Marshall et al., 1966).

#### **b) Neuronal and Glial Cells**

Many papers have reported the lipid composition of cell types and subcellular fraction in brain. however, only a few have examined the changes in lipid composition during development. Norton & Poduslo (1971) studied the lipid composition of neuronal and glial cell preparation in rats during myelination. The study revealed that neuronal and glial cell lipid composition was similar. Both neuronal and glial cells showed high levels of phospholipid content (71% of total lipid) and neither cell type exhibited obvious changes with age (Norton & Poduslo, 1971). Interestingly, glial cells have less PI but more PS than neuronal cells, and both cell types have less PS than whole brain at any age (Norton & Poduslo, 1971). The levels of SM were similar in the two cell types and did not seem to vary with age, despite observed changes of about 45% in whole brain (Norton & Poduslo, 1971). Thus, the study reveals that both neuronal and glial cell phospholipid composition remain relatively unchanged during development.

#### **c) Synaptic Plasma Membrane**

In rat SPM, there is an early rise in total phospholipids, which reflects the general increase in whole brain (Cuzner & Davidson, 1968). Differences in the absolute amount of phospholipids per brain in each fraction were observed (Cuzner & Davidson, 1968). However, the differences observed in amount of phospholipids may be related to the contribution of each fraction to the whole brain weight (Cuzner & Davidson, 1968). For example, myelin and synaptosomes together make up about 50% of the phospholipids in whole brain homogenates while microsomes constitute about 11.5% (Cuzner & Davidson, 1968). Nevertheless, changes in phospholipid content of SPM do occur with age.

Alterations of brain synaptosomal and microsomal membrane content and composition by diet fat was examined by Foot et al. (1982). The composition of these

membranes was compared for rats fed different types of fat. Synaptosomal membrane content of PE, ethanolamine plasmalogen, or SM was not affected by dietary fat treatment (Foot et al., 1982). Levels of PC and cholesterol were altered by diet fat (Foot et al., 1982). Increase in PC content of the membrane was strongly correlated with an increase in membrane cholesterol content (Foot et al., 1982).

### **5. Effect on Sodium-Potassium Adenosine Triphosphatase**


Phospholipids are important for optimum activity of the Na, K-ATPase and purified preparation contain 250-300 mol phospholipid/mol enzyme (reviewed by Stahl, 1986). The negatively charged phospholipids, PS and PI are present in these preparations and it has been suggested that they have an important role in modulating enzymatic activity (Kimelberg & Papahadjopoulos, 1974; Roelofsen, 1981). However, De Pont et al. (1978) exchanged PS for PE in membrane preparations and found that Na, K-ATPase activity was not significantly affected, suggesting that PS is not specifically important for modulating Na, K-ATPase activity. However, this issue has not been completely resolved, since preparations devoid of PS may still contain negatively charged detergents, or tightly bound PI, which might modulate enzymatic activity (Brotherus et al., 1980). Brotherus et al. (1980) suggested that basic amino acids residues of the Na, K-ATPase e.g. arginine and lysine, may be located near the surface boundary of the lipid layers. Specific phospholipids like PS and PI in the bilayer may segregate to match appropriate hydrophobic and hydrophilic portions of the enzyme so that acidic phospholipids are required for optimum Na, K-ATPase activity (Brotherus et al., 1980). Stekhoven et al (1994) reinforced the importance of PS for Na, K-ATPase activity by demonstrating that monoclonal antibodies to PS inhibited the Na, K-ATPase activity. Alternatively, it has been suggested that enzymatic activity is primarily modulated by the fluidity of the acyl chains of the fatty acids present in the bulk membrane phospholipids (Kimelberg & Papahadjopoulos, 1974). Thus, Na, K-ATPase activity can be modulated by phospholipids, in particular, PS and PI, and/or the fatty acyl constituents of phospholipids. Also, other ATPases, such as, mitochondrial oligomycin-sensitive ATPase, has been shown to be affected by the membrane polar head group content by diet fat, indicated by altered membrane PC to PE ratios with subsequent changes in the

thermotropic and kinetic properties of mitochondrial ATPase exchange reactions (Innis & Clandinin, 1981).

## E. SPHINGOLIPIDS

### 1. Sphingomyelin

SM is different from PC, PE, PS, and PI. In SM, a fatty acid is acylated to ceramide instead of glycerol (Ong & Brady, 1973; Figure 1.7). SM is ubiquitously distributed in all membranes of mammalian cells and in serum lipoproteins (Barenholz & Gatt, 1982). Generally, SM distribution coincides with that of cholesterol, and in most cells, there is an increasing gradient of SM and cholesterol compared to other lipids from the nuclear membrane through the various organelles to the plasma membrane (Barenholz & Thompson, 1980). SM is located predominately in the outer leaflet of the plasma membrane (reviewed by Kolesnick, 1991).



**Figure 1.7 Structure of Sphingomyelin**

#### a) Serine Palmitoyl Transferase

The de novo rate-limiting step in SM synthesis begins with condensation of L-serine and palmitoyl-CoA to produce a C18 carbon molecule, D-3-ketosphinganine (Figure 1.8; Merrill & Jones, 1990; van Echten & Sandhoff, 1993). This reaction, catalyzed by serine palmitoyl transferase (SPT) was first demonstrated in cell-free extracts made from the yeast *H. ciferrii* (Stoffel et al., 1967) and later in rat liver (Stoffel et al., 1968) and mouse brain (Braun et al., 1970). SPT requires pyridoxal phosphate for its activity (Brady et al., 1969). This enzyme is highly specific for saturated fatty acyl-

CoA's, particularly, 16-carbon atoms, which explains the prevalence of the 18-carbon sphingoid bases found in most sphingolipids (Karlsson, 1970). SPT has not yet been purified from any organism despite only a 100-fold enrichment in activity (Merrill, 1983). SPT is membrane-bound, particularly, in the endoplasmic reticulum (Mandon et al., 1992). In *S. cerevisiae*, at least two genes, LCB (long chain base) 1 (Buede et al., 1991) and LCB 2 (Nagiec et al., 1994) have been found and are necessary for SPT activity. Mammalian cDNA homologs of both LCB 1 (Hanada et al., 1997; Weiss & Stoffel, 1997) and LCB 2 (Nagiec et al., 1996; Weiss & Stoffel, 1997) have been identified.


**b) 3-Ketosphinganine Reductase**

3-Ketosphinganine reductase reduces 3-ketosphinganine to dihydrosphingosine (sphinganine: Figure 1.8; Stoffel et al., 1968). This enzyme is NADPH-dependant and is very active *in vivo* since 3-ketosphinganine is not detected in cells (Merrill et al., 1985; Merrill & Wang, 1986). 3-Ketosphinganine reductase has been shown to be localized to the cytosolic side of the endoplasmic reticulum (Mandon et al., 1992). In *S. cerevisiae* *csg 2Δ* mutants that were calcium sensitive to temperature, the gene TSC10/YBR265w was found to encode the 3-ketosphinganine reductase (Beeler et al., 1998). However, characterization of 3-ketosphinganine reductase has not been done in mammalian tissues.

**c) Sphinganine N-Acyl Transferase**

Sphinganine N-acyl transferase (ceramide synthase) is responsible for the acylation of sphingosine with fatty-acyl CoA to form dihydroceramide (Figure 1.8; Morell & Radin, 1970; Akanuma & Kishimoto, 1979; Merrill & Wang, 1986). However, a fatty acyl CoA independent synthesis of dihydroceramide has also been described (Singh, 1983). The acylation of sphinganine occurs very rapidly *in vivo* since free sphingosine is not detected in cells unless stimulated by hormones and cytokines (Merrill & Wang, 1986). This reaction has been shown to take place at the cytosolic surface of the endoplasmic reticulum (Mandon et al., 1992; Hirschberg et al., 1993). Shimeno et al. (1998) partially purified sphinganine N-acyl transferase from bovine liver mitochondria. Western blot analysis showed that this enzyme migrated as two major protein bands

(subunits) of 62 and 72 kDa (Shimeno et al., 1998). The molecular mass of the enzyme was estimated to be approximately 240-260 kDa (Shimeno et al., 1998). Future studies on the purification of ceramide synthase to homogeneity are needed.



**Figure 1.8 Biosynthesis of Sphingomyelin**

**d) Dihydroceramide Desaturase**

Dihydroceramide desaturase catalyzes the conversion of dihydroceramide to ceramide (Figure 1.8; Michel et al., 1997; Geeraert et al., 1997). This reaction introduces a 4,5 trans double bond in the dihydroceramide not sphinganine (Michel et al., 1997; Geeraert et al., 1997; Mikami et al., 1998). Dihydroceramide desaturase in mouse has been found to be localized at the cytosolic face of the endoplasmic reticulum (Mandon et al., 1992). The *in vitro* assay of this enzyme has recently been described in the microsomal fraction of rat liver (Michel et al., 1998). Recently, Causeret et al (2000) has further characterized dihydroceramide desaturase activity in rat. Dihydroceramide desaturase was found to be enriched in rat liver (Causeret et al., 2000). Subcellular fractionation of liver homogenate and density gradient separation of microsomal fraction demonstrated dihydroceramide desaturase activity to be localized in the endoplasmic reticulum (Causeret et al., 2000). Unfortunately, little is known about this enzyme in humans since it has not been isolated and characterized.

**e) Sphingomyelin Synthase**

The major pathway for the synthesis of SM is by transfer of the phosphoryl choline groups from PC to ceramide, yielding diacylglycerol and SM (Figure 1.8; Ullman & Radin, 1974). The formation of SM does not occur via CDP-choline (Diringer et al., 1973; Kurtz & Kanfer, 1973; Voelker & Kennedy, 1982). This reaction is catalyzed by SM synthase (PC; ceramide-phosphoryl choline transferase; Ullman & Radin, 1974). SM synthase activity has been detected in isolated plasma membrane and microsomal preparations (Ullman & Radin, 1974). Controversy still exists as to the major site of SM synthesis *in vivo*. However, it is believed that SM synthesis occurs in the Golgi apparatus using fluorescent analogs of ceramide (Barenholz & Thompson, 1980; Lipsky & Pagano, 1983 and 1985; Merrill & Jones, 1990; Koval & Pagano, 1991). Further evidence for the localization of SM synthesis at the Golgi apparatus was provided by the separation and characterization of subcellular components (Futerman et al., 1990; Jeckal et al., 1990). Interestingly, the brain which is enriched with SM has little SM synthase activity (Nikolova-Karakashian, 1999). Purification and characterization of SM synthase has been

difficult because mild detergent treatment causes loss of activity (Nikolova-Karakashian, 2000).

## **2. Gangliosides**

To date, brain lipids, more specifically, gangliosides have not been extensively examined in relation to compositional changes due to alteration in dietary fat. This section will discuss the role of gangliosides and their importance in brain.


### **a) Nomenclature**

Ganglioside nomenclature was developed by Lars Svennerholm in 1963 (Svennerholm, 1963; reviewed by Svennerholm, 1980 and 1988). In Svennerholm's notation, G denotes ganglio-family, the capital letters M, D, T, and Q refer to the number of neuraminic (NANA) or sialic acid residues in the ganglioside (Svennerholm & Raal, 1961; Svennerholm, 1963; reviewed by Brunngraber, 1979). Numbers one, two, or three refer respectively to gangliosides whose total hexose and hexosamine residues are four, three, and two, respectively (reviewed by Brunngraber, 1979 and Svennerholm, 1980 and 1988). Small letters a, b, or c following the numbers distinguish between the position of the sialo-isomers (reviewed by Brunngraber, 1979 and Van Echten & Sandhoff, 1993). This notation developed by Svennerholm used to designate gangliosides is the least complex of all the other systems and will be used to describe the gangliosides in this thesis.

### **b) Chemical Structure and Composition**

Gangliosides, a subclass of glycosphingolipids, are acidic complex lipids that are composed of two regions (Figure 1.9; reviewed by Rapport, 1981 and Svennerholm, 1988). The first is the hydrophobic region. The hydrophobic region consists of two long chain molecules: a long-chain base, sphingosine, which can be eighteen or twenty carbons in chain length, and a fatty acid chain (usually stearic acid; C18:0) that is linked to the sphingosine by an amide bond (reviewed by Rapport, 1981 and Svennerholm, 1988). The two long chain molecules together are called a ceramide (reviewed by Rapport, 1981 and Svennerholm, 1988). The second is the hydrophilic region, which is

composed of sugar residues; mainly glucose, galactose, and N-acetylgalactosamine (hexosamine) that are bonded to the primary hydroxyl group of the sphingosine (reviewed by Brunngraber, 1979). In addition to the sugar residues in the hydrophilic region, there are neuraminic acid residues, which characterize gangliosides from other glycosphingolipids (Klenk, 1942; reviewed by Rapport, 1981 and Svennerholm, 1988). These neuraminic acid residues can attach to galactose or other neuraminic acid molecules by a glycoside bond (reviewed by Rapport, 1981 and Svennerholm, 1988). Thus, this addition of neuraminic acid in the hydrophilic region of the molecule gives the gangliosides their acidic nature and different mobility in thin-layer chromatography.




$x$  = varying number of carbon atoms

**Figure 1.9 Structure of a Ganglioside**

There are more than sixty different ganglioside molecules that have been identified all varying in structure and composition (reviewed by Rapport, 1981 and Svennerholm, 1988). Variations in these structures result from a number of factors, such

as. the number of sugar residues, the number of neuraminic acid residues, the position of attachment of the neuraminic acid, the presence of fucose residues, the substitution of glucosamine for galactosamine, and the presence of O-acetyl groups (reviewed by Rapport, 1981 and Svennerholm, 1988). However, this thesis will focus only on four of these gangliosides: GM1a, GD1a, GD1b, and GT1b (Figure 1.10).




**Figure 1.10 Gangliosides GM1a, GD1a, GD1b, and GT1b**

**c) Cellular Localization**

Gangliosides occur on the outside of cellular plasma membrane especially at the synaptic regions in which there are enriched amounts (reviewed by Wiegandt, 1985 and Svennerholm, 1988; Figure 1.11). However, it is not clear whether or not gangliosides are evenly or unevenly distributed on the outer surface of the neuron (reviewed by Wiegandt, 1985 and Svennerholm, 1988). Low levels of gangliosides have also been

detected in the membrane of the Golgi apparatus, endoplasmic reticulum, and lysosome (reviewed by Wiegandt, 1985). These findings suggest that ganglioside metabolism is localized in these structures and that they may serve some special biological functions (reviewed by Wiegandt, 1985 and Svennerholm, 1988).



**Figure 1.11 Gangliosides in Cell Membrane**

**d) Distribution in Central and Peripheral Nervous System**

Gangliosides are found in most, if not all, mammalian tissues with their concentrations being highest in gray matter of the brain (reviewed by Rapport, 1981 and Wiegandt, 1985). Sixty-five to eighty-five percent of the gangliosides content in mammalian brain is of four molecular species: GM1a, GD1a, GD1b, and GT1b (reviewed by Rapport, 1981; Wiegandt, 1985). However, gangliosides from the peripheral nervous system are quite different to those of the central nervous system (reviewed by Wiegandt, 1985). Peripheral nervous system gangliosides are of the lacto-

series rather the ganglio-series found in the central nervous system (reviewed by Wiegandt, 1985). This difference in composition might be related to their function. Nevertheless, gangliosides localized in the central nervous system are different in sugar composition than in peripheral nervous system.

**e) Composition in Neuronal Membranes**

Gangliosides are the most specific lipids in neuronal membranes. The amount of neuraminic acid per gram wet weight of human brain gray and white matter are approximately 880 and 275  $\mu\text{g}$ , respectively (reviewed by Thomas & Brewer, 1990). Although gangliosides constitute approximately 10% of the total membrane-bound lipids (Wiegandt, 1985) on the whole neuron surface, gangliosides are more concentrated in the synaptic region (Hansson et al., 1977). In the SPM, there are higher ratios of ganglioside to phospholipid compared to the plasma membrane of most non-neuronal tissues (reviewed by Thomas & Brewer, 1990). The SPMs from human and rat brain contains approximately 15% GM1a, 40% GD1a, 14% GD1b, and 21% GT1b (reviewed by Thomas & Brewer, 1990). Interestingly, it has been shown that there is an increased amount of GD1b and GT1b (70-80%) in the synaptic junction (reviewed by Thomas & Brewer, 1990).

**f) Physiochemical Properties**

Gangliosides, because of their hydrophobic (ceramide) and hydrophilic (oligosaccharide) regions, are amphiphilic and can form micelles above  $10^{-10}$  M range (Corti et al., 1987). In contrast to other amphiphilic molecules like phospholipids, gangliosides do not have bilayer structures (reviewed by Curatolo, 1987). In addition, the neuraminic acid residues on the gangliosides molecule contribute significantly to the negative electrical charge on the membrane (reviewed by Langner et al., 1988 and Thompson & Brown, 1988).

It is well established that under certain conditions gangliosides can form microdomains (clusters) (Myers et al., 1984; Masserini & Freire, 1986). These clusters indicate that not only do gangliosides have chemical diversity but also aggregational diversity which may play a significant role in allowing ganglioside-ligand interaction to occur (Myers et al., 1984; Masserini & Freire, 1986).

Due to the location of the gangliosides on the outer leaflet of the synaptic membrane, it is not surprising that gangliosides possess high binding potential. Numerous agents such as viruses, serotonin, fibronectin, and antibodies have been demonstrated to bind primarily the oligosaccharide region of the ganglioside (Tettamanti & Masserini, 1987). The specificity of binding of these agents seems to be due to a particular sequence of oligosaccharides that can be shared by different gangliosides. This is most evident with cholera toxin binding GM1a (Holmgren et al., 1994) and Fuc-GM1a (Masserini et al., 1992).


Gangliosides interaction with proteins in the membrane have also been demonstrated, but it is not clear whether aggregated or molecularly dispersed forms are involved (Myers et al., 1984). These ganglioside-protein interactions have been seen specifically in GM1a and GT1b and it is speculated that these proteins are responsible for ganglioside internalization via endocytosis (Yasuda et al., 1988; Tiemeyer et al., 1990; Fueshko & Schengrund, 1990; Sonnino et al., 1992).

**g) Metabolism**

**i) Biosynthesis**

The oligosaccharide chain of gangliosides is formed by a stepwise addition of nucleotide bound monosaccharides like uridine diphosphate (UDP)-galactose or cytidine monophosphate (CMP)-neuraminic acid onto an acceptor molecule, ceramide, which is the product of condensation and reduction between L-serine and palmitoyl-CoA in the endoplasmic reticulum (Walter et al., 1983). The transfer of nucleotide-activated monosaccharides takes place in the Golgi apparatus, with the involvement of specific membrane-bound glycosyltransferases (Hirschberg & Snider, 1987). The reaction sequences for the biosynthesis of gangliosides and the involved enzymes are shown in Figure 1.12. Initiation of the three distinct ganglioside pathways (A, B, C) are dependant on the strict specificity of sialic acid transferases (SAT), SAT-1, SAT-2, and SAT-3, which act on lactosylceramide, GM3, and GD3, respectively (reviewed by Tettamanti & Masserini, 1987). Further glycosylation are catalyzed by enzymes like N-acetylgalactosamine (GalNAc) transferase-1, which converts GM3 to GM2, GD3 to GD2, and GT3 to GT2 (reviewed by Tettamanti & Masserini, 1987). Similarly, (1)

galactosyltransferase-2 catalyzes the transformation of GM2 to GM1a, GD2 to GD1b, and GT2 to GT1c; (2) SAT-4 converts GM1a to GD1a, GD1b to GT1b, and GT1c to GQ1c; and (3) SAT-5 converts GD1a to GT1a, GT1b to GQ1b, and GQ1c to GP1c (reviewed by Tettamanti & Masserini, 1987). After synthesis in the Golgi apparatus of the neuronal cell body, the gangliosides travel by fast axonal transport to the SPMs (reviewed by Ledeen, 1989).



UDP = Uridine diphosphate      Gal = Galactose      Glc=glucose      GalNAc = N-acetylgalactosamine

CMP = Cytidine monophosphate      NeuAc = Neuraminic acid      SAT= Sialic acid Transferase

**Figure 1.12 Biosynthesis of Gangliosides**

The regulation of ganglioside biosynthesis has not been fully elucidated. Changes in the pattern of ganglioside expressed on cells during development, differentiation, and oncogenic transformation have been observed, as well as differences in the composition of mammalian organs (reviewed by Ledeen, 1989, Hakomori, 1990 and Rahmann, 1992). The changes or differences observed in ganglioside patterns are thought to be regulated at the transcription level via the expression of certain glycosyltransferase (Sandhoff & van Echten, 1993). Using transfected cells with cDNA probes for specific glycosyltransferase has been shown to increase the respective ganglioside (Kojima et al., 1994). Other studies have suggested that glycosyltransferase might be regulated by protein phosphorylation/dephosphorylation reaction (Scheidler & Dawson, 1986). Sugar nucleotides can also modulate the synthesis of gangliosides (Burczak et al., 1984). The sugar nucleotide is transported into the Golgi by specific transport proteins in the Golgi membrane, which may regulate the availability of sugar nucleotides for ganglioside biosynthesis (Burczak et al., 1984).

## ii) Biodegradation

Ganglioside catabolism consists of the sequential removal of individual sugar residues by exoglycohydrolases, with formation of ceramide (Sandhoff et al., 1987). Ceramide is then degraded by ceramidase (CDase) into sphingosine and fatty acid (Spence et al., 1986). The glycohydrolases involved in neural ganglioside degradation reside in the lysosomes (Riboni et al., 1991). In fact, it was shown by Fiorilli et al. (1989) that in highly purified lysosome preparations from rat brain that glycohydrolases affecting ganglioside catabolism were present. However, if any of these enzymes in the lysosomes are absent or defective, gangliosidosis develops (Fiorilli et al., 1989). Therefore, demonstrating the significance of these enzymes in ganglioside catabolism.

### (1) Glycosidases

The constitutive degradation of gangliosides occurs in the acidic compartments of the cell: endosomes and lysosomes. Gangliosides reach the lysosomal compartment by endocytic membrane flow, presumably on the surface of intraendosomal and intralysosomal vesicles (Sandhoff et al., 1998). In the lysosomes, the gangliosides are

cleaved by stepwise action of hydrolytic enzymes (Sandhoff et al., 1998). Glycosidases cleave off the sugar residues from the non-reducing end of gangliosides (Sandhoff et al., 1998). Gangliosides with short oligosaccharide chains of less than four sugar residues, the glycosidases need protein cofactors, sphingolipid activator protein (SAP; Sandhoff et al., 1998). There are four SAP that are involved in ganglioside degradation: SAP-A, SAP-B, SAP-C, and SAP-D (Sandhoff et al., 1998). These proteins seem to facilitate interaction of gangliosides with glycosidases in or at the membrane (Kolter & Sandhoff, 1998). Deficiencies of glycosidases and/or SAPs cause accumulation of sphingolipids in lysosomes leading to lysosomal storage diseases such as Tay-Sachs and Gaucher's disease (Kolter & Sandhoff, 1998).

## (2) Ceramidases

CDase hydrolyses ceramide to a free sphingoid base (usually sphingosine) and a fatty acid (Gatt, 1966). CDase activity was first characterized as an enzyme with an acidic pH optimum present in all tissues examined (Gatt, 1966; Yavin & Gatt, 1969). A genetic deficiency of this enzyme was later shown to account for Farber's disease where there is an accumulation of ceramides in the lysosomes of spleen, cerebellum, fibroblasts, and kidney (Levade et al., 1995; Nikolova-Karakashian & Merrill, 2000). CDases with neutral (pH 7.6) and alkaline (pH 9.0) pH optimum have been found (Nilsson et al., 1969; Morell & Braun, 1972; Yada et al., 1995). Recently, the acid CDase from human urine was purified (Bernardo et al., 1995) and the cDNA encoding human and mouse acid CDase has been cloned (Koch et al., 1996; Li et al., 1998).

Neutral CDase was purified and characterized in mouse liver (Tani et al., 2000). The enzyme was a monomeric polypeptide with a molecular mass of 94 kDa and was highly glycosylated with N-glycans (Tani et al., 2000). The amino acid sequence of the mouse liver neutral CDase was homologous to that of the alkaline CDase in *P. aeuriginosa* (Okino et al., 1998) and *D. discoideum* (Tani et al., 2000). The neutral CDase was cloned from mouse liver and the cDNA encoded for polypeptide of 756 amino acids with nine putative N-glycosylation sites (Tani et al., 2000). Northern blot analysis revealed that the enzyme is expressed widely in mouse tissues with liver and kidney showing the highest levels (Tani et al., 2000).

Two alkaline CDase have been best characterized in guinea pig skin epidermis, one to apparent homogeneity and the other only partially (Yada et al., 1995). These two enzymes were membrane-bound, and their estimated molecular masses on SDS-PAGE were 60 and 148 kDa, respectively. Recently, El Bawab et al. (1999) purified a membrane-bound non-lysosomal (neutral/alkaline) CDase from rat brain and human mitochondria (El Bawab et al., 2000) to apparent homogeneity. The enzyme appeared as a single protein of 90 kDa (El Bawab et al., 1999). Interestingly, the activity of this enzyme was stimulated by PS and PA and does not require cations (El Bawab et al., 1999).

### (3) Sphingosine Kinase

Sphingosine kinase catalyzes the phosphorylation of long-chain sphingoid bases (usually sphingosine) on their primary hydroxyl group to sphingosine-1-phosphate (SPP; Kohama et al., 1998). Rat sphingosine kinase has been purified to homogeneity with an apparent molecular mass of approximately 49 kDa (Kohama et al., 1998). Based on peptide sequences derived from the purified rat sphingosine kinase, the mammalian sphingosine kinase were cloned from the mouse (Kohama et al., 1988). Amino acid sequence analysis indicate that sphingosine kinases are correlated to other known kinases, yet comparison of sphingosine kinase sequence with that cloned from *S. cerevisiae* (Dickson et al., 1997) and *C. elegans* (Kohama et al., 1998) reveals several domains that are highly conserved in all of these sphingosine kinases (Kohama et al., 1998). Northern blot analysis of mouse tissues showed that sphingosine kinase mRNA was most abundant in the adult lung and spleen (Kohama et al., 1998). Further characterization of mammalian sphingosine kinase in mammalian tissues are needed.

### (4) Sphingosine-1-Phosphate Lyase

Sphingosine-1-phosphate lyase belongs to the class of pyridoxal phosphate dependant carbon-carbon lyases and acts on the 1-phosphorylated derivatives of sphingoid base (sphingosine; Merrill & Wang, 1992; Zhou & Saba, 1998). The cleavage products are an aliphatic fatty aldehyde (2-trans-hexadecanal) and phosphoethanolamine (Merrill & Wang, 1992; Zhou & Saba, 1998). This enzyme is present in all tissues in

vertebrates, invertebrates, plants, fungi, and unicellular protozoa (Merrill & Wang, 1992; Zhou & Saba, 1998). The sphingosine-1-phosphate lyase is associated with the endoplasmic reticulum and has its catalytic site facing the cytosol (Merrill & Wang, 1992; Zhou & Saba, 1998). The yeast sphingosine-1-phosphate lyase cDNA has been cloned (Saba et al., 1997) and subsequently by homology the murine (Zhou & Saba, 1998). The mRNA encodes a protein with a molecular mass of approximately 61-65 kDa (Zhou & Saba, 1998). Characterization of a human sphingosine-1-phosphate lyase has not been done.

### iii) Recycling

Studies administering exogenous radioactive gangliosides to cultured cells or to animals to ascertain recycling processes in ganglioside biosynthesis have been very useful. It was demonstrated in liver (Ghidoni et al., 1983; Trinchera & Ghidoni, 1990) and in cultured cerebellar granule cells (Riboni & Tettamanti, 1991) that gangliosides upon degradation release galactose, N-acetylgalactosamine, neuraminic acid, fatty acid, and sphingosine that are re-used for the synthesis of new gangliosides, glycoproteins, phospholipids, and sphingomyelin. Moreover, the recycling process appeared to be blocked by inhibiting lysosome function by chloroquine or preventing endocytosis (Riboni & Tettamanti, 1991; Riboni et al., 1992). Thus, suggesting that lysosomes play a role in ganglioside recycling processes.

### h) Composition and Developmental Changes in Brain

Early research has demonstrated that there is an increase in concentration for all major gangliosides with age in the brain of rats and humans, but the rate of increase of each ganglioside is different (Svennerholm, 1964; Suzuki, 1965). Vanier et al. (1971) proposed that there are three major periods of ganglioside development. The first period is characterized by a growth of neurons and glial cells with a moderate increase in ganglioside concentration (Vanier et al., 1971). In this period, GM1a and GT1b predominate with GD1a gradually increasing in concentration (Vanier et al., 1971). The duration of this period is until birth for rats and until the twenty-fifth week of gestation in humans (Vanier et al., 1971). The second period shows the outgrowth of dendrites and

axons with the production of neural connection (Vanier et al., 1971). This period corresponds to the first ten days after birth in rats and the thirtieth week of gestation to term in humans (Vanier et al., 1971). In this period, there is a maximal rate of increase in ganglioside concentration for GD1a but a decline for GM1a and GT1b (Vanier et al., 1971). The last period which represents between ten and twenty days of age in the rat and the first eight months in humans demonstrates an increase in neural connection as well as the beginning of myelination (Vanier et al., 1971). During this stage, GD1a becomes the predominant ganglioside fraction (Vanier et al., 1971).

Changes in the ceramide composition with increasing age have also been shown in human brain gangliosides (Mansson et al., 1978). Until the age of ten, the ratio of twenty carbon and eighteen-carbon sphingosine increases rapidly (Mansson et al., 1978). The sphingosine content in brain levels off with 60-70% of sphingosine being the twenty-carbon type after thirty years of age (Mansson et al., 1978). The fatty acids composition of ceramide from gangliosides also changes with age (Mansson et al., 1978). At birth, 93% of the ganglioside fatty acids is C18:0, whereas at age 98 only 78% of this fatty acid is present (Mansson et al., 1978). Concomitantly, there is an increase from 3 to 9% of fatty acids in gangliosides with twenty or more carbons (Mansson et al., 1978). Thus the developmental patterns of individual gangliosides in the brain are different, however, between rat and human brain the patterns are quite similar (reviewed by Ledeen, 1985 and Yu and Saito, 1989). Hence, the rat serves as a good model for extrapolating to humans.

#### **i) Biological Functions**

Presently, the function of gangliosides have not been fully elucidated (Tettamanti & Riboni, 1994). It appears that gangliosides can serve multivalent roles that are now beginning to be understood. There is increasing evidence that gangliosides can serve as: (1) molecular tools for appropriate interactions between the cell plasma membrane and extracellular substances (Bird & Kimber, 1984), (2) modulators of membrane-bound or intracellular functional proteins like receptors, ion channels, enzymes, and ion carriers (Benos & Sorscher, 1992), and (3) precursors of intracellular metabolic regulators, for

examples. sphingosine and ceramide derivatives (Hannun & Bell, 1989; Merrill & Jones, 1990; Younes et al., 1992)

**j) Sphingolipid Metabolites as Modulators of Cellular Processes**

**i) Sphingomyelinase Cycle**

The SM cycle was first described by Okazaki et al (1989 and 1990). This cycle is composed of six major components (1) a ligand like a hormone or a cytokine which can bind to a receptor on the surface of a cell ; (2) a receptor on the surface of the cell which can receive a ligand; (3) a SM which is predominantly at the cell's plasma membrane that can act as the substrate for SMase; (4) the SMase which hydrolyzes the SM; (5) the ceramide and the choline-phosphate that results from the SM hydrolysis; and (6) enzymatic pathways for the resynthesis of SM. This cycle is initiated when an agonist such as TNF- alpha (Kim et al., 1991; Dressler et al., 1992) or IL-1 (Mathias et al., 1993) binds to a receptor on the cell this causes the activation of SMase. The ceramides generated by SMase action can now act as a second messenger by transmitting messages through the cell's interior like inhibiting or stimulating other enzymes within the cell like phospholipase D (PLD) and ceramide-activated protein kinase (CAPK), respectively (Mathias et al., 1991; Hannun & Linares, 1993). Consequently, the inhibition or stimulation of these intracellular enzymes by ceramides can alter biological response by affecting other downstream effectors or substrates. The SM cycle is completed when SM and ceramide return to basal levels.

**ii) Ceramide**

**(1) Role in Growth Suppression**

Growth suppression is the inability of a cell to grow when the proper factors e.g. hormones or cytokines are received by the cell. Experiments with HL-60 cell line revealed that these cells which responded to 1-alpha -25-dihydroxyvitamin D<sub>3</sub> to differentiation caused the inhibition of their cell growth (Miyaura et al., 1981). With the recent knowledge that 1-alpha -25-dihydroxyvitamin D<sub>3</sub> caused SM hydrolysis in these cells, it was suggested that the growth inhibition effects of 1-alpha -25-dihydroxyvitamin D<sub>3</sub> might be mediated via the SM cycle (Hannun & Linares, 1993). The findings by

Wolff et al. (1994) confirmed this idea by demonstrating that cell permeable C2-ceramide can cause growth inhibition by down regulation of c-myc proto-oncogene, which is known to be up-regulated in cells during proliferation. This down regulation of c-myc which occurs within thirty minutes after receiving C2-ceramide is due to the inhibition of RNA accumulation by blocking transcription elongation between the first and third exon in the gene (Kronke et al., 1987; Tobler et al., 1987). This mechanism of ceramide on c-myc is similar to the effects of TNF-alpha (Wolff et al., 1994). Hence, the connection between C2-ceramide inducing the down regulation of c-myc by similar mechanism is important because it shows a link between extracellular messengers, signal transduction and nuclear events.

## (2) Role in Cell-Cycle Arrest

Initial studies using the HL-60 cells demonstrated anti-proliferative activity of ceramides (Okazaki et al., 1990). In subsequent studies with serum-dependant MOLT-4 leukemia cells, the withdrawal of serum led to a significant accumulation of ceramides this coincided with the development of cell-cycle arrest in G<sub>0</sub>G<sub>1</sub> phase (Jayadev et al., 1995). Further investigation with this cell line with C6-ceramides revealed a specific arrest in the cell cycle that was dose and time dependant (Jayadev et al., 1995). The specificity of the cell cycle arrest by C6-ceramide was demonstrated when C6-dihydroceramide did not result in cell cycle arrest. The retinoblastoma gene product (Rb), a tumor suppressor or nuclear phosphoprotein has been implicated as an important inhibitor of cell cycle progression (Weinberg, 1990). In the serum-dependant Molt-4 cell line the removal of serum resulted in a substantial amount of dephosphorylation of Rb (Weinberg, 1990). The dephosphorylation of Rb is the mechanism that is responsible for the cell cycle arrest (Weinberg, 1990). It has been shown *in vitro* that 10- 20 uM of C6-ceramide can cause an early dose-dependant dephosphorylation of Rb which leads to cell cycle arrest within four hours (Dbaiibo et al., 1995). Therefore, linking intracellular ceramide generation to Rb dephosphorylation, which results in cell cycle arrest.

### (3) Role in Cell Differentiation

In HL-60 cell line there appears to be a direct relationship between activation of SM signaling pathway and the differentiation of HL-60 cells (Kim et al., 1991; Okazaki et al., 1989 and 1990). When 1-alpha -25-dihydroxyvitamin D<sub>3</sub> were added to these cells in tissue culture the HL-60 cells began to differentiate along the monocytic lineage (Okazaki et al., 1989 and 1990). Further, the addition of C2-ceramide (a short-chain fatty acid ceramide) and 1-alpha -25-dihydroxyvitamin D<sub>3</sub> at sub-threshold concentrations also induced monocytic differentiation in HL-60 cells (Okazaki et al., 1989 and 1990). In addition, other studies have shown that TNF-alpha and IFN-gamma were also able to cause differentiation of the HL-60 cells to monocytes (Kim et al., 1991). The effects seen in these cell lines by 1-alpha -25-dihydroxyvitamin D<sub>3</sub>, TNF-alpha, and IFN are due to these agonists binding onto a cell surface receptor that causes the activation of SMases which in turn can cleave SM to ceramide and choline-phosphate (Kim et al., 1991; Dressler et al., 1992). The ceramide, in turn, by some unknown mechanism causes the activation of protein kinase C (Kim et al., 1991). The activated protein kinase C can then cause phosphorylation of an unknown substrate which can cause the transcription factor (NF-kB) to bind to a specific region on a DNA in the nucleus allow the HL-60 cells to differentiate into the observed monocytes (Kim et al., 1991).

### (4) Role in Apoptosis

Apoptosis or programmed cell death is an integral component of embryonic development and organogenesis and is characterized by distinct morphological features like nuclear and cytoplasm shrinking and fragmentation, membrane blebbing and breakdown of DNA by specific endonucleases as seen on a agarose gel electrophoresis of DNA ladder indicative of DNA degradation (Ribeiro, 1993). Studies with C2- ceramide on U937 myeloid cells resulted in potent induction of internucleosomal DNA fragmentation which were seen as early as two hours after 1- 6 uM of C2-ceramide was added (Hannun & Bell, 1993; Merrill et al., 1997). However, the dihydroceramide (a ceramide with no 4-5 trans double bond) when given to these same cells did not demonstrate apoptosis (Hannun & Bell, 1993; Merrill et al., 1997). The target for the ceramide-induced apoptosis was shown in vitro to be a ceramide-activated protein

phosphatase (CAPP; Hannun & Obeid, 1995; Merrill et al., 1997). CAPP is a serine / threonine phosphatase of the PP2A subfamily. The PP2A subfamily is defined by a common catalytic subunit (C), which may exist as a monomer, as a heterodimer with an A-subunit of unknown function or as a heterotrimer with the A and an additional B-subunit (Hannun & Obeid, 1995; Merrill et al., 1997). The B-subunit appears to suppress the activity of the phosphatases and has been suggested to function as a regulation of cellular phosphatase activity (Hannun & Obeid, 1995; Merrill et al., 1997). Ceramides activate the heterotrimer phosphatase but not monomeric or heterodimeric PP2A, thus demonstrating a requirement for the B-subunit of PP2A in mediating the activation by ceramide (Hannun & Obeid, 1995; Merrill et al., 1997). Therefore, the mechanism by which ceramides can induced apoptosis in these cells could be that the agonists such as TNF-alpha, fas-ligand, and ionizing irradiation (Uckun et al. 1992 and 1993) can cause activation of SMases which generates ceramides that cause the activation of CAPP and its down regulation of c-myc which in turn can lead to apoptosis (Cifone et al., 1994). Further research has also shown that Jurkat T cells and HUT-78 (a human T-cell lymphoma line) cells are induced to apoptosis by ceramides.

iii) Sphingosine


Sphingosine-1-phosphate (SPP) produced by sphingosine kinase has been reported to be involved in the modulation of cell functions. Cellular processes modulated by SPP include proliferation (Zhang et al., 1991; Olivera & Spiegel, 1993; Rani et al., 1997), survival (Cuvillier et al., 1996; Kleuser et al., 1998), organization of the cytoskeleton (Bornfeldt et al., 1995; Wang et al., 1997), motility (Wang et al., 1999), neurite retraction and cell rounding (van Brocklyn et al., 1999), and differentiation (Edsall et al., 1997; Rius et al., 1997). SPP has also been shown to modulate several signaling pathways, including the activation of phospholipase D leading to the formation of PA (Desai et al., 1992), activation of the Raf/MEK/ERK signaling cascade (Wu et al., 1995), and mobilization of calcium from internal stores via a mechanism that is independent of PI hydrolysis and C20:4n-6 release (Mattie et al., 1994; Melendez et al., 1998). Moreover, SPP can have dual actions, acting intracellularly as a second messenger and receptors (van Brocklyn et al., 1998).

## **F. CHOLESTEROL**

Extensive studies on the biosynthesis of cholesterol in the central nervous system have been performed (Galli et al., 1968; Gautheron et al., 1969; Fumagalli et al., 1969). The endoplasmic reticulum enzyme HMG-CoA reductase catalyzes the rate-determining step in the synthesis of cholesterol and other polyisoprenoid compounds in animal cells (reviewed by Goldstein & Brown, 1990). A previous study has shown that the rate of brain cholesterol biosynthesis is high in the fetus and newborn animal and that as the animal matures, cholesterol synthesis in brain is low (Dietschy, 1997).

Cholesterol (Figure 1.13) and cholesterol esters are abundant in mammalian tissues but can also be found in lesser quantity in mitochondria, Golgi complexes, and nuclear membranes (reviewed by Yeagle, 1985). Plasma membranes are highly enriched in cholesterol. In SPM, cholesterol accounts for over 40 mol % of the total membrane lipid (Wood et al., 1989; Schroeder et al., 1991). Cholesterol in the SPM is not evenly distributed throughout but is located in different pools or domains (Schroeder et al., 1991; Wood et al., 1993). Lateral domains of cholesterol have been described and these domains have been identified in neuronal tissue (Leibel et al., 1987; Rao et al., 1993; Wood et al., 1993). In addition to lateral domains, transbilayer cholesterol domains (exofacial and cytofacial leaflet) have also been described in neuronal tissues (Wood et al., 1990; Igbavboa et al., 1996 & 1997). The SPM cytofacial leaflet contains over 85% of the total SPM cholesterol (Igbavboa et al., 1996 & 1997).

Cholesterol interrelates among the phospholipids of the membrane, with its hydroxyl group at the aqueous interface and the remainder of the molecule within the bilayer (reviewed by Kabara, 1973). The importance of cholesterol in mammalian cells is most likely for regulation and maintenance of membrane properties such as, membrane fluidity and rigidity (reviewed by Yeagle, 1991) which in turn may modulate the activities of numerous membrane proteins (reviewed by Bloch, 1965). The interaction of cholesterol with membrane proteins has been described in both neuronal and non-neuronal tissues (Michelangeli et al., 1990; reviewed by Bastiaanse et al., 1997). However, the biological role of cholesterol in neuronal cells is still not completely understood (Yao et al., 1988; Yao, 1988).




**Figure 1.13 Structure of Cholesterol**

## **G. N-6 AND N-3 FATTY ACIDS**

### **1. Classification**

N-6 and n-3 fatty acids are two families of PUFAs that can be distinguished from each other by the position of their first double bond (reviewed by Gurr & Harwood, 1991). C18:2n-6 and C18:3n-3 are examples of n-6 and n-3 fatty acids which have their first double bond six and three carbons away from the terminal methyl carbon, respectively (Figure 1.14; reviewed by Gurr & Harwood, 1991). These two fatty acids, in addition to being the precursors of C20:4n-6 and C22:6n-3 biosynthesis (Figure 1.14) are essential for mammals (reviewed by Gurr & Harwood, 1991 and Sprecher, 2000). These fatty acids are essential because mammals do not have the enzymes necessary for inserting double bonds beyond the ninth carbon atom in the fatty acid chain (reviewed by Gurr & Harwood, 1991). Therefore, these fatty acids must be supplied by the diet (Sprecher, 2000).




**Figure 1.14 N-6 and N-3 Fatty Acid Structures**

## 2. Metabolism

The metabolism of n-6 and n-3 fatty acid involves several enzymes called desaturases and elongases (reviewed by Gurr & Harwood, 1991 and Sprecher, 2000; Figure 1.15). The formation of long-chain PUFAs from C18:2n-6 and C18:3n-3 begins with the delta-6 desaturase and is followed by elongation to a twenty-carbon molecule (reviewed by Gurr & Harwood, 1991 and Sprecher, 2000; Figure 1.14). This twenty carbon molecule is further desaturated and elongated until the most prominent long-chain PUFA of n-6, C20:4n-6; and n-3, eicosapentanoic acid (C20:5n-3) and C22:6n-3 are formed (reviewed by Gurr & Harwood, 1991 and Sprecher, 2000).

The final steps in the pathway of C22:5n-6 and C22:6n-3 formation independent of delta-4 desaturase were recently elucidated with *in vitro* studies using animal cells (Voss et al., 1991; reviewed by Sprecher, 2000; Figure 1.15). The synthesis of C22:5n-6 from C20:4n-6 proceeds via elongation to C22:4n-6 and then to C24:4n-6 with a delta-6 desaturase to form C24:5n-6 and partial beta-oxidation in peroxisomes to C22:5n-6 (Voss et al., 1991; and reviewed by Sprecher, 2000). The synthesis of C22:6n-3 from C20:5n-3 seems to be similar to that of the n-6 fatty acids: C20:5n-3 to C22:5n-3 to C24:5n-3 to C24:6n-3, with beta-oxidation to C22:6n-3 (Voss et al., 1991; and reviewed by Sprecher, 2000). Recently, Li et al. (2000) unequivocally demonstrated in developing piglets that

microsomes and peroxisomes are both required for biosynthesis of C22:6n-3 from C18:3n-3. It is still uncertain as to the type of delta-6 desaturase and elongase enzymes required by this pathway but further research should provide an understanding of this point (Sprecher, 2000).



**Figure 1.15 Polyunsaturated Fatty Acid Biosynthesis**

**a) Delta-6-Desaturase**

The delta-6 desaturase has been isolated and characterized from different species, including plants (Sayonara et al., 1997), moss (Grime et al., 1998), nematodes (Napa et al., 1998), and recently human (Cho et al., 1999). Tissue distribution analysis of human delta-6 desaturase revealed that there are high mRNA levels in brain, liver, heart, and lung (Cho et al., 1999). The human delta-6 desaturase gene encodes a 444 amino acid protein which contains a membrane spanning domain, a cytoplasmic b<sub>5</sub>-like domain and three conserved histidine-rich domains (Cho et al., 1999).

**b) Delta-5-Desaturase**

The delta-5 desaturase has also been isolated and characterized from several sources, including bacteria (Aguilar et al., 1998), fungus (Knutzon et al., 1998), and nematode (Watts & Browse, 1999). Recently, Leonard et al (2000) cloned and characterized delta-5 desaturase in human liver. It was found that the human delta-5 desaturase gene also encodes a 444 amino acid protein which contains an N-terminal cytochrome b<sub>5</sub>-like domain, as well as three histidine rich domains (Leonard et al., 2000). The delta-5 and delta-6 desaturase had approximately 62% homology based on the predicted amino acid sequence encoded by the cDNA and both enzymes were localized on chromosome 11q12 (Leonard et al., 2000). The tissue expression profile of delta-5 desaturase revealed that this gene was highly expressed in fetal liver and brain, adult brain, and adrenal gland (Leonard et al., 2000). Interestingly, the level of delta-5 desaturase mRNA was six-fold greater in fetal liver than adult liver (Leonard et al., 2000).

**c) Elongase**

In plants and mammals, the microsomal fatty acid elongation system depends on four distinct enzymatic activities: a  $\beta$ -ketoacyl-CoA synthase, a  $\beta$ -ketoacyl-CoA reductase, a  $\beta$ -hydroxylacyl-CoA dehydratase and an enoyl-CoA reductase (Fehling & Mukherjee, 1991; reviewed by Cinti et al., 1992). It is assumed that the first enzyme,  $\beta$ -ketoacyl-CoA synthase, in this sequence determines the substrate specificity of elongase system as well as the extent of fatty acid elongation (Millar & Kunst, 1997). Several

genes for the elongation enzymes have been cloned from plant (Lassner et al., 1996; Todd et al., 1999) and yeast (Toke & Martin, 1996; Oh et al., 1997). However, these elongase enzymes have been responsible for the synthesis of saturated and/or monounsaturated very long-chain fatty acids not PUFAs. Zank et al (2000) cloned and characterized a fatty acid elongase enzyme specific for n-6 PUFAs in moss, *P. patens*. The complete nucleotide sequence for the *P. patens* cDNA consisted of 1200 base pairs which contained an open reading frame of 873 base pairs encoding a protein of 290 amino acids with a calculated molecular mass of 33.4 kDa. Recently, the elongase enzyme has been isolated and characterized from yeast (Lassner et al., 1996; Millar & Kunst, 1997) and fungus (Parker-Barnes et al., 2000). Recently, Zhang et al. (2001) found a gene in humans with Stargardt-like macular dystrophy that has DNA sequence homology to yeast elongase. This gene (ELOVL4) found on chromosome 6q14 (Stone et al., 1994; Edwards et al., 1999) encodes a putative protein of 314 amino acids with approximately 35% identity to the yeast elongase protein (Zhang et al., 2001). Tissue distribution analysis of elongase mRNA showed that this gene was only expressed in retina and brain (Zhang et al., 2001). Future work on the elongase gene expression will be needed to fully elucidate their role in PUFA biosynthesis.

### **3. Very-Long Chain N-6 and N-3 Fatty Acids**

#### **a) Structure and Tissue Distribution**

Very long chain fatty acids with carbon chain lengths >22 occur in human and rat brain (Poulos et al., 1988; Robinson et al., 1990). High levels of these fatty acids are also found in human brain with inherited peroxisomal disease, such as Zellweger's syndrome and adrenoleukodystrophy (Poulos et al., 1986a; Poulos et al., 1988). In brain, very long chain fatty acid are polyenoic with 4, 5, or 6 double bonds and belong to n-6 and n-3 families with carbon chain lengths up to forty in brain (Poulos et al., 1986b; Sharp et al., 1991). These fatty acids occur exclusively in PC and are esterified mainly in the sn-1 position of the glycerol backbone, whereas saturated, monounsaturated, and other PUFAs are part of the sn-2 position (Avelano, 1988; Poulos et al., 1988; Robinson et al., 1990). This positioning contrasts to that typical of most membrane phospholipid species in other tissues (Poulos et al., 1988). In normal brain, the polyenoic very long chain fatty acids

represent a minor component of the total fatty acid fraction (<1%) but is increased in brain with Zellweger's syndrome, an inherited metabolic disease characterized by peroxisomal deficiency (Poulos et al., 1986a and 1986b and 1988). The fatty acid composition of the very long chain polyenoic fatty acids is also different in normal and diseased brain. Tetra- and pentaenoic n-6 derivatives are the major 32-38 carbon fatty acids in normal brain, whereas Zellweger patients contain predominately pentaenoic and hexaenoic acids (Poulos et al., 1988; Sharp et al., 1991). In normal rat brain, these fatty acids belong to both n-6 and n-3 series up to 38 carbons (Robinson et al., 1990). Johnson et al. (1992) reported the existence of very long chain monoenoic fatty acids in human brain up to 28 carbons in chain length. These fatty acids contain predominately two positional isomer series, the n-7 and n-9 cis homologues (Johnson et al., 1992). Robinson et al. (1990) speculated that this unique brain lipid may be required for the correct orientation of integral membrane proteins.


#### **b) Biosynthesis**

Synthesis of polyenoic very long chain fatty acid has been shown to occur in a number of different mammalian tissues using either radiolabeled polyenoic fatty acids or acetate as precursors. Labeled polyenoic very long chain fatty acids are formed from [ $^{14}\text{C}$ ] acetate and [ $^{14}\text{C}$ ] C20:4n-6, respectively, by isolated rat spermatocytes and spermatids (Grogan & Lam, 1982; Grogan & Heath, 1983). [ $^{14}\text{C}$ ] C20:4n-6 injected into rat testis was also elongated in vivo to form n-6 tetra- and pentaenoic very long chain fatty acids with up to thirty carbon atoms (Grogan, 1994). Very long chain polyenoic fatty acids have been shown to be synthesized by elongation from shorter chain polyenoic fatty acids in brain (Figure 1.16; Robinson et al., 1990). Also, the presence of n-6 hexaenoic very long chain fatty acids in brain suggests some desaturation of PUFAs with >24 carbon atoms may also occur (Poulos et al., 1986a; Sharp et al., 1991).

Intracerebral injection of [ $1\text{-}^{14}\text{C}$ ] C26:4n-6 into rats was elongated to form polyenoic very long chain fatty acids with up to 36 carbons (Robinson et al., 1990). Also, significant amounts of label were detected in C26:5n-6 and C28:5n-6, indicating that desaturation of the 26 carbon fatty acids can take place in brain (Robinson et al., 1990). Recently, Suh et al. (2000) has shown that long chain PUFAs are involved in the

synthesis of very long-chain polyenoic fatty acids in retina. It was found that C20:5n-3 but not C22:6n-3 injected into the vitreal fluid of the eye of rats was a substrate for formation of very long chain polyenoic fatty acids. The C22:5n-3 fatty acid derived from C20:5n-3 was highly labeled and was detected in the pentaenoic and hexaenoic very long chain fatty acids while greater than 90% of the injected  $^3\text{H}$ -C22:6n-3 into the eye remained as C22:6n-3. Therefore, this study suggests that long chain PUFAs particularly, C20:5n-3 and C22:5n-3 can synthesize very long chain polyenoic fatty acids in the retina. However, it is still not known whether there are separate elongases or individual elongases specific for the very long chain n-6 and n-3 fatty acids (Poulos et al., 1986a).

/



**These reactions are catalyzed by elongase enzymes.**

**Figure 1.16 Very Long Chain N-6 and N-3 Fatty Acid Biosynthesis**

**c) Biological Function**

The physiological role of the polyenoic very long chain fatty acids is not known. Recently, the possible involvement of very long chain fatty acids in membrane signal transduction has been explored in rat brain (Hardy et al., 1994). C32:4n-6 and C34:6n-3 activates purified rat brain protein kinase C in vitro with maximal activity being between 25 and 50 uM (Hardy et al., 1994). The same effect was also observed by the same authors when long-chain fatty acid (C20:4n-6, C20:5n-3, or C22:6n-3) were used (Hardy et al., 1994). Therefore, it is hard to distinguish the unique role of very long chain fatty acids in brain.

**4. Composition and Developmental Changes in Brain**

Similar to brain phospholipids profiles during development, the fatty acid composition of these phospholipids are also distinct and exhibit changes with age. Some studies examining changes in fatty acyl constituents of phospholipids during development have analyzed total phospholipids, while others analyzed individual phospholipids which is a weakness in brain lipid research because of the selectivity of individual phospholipids for specific fatty acids.

**a) Total Phospholipids**

Crawford et al. (1977) examined human fetuses and infants up to two years of age. The study found that 60-70% of adult long-chain polyene levels were accumulated at birth. After this period, the rate of accumulation of these fatty acids declines. Changes between the types of long-chain polyenoic families in human brain were different (Martinez et al., 1974).

Biran & Bartley (1964) and Kishimoto et al. (1965a) studied the fatty acid composition of total phospholipids in developing rodent brain. They suggested that some fatty acid ratios could be correlated to brain maturity. For example, the C16:0/C18:0 ratio drops with increasing age while C18:1/C18:0 increases. Sinclair and Crawford (1972a) correlated myelination in brain to the accumulation of C20:4n-6 and C22:6n-3 in gray matter and C24:1 and C20:1 in myelin.

**b) Individual Phospholipids**

In human brain, Svennerholm et al. (1964, 1965, 1968, 1973, 1978a. & 1978b) reported the fatty acid composition of individual phospholipids with varying ages.

**i) Phosphatidylcholine**

Differences in the acyl group profiles of PC are found in cerebral cortex during development (Svennerholm, 1968). Fatty acids of the n-6 series, mainly C20:4n-6 are low during the fetal period but increase shortly after birth (Svennerholm & Vanier, 1973)

**ii) Phosphatidylethanolamine**

In the cerebral cortex of human brain. the PE C20:4n-6 and C22:4n-6 decline with age, whereas the n-3 series C22:5n-3 and C22:6n-3 increase with age (Svennerholm, 1968; Svennerholm & Vanier, 1973).

**iii) Phosphatidylserine**

In human brain cortex, the PS C20:4n-6 and C22:4n-6 content increase during fetal development to term and then decrease with age (Svennerholm, 1968; Svennerholm & Vanier, 1973). On the other hand, C22:6n-3 increases with age (Svennerholm, 1968; Svennerholm & Vanier, 1973).

**iv) Phosphatidylinositol**

The fatty acid composition of PI in human brain during fetal and postnatal maturation into aging has been reported (Svennerholm, 1968; Svennerholm & Vanier, 1973). PI is characterized by high levels of C20:4n-6 and modest level of C22:6n-3 (Svennerholm, 1968). The C20:4n-6 content of PI increases up to four years of age in cerebral cortex (Svennerholm, 1968; Svennerholm & Vanier, 1973).

**c) Sphingolipids**

In general, brain sphingolipids contain less than twenty different fatty acids (Giusto et al., 1992). The fatty acids that are amide linked to the sphingosine moiety varies from twelve to over thirty carbons in chain length, but are mainly C16:0, C18:0,

C22:0, C24:0, and C24:1 (O'Brien & Sampson, 1965; Stallberg-Stenhagen & Svennerholm, 1965; Rouser et al., 1972; Rouser & Yamamoto, 1972; White, 1974; Barenholz & Thompson, 1980). Sphingolipids species with polyenoic long-chain fatty acids, and with 2-hydroxy fatty acid have been described (Dawson & Vartanian, 1988; Robinson et al., 1992). Sphingolipid levels tend to increase with age in different organs, and may also vary with diet (Myher et al., 1981; Barenholz & Thompson, 1981). Dietary fat induced changes in brain sphingolipid n-6 and n-3 fatty acids composition with development are limited.

## 5. Accretion in Brain

Formation of neuronal membranes requires synthesis and assembly of membrane phospholipids containing significant amounts of essential fatty acid, primarily C20:4n-6 and C22:6n-3. Little quantitative evidence exists prior to twenty-four weeks of gestation in the human. Accretion of essential fatty acids during the last trimester of intrauterine development has been estimated (Clandinin et al., 1981a).

Analyses of whole-body fat content (Widdowson, 1968; Widdowson et al., 1979) indicates that preterm infants, with appropriate weight for gestational age of 1300 g at birth, have a total body fat content of about 30 g compared with the term infant of 3500 g with a total body fat content of 340 g. Clandinin et al. (1981b) estimated that approximately 2783 mg of n-6 fatty acids and 387 mg n-3 fatty acids accrue in adipose tissue each week *in utero*. For premature infants, birth after only a few more weeks of intrauterine development would dramatically increase the potential reserve of fatty acids in adipose tissue both for total fatty acids used for energy production and for essential fatty acids used for synthesis of structural tissues (Clandinin et al., 1981b). These estimates are also supported by the body of research by Van Houwelingen et al. (1992), suggesting that the growing fetus represents a large draw upon maternal essential fatty acid stores and perhaps that a limitation in the size of the maternal essential fatty acid stores may impact on fetal growth and development, particularly brain growth and development.

During the third trimester of human development, n-6 and n-3 fatty acids accrue in fetal tissues as an essential component of structural lipids and rapid synthesis of brain

tissues occurs (Clandinin et al., 1980a). This rapid synthesis causes increases in cell size, cell type and cell number (Clandinin et al., 1980a). Brain lipid levels increase rapidly during this period (Clandinin et al., 1980a). Levels of C18:2n-6 and C18:3n-3 are consistently low in the brain during the last trimester of pregnancy (Clandinin et al., 1980a). However, accretion of long-chain essential fatty acid desaturation products C20:4n-6 and C22:6n-3 occur and the absolute accretion rates of the n-3 fatty acids, specifically, C22:6n-3, are greater in the prenatal period compared with the postnatal period (Clandinin et al., 1980a and 1980b). It is apparently critical that the developing fetus obtains the correct types and amounts of fatty acids to ensure complete and proper development of brain membranes (Clandinin et al., 1980a and 1980b). Timing of the availability of these fatty acids is also a factor (Clandinin et al., 1980a and 1980b). Collectively, this quantitative information indicates that large amounts of C22:6n-3 and C20:4n-6 are required during development of neural tissue when cellular differentiation and active synaptogenesis are taking place (Clandinin et al., 1980a and 1980b; reviewed by Cunnane et al., 2000).

## **6. Endogenous Sources for Fetal Brain**

### **a) Placenta**

The placenta is a specialized organ that provides nutrients to the fetus and exchanges metabolic waste products from the fetus (Crawford et al., 1976; reviewed by Crawford, 2000). Research has shown that all of the n-6 and n-3 fatty acids acquired by the fetus come from maternal circulation via the placenta (reviewed by Innis, 1991, Dutta-Roy, 2000, Crawford, 2000). This transfer of fatty acids from the mother to the fetus influences the composition of fatty acid in the developing tissue of the fetus especially the central nervous system (reviewed by Innis, 1991, Dutta-Roy, 2000, and reviewed by Crawford, 2000). Since glycerolipids and triglycerides can not enter the fetal circulation, hydrolysis of these lipids to free fatty acids by lipoprotein lipase on the maternal side of the placenta are required (Hummel et al., 1976; Elphick & Hull, 1977).

The long-chain products from C18:2n-6 and C18:3n-3 metabolism, specifically, C20:4n-6 and C22:6n-3 are higher in fetal plasma compared to maternal plasma with even a greater accumulation in the fetal tissue (Crawford et al., 1976; reviewed by

Crawford, 2000). This process of increased long-chain PUFAs in fetal versus maternal blood is known as biomagnification (Crawford et al., 1976; reviewed by Crawford, 2000). It has been hypothesized that this process is the result of a specific mechanism within the placenta that can sequester and release C20:4n-6 and C22:6n-3 into the fetal circulation (Crawford et al., 1976; reviewed by Crawford, 2000). This unidirectional transport of long-chain PUFAs, particularly, C22:6n-3, from maternal to fetal circulation have been shown to be driven by high-affinity C22:6n-3-specific transport proteins in the placenta (Campbell et al., 1998; reviewed by Crawford, 2000). Thus, providing the fetus with long-chain PUFAs needed for growth and development.

#### **b) Intestine**

After dietary lipids have been digested by a series of lipases, long-chain fatty acids in bile salt micelles are protonated by the acidified unstirred water layer adjacent to the brush border membrane (BBM; Isola et al., 1995). This protonation of micelles in the unstirred water layer releases the long-chain fatty acids and allows for their uptake by either fatty acid binding or fatty acid transporter proteins in the BBM (Zhou et al., 1995; Poirier et al., 1996; Abumrad et al., 1999; Stahl et al., 1999). The long-chain fatty acids in the intestinal cells will be reassembled into triacylglycerols and packaged into chylomicrons (reviewed by Thomson et al., 1997). Moreover, these chylomicrons will be transported into the lymphatics and enter the blood via the portal vein (Linscheer & Vergroesen, 1988). Once in the blood, the long-chain fatty acids can cross the placenta and go into the fetal circulation where it can be taken up by the fetal brain (Sinclair, 1975; Green & Yavin, 1993). Interestingly, a major serum protein during fetal development, alpha-fetoprotein, has been suggested to be involved in the transfer of C20:4n-6 and C22:6n-3 (Lampreave et al., 1982; Calvo et al., 1988). Garg et al. (1988) found that intestinal cells have a delta-6 and delta-9 desaturase activity. These desaturases may have a role in the modification of dietary n-6 and n-3 fatty acid, C18:2n-6 and C18:3n-3, respectively, into long-chain PUFAs that may be transported out of the enterocytes and go into the fetal circulation where it can be taken up by the fetal brain via a long-chain PUFAs-specific fatty acid binding protein (Balendirian et al., 2000). Recently, delta-5 and delta-6 desaturase mRNA were found in the small intestine of the

human using quantitative polymerase chain reaction methodology (Leonard et al., 2000). However, whether or not these enzymes are fully active in premature infants have yet to be examined.

**c) Liver**

Recent research by Bazan & Scott (1990) has established that the liver can synthesize and transfer C20:4n-6 and C22:6n-3 via lipoproteins to the brain but this phenomenon has not been demonstrated in neonates. However, later studies by Green & Yavin (1993) and Burdge & Postle (1994) indicated that the contribution of liver to C20:4n-6 and C22:6n-3 in the brain is negligible. Therefore, indicating that placental transfer may play a significant role in providing long-chain PUFAs to the fetal brain especially during the third trimester.

**d) Metabolism in Brain Cells**

Many questions remain about the role of brain in synthesizing C20:4n-6 and C22:6n-3 from dietary precursors. Animal studies with radio-labeled C18:2n-6 and C18:3n-3 indicate that the brain is capable of desaturating and elongating C18:2n-6 and C18:3n-3 to C20:4n-6 and C22:6n-3, respectively (Dhopeshwarkar et al., 1971a and 1971b; Sinclair & Crawford, 1972b; Dhopeshwarkar & Subramanian, 1976; Cohen & Bernsohn, 1978; Cook, 1978; Purvis et al. 1983; Clandinin et al., 1985; Anderson & Connor, 1988). These studies of brain fail to clarify which cell types within this tissue can provide C20:4n-6 and C22:6n-3. Studies with isolated brain cells provide evidence that both neuronal and glial cells may desaturate and elongate C18:2n-6 and C18:3n-3 to C20:4n-6 and C22:6n-3, respectively (Yavin & Menkes, 1974; Dhopeshwarkar & Subramanian, 1976; Cohen & Bernsohn, 1978; Clandinin et al., 1985a; Anderson & Connor, 1988).

Microvessels and plasma contain amounts of C18:3n-3 and C20:5n-3, thus it is possible that these fatty acids could supply C22:6n-3 to brain (Edelstein, 1986; Clandinin et al., 1997). Moore et al. (1990) investigated whether cerebroendothelial cells could desaturate and elongate C18:2n-6 and C18:3n-3 to C20:4n-6 and C22:6n-3, respectively. Isolated cerebroendothelial cells were incubated with radiolabeled C18:2n-6 or C18:3n-3

and were found to take up C18:2n-6 and C18:3n-3 equally and desaturate and elongate C18:2n-6 to C22:4n-6 and C18:3n-3 to C22:5n-3 (Moore et al., 1990). The major metabolite of C18:2n-6 was C20:4n-6 and of C18:3n-3 was C20:5n-3 (Moore et al., 1990). Desaturation and elongation of C18:3n-3 by cerebroendothelial cells far exceeded that of C18:2n-6, suggesting some specificity for n-3 fatty acids (Moore et al., 1990). Delton-Vandenbroucke et al. (1997) demonstrated that cerebroendothelial cells can metabolize C22:5n-3 to C20:5n-3, C22:6n-3, C24:5n-3, and C24:6n-3. The presence of twenty-four carbon n-3 metabolites in cerebroendothelial cells lipids and culture media suggests that metabolism of n-3 fatty acids in cerebroendothelial cells were using a delta-4 desaturase independent pathway similar to that shown in rat liver (Voss et al., 1991). Thus, cerebroendothelial cells can desaturate and elongate C18:2n-6 and C18:3n-3 to C20:4n-6 and produce a small amount of C22:6n-3, respectively.

Moore et al. (1991) determined that astrocytes from rat brain can desaturate and elongate C18:2n-6 and C18:3n-3 to C20:4n-6 and C22:6n-3, respectively. Rat type I astrocytes from either cerebrum or cerebellum cultured for twelve days were incubated with radio-labeled C18:2n-6 or C18:3n-3 formed C20:4n-6 and C22:6n-3, respectively (Moore et al., 1990). In contrast, cultures of rat cerebral or cerebellum neuronal cells did not desaturate fatty acid to produce C20:4n-6 and C22:6n-3 (Moore et al., 1990). Instead, the neuronal cells appear to only elongate C18:2n-6 and C18:3n-3 (Moore et al., 1990). Hence, astrocytes, not neuronal cells, appear to synthesize C20:4n-6 and C22:6n-3 in brain. Cerebroendothelial cells and astrocytes together supply C22:6n-3 to neuronal cells (Moore, 1993). In co-cultures, astrocytes synthesize and release large amounts of C22:6n-3 from C20:5n-3 made by the cerebroendothelial cells (Moore, 1993). Neuronal cells then take up C22:6n-3 released from astrocytes and incorporate fatty acid into neuronal cell plasma membranes (Moore, 1993). Thus, cerebroendothelial cells and astrocytes seem to be needed together to synthesize C22:6n-3 for uptake by the neuronal cell during growth. These observations on the cellular partitioning of C20:4n-6 and C22:6n-3 synthesis in brain cells are based primarily on the rat and are largely undetermined for the human brain.

## **7. Exogenous Sources for Neonatal Brain**

### **a) Human Milk**

The n-6 and n-3 fatty acid composition of human milk is partly dependent on the maternal diet (Chappell et al., 1985). The content of C18:2n-6, C20:5n-3, and C22:6n-3, but not C20:4n-6, in breast milk responds to the quantity of these fatty acids in the mother's diet (Chappell et al., 1985). The fat in mature human milk is contained within membranes called fat globules. The core of the fat globules has 98-99% triglyceride with the membrane mainly composed of phospholipids, cholesterol, and proteins (Hamosh et al., 1987).

Human milk contains both n-6 and n-3 fatty acids (Clandinin et al., 1981a). Ten to fifteen percent C18:2n-6 and one percent C18:3n-3 are typical amounts of essential fatty acids in the breast milk fat of North American and European women (Clandinin et al., 1981a). Based on quantitative analysis of twenty-four hour milk collections, the n-6 long-chain polyenes are at 0.5-1.5% and the n-3 long-chain polyenes at 0.3-0.6% (Clandinin et al., 1981a; Jensen, 1989; reviewed by Hamosh & Salem, 1998). The long-chain polyenes in human milk is predominately C20:4n-6 for n-6 and C22:6n-3 for n-3 fatty acids (Clandinin et al., 1981a).

The fatty acid composition in human milk is not only a result of maternal dietary fat intake, but also other factors, such as, mobilization of fat from maternal fat stores (adipose tissue) and endogenous synthesis by the mammary glands (Jensen, 1989). But, C18:2n-6 and C18:3n-3 is not synthesized by the mammary gland and must be supplied by the maternal diet (Chappell et al., 1985). The synthesis of long-chain polyenes of n-6 and n-3 fatty acids might occur in the mammary gland independently of the length of gestation (Hamosh et al., 1992). However, the proportion of long-chain PUFAs to saturated fatty acids present in human milk has been shown to correspond with the ratio of polyunsaturated to saturated fatty acids in the maternal diet (Chappell et al., 1985).

Studies have shown that there are differences in the fat content of milk from mothers of term and preterm infants. Chappell et al. (1983) found that milk from mothers who delivered preterm infants showed a higher content of C18:2n-6 and C18:3n-3 and their long-chain polyenoic homologues compared to term mothers. Furthermore, the level of their long-chain polyenoic homologues were shown to be significantly higher in

colostrum and milk of mothers of premature infants than mothers delivering full term infants (Bitman et al., 1983). Luukkainen et al. (1994) studied the content of C20:4n-6 and C22:6n-3 in human milk of mothers who delivered preterm and term infants from one week to six months of lactation. The results from this study demonstrated that the concentrations of C20:4n-6 and C22:6n-3 in human milk after six months of lactation were higher in preterm than term infants. This suggests that human milk can provide and meet the C20:4n-6 and C22:6n-3 requirements in preterm infants when there is a reduced supply of these fatty acids to the fetus via placenta *in utero* (reviewed by Cunnane et al., 2000).

#### **b) Infant Formulas**

Human milk provides the optimal source of nutrition for infants to at least three months of age (FAO Expert Committee, 1977). Hence, it is conceivable that formulas intended for feeding infants for whom mother's milk is not available should mimic the composition of human milk as closely as possible. Special formulas have been designed to provide adequate intake of calories, proteins, carbohydrates, fluids, vitamins, and minerals, necessary to support the rapid growth and development of the infant (Reichman et al., 1981; Garza et al., 1987). The fat content of infant formulas whether cow's milk or soy protein based is provided by one or more vegetable oils (Jensen et al., 1978; Jensen, 1989). However, the vegetable oils used in these infant formulas do not contain n-6 and n-3 long-chain PUFAs (Clandinin et al., 1980a and 1980b). Research over the past three decades has focussed on the essential fatty acid requirements of preterm infants and the quantities of C18:2n-6, C18:3n-3, C20:4n-6, C20:5n-3, and C22:6n-3 that should be added to infant formulas. Although dietary intake of 1-2 % kilocalories for C18:2n-6 prevents and avoids signs of essential fatty acid deficiency in infants, such low intake of C18:3n-3 can not support adequate accretion of C22:6n-3 in the neonate (Clandinin et al., 1980a and 1980b). Infant formulas supplemented with C20:4n-6 and C22:6n-3 produce a clear dose response in the content of C20:4n-6 and C22:6n-3 in erythrocyte total plasma membrane phospholipids with 0.6% C20:4n-6 and 0.4% C22:6n-3 in the formula fat providing sufficient amounts of these fatty acids to achieve a fatty acid composition of C20:4n-6 and C22:6n-3 similar to that of infants fed human milk (Clandinin et al., 1992:

Clandinin et al., 1997). Recently, Clandinin et al. (1999) determined the magnitude of the plasma essential fatty acid pools in individual lipoprotein fractions of preterm infants fed commercial formula devoid of C20:4n-6 and C22:6n-3 and compared this with similar infants fed formulas containing a range of 0.32-1.1% C20:4n-6 and 0.24-0.75% C22:6n-3 of the total fatty acids in the formula. The results of the study revealed that on a quantitative basis the phospholipid fraction of lipoproteins contain >75% of the C20:4n-6 and C22:6n-3 in plasma (Clandinin et al., 1999). Moreover, high density (HDL) and low density (LDL) lipoprotein phospholipids and cholesterol esters contained the largest pool of C20:4n-6 and C22:6n-3 in plasma lipoproteins (Clandinin et al., 1999). Infants fed a formula without C20:4n-6 and C22:6n-3 showed a reduction in C20:4n-6 level in the phospholipid fraction of all lipoprotein and HDL and LDL cholesterol ester fraction (Clandinin et al., 1999). Supplementing infant formulas with increasing levels of C20:4n-6 and C22:6n-3 produced a clear dose response in the level of C20:4n-6 found in the HDL and LDL phospholipid fraction (Clandinin et al., 1999). From comparison of the fatty acid levels present in the lipoproteins it appears that a formula level of 0.49% C20:4n-6 and 0.35% C22:6n-3 provides sufficient levels of these fatty acids to achieve a similar fatty acid content to that of infants fed breast milk for the major lipoprotein fraction (Clandinin et al., 1999).

Many international advisory committees, such as, European Society of Pediatric Gastroenterology and Nutrition (1991) (ESPGAN), British Nutrition Foundation (1992) (BNF), International Society for the Study of Fatty Acids and Lipids (1994) (ISSFAL), and Food and Agriculture Organization (FAO)/ World Health Organization (1994) (WHO) have recommended that infant formulas be supplemented with n-6 and n-3 long-chain PUFAs. However, despite these recommendations, a few countries continue to use formulas based on vegetable oils. In North America, there are no commercial formulas that contain polyunsaturated fatty acids greater than eighteen carbons in chain length (Raiten et al., 1998; Clandinin, 1999). Therefore, it is important to establish if infants possess the enzymes and their level of activities for elongation and desaturation of long-chain PUFAs that are required for growth and development of the infant.

## **H. FACTORS AFFECTING NEURAL TISSUE N-6 AND N-3 FATTY ACID COMPOSITION AND FUNCTION**

### **1. Diet**

Brain membranes were generally viewed as resistant to structural change by both endogenous and exogenous factors. Data has shown that brain membranes are much more sensitive to changes in composition induced by dietary fat than previously thought (Jope & Jenden, 1979; Wurtman et al., 1981; Foot et al., 1982; Lee, 1985; Bourre et al., 1989a; reviewed by Clandinin, 1999). Moreover, the extent of the changes in brain membrane composition by dietary fat varies between brain regions, cell types, and organelles (reviewed by Hargreaves & Clandinin, 1990, Clandinin et al., 1991 and Clandinin et al., 1997).

Earlier studies examining the role of dietary fat on brain membrane composition have used rodents that were fed C18:2n-6 deficient diets for several weeks to a few generations. Results from these studies demonstrate qualitative changes in brain membrane fatty acid composition associated with essential fatty acid deficiency (i.e. increase in C20:3n-9 and decrease in C20:4n-6; Paoletti & Galli, 1972; Sun & Sun, 1974).

By feeding nutritionally adequate diets, dietary intake of C18:2n-6, C18:3n-3, or the proportion of C18:2n-6 to C18:3n-3, particularly during development, has been shown to influence the content of PUFAs in membrane lipids by changing the composition of whole brain, oligodendrocytes, myelin, astrocytes, mitochondrial, microsomal, synaptosomal membrane, and recently neurites (axons and dendrites) (Lamprey & Walker, 1976; Tahin et al., 1981; Foot et al., 1982; Bourre et al., 1984; Hargreaves & Clandinin, 1989; Innis & de la Presa Owens, 2001). Feeding diets with a C18:2n-6 to C18:3n-3 fatty acid ratio between four to one to seven to one to rats from birth to one, two, three, and six weeks of age indicates that diet alters neuronal and glial cell membrane fatty acid composition differently, and in a region and time specific manner (Jumpsen et al., 1997a and 1997b).

The functional effect of diet-induced changes in the fatty acid composition of membrane phospholipids in brain has been the subject of some research (reviewed by

Stubbs & Smith, 1984; Lee et al., 1986; Salem et al., 1988). Dietary fat induced change in membrane fatty acid composition can affect membrane function by modifying membrane fluidity and thickness, lipid phase properties, polar lipid composition or specific interactions with membrane proteins (Clandinin et al., 1985b; Litman & Mitchell, 1996; reviewed by Clandinin et al., 1997 and Fernstrom, 1999). Previous studies showed that deficiency of n-3 fatty acid in the diet changed membrane physical properties (Park & Ahmed, 1992; Yoshida et al., 1997; Huster et al., 1998), membrane-bound enzymes (Bourre et al., 1989; Vaidyanathan et al., 1994; Tsutsumi et al., 1995; Martin, 1998), membrane channels (Poling et al., 1995; Hamano et al., 1996), receptor activity (Delion et al., 1994), and neurotransmission (Chalon et al., 1998). However, these changes induced by dietary n-3 deficiency do not reflect an overall change in membrane fluidity but rather indicate selective changes in the microenvironment of the membrane-bound proteins (Dratz & Deese, 1986; Salem et al., 1988). Many membrane-bound proteins have a specific requirement for the annular lipids surrounding them (reviewed by Yeagle, 1989). The annular lipids allow the membrane protein to achieve an active conformation for function in brain (Capaldi, 1977; Tanford, 1978; Marinetti & Cattieu, 1982; reviewed by Yeagle, 1989). Hence, any changes in these annular lipids by dietary fat may influence the function of proteins in the membrane. Several studies have shown that diets, in the absence of essential fatty acid deficiency, containing various dietary fats change the activities of membrane-bound enzymes, receptors, and carrier-mediated transport (reviewed by Clandinin et al., 1997). It is conceivable that these changes in membrane function by dietary fat can have an impact on brain function.

Animal studies have shown that when rodents or monkeys were maintained on a n-3 deficient diet, electroretinogram abnormalities (Benolken et al., 1973; Bourre et al., 1989b; Weisinger et al., 1996a), reduced visual acuity (Neuringer et al., 1984, 1986), altered stereotyped behavior (Reisbick et al., 1994), and decreased level of learning and memory occur (Lamprey & Walker, 1976; Yamamoto et al., 1987, 1988; Mills et al., 1988; Bourre et al., 1989b). Dietary n-3 fatty acid deficiency affects brain functions of preterm infants as measured by cortical visual evoked potential, electroretinograms and behavioral testing of visual acuity (Uauy et al., 1990; Birch et al., 1992; Carlson et al., 1993a). Human term and preterm infants fed infant formulas without C22:6n-3 were also

shown to have abnormal electroretinograms, as well as, decreased visual acuity compared to infants fed formulas containing C22:6n-3 (Uauy et al., 1990; Carlson et al., 1993a; Birch et al., 1998; Hoffman et al., 2000). Furthermore, infants fed formulas with no C22:6n-3 had lower cognitive scores compared to infants fed formulas with C22:6n-3 (Lucas et al., 1992; Carlson et al., 1994; Makrides et al., 1995; Agostoni et al., 1995; Werkman & Carlson, 1996; Willatts et al., 1998; Birch et al., 2000). The mechanism for these changes in membrane proteins and brain function induced by diet fat is not known.

## **2. Gene Expression of Desaturases and Elongases**

The content of n-6 and n-3 fatty acids in neural tissues may be influenced by the expression of delta-6 and delta-5 desaturase and elongase enzymes. Recent cloning and characterization of delta-6 and delta-5 desaturase and elongase enzymes have allowed for analysis of their content and distribution in different tissues. Using the mouse cDNA for delta-6 desaturase, it was found that the level of delta-6 desaturase mRNA in human brain was several-fold higher than other tissues, such as, liver and lung (Cho et al., 1999). Similarly, delta-5 desaturase was expressed in human brain at comparable levels to delta-6 desaturase (Leonard et al., 2000). Recently, Northern blot analysis with a probe for elongase revealed the presence of EL0VL4 mRNA in only human retina and brain. The level of elongase mRNA was higher in retina than brain (Zhang et al., 2001). The expression of mRNA for delta-6 and delta-5 desaturase and elongase enzymes in human brain is consistent with >30% of the total fatty acids in brain phospholipids being PUFAs (Martinez, 1992). However, future work will be needed to determine whether gene expression of delta-6 and delta-5 desaturase and elongase enzymes in neural tissue is correlated and regulated by n-6 and n-3 PUFA content.

## **3. Phenylketonuria**

Phenylketonuria (PKU) is an inborn error of phenylalanine (PHE) metabolism that occurs once in approximately seven thousand to one in fifteen thousand live births (Bickel et al., 1981; Elsas & Acosta, 1994). PKU is inherited as an autosomal recessive disorder and occurs in all ethnic groups (reviewed by Eisensmith & Woo, 1992 and Eisensmith et al., 1992). One in fifty people is a heterozygous carrier of this disease

(Pietz, 1998). PKU is caused by a deficiency or absence of phenylalanine hydroxylase (PAH) (Enzyme commission 1.14.16.1), which converts PHE, an essential amino acid in humans, to tyrosine (Jervis, 1953; Hsia, 1966; Guttler et al., 1987). The deficiency or absence of PAH causes a metabolic block in PHE catabolism which results in accumulation of PHE and reduced levels of tyrosine plasma and urine (Jervis, 1940). In untreated PKU, plasma concentrations of PHE are sufficiently high such that alternate pathways of PHE metabolism are activated leading to formation of PHE metabolites, such as, phenylpyruvate, phenylacetate, phenylacetylglutamine, and phenyllactate (Bowden & McArthur, 1972). High levels of these metabolites if not immediately diagnosed and treated in infancy can cause severe central nervous system abnormalities (Okano et al., 1991; Burgard et al., 1996).

**a) Phenylketonuria causes loss of brain myelin**

In both animal models and human PKU, there is defective myelination (Alvord et al., 1950; Prensky et al., 1971; Shah et al., 1972; Loo et al., 1978; Lane et al., 1980). The reduced amount of myelin in hyperphenylalanemic (HPH) rats and brain of PKU individuals was either caused by inhibition of myelin synthesis or increased myelin degradation. It was demonstrated in HPH rats using radio-labeled lysine that myelin turnover was increased compared to healthy control rats (7 days for HPH rats versus 17 days for control rats) (Hommes, 1982). Hommes et al. (1982) showed that the increased turnover of myelin in HPH rats was due to the fast component of myelin (the myelin fraction that has the shortest half-life) and was not due to inhibition of myelin synthesis. Taylor & Hommes (1983) confirmed increased myelin turnover in HPH rats but also showed that this increase in myelin turnover in HPH rats continued at later stages of brain development. Hence, the increase turnover of myelin in HPH rats is not compensated by an increased rate of myelin synthesis, leading to a net loss of myelin (Hommes, 1985). Thus, HPH in rats causes reduced amounts of brain myelin that is a result of increased myelin degradation.

**b) Phenylketonuria causes a loss of brain fatty acids**

**i) Monounsaturated Fatty Acids**

In human PKU, the content of monounsaturated fatty acids (MUFAs) is decreased in brain phospholipids, although the extent of the reduction varies for each type of phospholipids. In brain from autopsied PKU individuals, the amount of MUFAs in myelin PE and PC was decreased by 7% and 15%, respectively, compared to non-PKU individuals (Shah, 1979). PS and PI MUFA content from myelin of PKU individuals was reduced by 28% (Shah, 1979). The MUFA content of sphingolipids in myelin, SM and cerebroside, was reduced by 31% and 11% compared to non-PKU individuals (Shah, 1979). In synaptosomes, oleic acid is the major MUFA present in phospholipids (Sun, 1973). The amount of oleic acid in PC of synaptosomes in PKU subjects was reduced by 12% compared to non-PKU subjects (Shah, 1979). The MUFA content in synaptosomes PE, PS and PI, and SM were also decreased by PKU (Shah, 1979). Therefore, the content of MUFAs in myelin and synaptosome phospholipids and sphingolipids are reduced in PKU.

**ii) Polyunsaturated Fatty Acids**

The PUFA content of each phospholipid in myelin is different and the values for the proportion of PUFA in the same phospholipid fatty acid component varies widely (O'Brien & Sampson, 1965). PUFA, particularly, C20:4n-6 and C22:6n-3 are predominant in myelin phospholipids, especially PE and PS (O'Brien & Sampson, 1965). The content of PUFA in brain of autopsied PKU individuals are significantly reduced compared to non-PKU individuals (Shah, 1979). In myelin phospholipids, the content of PUFA in PE, and PS and PI is reduced by 15% and 9%, respectively, compared to non-PKU individuals (Shah, 1979). The synaptosome PUFA content is also significantly reduced in PKU. In PC of synaptosome, the PUFA content was decreased by 4% and in PE by 19% in PKU versus non-PKU individuals. The greatest decrease in PUFA content in synaptosome phospholipids of PKU was in PS and PI which was approximately 33% (Shah, 1979). However, since the content of PE in synaptosome is greater than PS and PI combined, the reduction in PUFA, mostly C20:4n-6 and C22:6n-3, is more pronounced in PE of synaptosome (Johnson et al. 1977). Thus, the finding of these studies

demonstrate that the content of PUFAs is reduced in brain myelin and synaptosome of PKU.

The reason for the low content of MUFAs and PUFAs in PKU compared to normal brain could be due to the metabolites of phenylalanine, which has been shown to inhibit substrates, and enzymes that are important for MUFA and PUFA biosynthesis. The formation of phenylacetate in PKU brain has been shown to use acetyl-CoA generated in brain (Loo et al. 1976). The depletion of acetyl-CoA in brain by the formation of phenylacetate inhibits the synthesis of fatty acids in brain (Loo et al. 1985). This inhibition of fatty acids in brain by phenylacetate may contribute to the low levels of MUFAs and PUFAs observed in PKU. A study by Shah & Johnson (1975) has shown that two other metabolites of phenylalanine, phenylacetate and phenyllactate, cause in vitro inhibition of brain desaturase activity. Elevated levels of phenylalanine have also been shown to interfere with the availability of nicotinamide adenine dinucleotide, which is a cofactor for fatty acyl CoA desaturase (Shah et al. 1970; Glazer & Weber, 1971). Thus, MUFAs and PUFAs are decreased in brain of PKU individuals by inhibition of enzymes involved in their biosynthesis.

## **I. CHAPTER SUMMARY**

The studies presented in this chapter indicate that n-6 and n-3 fatty acids are important for brain growth and development and that alterations in dietary n-6 and n-3 fatty acids can alter brain membrane composition and function. However, the question of whether high levels of C18:2n-6 and C18:3n-3 can be synthesized to C20:4n-6 and C22:6n-3, respectively, and if providing C18:2n-6 and C18:3n-3 or their long-chain homologues in the diet will have an effect on brain structure and function still persists. Therefore, the purpose of this thesis is to investigate whether dietary n-6 and n-3 fatty acids, specifically, C18:2n-6 and C20:4n-6; and C18:3n-3 and C22:6n-3 can alter brain structure and function. Sprague-Dawley rats will be used as an animal model in this thesis because of similar brain growth and development patterns to that of humans. Thus, the results from this thesis will provide further understanding as to the role of the quality of dietary fat on brain structure and function.

## J. REFERENCES

Abumrad, N., Coburn, C., & Ibrahimi, A. (1999) Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm. *Biochim Biophys Acta* 1441: 4-13

Agranoff, B. W., Bradley, R. M., & Brady, R. O. (1958). The enzymatic synthesis of inositol phosphatide. *J. Biol. Chem.* 233: 1077-1083.

Agostoni, C., Trojan, S., Bellu, R., Riva, E., & Giovannini, M. (1995) Neurodevelopmental quotient of healthy term infants at 4 months and feeding practice: the role of long-chain polyunsaturated fatty acids. *Pediatr Res* 38:262-266.

Aguilar, P. S., Cronan, J. E. Jr., & de Mendoza, D. A. (1998). *Bacillus subtilis* gene induced by cold shock encodes a membrane phospholipid desaturase. *J. Bacteriology.* 180:2194-2200.

Akanuma, H. & Kishimoto, Y. (1979). Synthesis of ceramides and cerebroside containing both alpha-hydroxy and nonhydroxy fatty acids from lignoceroyl-CoA by rat brain microsomes. *J. Biol. Chem.* 254: 1050-1060.

Akerman, K. E. & Nicholls, D. G. (1981). ATP depletion increases Ca<sup>2+</sup> uptake by synaptosomes. *FEBS Lett.* 135: 212-214.

Albers, R. W. (1967). Biochemical aspects of active transport. *Ann. Rev. Biochem.* 36: 727-756.

Albers, R. W. (1985). Coordination of brain mechanism with function during development. In R. C., Wiggins, D. W., McCandles, and S. J., Enna (Eds.). *Developmental Neurochemistry* (pp. 180-192). Austin, TX: University of Texas Press.

Alling, C. & Karlsson, I. (1973). Changes in lipid concentrations and fatty acid compositions in rat cerebrum during maturation. *J. Neurochem.* 21: 1051-1057.

Alvord, E. C., Stevenson, L.D., Vogel, F.S. & Engle, R.L. (1950) Neuropathological findings in phenylpyruvic oligophrenia. *J. Neuropathol. Exp. Neurol* 9: 298-310.

Anderson, G. J. & Connor, W. E. (1988) Uptake of fatty acids by the developing rat brain. *Lipids* 23: 286-290.

Angevine, J. B. & Sidman, R. L. (1961). Autoradiographic study of cell migration during histogenesis of cerebral cortex in the mouse. *Nature* 192: 766-768.

Ansell, G. B. & Spanner, S. (1961). Studies on cerebral sphingomyelin. *Biochem. J.* 79: 176-184.

Ansell, G. B. & Spanner, S. (1967). The metabolism of labelled ethanolamine in the brain of the rat in vivo. *J. Neurochem.* 14: 873-885.

Ansell, G. B. & Spanner, S. (1968). The metabolism of [Me-14C] choline in the brain of the rat in vivo. *Biochem. J.* 110: 201-206.

Ansell, G. B. & Metcalfe, R. F. (1971). Studies on the CDP-ethanolamine-1,2-diglyceride ethanolaminephosphotransferase of rat brain. *J. Neurochem.* 18: 647-665.

Apell, HJ. (1997) Kinetic and energetic aspects of Na<sup>+</sup>/K<sup>+</sup>-transport cycle steps. *Ann NY Acad Sci.* 834:221-30.

Aveldano, M. I. & Sprecher, H. (1987). Very long chain (C24 to C36) polyenoic fatty acids of the n-3 and n-6 series in dipolyunsaturated phosphatidylcholines from bovine retina. *J. Biol. Chem.* 262: 1180-1186.

Aveldano, M. I. (1988). Phospholipid species containing long and very long polyenoic fatty acids remain with rhodopsin after hexane extraction of photoreceptor membranes. *Biochemistry* 27:1229-1239.

Balinsky, B. I. (1975). An introduction to embryology. (4th Ed.) Philadelphia: W. B. Saunders.

Balendiran, G.K., Schnutgen, F., Scapin, G., Borchers, T., Xhong, N., Lim, K., Godbout, R., Spener, F. & Sacchettini, J. (2000). Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein. *J. Biol Chem.* 275: 27045-27054.

Barenholz, Y. & Thompson, T. E. (1980). Sphingomyelins in bilayers and biological membranes. *Biochim Biophys Acta.* 604: 129-158.

Barenholz, Y. and Gatt, S. (1982). In: *Phospholipids* (J.W. Hawthorne and G.B. Ansell, eds.), pp 129-177. Elsevier, Amsterdam.

Bastiaanse, EM., Hold, KM. & Van der Laarse A. (1997) The effect of membrane cholesterol content on ion transport processes in plasma membranes *Cardiovascular Res.* 33:272-83

Bayer, S. A. & Altman, J. (1975). Radiation-induced interference with postnatal hippocampal cytogenesis in rats and its long-term effects on the acquisition of neurons and glia. *J. Comp. Neurol.* 163: 1-20.

Bayer, S. A. (1977). Glial recovery patterns in rat corpus callosum after x-irradiation during infancy. *Exp. Neurol.* 54: 209-216.

Bayer, S. A. (1985). The development of CNS. In R. C. Wiggins, D. W. McCandles, and S. J. Enna. (Eds.). *Developmental neurochemistry*. Texas: University of Texas Press.

Bazan, N. G. & Scott, B. L. (1990). Dietary omega-3 fatty acids and accumulation of docosahexaenoic acid in rod photoreceptor cells of the retina and at synapses. *Upsala J. Med. Sci. - Suppl.* 48:97-107.

Beeler, T., Bacikova, D., Gable, K., Hopkins, L., Johnson, C., Slife, H., & Dunn T. (1998). The *Saccharomyces cerevisiae* TSC10/YBR265w gene encoding 3-ketosphinganine reductase is identified in a screen for temperature-sensitive suppressors of the Ca<sup>2+</sup>-sensitive *csg2* Delta mutant. *J. Biol. Chem* 273: 30688-30694.

Beguín, P., Wang, X., Firsov, D., Puoti, A., Claeys, D., Horisberger, J. D., & Geering, K. (1997). The  $\alpha$  subunit is a specific component of the Na, K-ATPase and modulates its transport function. *EMBO J.* 16: 4250-4260.

Benjamins, J. A. & Agranoff, B. W. (1969). Distribution and properties of CDP-diglyceride:inositol transferase from brain. *J. Neurochem.* 16:513-527.

Benolken, R. M., Anderson, R. E., & Wheeler, T. G. (1973). Membrane fatty acids associated with the electrical response in visual excitation. *Science* 182: 1253-1254.

Benos, D. J. & Sorscher, E. J. (1992). Transport proteins: ion channels. In G. Giebisch & D. Seldin (Eds.), *The kidney: physiology and pathophysiology* (pp. 587-623). New York: Raven.

Bernardo, K., Hurwitz, R., Zenk, T., Desnick, R. J., Ferlinz, K., Schuchman, E. H., & Sandhoff, K. (1995). Purification, characterization, and biosynthesis of human acid ceramidase. *J. Biol Chem* 270: 11098-11102.

Bickel, H., Bachmann, C., & Beckers, R. (1981). Neonatal mass screening for metabolic disorders. *Eur. J. Pediatr.*, 137: 133-139.

Biran, L. A., Bartley, W., Carter, C. W. & Renshaw, A. (1964). Studies on essential fatty acid deficiency. Effect of the deficiency on the lipids in various rat tissues and the influence of dietary supplementation with essential fatty acids on deficient rats. *Biochem. J.* 93: 492-498.

Birch, E. E., Birch, D. G., Hoffman, D. R., & Uauy, R. (1992) Dietary essential fatty acid supply and visual acuity development. *Invest. Ophthalmol. Vis. Sci.* 33: 3242-3253.

Birch, E.E., Hoffman, D.R., Uauy, R., Birch, D.G. & Prestidge, C. (1998) Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants. *Ped Res* 44:201-209.

Birch, EE., Garfield, S., Hoffman, DR., Uauy, R. & Birch, DG. (2000) A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. *Dev Med & Child Neurol* 42:174-81.

Bird, J. M. & Kimber, S. J. (1984). Oligosaccharides containing fucose linked alpha(1-3) and alpha(1-4) to N-acetylglucosamine cause decompaction of mouse morulae. *Dev. Biol. (Orlando)*. 104:449-460.

Bitman, J., Wood, L., Hamosh, M., & Mehta, N. R. (1983). Comparison of the lipid composition of breast milk from mothers of term and preterm infants. *Am. J. Clin. Nutr.* 38: 300-312.

Blanco, G., DeTomaso, A. W., Koster, J., Xie, Z. J., & Mercer, R. W. (1994). The  $\alpha$ -subunit of the Na,K-ATPase has catalytic activity independent of the alpha-subunit. *J. Biol. Chem.* 269: 23420-23425.

Bloch, K. (1965). The biological synthesis of cholesterol. *Science* 150: 19-28.

Bonting, L. S., Caravaggio, L. L., & Hawkins, M. N. (1962). Studies on sodium-potassium-activated adenosine triphosphatase. IV. Correlation with cation transport sensitive to cardiac glycosides. *Archs. Biochem. Biophys.* 98: 413-419.

Bornfeldt, K. E., Graves, L. M., Raines, E. W., Igarashi, Y., Wayman, G., Yamamura, S., Yatomi, Y., Sidhu, J. S., Krebs, E. G., & Hakomori, S. (1995). Sphingosine-1-phosphate inhibits PDGF-induced chemotaxis of human arterial smooth muscle cells: spatial and temporal modulation of PDGF chemotactic signal transduction. *J. Cell Biol* 130: 193-206.

Bourre, J. M., Pascal, G., Durand, G., Masson, M., Dumont, O., & Piciotti, M. (1984). Alterations in the fatty acid composition of rat brain cells (neurons, astrocytes and oligodendrocytes) and of subcellular fractions (myelin and synaptosomes) induced by a diet devoid of n-3 fatty acids. *J. Neurochem.* 43: 342-348.

Bourre, J. M., Durand, G., Pascal, G., & Youyou, A. (1989). Brain cell and tissue recovery in rats made deficient in n-3 fatty acids by alteration of dietary fat. *J. Nutr.* 119: 15-22.

Bourre, J.M., Piciotti, M., & Dumont, O. (1990a) Delta-6-desaturase in brain and liver during development and aging. *Lipids* 25: 354-356.

Bourre, J. M., Bonneil, M., Dumont, O., Piciotti, M., Calaf, R., Portugal, H., Nalbhone, G. & Lafont, H. (1990b) Effect of increasing amounts of dietary fish oil on brain and liver fatty acid composition. *Biochim. Biophys. Acta* 1124: 119-122.

Brady, R. N., Di Mari, S. J. & Snell, E. E. (1969). Biosynthesis of sphingolipid bases. 3. Isolation and characterization of ketonic intermediates in the synthesis of sphingosine and dihydrosphingosine by cell-free extracts of *Hansenula ciferri*. *J. Biol. Chem* 244: 491-496.

Braun, P. E., Morell, P., & Radin, N. S. (1970). Synthesis of C18- or C20-dihydrosphingosines, ketodihydrosphingosines, and ceramides by microsomal preparations from mouse brain. *J. Biol. Chem.* 245: 335-341.

Bray, D. & Hollenbeck, P. J. (1988). Growth cone motility and guidance. *Ann. Rev. Cell Biol.* 4: 43-61.

Bremer, J., Figard, P. H., & Greenberg, D. M. (1960). The biosynthesis of choline and its relation to phospholipid metabolism. *Biochim. Biophys. Acta* 43: 477-488.

British Nutrition Foundation (1992). *The Report of the British Nutrition Foundation's Task Force. Recommendations for intakes of Unsaturated Fatty Acids* (pp. 152-163). Chapman & Hall, New York.

Brotherus, J. R., Jost, P. C., Griffith, O. H., Keana, J. F., & Hokin, L. E. (1980). Charge selectivity at the lipid-protein interface of membranous Na,K-ATPase. *Proc. Natl. Acad. Sci. USA* 77:272-276.

Brown, M. C., Hopkins, W. G., & Keynes, R. J. (1991). *Essentials of neural development*. Ch. 1 & 3. Cambridge: Cambridge University Press.

Brunngraber, E. G. (1979). In *Neurochemistry of aminosugars: neurochemistry and neuropathology of the complex carbohydrates* (pp. 1-127). C. C. Thomas.

Buchanan, A. G. & Kanfer, J. N. (1980). Topographical distribution of base exchange activities in rat brain subcellular fractions. *J. Neurochem.* 34:720-725.

Buede, R., Rinker-Schaffer, C., Pinto, W. J., Lester, R. L. & Dickson, R. C. (1991). Cloning and characterization of LCB1, a *Saccharomyces* gene required for biosynthesis of the long-chain base component of sphingolipids. *J. Bact.* 173: 4325-4332.

Burczak, J. D., Soltysiak, R. M., & Sweeley, C. C. (1984). Regulation of membrane-bound enzymes of glycosphingolipid biosynthesis. *J. Lipid Res.* 25: 1541-1547.

Calvo, M., Naval, J., Lampreave, F., Uriel, J., & Peineiro, A. (1988). Fatty acids bound to alpha-fetoprotein and albumin during rat development. *Biochim. Biophys. Acta* 959: 238-246.

Campbell, F.A., Gordon, M.J. & Dutta-Roy, A.K. (1998) Placental membrane fatty acid-binding protein preferentially binds arachidonic and docosahexaenoic acids. *Life Sci* 63:235-40.

Capaldi, R. A. (Ed.) (1981). *Membrane proteins and their interactions with lipids* (pp.1). New York: Marcel Dekker.

- Carlson, S. E., Werkman, S. H., Peeples, J. M., Cooke, R. J., & Tolley, E. A. (1993) Arachidonic acid status correlates with first year growth in preterm infants. *Proc. Natl. Acad. Sci. USA* 90: 1073-1077.
- Carlson, S. E., Werkman, S. H., Peeples, J. M., & Wilson, III W. M.. (1994) Growth and development of premature infants in relation to n-3 and n-6 fatty acid status. *World Rev. Nutr. Diet* 75: 63-69.
- Causeret, C., Geeraert, L., Van der Hoeven, G., Mannaerts, G.P., Van Veldhoven, P.P. (2000). Further characterization of rat dihydroceramide desaturase:tissue distribution, subcellular localization, and substrate specificity. *Lipids* 35: 1117-1125.
- Chalon, S., Delion-Vancassel S., Belzung., Guilloteau, D., Leguisquet, A.M., Besnard, J.C., & Durand, G. (1998) Dietary fish oil affects monoaminergic neurotransmission and behaviour in rats. *J. Nutr.* 128: 2512-2519.
- Chappell, J., Clandinin, M. t., Barbe, G. J. & Armstrong, D. T. (1983). Prostanoid content of human milk: relationships to milk fatty acid content. *Endocrinol. Exp.* 17: 351-358.
- Chappell, J., Clandinin, M. T., & Kearney-Volpe, C. (1985). Trans fatty acids in human milk lipids: influence of maternal diet and weight loss. *Am. J. Clin. Nutr.* 42: 49-56.
- Chin, H. & Goldstein, D. B. (1984) Cholesterol blocks the disordering effects of ethanol in biomembranes. *Lipids* 19: 929-935.
- Cho, H. P., Nakamura, M. T., & Clarke, S. D. (1999). Cloning, expression, and nutritional regulation of the mammalian delta-6 desaturase. *J. Biol. Chem.* 274: 471-477.
- Cifone, M. G., De Maria, R., Roncaioli, P., Rippo, M. R., Azuma, M., Lanier, L. L., Santoni, A. & Testi, R. (1994). Apoptotic signaling through CD95 (Fas/Apo-1) activates anacidic sphingomyelinase. *J. Exp. Med.* 180: 1547-1552.
- Cinti, DL., Cook, L., Nagi, MN.& Suneja, SK. (1992) The fatty acid chain elongation system of mammalian endoplasmic reticulum. *Prog Lipid Res* 31:1-51.
- Clandinin, M.T ., Chappell, J.E., Leong, S., Heim, T., Swyer, P. R., & Chance, G.W. (1980a) Intrauterine fatty acid accretion rates in human brain: Implications for fatty acid requirements. *Early Human Dev.* 4:121-129.
- Clandinin, M.T., Chappell, J.E., Heim, T., Swyer, P. R., & Chance, G.W. (1981a). Fatty acid accretion in fetal and neonatal liver: Implications for fatty acid requirements. *Early Human Dev.* 5: 7-14.
- Clandinin, M. T., Chappell, J.E., Heim, T., Swyer, P. R., & Chance, G.W. (1981b) Fatty acid utilization in perinatal de novo synthesis of tissues. *Early Human Dev.* 5: 355-366.

Clandinin, M. T., Field, C. J., Hargreaves, K., Morson, L. A., & Zsigmond, E. (1985a) Role of diet fat in subcellular structure and function. *Can. J. Physiol. Pharmacol.* 63: 546-556.

Clandinin, M. T., Wong, K., & Hacker, R. R. (1985b) Synthesis of chain elongation-desaturation products of linoleic acid by liver and brain microsomes during development of the pig. *Biochem. J.* 226: 305-309.

Clandinin, M. T., Garg, M. L., Parrott, A., Van Aerde, J., Hervada, A., & Lien, E. (1992a) Addition of long-chain polyunsaturated fatty acids to formula for very low birth weight infants. *Lipids* 27: 896-900.

Clandinin, M. T., Parrott, A., Van Aerde, J.E., Hervada, A. R., & Lien, E. (1992b) Feeding preterm infants a formula containing C20 and C22 fatty acids simulates plasma phospholipid fatty acid composition of infants fed human milk. *Early Human Dev.* 31: 41.

Clandinin, M. T., Suh, M., & Hargreaves, K. (1992c). Impact of dietary fatty acid balance on membrane structure and function of neural tissues. In N. G. Bazan (Ed.), *Neurobiology of essential fatty acids* (pp.197-211). New York: Plenum Press.

Clandinin, M. T. (1997). Influence of diet fat on membranes. In: *Membrane and cell signaling. Principles of medical biology.* Vol. 7A. Pp. 93-119. JAI Press Inc.

Clandinin, M.T (1999). Brain Development and Assessing the supply of Polyunsaturated Fatty Acid. *Lipids*, 34: 131-137.

Cohen, S. R., & Bernsohn, J. (1978). The in vivo incorporation of linolenic acid into neuronal and glial cells and myelin. *J. Neurochem.* 30: 661-669.

Colello, R.J. & Pott, U. (1997) Signals that initiate myelination in the developing mammalian nervous system. *Mol Neurobiol* 15:83-100.

Conel, J. (1939). *The postnatal development of the human cerebral cortex.* Cambridge, MA: Harvard University Press.

Cook, H. W. (1978). In vitro formation of polyunsaturated fatty acids by desaturation in rat brain: Some properties of the enzymes in developing brain and comparisons with liver. *J. Neurochem.* 30: 1327-1334.

Cornell, R. (1989) Chemical cross-linking reveals a dimeric structure for CTP:phosphocholine cytidyltransferase. *J. Biol. Chem.* 264: 9077-9082.

Corti, M., Cantù, L., & Sonnino, S. (1987). Fundamentals of physico-chemical properties of gangliosides in solution. In H. Rahmann (Ed.), *Gangliosides and modulation of*

neuronal functions, NATO ASI Series, Series H: Cell Biology, Vol. 7 (pp.101-118). Berlin: Springer/Verlag.

Cowan, W. M. (1979). The development of the brain. In *The brain, a Scientific American book*. New York: W. H. Freeman and Company.

Crawford, M. A. & Sinclair, A. J. (1972). Nutritional influences in the evolution of the mammalian brain. In *Lipids, Malnutrition and the Developing Brain*. Ciba Foundation Symposium. Amsterdam: Elsevier. Pp. 267-292.

Crawford, M. A., Casperd, N. M., & Sinclair, A. J. (1976). The long-chain metabolites of linoleic and linolenic acids in liver and brain herbivores and carnivores. *Comp. Biochem. Physiol.* 54B: 395-401.

Crawford, M.A. (2000) Placental delivery of arachidonic and docosahexaenoic acid: implications for the lipid nutrition of preterm infants. *Am J. Clin Nutr* 71:275S-284S.

Cummins, J. & Hyden, H. (1962). Adenosine triphosphate levels and adenosine triphosphatase in neurons, glia and neuronal membranes of the vestibular nucleus. *Biochim. Biophys. Acta* 60: 271-275.

Cunnane, C.C., Francescutti, V., Brenna, J.T. & Crawford, M.A. (2000) Breast-fed infants achieve a higher a rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. *Lipids* 35: 105-111.

Curatolo, W. (1987). The physical properties of glycolipids. *Biochim. Biophys. Acta* 906: 111-136.

Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coso, O. A., Gutkind, S. & Spiegel, S. (1996). Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. *Nature* 381: 800-803.

Cuzner, M. L. & Davison, A. N. (1968). The lipid composition of rat brain myelin and subcellular fractions during development. *Biochem. J.* 106: 29-34.

Dalton, M. (1999) Source: [www.cbc.umn.edu/~mwd/cell-www/Chapter2/Na-K\\_pump.html](http://www.cbc.umn.edu/~mwd/cell-www/Chapter2/Na-K_pump.html)

Das, G. D. (1977). Gliogenesis during early embryonic development in the rat. *Experientia* 33: 1648-1649.

Dawson, G. & Vartanian, T. (1988). Glycolipids as the source and modulator of receptor-mediated second messengers. In Ledeen, R.W., Hogan, E.L., Tettamanti, G., Yates, A.J. & Yu, R.K. (Eds.), *New Trends in Ganglioside Research* (pp. 219-228). Berlin: Liviana Press.

Dbaiibo, G. S., Wolff, R. A., Obeid, L. M. & Hannun, Y. A. (1995). Activation of a retinoblastoma-protein-dependent pathway by sphingosine. *Biochem J.* 310: 453-459.

De Pont, J. J. H. H. M., Van Prooijen-Van Eeden, A. & Bonting, S. L. (1978). Studies on (Na<sup>+</sup> + K<sup>+</sup>)-activated ATPase. XXXIX. Role of negatively charged phospholipids in highly purified (Na<sup>+</sup> + K<sup>+</sup>)-activated ATPase from rabbit kidney outer medulla. *Biochim. Biophys. Acta* 508: 464-477.

Delton-Vandenbroucke, I., Grammas, P. & Anderson, R. E. (1997). Polyunsaturated fatty acid metabolism in retinal and cerebral microvascular endothelial cells. *J. Lipid Res.* 38: 147-159.

Dennis, E. A. & Kennedy, E. P. (1972). Intracellular sites of lipid synthesis and the biogenesis of mitochondria. *J. Lipid Res.* 13:263-267.

Desai, N. N., Zhang, H., Olivera, A., Mattie, M. E., & Spiegel S. (1992). Sphingosine-1-phosphate, a metabolite of sphingosine, increases phosphatidic acid levels by phospholipase D activation. *J. Biol. Chem.* 267: 23122-23128.

DeTomaso, A. W., Xie, Z. J., Liu, G., & Mercer, R. W. (1993). Expression, targeting, and assembly of functional Na,K-ATPase polypeptides in baculovirus-infected insect cells. *J. Biol. Chem.* 268: 1470-1478.

Dhopeswarkar, G. A., Subramanian, C., & Mead, J. F. (1971a). Fatty acid uptake by the brain. IV. Incorporation of [1-14C] linoleic acid into the adult rat brain. *Biochim. Biophys. Acta* 231: 8-14.

Dhopeswarkar, G. A., Subramanian, C., & Mead, J. F. (1971b). Fatty acid uptake by the brain. V. Incorporation of [1-14C] linolenic acid into adult rat brain. *Biochim. Biophys. Acta* 2331: 162-167.

Dhopeswarkar, G. A. & Subramanian, C. (1976). Intracranial conversion of linoleic acid to arachidonic acid: Evidence for lack of delta-8 desaturase in the brain. *J. Neurochem.* 26: 1175-1179.

Dietschy, J.M. (1997) Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. *Am J Clin Nutr* 65:1581S-1589S

DiPolo, R. & Beauge, L. (1983). The calcium pump and sodium-calcium exchange in squid axons. *Ann. Rev. Physiol.* 45: 313-324.

Diringer, H. & Koch, M. A. (1973). Biosynthesis of sphingomyelin. Transfer of phosphorylcholine from phosphatidylcholine to erythro-ceramide in a cell-free system. *Hoppe-Seylers Zeitschrift für Physiologische Chemie.* 354: 1661-1665.

Dobbing, J. & Sands, J. (1970). Timing of neuroblast multiplication in developing human brain. *Nature* 226: 639-640.

Dobbing, J. & Sands, J. (1979) Comparative aspects of the brain growth spurt. *Early Human Dev.* 3: 79-83.

Dobbing, J. (1990) Early nutrition and later achievement. *Proc. Nutr. Soc.* 49: 103-118.

Dratz, E. A & Deese, A. J. (1986). The role of docosahexaenoic acid (22:6n-3) in biological membranes: examples from photoreceptors and model membrane bilayers. In A. P. Simopoulos, R. R. Kiffer, R. E. Martin (Eds.). *Health effects of polyunsaturated fatty acids in seafoods* (pp. 319-351). New York: Academic Press.

Dressler, K. A., Mathias, S. & Kolesnick, R. N. (1992). Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system. *Science*. 255: 1715-1718.

Dutta-Roy, A. K. (2000). Transport mechanisms for long-chain polyunsaturated fatty acids in the human placenta. *Am. J. Clin. Nutr.* 71 (suppl): 315S-322S.

Edelman, G. M. (1983). Cell adhesion molecules. *Science* 219: 450-457.

Edelstein, C. (1986). Biochemistry and biology of the plasma lipoproteins. A. M. Scanu & A. A. Spector (Eds.), (pp.495-505). New York: Marchel Dekker.

Edsall, L. C., Pirianov, G. G. & Spiegel, S. (1997). Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. *J. Neurosci.* 17: 6952-6960.

Edwards, AO., Miedziak, A., Vrabec, T., Verhoeven, J., Acott, TS., Weleber, RG., & Donoso, LA. (1999) Autosomal dominant Stargardt-like macular dystrophy: I. Clinical characterization, longitudinal follow-up, and evidence for a common ancestry in families linked to chromosome 6q14. *Am J Ophthal* 127:426-35.

Eisensmith, R. C. & Woo, S.L.C. (1992). Molecular basis of phenylketonuria and related hyperphenylalanemias: mutations and polymorphisms in the human phenylalanine hydroxylase gene. *Hum. Mutat.*, 1: 11-23.

Eisensmith, R. C., Okano, Y., Dasovich, M., Wang, T., Guttler, F., & Lichter-Konecki, U. (1992). Multiple origins for phenylketonuria in Europe. *Am. J. Hum. Genet.* 51: 1355-1365.

El Bawab, S., Bielawska, A. & Hannun, Y. A. (1999). Purification and characterization of a membrane-bound nonlysosomal ceramidase from rat brain. *J. Biol. Chem.* 274: 27948-27955.

El Bawab, S., Roddy, P., Qian, T., Bielawska, A., Lemasters, J. J. & Hannun, Y. A. (2000). Molecular cloning and characterization of a human mitochondrial ceramidase. *J. Biol. Chem.* 275: 21508-21513.

Elphick, M. C. & Hull, D. (1977). The transfer of free fatty acids across the rabbit placenta. *J. Physiol. (Lond.)* 264: 751-766.

Elsas, L., & Acosta, P. B. (1994). Nutritional support of inherited metabolic disease. In M. E. Shils, J. A. Olson, & M. Shike (Eds.), *Modern nutrition in health and disease* (8th ed.). Philadelphia: Lea & Febiger.

Emanuel, J. R., Garetz, S., Stone, L., & Levenson, r. (1987). Differential expression of Na, K-ATPase  $\alpha$  - and  $\beta$ -subunit mRNAs in rat tissues and cell lines. *Proc. Natl. Acad. Sci. USA* 84: 9030-9034. /

Erickson, N. E. & Lands W. E. M. (1959). Plasmalogen in the developing brain. *Proc. Soc. Exp. Biol. Med.* 102: 512-514.

European Society of Paediatric Gastroenterology and Nutrition: Committee on Nutrition (1991). Comment on the content and composition of lipids in infant formulas. *Acta Paediatr. Scand.* 80: 887-896.

Eyal-Giladi, H. (1984). The gradual establishment of cell commitments during early stages of chick development. *Cell Diff.* 14: 245-256.

FAO/WHO (1994). *Fats and Oils in Human Nutrition*. Report of a Joint Expert Consultation, Chap. 7, Lipids in Early Development, Food and Nutrition Paper No. 57. FAO, Rome.

Farquharson, J., Cockburn, F., Patrick, W.A., Jamieson, E.C., & Logan, R.W. (1992) Infant cerebral cortex phospholipid fatty-acid composition and diet. *Lancet* 340:810-813.

Favreliere, S., Barrier, L., Durand, G., Chalon, S., & Tallineau, C. (1998). Chronic dietary n-3 polyunsaturated fatty acids deficiency affects the fatty acid composition of plasmenylethanolamine and phosphatidylethanolamine differently in rat frontal cortex, striatum, and cerebellum. *Lipids* 33: 401-407.

Fehling, E. & Mukherjee, KD. (1991) Acyl-CoA elongase from a higher plant (*Lunaria annua*): metabolic intermediates of very-long-chain acyl-CoA products and substrate specificity *Biochim Biophysica Acta.*1082:239-46.

Fernstrom (1999) Effects of dietary polyunsaturated fatty acids on neuronal function. *Lipids* 34: 161-169.

- Firorilli, A., Venerando, B., Siniscalco, C., Monti, E., Bresciani, R., Caimi, L., Preti, A., & Tettamanti, G. (1989). Occurrence in brain lysosomes of a sialidase active on gangliosides. *J. Neurochem.* 53: 672-680.
- Foot M., Cruz T. G., & Clandinin M. T. (1982). Influence of dietary fat on the lipid composition of rat brain synaptosomal and microsomal membranes. *Biochem. J.* 208: 631-641.
- Fueshko, S. M. & Schengrund, C. L. (1990). Murine neuroblastoma cells express ganglioside binding sites on their cell surface. *J. Neurochem.* 54: 1791-1797.
- Fujita, S. (1962). Kinetics of cellular proliferation. *Exp. Cell Res.* 28: 52-56.
- Fujita, S. (1967). Quantitative analysis of cell proliferation and differentiation in the cortex of the postnatal mouse cerebellum. *J. Cell Biol.* 32: 277-288.
- Fumagalli, R., Smith, M.E., Urna, G. & Paoletti, R. (1969) The effect of hypercholesterolemic agents on myelinogenesis. *J. Neurochem* 16:1329-39.
- Futerman, A. H., Stieger, B., Hubbard, A. L. & Pagano, R. E. (1990). Sphingomyelin synthesis in rat liver occurs predominantly at the cis and medial cisternae of the Golgi apparatus. *J. Biol. Chem.* 265: 8650-8657.
- Galli, C. & Cecconi, D. R. (1967). Lipid changes in rat brain during maturation. *Lipids* 2: 76-82.
- Galli, G., Paoletti, EG., & Weiss, JF. (1968) Sterol precursors of cholesterol in adult human brain. *Science.* 162:1495-6,
- Garg, M. L., Keelan, M., Thomson, A. B. R., & Clandinin, M. T. (1988). Fatty acid desaturation in the intestinal mucosa. *Biochim. Biophys. Acta* 918: 139-141.
- Garza, C., Schanler, R. J., Butte, N. F., & Motil, K. J. (1987) Special properties of human milk. *Clinic in Perinatology* 14: 11-32.
- Gatt, S. (1966). Enzymatic hydrolysis of sphingolipids. I. Hydrolysis and synthesis of ceramides by an enzyme from rat brain. *J. Biol. Chem.* 241: 3724-3730.
- Gautheron, C., Petit, L., & Chevallier, F. (1969) Synthesis of cholesterol into the central nervous system and its radioautographic localization. *Exp Neurology.* 25:18-23
- Geeraert, L., Mannaerts, G. P. & van Veldhoven, P. P. (1997). Conversion of dihydroceramide into ceramide: involvement of a desaturase. *Biochem. J.* 327: 125-132.

- Geering, K., Theulaz, I., Verrey, F., Hauptle, M. T., & Rossier, B. C. (1989). A role for the beta-subunit in the expression of functional Na<sup>+</sup>-K<sup>+</sup>-ATPase in *Xenopus* oocytes. *Am. J. Physiol.* 257: C851-C858.
- Ghalayini, A. & Eichberg, J. (1985). Purification of phosphatidylinositol synthase from rat brain by CDP-diacylglycerol affinity chromatography and properties of the purified enzyme. *J. Neurochem.* 44: 175-182.
- Ghidoni, R., Sonnino, S., Chigorno, V., Venerando, B., & Tettamanti, G. (1983). Differences in liver ganglioside patterns in various inbred strains of mice. *Biochem. J.* 209: 885-888.
- Girke, T., Schmidt, H., Zahringer, U., Reski, R., & Heinz, E. (1998). Identification of a novel delta 6-acyl-group desaturase by targeted gene disruption in *Physcomitrella patens*. *Plant J.* 15:39-48.
- Giusto, N. M., Roque, M. E., & Ilincheta de Boschero, M. G. (1992). Effects of aging on the content, composition and synthesis of sphingomyelin in the central nervous system. *Lipids* 27:835-839.
- Glazer, R. & Weber, G. (1971). The effects of L-phenylalanine and phenylpyruvate on glycolysis in rat cerebral cortex. *Brain Res.* 33: 439-450.
- Glynn, I. M. (1993). All hands to the sodium pump. *J. Physiol. (Lond.)* 462: 1-30.
- Goddard, G. A. & Robinson, J. D. (1976). Uptake and release of calcium by rat brain synaptosomes. *Brain Res.* 110: 331-350.
- Goldman, S.A. & Rakic, P. S. (1983). The neurobiology of cognitive development. In P. Mussen. (Ed.), *Handbook of child psychology: biology and infancy development*. New York: John Wiley & Sons.
- Goldman, S.A. & Luskin, M.B. (1998) Strategies utilized by migrating neurons of the postnatal vertebrate forebrain. *Trends in Neurosci* 21:107-14.
- Goldstein, J. L. & Brown, M. S. (1990). Regulation of the mevalonate pathway. *Nature* 343: 425-430.
- Gottlieb, A., Keyder, I., & Epstein, H.T. (1977). Rodent brain growth stages: An analytical review. *Biol. Neonat.* 32: 166-176.
- Green, P. & Yavin, E. (1993). Elongation, desaturation, and esterification of essential fatty acids by fetal rat brain in vivo. *J. Lipid Res.* 34: 2099-2107.
- Greenberg, M. L., Klig, L. S., Letts, V. A., Loewy, B. S., & Henry, S. A. (1983). Yeast mutant defective in phosphatidylcholine synthesis. *J. Bacteriology.* 153:791-799.

- Grogan, W. M. & Lam, J. W. (1982). Fatty acid synthesis in isolated spermatocytes and spermatids of mouse testis. *Lipids* 17:604-611.
- Grogan, W. M. & Huth, E. G. (1983). Biosynthesis of long-chain polyenoic acids from arachidonic acid in cultures of enriched spermatocytes and spermatids from mouse testis. *Lipids* 18:275-284.
- Gurr, M. I. & Harwood, J. L. (1991). *Lipid biochemistry: an introduction* (pp. 1-200). New York: Chapman & Hall.
- Guttler, F., Dilella, A. G., & Ledley, F. D. (1987). Molecular biology of phenylketonuria. *Eur. J. Pediatr.* 146 (suppl. 1): A5-A11.
- Hakomori, S.-I. (1990). Bifunctional role of glycosphingolipids. *J. Biol. Chem.* 265: 18713-18716.
- Hamosh, M. (1987). Lipid metabolism in premature infants. *Biol. Neonat.* 52: 50-64.
- Hamosh, M. (1992). Lipids in human milk and their digestion by the new born infant. In J. Ghisolfi & G. Putet (Eds.), *Essential fatty acids and infant nutrition* (pp. 119-137). Paris: J. Libbey Eurotext.
- Hamosh, M., Iverson, S. J., Kirk, C. L., & Hamosh, P. (1994). Milk lipids and neonatal fat digestion: relationship between fatty acid composition, endogenous and exogenous digestive enzymes and digestion of milk fat. *World Rev. Nutr. Diet* 75: 86-91.
- Hamosh, M. & Salem, N. (1998) Long-chain polyunsaturated fatty acids. *Biol Neonate* 74: 106-120.
- Hanada, K., Hara, T., Nishijima, M., Kuge, O., Dickson, R. C. & Nagiec, M. M. (1997). A mammalian homolog of the yeast LCB1 encodes a component of serine palmitoyltransferase, the enzyme catalyzing the first step in sphingolipid synthesis. *J. Biol. Chem.* 272: 32108-32114.
- Hannun, Y. A. & Bell, R. M. (1989). Function of sphingolipids and sphingolipid breakdown products in cellular regulation. *Science* 243: 500-507.
- Hannun, Y. A. & Bell, R. M. (1993). The sphingomyelin cycle: a prototypic sphingolipid signaling pathway. *Adv. Lipid Res.* 25: 27-41.
- Hannun, Y. A. & Linardic, C. M. (1993). Sphingolipid breakdown products: anti-proliferative and tumor-suppressor lipids. *Biochim. Biophys. Acta.* 1154: 223-236.
- Hannun, Y. A. & Obeid, L. M. (1995). Ceramide: an intracellular signal for apoptosis. *Trends Biochem. Sci.* 20:73-77.

Hansson, H. A., Holmgren, J., & Svennerholm, L. (1977). Ultrastructural localization of cell membrane GM1 ganglioside by cholera toxin. *Proc. Natl. Acad. USA* 74: 3782-3786.

Hardwicke, P. M. & Freytag, J. W. (1981). A proteolipid associated with Na,K-ATPase is not essential for ATPase activity. *Biochem. Biophys. Res. Commun.* 102: 250-257.

Hardy, S. J., Ferrante, A., Robinson, B. S., Johnson, D. W., Poulos, A., Clark, K. J., & Murray, A. W. (1994). In vitro activation of rat brain protein kinase C by polyenoic very-long-chain fatty acids. *J. Neurochem.* 62: 1546-1551.

Hargreaves, K. M. & Clandinin, M. T. (1989). Coordinate control of CDP-choline and phosphatidylethanolamine methyltransferase pathways for phosphatidylcholine biosynthesis occurs in response to change in diet fat. *Biochim. Biophys. Acta* 1001: 262-267.

Hargreaves, K. M. & Clandinin, M. T. (1990). Dietary lipids in relation to postnatal development of the brain. *Upsala J. Med. Sci. Suppl.* 48: 79-95.

Herschkowitz, N. (1988) Brain development in the fetus, neonate and infant. *Biol. Neonate* 54: 1-19.

Herschkowitz, N. (1989). Brain development and nutrition. In P. Evarard & A. Minkowski (Eds.), *Developmental neurobiology* (pp.297). New York: Nestlé Nutrition Workshop Series.

Hertz, L. (1978). An intense potassium uptake into astrocytes. Its further enhancement by high concentration of potassium, and its possible involvement in potassium homeostasis at the cellular level. *Brain Res.* 145: 202-208.

Hirschberg, C. B. & Snider, M. D. (1987). Topography of glycosylation in the rough endoplasmic reticulum and golgi apparatus. *Ann. Rev. Bioch.* 56: 63-87.

Hirschberg, K., Rodger, J. & Futerman, A. H. (1993). The long-chain sphingoid base of sphingolipids is acylated at the cytosolic surface of the endoplasmic reticulum in rat liver. *Biochem. J.* 290: 751-757.

Hjelmstad, R. H. & Bell, R. M. (1990). The sn-1,2-diacylglycerol cholinephosphotransferases of *Saccharomyces cerevisiae*: Nucleotide sequence, transcriptional mapping, and gene product analysis of the CPT1 gene. *J. Biol. Chem.* 265: 1755-1764.

Hjelmstad, R. H. & Bell, R. M. (1991). Sn-1,2-Diacylglycerol choline- and ethanolaminephosphotransferases in *Saccharomyces cerevisiae*: Nucleotide sequence, of the EPT1 gene and comparison of the CPT1 and EPT1 gene products. *J. Biol. Chem.* 266: 5094-5103.

Hoffman, DR., Birch, EE., Birch, DG., Uauy, R., Castaneda, YS., Lopus, MG. & Wheaton, DH. (2000) Impact of early dietary intake and blood lipid composition of long-chain polyunsaturated fatty acids on later visual development. *J. Ped Gastroenteral & Nutr.* 31:540-553.

Holmgren, J., Czerkinsky, C., Lycke, N., & Svennerholm, A. M. (1994). Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. *Am. J. Tropical Med. & Hyg.* 50:42-54.

Holmgren, M., Wagg, J., Bezanilla, F., Rakowski, RF., De Weer, P. & Gadsby, DC. (2000) Three distinct and sequential steps in the release of sodium ions by the Na<sup>+</sup>/K<sup>+</sup>-ATPase. *Nature.* 403:898-901.

Holub, B. J. (1978). Differential utilization of 1-palmitoyl and 1-stearoyl homologues of various unsaturated 1,2-diacyl-sn-glycerols for phosphatidylcholine and phosphatidylethanolamine synthesis in rat liver microsomes. *J. Biol. Chem.* 253: 691-696.

Hommes, F. A., Eller, A. G., & Taylor, E. H. (1982). Turnover of the fast components of myelin and myelin proteins in experimental hyperphenylalaninemia. Relevance to termination of dietary treatment in human phenylketonuria. *J. Inherit. Metab. Dis.*, 5: 21-27.

Hommes, F. A. (1985) Myelin turnover at later stages of brain development in experimental hyperphenylalaninemia. In H., Bickel, & U., Wachtel (Eds.), *Inherited Disease of Amino Acid Metabolism*. Thieme Verlag, pp. 67-85

Hosaka, K., Kodaki, T., & Yamashita, S. (1989). Cloning and characterization of the yeast CKI gene encoding choline kinase and its expression in *Escherichia coli*. *J. Biol. Chem.* 264: 2053-2059.

Hosie, R. J. A. (1965). The localization of adenosine triphosphatases in morphologically characterized subcellular fractions of guinea-pig brain. *Biochem. J.* 96: 404-412.

Hsia, D. T. (1966). Phenylketonuria: a study of human biochemical genetics. *Pediatrics.* 38:173-184.

Hummel, L., Schwartze, A., & Schirmeister, W. (1976). Maternal plasma triglycerides as a source for fetal fatty acids. *Acta Biol. Med. Germ.* 35: 1635-1641.

Huster, D., Arnold, K., & Gawrisch, K. (1998) Influence of docosahexaenoic acid and cholesterol on lateral lipid organization in phospholipid mixtures. *Biochemistry* 49: 17299-17308.

Huttenlocher, P. R. (1979). Synaptic density in human frontal cortex: developmental changes and effects of aging. *Brain. Res.* 163: 195-205.

Huttenlocher, P. R., de Courten, C., Garey, L. J. & Vander Loos, H. (1982). Synaptogenesis in human visual cortex – evidence for synapse elimination during normal development. *Neurosci. Lett* 33: 247-252.

Huttenlocher, P. R. & de Courten, C. (1987). The development of synapses in striate cortex of man. *Hum. Neurobiol.* 6: 1-9.

Ichikawa, M. & Hirata, Y. (1982). Morphology and distribution of postnatally generated glial cells in the somatosensory cortex of the rat: An autoradiographic and electron microscopic study. *Dev. Brain Res.* 4: 369-377.

Igbavboa, U., Avdulov, NA., Schroeder, F., & Wood, WG. (1996) Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. *J. Neurochem* 66:1717-25.

Igbavboa, U., Avdulov, NA., Chochina, SV., & Wood, WG. (1997) Transbilayer distribution of cholesterol is modified in brain synaptic plasma membranes of knockout mice deficient in the low-density lipoprotein receptor, apolipoprotein E, or both proteins *J Neurochem* 69:1661-7.

Innis, S. M. & Clandinin, M. T. (1981). Dynamic modulation of mitochondrial inner-membrane lipids in rat heart by dietary fat. *Biochem. J.* 193: 155-167.

Innis, S. M. (1991). Essential fatty acids in growth and development. *Prog. Lipid Res.* 30: 39-103.

Innis, S.M., Sprecher, H., Hachey, D., Edmond, J. & Anderson, R.E. (1999) Neonatal polyunsaturated fatty acid metabolism. *Lipids* 34: 139-149.

Innis, S.M. & de la Presa Owens, S. (2001) Dietary fatty acids composition pregnancy alters neurite membrane fatty acid and dopamine in newborn rat brain. *J. Nutr* 131: 118-122.

International Society for the Study of Fatty Acids and Lipids (1994). Recommendations for the essential fatty acid requirements of infant formula. *ISSFAL Newsletter* 1, 4.

Isola, LM., Zhou, SL., Kiang, CL., Stump, DD., Bradbury, MW., & Berk, PD. (1995) 3T3 fibroblasts transfected with a cDNA for mitochondrial aspartate aminotransferase express plasma membrane fatty acid-binding protein and saturable fatty acid uptake. *Proc Natl Acad Sci USA* 92:9866-70.

Jacobson, A. G. (1991). Morphogenesis of the neural plate and tube. In T. G. Connelly (Ed.), *Morphogenesis and pattern formation*. New York: Raven Press.

Jacobson, M. (1970). Histogenesis and morphogenesis of the nervous system. In *Developmental Neurobiology* (pp. 1-74). New York: Holt, Rinehart, and Winston.

Jacobson, M. (1978). *Developmental Neurobiology*. New York: Plenum Press.

Jayadev, S., Liu, B., Bielawska, A. E., Lee, J. Y., Nazaire, F., Pushkareva, M. Y., Obeid, L. M. & Hannun, Y. A. (1995). Role for ceramide in cell cycle arrest. *J. Biol. Chem.* 270: 2047-2052.

Jensen, R. G., Hagerty, M. M., & McMahon, K. E. (1978). Lipids of human milk and infant formula: a review. *Am. J. Clin. Nutr.* 31: 990-1016.

Jensen, R. G. (1989) *The Lipids of Human Milk*, pp. 93-151. CRC Press, Boca Raton, FL.

Jervis, G.A., Block, R.J., Bolling, D., & Kanze, E. (1940). Chemical and metabolic studies on phenylalanine. II. The phenylalanine content of the blood and spinal fluid in phenylpyruvic oligophrenia. *J. Biol. Chem.*, 134: 105.

Jervis, G. (1953) Phenylpyruvic oligophrenia deficiency of phenylalanine oxidizing system. *Proc. Soc. Exp. Biol. Med.*, 82: 514-515.

Johnson, R.C., Mckean, C.M. & Shah, S.N. (1977) Fatty acid composition of lipids in cerebral myelin and synaptosomes in phenylketonuria and down syndrome. *Arch Neurol* 34: 288-294.

Johnson, D. W., Beckman, K., & Fellenberg, A. J. (1992). Monoenoic fatty acids in human brain lipids: isomer identification and distribution. *Lipids* 27: 177-180.

Jope, R. S. & Jenden, D. J. (1979). Choline and phospholipid metabolism and the synthesis of acetylcholine in rat brain. *J. Neurosci. Res.* 4: 69-82.

Jorgensen, P. L. & Anderson, J. P. (1988). Structural basis for E1-E2 conformational transitions in Na,K-pump and Ca-pump proteins. *J. Membrane Biol.* 103: 95-120.

Jorgensen, P. L. (1990). Structure and molecular mechanisms of the Na,K-pump. In *Monovalent cations in biological systems* (pp. 117-154). Boca Taton, FL: CRC.

Jumpsen, J. A., Lien, E., Goh, Y. K., & Clandinin, M. T. (1997a) Small changes of dietary n-3 and n-6 fatty acid fatty acid content ratioalter phosphatidylethanolamine and phosphatidylcholine fatty acid composition during development of neuronal and glial cells in rats. *J. Nutr.* 127: 724-731.

Jumpsen, J. A., Lien, E., Goh, Y. K., & Clandinin, M. T. (1997b) During neuronal and glial cell development diet n-6 to n-3 fatty acid ratio alters the fatty acid composition of phosphatidylinositol and phosphatidylserine. *Biochim. Biophys. Acta* 1347: 40-50.

Jungalwala, F. B., Koul, O., Stoolmiller, A., & Sapirstein, V. S. (1985) Regulation of cerebroside and sulfatide metabolism in glia cells. *J. Neurochem.* 45: 191-198.

Juraska, J. M. & Fikova, E. (1979). A golgi study of the early postnatal development of the visual cortex of hooded rats. *J. Comp. Neurol.* 183: 247-256.

Kabara, J. J. (1973) A critical review of brain cholesterol metabolism. *Prog Brain Res* 40:363-82

Kalmar, G. B., Kay, R. J., LaChance, A. C., & Cornell, R. B. (1994). Primary structure and expression of a human CTP:phosphocholine cytidyltransferase. *Biochim. Biophys. Acta* 1219: 328-334.

Kanfer, J. N. (1972). Base exchange reactions of the phospholipids in rat brain particles. *J. Lipid Res.* 13: 468-476.

Karlsson, K. A. (1970). On the chemistry and occurrence of sphingolipid long-chain bases. *Chem. & Phys. Lipids.* 5: 6-43.

Kawamura, M. & Noguchi, S. (1991). In J. H. Kaplan & P. DeWeer (Eds.), *The sodium pump: Structure, mechanism, and regulation* (pp. 45-62). New York: The Rockefeller University Press.

Kim, J. W., Lee, Y., Lee, I. A., Kang, H. B., Choe, Y. K., & Choe, I. S. (1997). Cloning and expression of human cDNA encoding Na, K-ATPase  $\alpha$ -subunit. *Biochim. Biophys. Acta* 1350: 133-135.

Kim, M. Y., Linardic, C., Obeid, L. & Hannun, Y. (1991). Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. *J. Biol. Chem.* 266: 484-489.

Kimelberg, H. K. & Papahadjopoulos, D. (1974) Effects of phospholipid acyl chain fluidity, phase transitions, and cholesterol on (Na<sup>+</sup> + K<sup>+</sup>)-stimulated adenosine triphosphatase. *J. Biol. Chem.* 249: 1071-1080.

Kishimoto, Y., Davies, W. E., & Radin, N. S. (1965a). Turnover of the fatty acids of rat brain gangliosides, glycerophosphatides, cerebroside and sulfatides as a function of age. *J. Lipid Res.* 6: 525-531.

Kishimoto, Y., Davies, W. E., & Radin, N. S. (1965b). Developing rat brain: changes in cholesterol, galactolipids, and the individual fatty acids of gangliosides and glycerophosphatides. *J. Lipid Res.* 6: 532-536.

Klenk, E. (1942) Über die Ganglioside, eine neue Gruppe von zuckerhaltigen Gehirnlipoiden. *Hoppe-Seyler's Z. Physiol. Chem.* 273: 76-86.

Kleuser, B., Cuvillier, O. & Spiegel, S. (1998). 1-Alpha,25-dihydroxyvitamin D<sub>3</sub> inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase. *Cancer Res.* 58: 1817-1824.

Knutzon, D. S., Thurmond, J. M., Huang, Y., Chaudhary, S., Bobik, E. G., Chan, G. M., Kirchner, S. J., & Mukerji, P. (1998) Identification of delta5-desaturase from *Mortierella alpine* by heterologous expression in bakers' yeast and canola. *J. Biol. Chem.* 273: 29360-29366.

Koblin, D. D., Dong, D. E., Deady, J. E. & Eger, E. I. (1980). Alteration of synaptic membrane fatty acid composition and anesthetic requirement. *J. Pharm. Exp. Thera.* 212: 546-552.

Koch, J., Gartner, S., Li C. M., Quintern, L. E., Bernardo, K., Levrán, O., Schnabel, D., Desnick, R. J. Schuchman, E. H. & Sandhoff, K. (1996). Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of the first molecular lesion causing Farber disease. *J. Biol. Chem.* 271: 33110-33115.

Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R. & Spiegel, S. (1998). Molecular cloning and functional characterization of murine sphingosine kinase. *J. Biol. Chem.* 273: 23722-23728.

Kojima, N., Lee, Y. C., Hamamoto, T., Kurosawa, N., & Tsuji, S. (1994). Kinetic properties and acceptor substrate preferences of two kinds of Gal beta 1,3GalNAc alpha 2,3-sialyltransferase from mouse brain. *Biochem.* 33:5772-5776.

Kolesnick, R. N. (1991). Sphingomyelin and derivatives as cellular signals. *Prog. Lipid Res.* 30: 1-38.

Kolter, T. & Sandhoff, K. (1998). Glycosphingolipid degradation and animal models of GM2-gangliosidosis. *J. Inherit. Metab. Dis.* 21: 548-563.

Koval, M. & Pagano, R. E. (1991). Intracellular transport and metabolism of sphingomyelin. *Biochim. Biophys. Acta.* 1082: 113-125.

Kronke, M., Schluter, C. & Pfizenmaier, K. (1987). Tumor necrosis factor inhibits MYC expression in HL-60 cells at the level of mRNA transcription. *Proc. Natl. Acad. Sci. USA* 84: 469-473.

Kuge, O., Nishijima, M., & Akamatsu, Y. (1991). A cloned gene encoding phosphatidylserine decarboxylase complements the phosphatidylserine biosynthetic defect of a Chinese hamster ovary cell mutant. *J. Biol. Chem.* 266: 6370-6376.

Kuge, O., Saito, K., Kojima, M., Akamatsu, Y., & Nishijima, M. (1996). Post-translational processing of the phosphatidylserine decarboxylase gene product in Chinese hamster ovary cells. *Biochem. J.* 319: 33-38.

Kuge, O., Saito, K., & Nishijima, M. (1997). Cloning of a Chinese hamster ovary (CHO) cDNA encoding phosphatidylserine synthase (PSS) II. Overexpression of which suppresses the phosphatidylserine biosynthetic defect of a PSS I-lacking mutant of CHO-K1 cells. *J. Biol. Chem.* 272: 19133-19139.

Kurokawa, M., Sakamoto, T., & Kato, M. (1965). Distribution of sodium-plus potassium-stimulated adenosine triphosphatase in isolated nerve-ending particles. *Biochem. J.* 97: 833-844.

Kurtz, D. J. & Kanfer, J. N. (1973). Composition of myelin lipids and synthesis of 3-ketodihydrosphingosine in the vitamin B<sub>6</sub>-deficient developing rat. *J. Neurochem* 20: 963-968.

Kuster, B., Shainskaya, A., Pu, H. X., Goldshleger, R., Blostein, R., Mann, M., & Karlsh, S. J. D. (2000). A new variant of the  $\alpha$  subunit of renal Na, K-ATPase. Identification by mass spectrometry, antibody binding and expression in cultured cells. *J. Biol. Chem.* 275: 19441-19446.

Lampreave, F., Calvo, M., Naval, J., & Pineiro, A. (1982). Long-chain fatty acids bound to alpha-fetoprotein and to serum albumin from fetal and adult pig. *Comp. Bioch. & Physiol. - B: Comp. Bioch.* 73:823-827.

Lamprey, M. S. & Walker, B. L. (1976) A possible role for dietary linoleic acid in the development of the young rat. *J. Nutr.* 106: 86-93.

Lane, J., Schoene, B., Langenbeck, U., & Neuhoff, V. (1980). Characterization of experimental phenylketonuria: augmentation of hyperphenylalanemia with alpha-methyl phenylalanine and p-chlorophenylalanine. *Biochim. Biophys. Acta.*, 627:144-156.

Langner, M., Winiski, A., Eisenberg, M., & McLaughlin, S. (1988). The electrostatic potential adjacent to bilayer membranes containing either charged phospholipids or gangliosides. In R. W. Ledeen, E. L. Hogan, Y. Nagai, G. Tettamanti, A. J. Yates, & R. K. Yu (Eds.), *New trends in ganglioside research: Neurochemical and neuroregenerative aspects*. Fidia Research Series, Vol. 14 (pp. 121-131). Berlin/Padova: Liviana Press/Springer Verlag.

Lassner, M.W., Lardizabal, K., & Metz, J.G. (1996) A jojoba beta-Ketoacyl-CoA synthase cDNA complements the canola fatty acid elongation mutation in transgenic plants. *Plant Cell.* 8:281-92

- Ledeen, R. W., Yu, R. K., & Eng, L. F. (1973). Gangliosides of human myelin: Sialosylgalactosylceramide (G7) as a major component. *J. Neurochem.* 21: 829-839.
- Lee R. E. (1985). Membrane engineering to rejuvenate the aging brain. *Can. Med. Assoc. J.* 132:325-327.
- Ledeen, R. (1985) Gangliosides of neurons. *Trends Neurosci* 8: 169-174.
- Ledeen, R. W. (1989). Biosynthesis, metabolism, and biological effects of gangliosides. In R. U. Margolis & R. K. Margolis (Eds.), *Neurobiology of glycoconjugates* (pp. 43-83). New York: Plenum Press.
- Lee, A. G., East, J. M., & Froud, R. J. (1986). Are essential fatty acids essential for membrane function? *Prog. Lipid Res.* 25: 41-46.
- Lees, G. J. (1991). Inhibition of sodium-potassium-ATPase: a potentially ubiquitous mechanism contributing to central nervous system neuropathology. *Brain Res. Rev.* 16: 283-300.
- Leibel, WS., Firestone, LL., Legler, DC., Braswell, LM., & Miller, KW. (1987) Two pools of cholesterol in acetylcholine receptor-rich membranes from Torpedo. *Biochim Biophys Acta.* 897:249-60.
- Leonard, A. E., Kelder, B., Bobik, E. G., Chuang, L., Parker-Barnes, J. M., Thurmond, J. M., Kroeger, P. E., Kopchick, J. J., Huang, Y., & Mukerji, P. (2000). cDNA cloning and characterization of human delta5-desaturase involved in the biosynthesis of arachidonic acid. *Biochem. J.* 347: 719-724.
- Levade, T., Moser, H. W., Fensom, A. H., Harzer, K., Moser, A. B. & Salvayre, R. (1995). Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells. *J. Neuro. Sci.* 134: 108-114.
- Levenson, R. (1994). Isoforms of the Na,K-ATPase: family members in search of function. *Rev. Physiol. Biochem. & Pharmacol.* 123: 1-45, 1994.
- Li, C. M., Hong, S. B., Kopal, G., He, X., Linke, T., Hou, W. S., Koch, J., Gatt, S., Sandhoff, K. & Schuchman, E. H. (1998). Cloning and characterization of the full-length cDNA and genomic sequences encoding murine acid ceramidase. *Genomics* 50: 267-274.
- Li, Z. Kaplan, M. & Hachey, D. (2000). Hepatic microsomal and peroxisomal docosahexaenote biosynthesis during piglet development. *Lipids* 35:1325-1333
- Lichtman, J. W. & Purves, D. (1980). The elimination of redundant preganglionic innervation to hamster sympathetic ganglion cells in early postnatal life. *J. Physiol.* 301: 213-228.

- Lingrel, J.B. (1992) Na,K-ATPase: isoform structure, function, and expression. *J. Bioenerg Biomembr.* 24:263-70.
- Linscheer, W. G. & Vergroesen, A. J. (1988). Lipids. In M. E. Shils & V. E. Young (Eds.), *Nutrition in health and disease*. Pennsylvania: Lea and Febiger.
- Lipsky, N. G. & Pagano, R. E. (1983). Sphingolipid metabolism in cultured fibroblasts: microscopic and biochemical studies employing a fluorescent ceramide analogue. *Proc. Natl. Acad. Sci. USA* 80: 2608-2612.
- Lipsky, N. G. & Pagano, R. E. (1985). Intracellular translocation of fluorescent sphingolipids in cultured fibroblasts: endogenously synthesized sphingomyelin and glucocerebroside analogues pass through the Golgi apparatus en route to the plasma membrane. *J. Cell Biol.* 100: 27-34.
- Litman, B.J. & Mitchell, D.C. (1996) A role for phospholipid polyunsaturation in modulating membrane protein function. *Lipids.* 31 Suppl:S193-7.
- Lou, H. C. (1982). *Developmental neurology*. New York: Raven Press.
- Loo, Y. H., Scotto, L., & Horning, M.G. (1976) Gas chromatographic determination of aromatic acid metabolites of phenylalanine in brain. *Anal. Biochem.*, 76: 111-118.
- Loo, Y. H., Scotto, L., & Wisniewski, H. M., (1978). Myelin deficiency in experimental phenylketonuria: contribution of the aromatic acid metabolites of phenylalanine. In *Myelination and Demyelination*, pp. 453-469, Plenum Press, New York.
- Loo, Y. H., Potempska, A. & Wisniewski, H. M. (1985). A Biochemical explanation of phenyl acetate neurotoxicity in experimental phenylketonuria. *J. Neurochem.*, 45: 1596-1600.
- Lucas, A., Morley, R., Cole, T. J., Lister, G., & Leeson-Payne, C. (1992) Breast milk and subsequent intelligence quotient in children born preterm. *Lancet* 339: 261-264.
- Luskin, M.B., Pearlman, A.L. & Sanes, J.R. (1988) Cell lineage in the cerebral cortex of the mouse studied in vivo and in vitro with a recombinant retrovirus. *Neuron* 1:635-47.
- Luskin, M.B. (1994) Neuronal cell lineage in the vertebrate central nervous system. *FASEB J.* 8:722-30.
- Lutsenko, S. & Kaplan, J. H. (1993). An essential role for the extracellular domain of the Na,K-ATPase isoform beta-subunit in cation occlusion. *Biochem.* 32: 6737-6743.
- Luukkainen, P., Salo, M. K., & Nikkari, T. (1994) Changes in the fatty acid composition of preterm and term human milk from 1 week to 6 months of lactation. *J. Pediatr. Gastroenterol. Nutr.* 18: 355-360.

Makrides, M., Neumann, M.A., Byard, R.W., Simmer, K. & Gibson, R. (1994). Fatty acid composition of brain, retina, and erythrocytes in breast and formula-fed infants. *Am J. Clin. Nutr.* 60:189-194.

Makrides, M., Neuman, M., Simmer, K., Pater, J., & Gibson, R. (1995) Are long-chain polyunsaturated fatty acids essential nutrients in infancy? *Lancet* 345: 1463-1468.

Mancini, A., Del Rosso, F., Roberti, R., Orvietani, P., Coletti, L., & Binaglia, L. (1999). Purification of ethanolaminephosphotransferase from bovine liver microsomes. *Biochim. Biophys. Acta* 1473: 80-92.

Mandon, E. C., Ehses, I., Rother, J., van Echten, G. & Sandhoff, K. (1992). Subcellular localization and membrane topology of serine palmitoyltransferase, 3-dehydrosphinganine reductase, and sphinganine N-acyltransferase in mouse liver. *J. Biol. Chem.* 267: 11144-11148.

Mansson, J. E., Vanier, M. T., & Svennerholm, L. (1978). Changes in the fatty acid and sphingosine composition of the major gangliosides of human brain with age. *J. Neurochem.* 30:273-275.

Marinetti, G. V. & Cattieu, K. (1982). Tightly (covalently) bound fatty acids in cell membrane proteins. *Biochim. Biophys. Acta* 685: 109-116.

Marshall, E., Fumagalli, R., Niemiro, R., & Paoletti, R. (1966). The change in fatty acid composition of rat brain phospholipids during development. *J. Neurochem.* 13: 857-862.

Martin, R.E. (1998) Docosahexaenoic acid decreases phospholipase A<sub>2</sub> activity in the neurites/ nerve growth cones of PC 12 cells. *J. Neurosci. Res* 54: 805-813.

Martinez, M. (1992) Tissue levels of polyunsaturated fatty acids during early human development. *J Pediatr* 120:S129-38

Martinez, M., Conde, C. & Ballabriga, A. (1974). Some chemical aspects of human brain development. II. Phosphoglyceride fatty acids. *Pediatr. Res.* 8: 93-102.

Martin-Vasallo, P., Dackowski, W., Emanuel, J. R., & Levenson, R. (1989). Identification of a putative isoform of the Na, K-ATPase  $\alpha$ - subunit: primary structure and tissue-specific expression. *J. Biol. Chem.* 264: 4613-4618.

Masserini, M. & Freire, E. (1986). Thermotropic characterization of phosphatidylcholine vesicles containing GM1 gangliosides with homogeneous ceramide chain length composition. *Biochem.* 25: 1043-1049.

Masserini, M., Freire, E., Palestini, P., Calappi, E., & Tettamanti, G. (1992). Fuc-GM1 ganglioside mimics the receptor function of GM1 for cholera toxin. *Biochem.* 31: 2422-2426.

- Mathias, S., Dressler, K. A. & Kolesnick, R. N. (1991). Characterization of a ceramide-activated protein kinase: stimulation by tumor necrosis factor alpha. *Proc. Natl. Acad. Sci. USA* 88: 10009-10013.
- Mathias, S., Younes, A., Kan, C. C., Orlow, I., Joseph, C. & Kolesnick, R. N. (1993). Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta. *Sci.* 259: 519-522.
- Mathieu, J. M., Widmer, S., & Herschowitz, N. (1973). Biochemical changes in mouse brain composition during myelination. *Brain Res.* 55: 391-402.
- Mattie, M., Brooker, G. & Spiegel, S. (1994). Sphingosine-1-phosphate, a putative second messenger, mobilizes calcium from internal stores via an inositol trisphosphate-independent pathway. *J. Biol. Chem.* 269: 3181-3188.
- McCaman, R. E. (1962). Intermediary metabolism of phospholipids in brain tissue (microdetermination of choline phosphokinase). *J. Biol. Chem.* 237: 672-676.
- McCaman, R. E. & Cook, K. (1966). Intermediary metabolism of phospholipids in brain tissue. *J. Biol. Chem.* 241: 3390-3394.
- Melendez, A., Floto, R. A., Gillooly, D. J., Harnett, M. M., Allen, J. M. & Fcgamma, R. I. (1998). Coupling to phospholipase D initiates sphingosine kinase-mediated calcium mobilization and vesicular trafficking. *J. Biol. Chem.* 273: 9393-9402.
- Mercer, R. W., Schneider, J. W., Savitz, A., Emanuel, J. R., Benz, E. J. Jr., & Levenson, R. (1986). Rat brain Na, K-ATPase  $\alpha$ -chain gene: primary structure, tissue-specific expression, and amplification in ouabain-resistant HeLa C+ cells. *Mol. Cell Biol.* 6: 3884-3890.
- Mercer, R. W., Biemesderfer, D., Bliss, D. P. Jr., Collins, J. H., & Forbush, B. III. (1993). Molecular cloning and immunological characterization of the  $\alpha$  polypeptide, a small protein associated with the Na, K-ATPase. *J. Cell Biol.* 121: 579-586.
- Mercer, R.W. (1999) Source:[www.cellbio.wustl.edu/FACULTY/mercer](http://www.cellbio.wustl.edu/FACULTY/mercer)
- Merrill, A. H Jr. (1983). Characterization of serine palmitoyltransferase activity in Chinese hamster ovary cells. *Biochim. Biophys. Acta* 754: 284-291.
- Merrill, A. H. Jr., Wang, E. & Hargrove, J. L. (1985). Hepatic enzymes of sphingolipid and glycerolipid biosynthesis in rats from Spacelab 3. *Physiologist.* 28: S229.
- Merrill, A. H. Jr. & Wang, E. (1986). Biosynthesis of long-chain (sphingoid) bases from serine by LM cells. Evidence for introduction of the 4-trans-double bond after de novo biosynthesis of N-acylsphinganine(s). *J. Biol. Chem.* 261: 3764-3769.

Merrill, A. H. Jr. & Jones, D. D. (1990). An update of the enzymology and regulation of sphingomyelin metabolism. *Biochim. Biophys. Acta* 1044: 1-12.

Merrill, A. H. Jr. & Wang, E. (1992). Enzymes of ceramide biosynthesis. *Methods in Enzymol.* 209: 427-437.

Merrill, A. H. Jr., Schmelz, E. M., Dillehay, D. L., Spiegel, S., Shayman, J. A., Schroeder, J. J., Riley, R. T., Voss, K. A. & Wang, E. (1997). Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology. *Toxicol. Appl. Pharmol.* 42: 208-225.

Michel, C. & van Echten-Deckert, G. (1997). Conversion of dihydroceramide to ceramide occurs at the cytosolic face of the endoplasmic reticulum. *FEBS Lett.* 416: 153-155.

Michelangeli, F., East, J.M., & Lee, A.G. (1990) Structural effects on the interaction of sterols with the (Ca<sup>2+</sup> + Mg<sup>2+</sup>)-ATPase *Biochim Biophys Acta.* 1025:99-108

Mikami, T., Kashiwagi, M., Tsuchihashi, K., Akino, T. & Gasa, S. (1998). Substrate specificity and some other enzymatic properties of dihydroceramide desaturase (ceramide synthase) in fetal rat skin *J. Biol. Chem.* 273: 906-911.

Mills, D. E., Young, R. P., & Young, C. (1988). Effects of prenatal and early postnatal fatty acid supplementation on behavior. *Nutr. Res.* 8: 273.

Millar, A.A. & Kunst, L. (1997) Very-long-chain fatty acid biosynthesis is controlled through the expression and specificity of the condensing enzyme. *Plant Journal.* 12:121-31

Miyaura, C., Abe, E., Kuribayashi, T., Tanaka, H., Konno, K., Nishii, Y. & Suda, T. (1981). 1 alpha,25-Dihydroxyvitamin D<sub>3</sub> induces differentiation of human myeloid leukemia cells. *Biochem. Biophys. Res. Comm.* 102: 937-943.

Molliver, M. E., Kostovic, I., & Van der Loos, H. (1973) The development of synapses in cerebral cortex of the human fetus. *Brain Res.* 50: 403-407.

Moore, S. A., Yoder, E., & Spector, A. A. (1990). Role of the blood-brain barrier in the formation of long-chain n-3 and n-6 fatty acids from essential fatty acid precursors. *J. Neurochem.* 55: 391-402.

Moore, S. A., Yoder, E., Murphy, S., Dutton, G. R., & Spector, A. A. (1991). Astrocytes, not neurons, produce docosahexaenoic acid (22:6n-3) and arachidonic acid (20:4n-6). *J. Neurochem.* 56:518-524.

Moore, S. A. (1993). Cerebral endothelium and astrocytes cooperate in supplying docosahexaenoic acid to neurons. *Adv. Exp. Med. & Biol.* 331: 229-233.

Morell. P. & Radin. N. S. (1970). Specificity in ceramide biosynthesis from long chain bases and various fatty acyl coenzyme A's by brain microsomes. *J. Biol. Chem.* 245: 342-350.

Morell. P. & Braun. P. (1972). Biosynthesis and metabolic degradation of sphingolipids not containing sialic acid. *J. Lipid Res.* 13: 293-310.

Morgane. P. J., Austin-Lafrance, R., Bronzino, J., Tonkiss, J. Diaz-Cintra. S., Cintra. L., Kemper. T., & Galler, J. R. (1993). Postnatal malnutrition and development of brain. *Neurosci. Biobehav. Rev.* 17: 91-128.

Myers, M., Wortman, C., & Freire, E. (1984). Modulation of neuraminidase activity by the physical state of phospholipid bilayers containing gangliosides GD1a and GT1b. *Biochem.* 23: 1442-1448.

Myher, J. J., Kuksis, A., Shepherd, J., Packard, C. J., Morrisett, J. D., Taunton, O. D. & Gotto, A. M. (1981). Effect of saturated and unsaturated fat diets on molecular species of phosphatidylcholine and sphingomyelin of human plasma lipoproteins. *Biochim. Biophys. Acta.* 666:110-119.

Nagiec, M. M., Baltisberger, J. A., Wells, G. B., Lester, R. L. & Dickson, R. C. (1994). The LCB2 gene of *Saccharomyces* and the related LCB1 gene encode subunits of serine palmitoyltransferase, the initial enzyme in sphingolipid synthesis. *Proc. Natl. Acad. of Sci. USA* 91: 7899-7902.

Nagiec, M. M., Lester, R. L. & Dickson, R. C. (1996). Sphingolipid synthesis: identification and characterization of mammalian cDNAs encoding the Lcb2 subunit of serine palmitoyltransferase. *Gene.* 177: 237-241.

Nakashima, A., Hosaka, K., & Nikawa, J. (1997). Cloning of a human cDNA for CTP:phosphoethanolamine cytidyltransferase by complementation in vivo of a yeast mutant. *J. Biol. Chem.* 272: 9567-9572.

Napier, J. A., Hey, S. J., Lacey, D. J., & Shewry, P. R. (1998). Identification of a *Caenorhabditis elegans* Delta6-fatty-acid-desaturase by heterologous expression in *Saccharomyces cerevisiae*. *Biochem. J.* 330:611-614, 1998

Neuringer, M., Connor, W. E., Van Petten, C., & Bartad, L. (1984). Dietary omega-3 fatty acid deficiency and visual loss in infant rhesus monkeys. *J. Clin. Invest.* 73: 272-6.

Neuringer, M., Connor, W. E., Lin, D. S., Barstad, L., & Luck, S. (1986). Biochemical and functional effects of prenatal and postnatal omega-3 fatty acid deficiency on retina and brain of rhesus monkeys. *Proc. Natl. Acad. Sci. USA* 83: 4021-5.

Nieuwkoop, P. D. (1952) Activation and organization of the central nervous system in amphibians. I, II, and III. *J. Exp. Zool* 120: 1-30.

Nikolova-Karakashian, M. (2000). Assays for the biosynthesis of sphingomyelin and ceramide phosphoethanolamine. *Methods in Enzymol.* 311: 31-42.

Nikolova-Karakashian, M. & Merrill, A. H. Jr. (2000). Ceramidases. *Methods in Enzy* 311:194-201.

Nilsson, A. (1969). Metabolism of cerebroside in the intestinal tract of the rat. *Biochim. et Biophys. Acta.* 187:113-121.

Noble, M. (1986). Glial development and glial-neuronal interaction. In A. K. Asbury (Ed.), *Diseases of the nervous system* (pp. 109-124). London: Heinemann.

Norton, W. T. & Poduslo, S. E. (1971) Neuronal perikarya and astroglia of rat brain: chemical composition during myelination. *J. Lipids Res.* 12: 84-90.

Norton, W. T. & Poduslo, S. E. (1973). Myelination in rat brain: changes in myelin composition during brain maturation. *J. Neurochem.* 21: 759-773.

Nybroe, O. & Bock, E. (1989). Structure and function of the neural cell adhesion molecules NCAM and L 1. *Adv. Exp. Med. Biol.* 265: 185-196.

Oh, CS., Toke, DA., Mandala, S. & Martin, CE. (1997) ELO2 and ELO3, homologues of the *Saccharomyces cerevisiae* ELO1 gene. function in fatty acid elongation and are required for sphingolipid formation. *J. Biol Chem* 272:17376-84.

O. K.M. & Choy, P.C. (1990). Solubilization and partial purification of cholinephosphotransferase in hamster tissues. *Lipids* 25: 122-124.

O'Brien, J. S. & Sampson, E.L. (1965) Fatty acid and fatty aldehyde composition of the major brain lipids in normal human gray matter, white matter and myelin. *J. Lipid Res.* 6: 545-551.

O'Rahilly, R. & Gardner, E. (1979). The initial development of the human brain. *Acta Anat.* 104: 123-133.

Okazaki, T., Bell, R. M. & Hannun, Y. A. (1989). Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. *J. Biol. Chem.* 264: 19076-19080.

Okazaki, T., Bielawska, A., Bell, R. M. & Hannun, Y. A. (1990). Role of ceramide as a lipid mediator of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. *J. Biol. Chem.* 265: 15823-15831.

Okino, N., Tani, M., Imayama, S. & Ito, M. (1998). Purification and characterization of a novel ceramidase from *Pseudomonas aeruginosa*. *J. Biol. Chem.* 273: 14368-14373.

Oksche. A. (1968). Prenatal and comparative ontogenesis of the neuroglia. *Acta Neuropathologica Suppl.* 4: 4-19.

Olivera. A. & Spiegel. S. (1993). Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. *Nature* 365: 557-560.

Ong, D. E. & Brady, R. N. (1973). In vivo studies on the introduction of the 4-t-double bond of the sphingene moiety of rat brain ceramides. *J. Biol. Chem.* 248: 3884-3888.

Pajares. M. A., Alemany, S., Varela, I., Marin, P., Cao, D., & Mato, J. M. (1984). Purification and photoaffinity labeling of lipid methyltransferase from rat liver. *Biochem. J.* 223:61-66.

Paldino. A. M. & Purpura. D. P. (1979a). Quantitative analysis of the spatial distribution of axonal and dendritic terminals of hippocampal pyramidal neurons in immature human brain. *Exp. Neurol.* 64: 604-620.

Paldino. A. M. & Purpura. D. P. (1979b). Branching patterns of hippocampal neurons of human fetus during dendritic differentiation. *Exp. Neurol.* 64: 620-631.

Paoletti. R. & Galli. C. (1972). In: *Lipid malnutrition and the developing brain* (Ciba Foundation Symposium), pp. 121-140. Amsterdam: Elsevier Biomedical Press.

Park. C.C. & Ahmed. Z. (1992) Alterations of plasma membrane fatty acids composition modify the kinetics of Na<sup>+</sup> current in cultured rat diencephalic neurons. *Brain Res* 570: 75-84.

Parker-Barnes. JM., Das. T., Bobik. E., Leonard. AE., Thurmond. JM., Chaung. LT., Huang. YS., & Mukerji. P. (2000) Identification and characterization of an enzyme involved in the elongation of n-6 and n-3 polyunsaturated fatty acids. *Proc Natl Acad Sci USA* 97:8284-9

Paules. H. & Kennedy. E. P. (1958). The enzymatic synthesis of inositol monophosphate. *J. Am. Chem. Soc.* 80: 6689-6690.

Pavlath. G.K. & Luskin. M.B. (1999) Gene transfer to the rodent embryo by retroviral vectors. *Meth Mol Biol.* 97:519-38.

Peters. A. (1964) Observations on the connections between myelin sheath and glial cells in the optic nerves of young rats. *J. Anat.* 98: 125-130.

Pietz. J (1998) Neurological aspects of adult phenylketonuria. *Curr. Opin. Neurol.* 11: 679-688.

Poirier, H., Degrace, P., Niot, I., Bernard, A., & Besnard, P. (1996) Localization and regulation of the putative membrane fatty-acid transporter (FAT) in the small intestine. Comparison with fatty acid-binding proteins (FABP). *Eur J Biochem* 238:368-73

Porcellati, G. & Arienti, G. (1970). The cytidine triphosphate: cholinephosphate cytidyltransferase of normal and degenerating peripheral nerve: a study of its activation by phospholipids. *Brain Res.* 19:451-464.

Porcellati, G., Arienti, G., Pirotta, M., & Giorgini, D. (1971). Base-exchange reactions for the synthesis of phospholipids in nervous tissue: The incorporation of serine and ethanolamine into the phospholipids of isolated brain microsomes. *J. Neurochem.* 18: 1395-1417.

Porcellati, G., Amaducci, L., & Galli, C. (1976). *Function and metabolism of phospholipids in the central and peripheral nervous systems.* New York: Plenum.

Post, R. L., Kume, S., Tobin, T., Orcutt, B., & Sen, A. K. (1969). Flexibility of an active center in sodium-plus-potassium adenosine triphosphate. *J. Gen. Physiol.* 54: 306s-326s.

Poulos, A., Sharp, P., Singh, H., Johnson, D., Fellenberg, A., & Pollard, A. (1986a). Detection of a homologous series of C26-C38 polyenoic fatty acids in the brain of patients without peroxisomes (Zellweger's syndrome). *Biochem. J.* 235: 607-610.

Poulos, A., van Crugten, C., Sharp, P., Carey, W. F., Robertson, E., Becroft, D. M., Saudubray J. M., Poll-The, B. T., Christensen, E., & Brandt, N. (1986b). Prenatal diagnosis of Zellweger syndrome and related disorders: impaired degradation of phytanic acid. *Europ. J. Peds.* 145:507-510.

Poulos, A., Sharp, P., Johnson, D., & Easton, C. (1988). The occurrence of polyenoic very long chain fatty acids with greater than 32 carbon atoms in molecular species of phosphatidylcholine in normal and peroxisome-deficient (Zellweger's syndrome) brain. *Biochem. J.* 253: 645-650.

Prensky, A. L., Fishman, M. A., & Daftari, B. (1971). Differential effects of hyperphenylalaninemia on the development of the brain in the rat. *Brain Res.*, 33: 181-191.

Purpura, D. P. (1975). Dendritic differentiation in human cerebral cortex: normal and aberrant developmental patterns. In G. W. Kreutzber (Ed.). *Advances in neurology.* New York: Raven Press.

Purves, D. & Lichtman, J. W. (1980). Elimination of synapses in the developing nervous system. *Science* 210: 153-157.

Purvis, J. M., Clandinin, M. T. & Hacker, R. R. (1983) Chain elongation -desaturation of linoleic acid during the development of the pig: Implications for the supply of polyenoic

fatty acid to the developmental brain. *Comp. Biochem. Physiol.* 75B: 199-204.

Rahmann, H. (1992). Calcium-ganglioside interactions and modulation of neuronal functions. In N. N. Osborne (Ed.), *Current aspects of the neurosciences*. Vol. 4 (pp. 87-125). London: McMillan Press.

Raiten, D.J., Talbot, J.M. & Waters J.H. (1998) Assessment of nutrient requirement for infant formulas. *J. Nutr.* 128:S2089-2110.

Rakic, P. (1971a) Guidance of neurons migrating to the fetal monkey neocortex. *Brain Res* 33:471-6

Rakic, P. (1971b) Neuron-glia relationship during granule cell migration in developing cerebellar cortex. A Golgi and electronmicroscopic study in *Macacus Rhesus*. *J. Comp Neurol.* 141:283-312.

Rakic, P. J. (1977). Genesis of the dorsal lateral geniculate nucleus in the rhesus monkey: Site and time of origin, kinetics of proliferation, routes of migration and pattern of distribution of neurons. *Comp. Neurol.* 176: 23-52.

Rakic P. (1988a) Specification of cerebral cortical areas. *Science* 241:170-6.

Rakic, P. (1988b) Defects of neuronal migration and the pathogenesis of cortical malformations. *Prog Brain Res* 73:15-37.

Rakic, P. (1990) Principles of neural cell migration. *Experientia.* 46:882-91.

Rakic P. (1995) Radial versus tangential migration of neuronal clones in the developing cerebral cortex. *Proc Natl Acad Sci USA* 92:11323-7.

Ramsey, R. B. & Nicholas, H. J. (1972). Brain lipids. *Adv. Lipid Res.* 10:143-232.

Rani, C. S., Wang, F., Fuior, E., Berger, A., Wu, J., Sturgill, T. W., Beitner-Johnson, D., LeRoith, D., Varticovski, L. & Spiegel, S. (1997). Divergence in signal transduction pathways of platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors. Involvement of sphingosine 1-phosphate in PDGF but not EGF signaling. *J. Biol. Chem.* 272: 10777-10783.

Rao, AM., Igbavboa, U., Semotuk, M., Schroeder, F., & Wood, WG. (1993) Kinetics and size of cholesterol lateral domains in synaptosomal membranes: modification by sphingomyelinase and effects on membrane enzyme activity. *Neurochem Int* 23:45-52.

Rapport, M. M. (1981). *Gangliosides in neurological and neuromuscular function, development, and repair*. New York: Raven Press.

Reeves, A. S., Collins, J. H., & Schwartz, A. (1980). Isolation and characterization of (Na,K)-ATPase proteolipid. *Biochem. Biophys. Res. Commun.* 95: 1591-1598.

Reichman, B., Chessex, P., Putet, G., Verellen, G., Smith, J., Heim, T., & Swyer, P. R. (1981) Diet, fat accretion, and growth in premature infants. *N. Engl. J. Med.* 305: 1495-1500.

Reisbick, S., Neuringer, M., Hasnain, R., & Connor, W. E. (1994). Home cage behavior of rhesus monkeys with long-term deficiency of omega-3 fatty acids. *Physiol. Behav.* 55: 231-239.

Repke, K. R. & Schon, R. (1992). Role of protein conformation changes and transphosphorylations in the function of Na<sup>+</sup>/K<sup>+</sup> pump mechanism. *Biol. Rev. Camb. Philos. Soc.* 67: 31-78.

Ribeiro, E. A. (1993). Quantitative analysis of enzymic digests of DNA using gel electrophoresis. *J. Chromatography* 618: 181-201.

Riboni, L. & Tettamanti, G. (1991). Rapid internalization and intracellular metabolic processing of exogenous ganglioside by cerebellar granule cells differentiated in culture. *J. Neurochem.* 57: 1931-1939.

Riboni, L., Bassi, R., Sonnino, S., & Tettamanti, G. (1992). Formation of free sphingosine and ceramide from exogenous ganglioside GM1 by cerebellar granule cells in culture. *FEBS Lett.* 300: 188-192.

Rius, R. A., Edsall, L. C. & Spiegel, S. (1997). Activation of sphingosine kinase in pheochromocytoma PC12 neuronal cells in response to trophic factors. *FEBS Lett.* 417: 173-176.

Robinson, B. S., Johnson, D. W., & Poulos, A. (1990). Metabolism of hexacosatetraenoic acid (C26:4,n-6) in immature rat brain. *Biochem. J.* 267:561-564.

Robinson, B. S., Johnson, D. W. & Poulos, A. (1992). Novel molecular species of sphingomyelin containing 2-hydroxylated polyenoic very-long-chain fatty acids in mammalian testes and spermatozoa. *J. Biol. Chem.* 267: 1746-17451.

Rodier, P. M. (1980). Chronology of neuron development: Animal studies and their clinical implications. *Dev. Med. Child Neurol.* 22: 525-545.

Roelofsen, B. (1981). The (non)specificity in the lipid requirement of calcium and (sodium plus potassium) transport adenosine triphosphatases. *Life Sci.* 29: 2235-2247.

Rouser, G. & Yamamoto, A. (1968). Curvilinear regression course of human brain lipid composition changes with age. *Lipids* 3: 284-287.

Rouser, G. & Yamamoto, A. (1972). The fatty acid composition of total gangliosides in normal human whole brain at different ages. *J. Neurochem.* 19: 2697-2698.

Rouser, G., Kritchevsky, G., Yamamoto, A. & Baxter, C. F. (1972). Lipids in the nervous system of different species as a function of age: brain, spinal cord, peripheral nerve, purified whole cell preparations, and subcellular particulates: regulatory mechanisms and membrane structure. *Adv. Lipid Res.* 10:261-360.

Rutherford, M. S., Rock, C. O., Jenkins, N. A., Gilbert, D. J., Tessner, T. G., Copeland, N. G., & Jackowski, S. (1993). The gene for murine CTP:phosphocholine cytidyltransferase (Ctpct) is located on mouse chromosome 16, *Genomics* 18. Pp. 698-701.

Saba, J. D., Nara, F., Bielawska, A., Garrett, S. & Hannun, Y. A. (1997). The BST1 gene of *Saccharomyces cerevisiae* is the sphingosine-1-phosphate lyase. *J. Biol. Chem.* 272: 26087-26090.

Sachsand, G. & Munson, K. (1991). Mammalian phosphorylating ion-motive ATPases. *Curr. Opin. Cell Biol.* 3: 685-694.

Salem, N. Jr., Shingu, T., Kim, H. Y., Hullin, F., Bougnoux, P., & Karanian, J. W. (1988). Specialization in membrane structure and metabolism with respect to polyunsaturated lipids. In: Karnovsky, M. L., Leaf, A., Bollis, L. C., eds. *Biological membranes: aberrations in membrane structure and function*. New York: Alan R. Liss. pp. 319-333.

Sandhoff, K., Conzelmann, E., Neufeld, E. F., Kaback, M. M., & Suzuki, L. (1989). The GM2 gangliosidosis. In C. R. Scriver, A. L. Beaudet, W. S. Sly, & D. Valle (Eds.), *The metabolic basis of inherited disease*. New York: McGraw-Hill.

Sandhoff, K. & Van Echten, G. (1993). Ganglioside metabolism. Topology and regulation. *Adv. Lipid Res.* 26: 119-142.

Sandhoff, K., Kolter, T. & Van Echten-Deckert, G. (1998). Sphingolipid metabolism. Sphingoid analogs, sphingolipid activator proteins, and the pathology of the cell. *Ann. N. Y. Acad. of Sci.* 845: 139-151.

Sastry, P. S. (1985). Lipids of nervous tissue: composition and metabolism. *Prog. Lipid Res.* 24: 69-176.

Sato, A., Osakabe, T., Ikemoto, A., Watanabe, S., Kobayashi, T., & Okuyama, H. (1999). Long-term n-3 fatty acid deficiency induces no substantial change in the rate of protein synthesis in rat brain and liver. *Biol. Pharm. Bull.* 22(8): 775-779.

Sauer, F. C. (1935). Mitosis in the neural tub. *J. Comp. Neurol.* 62: 377-405.

Sauer, M. E. & Chittenden, A. E. (1959). Deoxyribonucleic acid content of cell nuclei in the neural tube of the chick embryo: Evidence for intermitotic migration of nuclei. *Exp. Cell res.* 16: 1-10.

Sayanova, O., Smith, M. A., Lapinskas, P., Stobart, A. K., Dobson, G., Christie, W. W., Shewry, P. R. & Napier, J. A. (1997) Expression of a borage desaturase cDNA containing an N-terminal cytochrome b5 domain results in the accumulation of high levels of delta6-desaturated fatty acids in transgenic tobacco. *Proc. Natl. Acad. Sci. USA* 94: 4211-4216.

Scarborough, G. A. & Nye, J. F. (1967). Properties of a phosphatidylmonomethylethanolamine N-methyl-transferase from *Neurospora crassa*. *Biochim. Biophys. Acta* 146:111-119.

Scheideler, M. A. & Dawson, G. (1986). Direct demonstration of the activation of UDP-N-acetylgalactosamine:[GM3]N-acetylgalactosaminyltransferase by cyclic AMP. *J. Neurochem.* 46: 1639-1643.

Schroeder, F., Nemezc, G., Wood, WG., Joiner, C., Morrot, G., Ayrault-Jarrier, M., & Devaux, PF. (1991) Transmembrane distribution of sterol in the human erythrocyte. *Biochim Biophys Acta.* 1066:183-92.

Shah, S. N., Peterson, N. A., & McKean, C. M. (1970) Cerebral lipid metabolism in experimental hyperphenylalanemia: Incorporation of <sup>14</sup>C-labelled glucose into total lipids. *J. Neurochem.*, 17: 279-284.

Shah, S.N., Peterson, N.A., & McKean, C. M. (1972). Impaired myelin formation in experimental hyperphenylalaninemia. *J. Neurochem.*, 19: 479-485.

Shah, S.N., & Johnson, R.C. (1975). Effect of deaminated metabolites of phenylalanine on desaturation of stearoyl Coa by cell free preparation from developing rat brain. *FEBS Lett.*, 49: 404-406.

Shah, S.N. (1979) Fatty acid composition of lipids of human brain myelin and synaptosomes: changes in phenylketonuria and down's syndrome. *Int. J. Biochem.*, 10: 477-482.

Sharp, P., Johnson, D., & Poulos, A. (1991). Molecular species of phosphatidylcholine containing very long chain fatty acids in human brain: enrichment in x-linked adrenoleukodystrophy brain and disease of peroxisome biogenesis brain. *J. Neurochem.* 56: 30-37.

Shimeno, H., Soeda, S., Sakamoto, M., Kouchi, T., Kowakame, T. & Kihara, T. (1998). Partial purification and characterization of sphingosine N-acyltransferase (ceramide synthase) from bovine liver mitochondrion-rich fraction. *Lipids* 33: 601-605.

Shull, G. E., Greb, J., & Lingrel, J. R. (1986). Molecular cloning of three distinct forms of the Na, K-ATPase  $\alpha$ -subunit from rat brain. *Biochem.* 25: 8125-8132.

Sidman, R. L., Miale, I. L., & Feder, N. (1959). Cell proliferation and migration in the primitive ependymal zone; an autoradiographic study of histogenesis in the nervous system. *Exp. Neurol.* 1: 322-333.

Sidman, R. L. & Rakic, P. (1973) Neuronal migration, with special reference to developing human brain. A review. *Brain Res.* 62: 1-35.

Sidman, R. L. & Rakic, P. (1982). Development of the human central nervous system. In W. Haymaker & R. A. Adams (Eds.). *Histology and histopathology of the nervous system.* Illinois: Caharles C. Thomas.

Siegel, G. J. Stahl, W. L., & Swanson, P. D. (1981). Ion transport. In G. J. Siegel, R. W. Albers, R. Katzman, & B. W. Agranoff (Eds.). *Basic neurochemistry* (pp.107-143). Boston: Little Brown.

Sinclair, A. J. & Crawford, M. A. (1972a) The accumulation of arachidonate and docosahexaenoate in developing rat brain. *Neurochem.* 19: 1753-1758.

Sinclair, A.J. & Crawford, M.A. (1972b). The incorporation of linolenic acid and docosahexaenoic acid into liver and brain lipids of developing rats. *FEBS Lett.* 86: 2903-2907.

Sinclair, A. J. (1975) Incorporation of radioactive polyunsaturated fatty acids into liver and brain of developing rat. *Lipids.* 10: 175-184.

Singer, S. J. & Nicholson, G. L. (1972). The fluid mosaic model of the structure of cell membranes. *Science* 175: 720-731.

Singh, I. (1983). Ceramide synthesis from free fatty acids in rat brain: function of NADPH and substrate specificity. *J. Neurochem.* 40: 1565-1570.

Skou, J. C. (1967). Enzymatic basis for active transport of sodium and potassium. *Protoplasma* 63: 303-308.

Skou, J. C. & Esmann, M. (1992). The Na,K-ATPase. *J. Bioenerg. Biomembr.* 24: 249-261.

Sonnino, S., Chigorno, V., Valsecchi, M., Pitto, M., & Tettamanti, G. (1992). Specific ganglioside-cell protein interactions: a study performed with GM1 ganglioside derivative containing photoactivable azide and rat cerebellar granule cells in culture. *Neurochem. Int.* 20: 315-321.

Spanner, S. & Ansell, G. B. (1979). Choline kinase and ethanolamine kinase activity in the cytosol of nerve endings from rat forebrain. *Biochem. J.* 178:753-760.

- Spemann, H. (1938). Embryonic development and induction. New York: University Press.
- Spence, M. W., Reed, S., & Cook, H. W. (1986). Acid and alkaline ceramidases of rat tissues. *Biochem. Cell Biol.* 64: 400-404.
- Sperry, R. W. (1963). Chemoaffinity in the orderly growth of nerve fiber patterns and connections. *Proc. Natl. Acad. Sci. USA* 50: 703-710.
- Spiegel, S. & Merrill, A. H. Jr. (1996). Sphingolipid metabolism and cell growth regulation. *FASEB J.* 10:1388-1397.
- Sprecher, H. D. (1981) Biochemistry of essential fatty acids. *Prog. Lipids Res.* 20:13-22.
- Sprecher, H.D. (2000) Metabolism of highly unsaturated n-3 and n-6 fatty acids. *Biochim Biophys Acta* 1486: 219-231.
- Sribney, M. & Kennedy, E. P. (1958). The enzymatic synthesis of sphingomyelin. *J. Biol. Chem.* 233: 1315-1322.
- Stahl, W. L. (1986). The Na, K-ATPase of nervous tissue. *Neurochem. Int.* 8: 449-476.
- Stahl, A., Hirsch, DJ., Gimeno, RE., Punreddy, S., Ge, P., Watson, N., Patel, S., Kotler, M., Raimondi, A., Tartaglia, LA., & Lodish, HF. (1999) Identification of the major intestinal fatty acid transport protein. *Mol Cell.* 4:299-308
- Ställberg-Stenhagen, S. K., & Svennerholm, L. (1965) Fatty acid composition of human brain sphingomyelins: normal variation with age and changes during myelin disorders. *J. Lipid Res.* 6: 146-155.
- Stekhoven, F.M., Tijmes, J., Umeda, M., Inoue, K., & DePont, J.J. (1994) Monoclonal antibody to phosphatidylserine inhibits Na, K-ATPase activity. *Biochim Biophys Acta* 1194:155-165.
- Stoffel, W. & Sticht, G. (1967). Metabolism of sphingosine bases. 3. Clinical syntheses of <sup>14</sup>C and <sup>3</sup>H labelled erythro- and threo-dihydrosphingosines and sphingosines. *Hoppe-Seylers Zeitschrift für Physiologische Chemie.* 348: 1561-1569.
- Stoffel, W., LeKim, D. & Sticht, G. (1968). Biosynthesis of dihydrosphingosine in vitro. *Hoppe-Seylers Zeitschrift für Physiologische Chemie.* 349: 664-670.
- Stone, EM., Nichols, BE., Kimura, AE., Weingeist, TA., Drack, A., & Sheffield, VC. (1994) Clinical features of a Stargardt-like dominant progressive macular dystrophy with genetic linkage to chromosome 6q *Arch Ophthalmol* 112:765-72

- Strickland, K. P. (1973). In G. B. Ansell, R. M. C. Dawson, & J. N. Hawthorne (Eds.), *Form and function of phospholipids* (pp. 9-42). Amsterdam: Elsevier.
- Stubbs, C. D. & Smith A. D. (1984). The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. *Biochim. Biophys. Acta.* 779: 89-137.
- Sun, G. Y. & Horrocks, L. A. (1970). The acyl and alk-1-enyl groups of the major phosphoglycerides from ox brain myelin and mouse brain microsomal, mitochondrial and myelin fractions. *Lipids* 5: 1006-1012.
- Sun, G. Y. (1973) Phospholipids and acyl groups in subcellular fractions from human cerebral cortex. *J. Lipid Res.*, 14: 656-662.
- Sun, G. Y. & Sun, A. Y. (1974). Synaptosomal plasma membranes: acyl group composition of phosphoglycerides and (Na<sup>+</sup> + K<sup>+</sup>)-ATPase activity during essential fatty acid deficiency. *J. Neurochem.* 22: 15-18.
- Sun, G. Y., DeSousa, B. N., Danopoulos, V., & Horrocks, L. A. (1983) Phosphoglycerides and their acyl group composition in myelin and microsomes of rat spinal cord during development. *Int. J. Devl. Neuroscience* 1: 59-64.
- Sundler, R. & Åkesson, B. (1975). Regulation of phospholipid biosynthesis in isolated rat hepatocytes. *J. Biol. Chem.* 250: 3359-3367.
- Suzuki, K. (1965). The pattern of mammalian brain gangliosides III. Regional and development differences. *J. Neurochem.* 12: 969-979.
- Svennerholm, L. (1963) Chromatographic separation of human brain gangliosides. *J. Neurochem* 10:613-623.
- Svennerholm, L. (1964). The distribution of lipids in the human nervous system. I. Analytical procedure lipids of fetal and newborn brain. *J. Neurochem.* 11: 839-853.
- Svennerholm, L. (1965). Gangliosides and other glycolipids of human placenta. *Acta Chem. Scand.* 19: 1506-1507.
- Svennerholm, L. (1968). Distribution and fatty acid composition of phosphoglycerides in normal human brain. *J. Lipid Res.* 9: 570-579.
- Svennerholm, L. (1980) Ganglioside designation. In: L. Svennerholm, P., Mandel, H., Dreyfus & P.F., Urban (Eds.) *Structure and Function of Gangliosides*. Adv. Exp. Med. Biol., Vol 125. Plenum Press, New York, pp.11.

Svennerholm, L. (1988) Immunological and tumoral aspects of gangliosides. In: R.W. Ledeen, E.L., Hogan, G., Tettamanti, A.J., Yates & R.K. Yu. (Eds.) *New Trends in Ganglioside Research*, Fidia Research Series, Vol 14. Liviana Press, Padova. pp. 135-150.

Svennerholm, L. & Raal, A. (1961) Composition of brain gangliosides. *Biochem Biophys Acta* 53: 422-424.

Svennerholm, L. & Vanier, M. T. (1973). The distribution of lipids in the human nervous system. IV. Fatty acid composition of the phosphoglycerides of hum fetal and infant brain. *Brain Res.* 50: 341-351.

Svennerholm, L. & Vanier, M. T. (1978). Lipid and fatty acid composition of human cerebral myelin during development. *Adv. Exp. Med. Biol.* 100: 27-41. /

Svennerholm, L. Vanier, M. T., & Jungbjer, B. (1978). Changes in fatty acid composition of human brain myelin lipids during maturation. *J. Neurochem.* 30: 1383-1390.

Sweadner, K. J. & Goldin, S. M. (1980). Active transport of sodium and potassium ions. *N. Engl. J. Med.* 302: 777-784.

Sweitzer, T. D. & Kent, C. (1994). Expression of wild-type and mutant rat liver CTP: phosphocholine cytidylyltransferase in a cytidylyltransferase-deficient Chinese hamster ovary cell line. *Arch. Biochem. Biophys.* 311: 107-116.

Tahin, Q. S., Blum, M., & Carafoli, E. (1981). The fatty acid composition of subcellular membranes of rat liver, heart and brain: Diet-induced modifications. *Eur. J. Biochem.* 121: 5-13.

Takenawa, T. & Egawa, K. (1977). CDP-diglyceride:inositol transferase from rat liver. Purification and properties. *J. Biol. Chem.* 252:5419-5423.

Tanaka, S. Nikawa, J., Hideaki, I., Yamashita, S., & Hosaka, K. (1996). Molecular cloning of rat phosphatidylinositol synthase cDNA by functional complementation of the yeast *Saccharomyces cerevisiae* pis mutation. *FEBS Lett.* 393: 89-92.

Tanford, C. (1978). The hydrophobic effect and the organization of living matter. *Science* 200: 1012-1018.

Tani, M., Okino, N., Mitsutake, S., Tanigawa, T., Izu, H. & Ito, M. (2000). Purification and characterization of a neutral ceramidase from mouse liver. A single protein catalyzes the reversible reaction in which ceramide is both hydrolyzed and synthesized. *J. Biol. Chem.* 275: 3462-3468.

Taylor, E. H., & Hommes, F. A. (1983). Effect of experimental hyperphenylalaninemia on myelin metabolism at later stages of brain development. *Int. J. Neurosci.*, 20: 217-228.

Tettamanti, G. & Masserini, M. (1987). Gangliosides and the transfer of information through the plasma membrane. In E. Bertoli, D. Chapman, A. Cambria, & U. Scapagnini (Eds.), *Biomembrane and receptor mechanism*, Fidia Research Series, Vol. 7 (pp. 223-260). Padova/Berlin: Liviana Press/Springer Verlag.

Tettamanti, G. & Riboni, L. (1994). Gangliosides turnover and neural cells function: a new perspective. *Prog. Brain Res.* 101: 11-16.

Tettamanti, G., Yates, A. J. & Yu, R. K. (Eds.). *New trends in ganglioside research: Neurochemical and neuroregenerative aspects*, Fidia Research Series, Vol. 14 (pp. 229-243). Padova/Berlin: Liviana Press/Springer Verlag.

Therien, A. G., Goldshleger, R., Karlsh, S. J. D., & Blostein, R. (1997). Tissue-specific distribution and modulatory role of the  $\gamma$  subunit of the Na, K-ATPase. *J. Biol. Chem.* 272: 32628-32634.

Therien, A. G., Karlsh, S. J. D., & Blostein, R. (1999). Expression and functional role of the  $\gamma$  subunit of the Na, K-ATPase. *J. Biol. Chem.* 274: 12252-12256.

Thomas, P. P. & Brewer, G. J. (1990) Gangliosides and synaptic transmission. *Biochim. Biophys. Acta* 1031: 277-289.

Thompson, T. E. & Brown, R. E. (1988). Biophysical properties of gangliosides. In R. w. Ledeen, E. L. Hogan, Y. Nagai, G. Tettamanti, A. J. Yates, & R. K. Yu (Eds.), *New trends in ganglioside research: Neurochemical and neuroregenerative aspects*, Fidia Research Series, Vol. 14 (pp. 65-78). Padova/Berlin: Liviana Press/Springer Verlag.

Thompson, J. M., McFarland, G. K., Hirsch, J. E., & Tucker, S. M. (1993). *Mosby's Clinical Nursing* [3<sup>rd</sup> ed.]. St. Louis: Mosby.

Thomson, A. B., De Pover, A., Keelan, M., Jarocka-Cyrta, E., & Clandinin, M. T. (1997). Inhibition of lipid absorption as an approach to the treatment of obesity. *Meth. in Enzymol.* 286: 3-44.

Thomson, AB., De Pover, A., Keelan, M., Jarocka-Cyrta, E., & Clandinin, MT. (1997) Inhibition of lipid absorption as an approach to the treatment of obesity. *Meth Enzymol* 286:3-44

Tiemeyer, M., Yasuda, Y., & Schnaar, R. L. (1990). Ganglioside specific binding protein on rat brain membranes. *J. Biol. Chem.* 264: 1671-1681.

Tobler, A., Munker, R., Heitjan, D. & Koeffler, H. P. (1987). In vitro interaction of recombinant tumor necrosis factor alpha and all-trans-retinoic acid with normal and leukemic hematopoietic cells. *Blood* 70: 1940-1946.

Todd, J., Post-Beittenmiller, D. & Jaworski, J.G. (1999) KCS1 encodes a fatty acid elongase 3-ketoacyl-CoA synthase affecting wax biosynthesis in *Arabidopsis thaliana*. *Plant Journal*. 17:119-30.

Toke, D.A. & Martin, C.E. (1996) Isolation and characterization of a gene affecting fatty acid elongation in *Saccharomyces cerevisiae*. *J. Biol Chem* 271:18413-22.

Trinchera, M. & Ghidoni, R. (1990). Subcellular biosynthesis and transport of gangliosides from exogenous lactosylceramide in rat liver. *Biochem. J.* 266: 363-369.

Uauy, R. D., Birch, D. G., Birch, E. E., Tyson, J. E., & Hoffman, D. R. (1990). Effect of dietary omega-3 fatty acids on retinal function of very-low-birth-weight neonates. *Pediatr. Res.* 28: 485-492.

Uchida, T. & Yamashita, S. (1992). Choline/ethanolamine kinase from rat brain. *Methods Enzymol.* 209: 147-153.

Uckun, F. M., Tuel-Ahlgren, L., Song, C. W., Waddick, K., Myers, D. E., Kirihara, J., Ledbetter, J. A. & Schieven, G. L. (1992). Ionizing radiation stimulates unidentified tyrosine-specific protein kinases in human B-lymphocyte precursors, triggering apoptosis and clonogenic cell death. *Proc. Natl. Acad. Sci. USA* 89: 9005-9009.

Uckun, F. M., Schieven, G. L., Tuel-Ahlgren, L. M., Dibirdik, I., Myers, D. E., Ledbetter, J. A. & Song, C. W. (1993). Tyrosine phosphorylation is a mandatory proximal step in radiation-induced activation of the protein kinase C signaling pathway in human B-lymphocyte. *Proc. Natl. Acad. of Sci. USA* 90: 252-256.

Ullman, M. D. & Radin, N. S. (1974). The enzymatic formation of sphingomyelin from ceramide and lecithin in mouse liver. *J. Biol. Chem.* 249: 1506-1512.

Vaidyanathan, V.V., Rao, K.V.R. & Salem, N. Jr. (1996) Regulation of diacylglycerol kinase in rat brain membranes by docosahexaenoic acid. *Neurosci Lett* 179: 171-174.

Van Brocklyn, J. R., Lee, M. J., Menzeleev, R., Olivera, A., Edsall, L., Cuvillier, O., Thomas, D. M., Coopman, P. J., Thangada, S., Liu, C. H., Hla, T. & Spiegel, S. (1998). Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. *J. Cell Biol.* 142: 229-240.

Van Brocklyn, J. R., Tu, Z., Edsall, L. C., Schmidt, R. R. & Spiegel, S. (1999). Sphingosine 1-phosphate-induced cell rounding and neurite retraction are mediated by the G protein-coupled receptor H218. *J. Biol. Chem.* 274: 4626-4632.

Van Echten, G. & Sandhoff, K. (1993) Ganglioside metabolism: enzymology, topology and regulation. *J. Biol Chem* 268: 5341-5344.

- Van Houwelingen, Puls, A. C., & Hornstra, G. (1992). Essential fatty acid status during early human development. *Early Hum. Dev.* 31: 97-111.
- Vance, D. E. & Vance, J. E. (1985) *Biochemistry of lipids and membranes*. Amsterdam, Netherlands: Elsevier Science.
- Vanderhoof, J., Gross, S., Hegyi, T., Clandinin, T., Porcelli, P. et al. (1999). Evaluation of a long-chain polyunsaturated fatty acid supplemented formula on growth, tolerance, and plasma lipids in preterm infants up to 48 weeks postconceptional age. *J. Ped. Gastroenterology Nutr.* 29: 318-326.
- Vanier, M. T., Holm, M., Ohman, R., & Svennerholm, L. (1971) Developmental profiles of gangliosides in human and rat brain. *J. Neurochem.* 18: 581-592.
- Voelker, D. R. & Kennedy, E. P. (1982). Cellular and enzymic synthesis of sphingomyelin. *Biochemistry* 21: 2753-2759.
- Voss, A., Reinhart, M., Sankarappa, S., & Sprecher, H. (1991). The metabolism of 7, 10, 13, 16, 19-docosapentaenoic acid to 4, 7, 10, 13, 16, 19-docosahexaenoic acid in rat liver is independent of a 4-desaturase. *J. Biol. Chem.* 266: 19995-20000.
- Walkey, C. J., Cui, Z., Agellon, L. B., & Vance, D. E. (1996). Characterization of the murine phosphatidylethanolamine N-methyl-transferase-2 gene. *J. Lipid Res.* 37: 2341-2350.
- Wallick, E. T., Lane, I. K., & Schwartz, A. (1979). Biochemical mechanism of the sodium pump. *A. Rev. Physiol.* 41: 397-411.
- Walter, V. P., Sweaney, K., & Morre, D. J. (1983). Neutral lipid precursors for gangliosides are not formed by rat liver homogenates or by purified cell fractions. *Biochim. Biophys. Acta* 750: 346-352.
- Wang, F., Nobes, C. D., Hall, A. & Spiegel, S. (1997). Sphingosine 1-phosphate stimulates rho-mediated tyrosine phosphorylation of focal adhesion kinase and paxillin in Swiss 3T3 fibroblasts. *Biochem. J.* 324: 481-488.
- Wang, F., Nohara, K., Olivera, A., Thompson, E. W. & Spiegel, S. (1999). Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate. *Exp. Cell Res.* 247: 17-28.
- Watterson, R. L. (1965). In R. L. DeHaan & H. Ursprung (Eds.), *Organogenesis* (pp. 129-159). New York: Holt, Rinehart, and Winston.
- Watts, J. L. & Browse, J. (1999) Isolation and characterization of a delta 5-fatty acid desaturase from *Caenorhabditis elegans*. *Archives Bioch. Biophys.* 362: 175-182.

- Weinberg, R. A. (1990). The retinoblastoma gene and cell growth control. *Trends Biochem. Sci.* 15: 199-202.
- Weinhold, P. A., Rounsifer, M. E., Charles, L., & Felman, D. A. (1989). Characterization of cytosolic forms of CTP: choline-phosphate cytidyltransferase in lung, isolated alveolar type II cells. A549 cell and Hep G2 cells. *Biochim. Biophys. Acta* 1006: 299-310.
- Weisinger, H. S., Vingrys, A. J., & Sinclair, A. J. (1996). The effect of docosahexaenoic acid on the electroretinogram of the guinea pig. *Lipids* 31: 65-70.
- Weiss, B. & Stoffel, W. (1997). Human and murine serine-palmitoyl-CoA transferase--cloning, expression and characterization of the key enzyme in sphingolipid synthesis. *Eur. J. Biochem.* 249: 239-247.
- Wells, M. E. & Dittmer, J. C. (1967). A comprehensive study of the postnatal changes in the concentration of the lipids of developing rat brain. *Biochemistry.* 6: 3169-3175.
- Werkman, S.H. & Carlson, S.E. (1996) A randomized trial of visual attention of preterm infants fed docosahexaenoic acid until nine months. *Lipids* 31:91-97.
- White, D.A. (1974). In: *Forms and Function of Phospholipids* (G.B. Ansell, J.N. Hawthorne, and R.M.C. Dawson, eds), pp 441-450. Elsevier, Amsterdam.
- Widdowson, E. M. (1968). Growth and composition of the human fetus and newborn. In *Biology of gestation*, N. S. Assali (Ed.). Vol. 2. New York: Academic Press. pp. 1-49.
- Widdowson, E. M., Southgate, D. A. T., & Hay, E. N. (1979). In *Proceedings of the fifth nutricia symposium on nutrition and metabolism of the fetus and infant*, H. K. A. Visser (Ed.). Martinus Nijhoff: The Hague. pp. 169-177.
- Wiegandt, H. (1985) Gangliosides. In: H., Wiegandt (Ed.), *New Comprehensive Biochemistry: Glycolipids*, Vol 10, Elsevier, Amsterdam, pp. 199-260.
- Willatts, P., Forsyth, J.S., DiModugno, M.K., Varma, S., & Colvin, M. (1998) Influence of long-chain polyunsaturated fatty acids on infant cognitive function. *Lipids* 33:973-980.
- Wilson, H. M., Neumuller, W., Eibl, H., Welch, W. H., & Reitz, R. C. (1995). Structural basis of the phospholipid acyltransferase enzyme substrate specificity: a computer modeling study of the phospholipid acceptor molecule. *J. Lipid Res.* 36: 429-439.
- Wolff, R. A., Dobrowsky, R. T., Bielawska, A., Obeid, L. M. & Hannun, Y. A. (1994). Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. *J. Biol. Chem.* 269: 19605-19609.

Wood, W.G., Cornwell, M., & Williamson, L.S. (1989) High performance thin-layer chromatography and densitometry of synaptic plasma membrane lipids. *J. Lipid Res* 30:775-9.

Wood, W.G., Schroeder, F., Hogy, L., Rao, A.M., & Nemezc, G. (1990) Asymmetric distribution of a fluorescent sterol in synaptic plasma membranes: effects of chronic ethanol consumption. *Biochim Biophys Acta.* 1025:243-6.

Wood, W.G., Rao, A.M., Igbavboa, U., & Semotuk, M. (1993) Cholesterol exchange and lateral cholesterol pools in synaptosomal membranes of pair-fed control and chronic ethanol-treated mice. *Alcoholism: Clin Exp Res* 17:345-50

Wu, J., Spiegel, S. & Sturgill, T. W. (1995). Sphingosine 1-phosphate rapidly activates the mitogen-activated protein kinase pathway by a G protein-dependent mechanism. *J. Biol. Chem.* 270: 11484-11488.

Wurtman, R. J., Hefti, F., & Melamed, E. (1981). Precursor control of neurotransmitter synthesis. *Pharmacol. Rev.* 32: 315-335.

Yada, Y., Higuchi, K. & Imokawa, G. (1995). Purification and biochemical characterization of membrane-bound epidermal ceramidases from guinea pig skin. *J. Biol. Chem.* 270: 12677-12684.

Yakovlev, P. I. & Lecours, A. R. (1967). The myelogenetic cycles of regional maturation of the brain. In A. Minkowski (Ed.), *Regional development of the brain in early life.* Oxford: Blackwell Scientific.

Yamamoto, N., Saitoh, M., Moriuchi, A., Nomura, M. & Okuyama, H. (1987) Effect of dietary linolenate/linoleate balance on brain lipid compositions and learning ability of rats. *J. Lipid Res.* 28: 144-151.

Yao, J. K. (1988) Biosynthesis of membrane cholesterol during peripheral nerve development, degeneration and regeneration. *Lipids* 23: 857-862.

Yao, J. S., Wang, J. F., Li, H. Y., Liu, T. M., Wu, G., & Duan, W. Z. (1988) Pathogenesis of atherosclerosis: I: Role of the nervous system. *Angiology.* 39:714-9

Yarowasky, P. J. & Ingvar, D. H. (1981). Symposium summary. Neuronal activity and energy metabolism. *Fed. Proc.* 40: 2353-2362.

Yasuda, Y., Tiemeyer, M., Blackburn, C. C., & Schnaar, R. (1988). Neuronal recognition of gangliosides: evidence for a brain ganglioside receptor. In R. W. Ledeen, E. L. Hogan,

Yavin, E. & Gatt, S. (1969). Enzymatic hydrolysis of sphingolipids. 8. Further purification and properties of rat brain ceramidase. *Biochemistry* 8: 1692-1698.

- Yavin. E. & Menkes, J. H. (1974). Polyenoic acid metabolism in cultured dissociated brain cells. *J. Lipid Res.* 15: 152-157.
- Yavin. E. & Zegler, B. P. (1977). Regulation of phospholipid metabolism in differentiating cells from rat brain cerebral hemispheres in culture. *J. Biol. Chem.* 252: 260-267.
- Yeagle, P. L. (1985) Cholesterol and the cell membrane. *Biochim Biophys Acta.* 822:267-87.
- Yeagle P. I. (1989). Lipid regulation of cell membrane structure and function. *FASEB J.* 3: 1833-1842.
- Yeagle, P. L. (1991) Modulation of membrane function by cholesterol. *Biochimie.* 73:1303-10
- Yoshida, S., Yasuda, A., Kawazato, H., Sakai, K., Shimada, T., Takeshita, M., Yuasa, S., Kobayashi, T., Watanabe, S. & Okuyama, H. (1997) Synaptic vesicle ultrastructural changes in the rat hippocampus induced by a combination of  $\alpha$ -linolenate deficiency and learning a task. *J. Neurochem* 68:1261-1268.
- Younes, A., Kahn, D. W., Besterman, J. M., Bittman, R., Byun, H. & Kolesnick, R. N. (1992). Ceramide is a competitive inhibitor of diacylglycerol kinase in vitro and in intact human leukemia (HL-60) cells. *J. Biol. Chem.* 267: 842-847.
- Young, R. M., Shull, G. E., & Lingrel, J. E. (1987). Multiple mRNAs from rat kidney and brain encode a single Na, K-ATPase  $\alpha$ - subunit protein. *J. Biol. Chem.* 262: 4905-4910.
- Yu, R.K. & Saito, M. (1989) Structure and localization of gangliosides In: R.U. Margolis & R.K. Margolis, (Eds.). *Neurobiology of Glycoconjugates*, Plenum Press, New York. pp.1-42.
- Zank, TK., Zahringer, U., Lerchl, J. & Heinz, E. (2000) Cloning and functional expression of the first plant fatty acid elongase specific for delta-6-polyunsaturated fatty acids. *Biochem Soc Trans* 28:654-658.
- Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G. & Spiegel, S. (1991). Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. *J. Cell Biol.* 114: 155-167.
- Zhang, K., Kniazeva, M., Han, M., Li, W., Yu, Z., Yang, Z., Li, Y., Metzker, M. L., Allikmets, R., Zack, DJ., Kakuk, LE., Lagali, PS., Wong, PW., MacDonald, IM., Sieving, PA., Figueroa, DJ., Austin, CP., Gould, RJ., Ayyagari, R., & Petrukhin, K. (2001) A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy *Nature Genetics.* 27:89-93


Zhou, J. & Saba, J. D. (1998). Identification of the first mammalian sphingosine phosphate lyase gene and its functional expression in yeast. *Biochem. Biophys. Res. Comm.* 242: 502-507.

Zhou, S. L., Stump, D., Kiang, C. L., Isola, L. M., & Berk, P. D. (1995) Mitochondrial aspartate aminotransferase expressed on the surface of 3T3-L1 adipocytes mediates saturable fatty acid uptake. *Proc Soc Exp Biol & Med* 208:263-70

## CHAPTER II. RESEARCH PLAN

### A. RATIONALE

Early studies on brain morphology by Dobbing and Sands (1979) demonstrated that brain growth is non-linear and occurs in "spurts" which, depending on species may be either before or after birth. Also, studies by Dobbing and Sands (1979) have led to the concept of precocial (neurologically mature at birth e.g. sheep and guinea pig) and non-precocial (neurologically immature at birth e.g. man and rat) species (Figure 2.1). In this context, the rat provides a useful animal model for human brain development providing that account is taken of different gestational time periods. Thus, the use of two and five-week old rats in this study is adequate to mimic the pattern of brain development in preterm infants which occurs postnatally (Dobbing & Sands, 1979; Figure 2.1).



**Figure 2.1 Brain Growth as a Function of Age in Different Species** (expressed as increase in brain weight as percentage of the adult brain weight) as a function of age where the units of time are: rat and guinea pig, days; rabbit, 2 days; monkey, 4 days; sheep, 5 days; pig, weeks; man, months (Adapted from Dobbing & Sands, 1979)

Most research in infant nutrition investigating the effects of diets with or without C20:4n-6 and/or C22:6n-3 has shown compositional differences in the C20:4n-6 and/or C22:6n-3 content of membrane phospholipids. However, no study to date has examined whether diets with or without C22:6n-3 can increase the C22:6n-3 content of neuronal and glial cell phospholipids from whole brain of rats. It is not known whether a high intake of C18:3n-3 or a low ratio of C18:2n-6 to C18:3n-3 will result in increased C22:6n-3 accumulation in neuronal and glial cell phospholipids from rat whole brain. The metabolic fate of C18:3n-3 in the whole body of developing rats is also not known.

The SPM plays a very important role in communication between brain nerve cells, and contains high levels of phospholipids (Cotman et al., 1971; Breckenridge et al., 1973; DeGeorge et al., 1991; Jones et al., 1997). However, there is little information pertaining to the effects of dietary C20:4n-6 and C22:6n-3 on SPM phospholipid content and fatty acid composition in developing rats.

Although gangliosides are enriched in the SPM (Hakomori & Igarashi, 1993). It is not known if C20:4n-6 and C22:6n-3 are present as the fatty acyl moiety of rat SPM gangliosides. It is also not known if dietary fat can alter the C20:4n-6 and C22:6n-3 content of rat SPM gangliosides.

Phospholipids and sphingolipids are important for cell membrane structure and functions (Singer & Nicholson, 1972). Membrane-bound enzymes, such as, Na, K-ATPase which are particularly located in the SPM, play a key role in neuronal conduction in brain (Skou, 1967). Previously, Tsutsumi et al. (1995) showed that rats fed C18:3n-3 deficient diets had significantly lower brain Na, K-ATPase activity ( $V_{max}$ ) than rats fed diets with adequate C18:3n-3. The affinity ( $K_m$ ) of Na, K-ATPase for ATP was not significantly different between rats fed diets with or without C18:3n-3 (Tsutsumi et al., 1995). However, current knowledge of the effects of dietary fat with C20:4n-6 and C22:6n-3 and age on SPM Na, K-ATPase kinetics in rats is limited.

Past research has shown that sphingolipid metabolites, ceramide and sphingosine, play an important role in biological functions, such as cell differentiation, proliferation, apoptosis and signal transduction (reviewed by Merrill et al., 1997). Since sphingolipids, particularly, SM and gangliosides are concentrated in the SPM, it would be of interest to determine whether membrane-bound CDase activity is present in the SPM. Thus,

studying the effects of diets with or without C18:3n-3 and/or C20:4n-6 and C22:6n-3 on brain membrane composition and function of rats may provide additional information on the role of these fatty acids in brain.

## **B. HYPOTHESES**

Dietary fat will induce changes in phospholipid content, phospholipid and ganglioside fatty acid composition in developing brain. Specifically, dietary C20:4n-6 and C22:6n-3 will increase the C20:4n-6 and C22:6n-3 content of rat brain phospholipids with subsequent increases in SPM Na, K-ATPase activity. /

It is specifically hypothesized that:

1. Feeding a high C18:3n-3 diet will not increase the C22:6n-3 content in neuronal cell phospholipids from whole brain of rats at two weeks of age.
2. Feeding a high C18:3n-3 diet will increase the C18:3n-3 content in whole body and tissue lipids of rats at two weeks of age.
3. Feeding diets with C22:6n-3 will increase the content of C22:6n-3 in neuronal and glial cell phospholipids from whole brain of rats at two weeks of age.
4. Feeding a diet with C20:4n-6 and C22:6n-3 will increase the total and individual phospholipids and decrease cholesterol content of the SPM of rats at two and five weeks of age.
5. Feeding a diet with C20:4n-6 and C22:6n-3 will increase the C20:4n-6 and C22:6n-3 content in phospholipids of the SPM of rats at two and five weeks of age.
6. The Km and Vmax of Na, K-ATPase will increase in the SPM of rats from two to five weeks of age.

7. Feeding a diet with C20:4n-6 and C22:6n-3 will not alter the  $K_m$  but increase the  $V_{max}$  of Na, K-ATPase in the SPM of rats at two and five weeks of age.
8. C20:4n-6 and C22:6n-3 are present as the fatty acid moiety of SPM gangliosides and feeding dietary fat will alter the C20:4n-6 and C22:6n-3 content of individual gangliosides in the SPM of two-week-old rats.
9. Alkaline CDase is present in the SPM of rat pups at two weeks of age.

### C. CHAPTER FORMAT

The hypotheses posed are tested in a sequence of experiments. These experiments are organized in chapters as follows:

#### **Chapter III** test hypothesis 1.

The effect of providing a high dietary C18:3n-3 level on the C22:6n-3 content of neuronal cell phospholipids from whole brain is determined using the control diet with C18:2n-6 or C18:3n-3 added. The 20% (wt/wt) fat diets supplying C18:3n-3 from 1.6% (C18:2n-6/C18:3n-3 =21.6) to 17.5% (C18:2n-6/C18:3n-3 =1.0) of the total fatty acids are fed to the dams at parturition. The rat pups received the C18:3n-3 diets from the dam's milk from birth to two weeks of age.

#### **Chapter IV** tests hypothesis 2.

The effects of feeding a high C18:3n-3 diet on the C18:3n-3 content in whole body and tissue lipids are determined using the control diet with C18:2n-6 or C18:3n-3. The 20% (wt/wt) fat diets supplying C18:3n-3 from 1.6% (C18:2n-6/C18:3n-3 =21.6) and 17.5% (C18:2n-6/C18:3n-3=1.0) of the total fatty acids are fed to the dams at parturition. The rat pups received the same diet fat treatments from the dam's milk from birth to two weeks of age.

**Chapter V** tests hypothesis 3.

The effect of dietary C22:6n-3 on the neuronal and glial cell phospholipid C22:6n-3 content from rat whole brain is examined. The 20% (wt/wt) fat diets are formulated to reflect the fatty acid composition of a conventional infant formula (SMA) providing a C18:2n-6 to C18:3n-3 ratio of 7.8:1 (control diet). The C18:2n-6 to C18:3n-3 ratio of 4:1 diet has been made by adding C18:3n-3 to the control diet. Diet with 0.7% C22:6n-3 has been made by adding this fatty acid to the control diet. The rat pups received the same diet fat treatments from the dam's milk from birth to two weeks of age.

**Chapter VI** tests hypothesis 4, 5, 6, and 7.

The effects of feeding diets with or without C20:4n-6 and C22:6n-3 on the total and individual content of phospholipids and cholesterol (hypothesis 4); the C20:4n-6 and C22:6n-3 content of phospholipids (hypothesis 5); the kinetics of Na, K-ATPase with age (hypothesis 6); and diet treatment (hypothesis 7) are measured using control, low C18:3n-3, and C20:4n-6 and C22:6n-3 diets. The low C18:3n-3 diet has been made by adding safflower oil (C18:2n-6) as the fat blend. The C20:4n-6 and C22:6n-3 diet has been made by adding these two fatty acids to the control diet. The rat pups received the same diet fat treatments from the dam's milk from birth to two weeks of age. After weaning, the rat pups will be fed the same diets as their dams to five weeks of age.

**Chapter VII** tests hypothesis 8.

The presence of C20:4n-6 and C22:6n-3 in SPM gangliosides and the effects of feeding diets with or without C20:4n-6 and C22:6n-3 on SPM ganglioside fatty acid content are determined using control, low C18:3n-3, and C20:4n-6 and C22:6n-3 diets. The low C18:3n-3 diet has been made by adding safflower oil (C18:2n-6) as the fat blend. The C20:4n-6 and C22:6n-3 diet has been made by addition of these two fatty acids to the control diet. The rat pups received the same diet fat treatments from the dam's milk from birth to two weeks of age.

**Chapter VIII** tests hypothesis 9.

The presence of alkaline CDase in the SPM will be determined with rat pups fed a maternal diet with a C18:2n-6 to C18:3n-3 fatty acid ratio of 7.8:1 from birth to two weeks of age.

**Chapter IX** provides a general summary, conclusions, implications and suggestions for future research

**Chapter I.**

(Selected sections from this chapter have been published in) /

Clandinin, M. T., Bowen, R. A. R., & Suh, M. (2001). Impact of Dietary Essential Fatty Acids on Neuronal Structure and Function. In *Neuronal Membrane to Physiological and Behavioral Function*. Humana Press (in press)

**Chapter III.**

Bowen, R. A. R. , Wierzbicki, A. A. & Clandinin, M. T. (1999) Does Increasing Dietary C18:3n-3 Content Increase the C22:6n-3 Content of Phospholipids in Neuronal Cells of Neonatal Rats? *Pediatr Res.* 45: 815-819.

**Chapter IV.**

Bowen, R. A. R. & Clandinin, M. T. (2000). High Dietary 18:3n-3 Increases the C18:3n-3 But Not the C22:6n-3 Content in the Whole Body, Brain, Skin, Epididymal Fat Pads, and Muscles of Suckling Rat Pups. *Lipids* 35: 389-394.

**Chapter V.**

Bowen, R. A. R & Clandinin, M. T. (2000). Dietary Preformed C22:6n-3 is More Effective than Higher Levels of C18:3n-3 in Increasing the C22:6n-3 Content in Phospholipids of Neuronal and Glial Cells from Whole Brain in Neonatal Rat (Submitted to *Lipids*).

**Chapter VI.**

**Bowen, R. A. R. & Clandinin, M. T. (2001). Dietary Linolenic and Docosahexaenoic Acid Alters Synaptic Plasma Membrane Phospholipid Fatty Acid Composition and Sodium-Potassium Adenosine Triphosphatase Kinetics in Developing Rats (Submitted to J. Neurochem).**

/

## E. REFERENCES

- Breckenridge, W. C., Morgan, I. G., Zanetta, J. P., & Vincendon, G. (1973). Adult rat brain synaptic vesicles II. Lipid composition. *Biochim. Biophys. Acta* 20: 681-6.
- Cotman, C. W. & Matthews, D. A. (1971). Synaptic plasma membranes from rat brain synaptosomes: isolation and partial characterization. *Biochim. Biophys. Acta* 249: 380-394.
- DeGeorge, J. J., Nariai, T., Yamazaki, S., Williams, W. M., & Rapoport, S. I. (1991). Arecoline-stimulated brain incorporation of intravenously administered fatty acids in anesthetized rats. *J. Neurochem.* 56: 352-355.
- Dobbing, J. & Sands, J. (1979) Comparative aspects of the brain growth spurt. *Early Human Dev.* 3: 79-83.
- Hakomori, S. & Igarashi, Y. (1993). Gangliosides and glycosphingolipids as modulators of cell growth, adhesion, transmembrane signaling. *Adv. Lipid Res.* 25: 147-162.
- Jones, C. R., Arai, T., & Rapoport, S. I. (1997). Evidence for the involvement of C22:6n-3 in cholinergic stimulated signal transduction at the synapse. *Neurochem. Res.* 22: 663-70.
- Kimelberg, H. K. & Papahadjopoulos, D. (1974) Effects of phospholipid acyl chain fluidity, phase transitions, and cholesterol on (Na<sup>+</sup> + K<sup>+</sup>)-stimulated adenosine triphosphatase. *J. Biol. Chem.* 249: 1071-1080.
- Merrill, A. H. Jr., Schmelz, E. M., Dillehay, D. L., Spiegel, S., Shayman, J. A., Schroeder, J. J., Riley, R. T., Voss, K. A. & Wang, E. (1997). Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology. *Tox. Appl. Pharmol.* 42: 208-225.
- Singer, S. J. & Nicholson, G. L. (1972). The fluid mosaic model of the structure of cell membranes. *Science* 175: 720-731.
- Skou, J. C. (1967). Enzymatic basis for active transport of sodium and potassium. *Protoplasma* 63: 303-308.
- Tsutsumi, T., Yamauchi, E., Suzuki, E., Watanabe, S., Kobayashi, T., & Okuyama, H. (1995). Effect of a high alpha-linolenate and high linoleate diet on membrane associated enzyme activities in rat brain - modulation of Na<sup>+</sup>-K<sup>+</sup>-ATPase activity at suboptimal concentration of ATP. *Biol. Pharm. Bull.* 18: 664-670.
- Wurtman, R. J., Hefti, F., & Melamed, E. (1981). Precursor control of neurotransmitter synthesis. *Pharmacol. Rev.* 32: 315-335.

### **CHAPTER III. DOES INCREASING DIETARY C18:3N-3 ACID CONTENT INCREASE THE C22:6N-3 CONTENT OF PHOSPHOLIPIDS IN NEURONAL CELLS OF NEONATAL RATS?**

#### **A. INTRODUCTION**

C20:4n-6 and C22:6n-3 are among the most abundant fatty acids in the central nervous system phospholipids. These fatty acids are found in high concentrations in brain SPM and in photoreceptor cells (Sinclair et al., 1972; Anderson et al., 1974; Fliesler & Anderson, 1983). C20:4n-6 plays an important role as a precursor of biologically active molecules like prostanoids, leukotrienes, and other lipoxygenase products (Kinsella et al., 1990). C22:6n-3 is involved in providing a specific structural environment within the phospholipid bilayer that influences important membrane functions, such as, ion or solute transport, receptor activity, and adenylate cyclase activity (Stubbs & Smith, 1984; Sastry, 1985).

Research in infant nutrition has demonstrated that during the last trimester of gestation the fetal brain accrues fatty acids of the n-6 and n-3 types (Clandinin et al., 1980a). These fatty acids may be derived from the placenta *in utero* with formation of major neural tissue requiring approximately 43 mg of n-6 and 22 mg of n-3 fatty acids per week (Clandinin et al., 1980a and 1980b; Clandinin et al., 1981). The accretion of essential fatty acids in neural tissues is predominately C20:4n-6 and C22:6n-3 (Clandinin et al., 1980b). It has also been estimated that requirements for n-6 and n-3 fatty acids in neuronal tissue synthesis can only be supplied from labile hepatic fatty acid reserves for 9 and 2.3 days, respectively, (Clandinin et al., 1981). The essential fatty acid reserves in the adipose tissue develops during the last trimester of fetal growth (Clandinin et al., 1981). Thus, the hepatic and adipose reserves cannot meet whole body needs for essential fatty acids and total fat if fetal development is interrupted by premature birth early in the third trimester.

Quantitative analysis of the composition of human milk from mothers giving birth to preterm infants (Clandinin et al., 1981) indicates that mothers' milk provides levels of C20:4n-6 and C22:6n-3 essential fatty acids approximating the predicted requirements at day 16 of life at oral intake levels of approximately 120 kcal / kg of body weight

(Clandinin et al., 1981). Long chain essential fatty acids are synthesized from C18:2n-6 or C18:3n-3; however, the amounts produced *in vivo* may be inadequate to support the accretion rates attained in breast-fed infants (Salem et al., 1996). Thus, it seems prudent to feed the preterm infant human milk or formulas with a fatty acid balance similar to human milk containing long chain polyenoic homologs of C18:2n-6 and C18:3n-3 (Clandinin et al., 1982).

Currently, infant formulas marketed in North America contain C18:2n-6 and C18:3n-3 and are devoid of C20:4n-6 and C22:6n-3 (Clandinin et al., 1992a and 1992b). Therefore, infants fed these formulas must rely on *in vivo* elongation and desaturation of C18:2n-6 and C18:3n-3 to support a similar rate of accretion of C20:4n-6 and C22:6n-3 to that attained in breast-fed infants (Clandinin et al., 1981; Salem et al., 1996). It has been proposed (Clandinin et al., 1981; Clandinin et al., 1982) and recommended (European Society of Pediatric Gastroenterology and Nutrition, 1991; British Nutrition Foundation, 1992; Food and Agriculture Organization/World Health Organization, 1994; International Society for the Study of Fatty Acids and Lipids, 1994) that formulas fed to preterm infants be designed with a fatty acid balance similar to human milk containing C20:4n-6 and C22:6n-3. In the United Kingdom, Europe, South America, and Australia C20:4n-6 and C22:6n-3 have been added to preterm infant formulas using single-cell oils and in Europe using phospholipids.

In infants formulas, the question persists if preformed C22:6n-3 is needed or if providing more C18:3n-3 can be synthesized into C22:6n-3. In weanling rats, increasing dietary C18:3n-3 by decreasing C18:2n-6 to C18:3n-3 ratio from 7.3:1 to 4:1 increased the C22:6n-3 content in neuronal cell PE but not in other phospholipids from the cerebellum (Jumpsen et al., 1997). Results from other studies using whole brain (Woods et al., 1996) or subcellular fractions (Dyer & Greenwood, 1991) have also shown increases in C22:6n-3 content with increasing dietary C18:3n-3. However, none of these studies have investigated the effects of increasing C18:3n-3 on individual cell types from whole brain. Therefore, the present study utilized neonatal rat brain at two weeks of age, before the consumption of solid food, to test the hypothesis that increasing maternal dietary C18:3n-3 content from 1.6% (C18:2n-6 to C18:3n-3=21.6:1) to 17.5% (C18:2n-6 to C18:3n-3=1:1) of the total fatty acids will increase the C22:6n-3 content of neuronal

cell phospholipids of rat pups. The results from this present study show that increasing maternal dietary C18:3n-3 by decreasing C18:2n-6 to C18:3n-3 ratio does not significantly increase the C22:6n-3 content in PC, PE, and PS of neuronal cell phospholipids of rat pups at two weeks of age.

## **B. MATERIALS AND METHODS**

### **1. Animal Care**

All animal procedures were approved by the University of Alberta Animal Ethics Committee. Sprague-Dawley rats were obtained from the University of Alberta vivarium. During breeding, three females and one male were housed together for a two-week mating period. Females were then moved to individual cages in a room maintained at 21°C with a 12 hr light and 12 hr dark cycle. Water and food were supplied *ad libitum*. Laboratory rodent diet, 5001 (PMI Feeds, Inc., St. Louis, MO) was fed to the rats when not receiving experimental diets. Rats were switched to experimental diet on the day of parturition. All litters were culled to twelve pups within 24 hr of parturition. Pups received only maternal milk. Pups were sacrificed at two weeks of age.

One entire litter of rat pups fed the same diet was sexed and weighed prior to decapitation. Excised brains were placed in ice-cold 0.32 mol/L sucrose. Six brains from the same sex were pooled per sample. Stomach contents of three rats from each litter were also removed and analyzed for fatty acid composition to reflect the composition of maternal milk. Three litters per diet treatment were used.

### **2. Diets**

The basal diet fed meets all essential nutrient requirements and contained 20% (wt/wt) fat of varying C18:2n-6 and C18:3n-3 fatty acid composition (Clandinin & Yamashiro, 1980). Diet fats were formulated to approximate the fatty acid composition of an existing infant formula providing an C18:2n-6 to C18:3n-3 ratio of 7.3 to 1. This fat blend served as the control fat treatment. Three experimental diets were formulated by addition of various triglycerides to alter the fatty acid composition of this control fat formulation (Table 3.1). An C18:2n-6 to C18:3n-3 fatty acid ratio of 21.6 to 1 was

obtained by addition of corn oil to the diet fat blend. The C18:2n-6 to C18:3n-3 fatty acid ratio of 4.4 to 1 and 1 to 1 was obtained by the addition of flaxseed oil. These diets were nutritionally adequate, providing for all known essential nutrient requirements [ingredient and concentration (g/kg diet), respectively]: fat 200; starch, 200; casein, 270; glucose, 207.65; nonnutritive fiber, 50; vitamin mix, 10; mineral mix, 50.85; L-methionine, 2.5; choline 2.75; and inositol, 6.25. The A.O.A.C. vitamin mix (Teklad Test Diets, Madison, WI) provided the following per kilogram of complete diet: 20,000 IU of vitamin A; 2,000 IU of vitamin D; 100 mg of vitamin E; 5 mg of menadione; 5 mg of thiamine-HCl; 8 mg of riboflavin; 40 mg of pyridoxine-HCl; 40 mg of niacin; 40 mg of pantothenic acid; 2,000 mg of choline, 100 mg of myoinositol; 100 mg of *p*-aminobenzoic acid; 0.4 mg of biotin; 2 mg of folic acid, and 30 mg of vitamin B<sub>12</sub>; Bernhart Tomarelli mineral mix (General Biochemicals, Chargin Falls, OH) was modified to provide 77.5 mg of Mn<sup>2+</sup> and 0.06 mg Se<sup>2+</sup> per kilogram of complete diet. In order to minimize any changes in sample composition due to fatty acid oxidation, the diets were sealed under nitrogen and stored in a freezer at -30°C in darkness. Every day the required amount of diet was taken out, mixed, and placed in individual feed cups.

**Table 3.1 Fatty Acid Composition of Experimental Diets Fed to Lactating Dams at Two Weeks of Age**

	Diet C18:2n-6 to C18:3n-3 Ratio			
	21.6:1 <sup>1</sup>	7.8:1 <sup>2</sup>	4.4:1 <sup>3</sup>	1:1 <sup>3</sup>
<b>Diet Fatty Acid Composition (% wt/wt)</b>				
<b>C12:0</b>	6.4	8.4	9.4	6.0
<b>C14:0</b>	3.8	5.2	5.5	3.6
<b>C16:0</b>	12.2	14.0	13.9	11.4
<b>C18:0</b>	9.8	7.4	6.9	6.4
<b>C18:1n-7+n-9</b>	29.2	39.9	37.4	33.8
<b>C18:2n-6</b>	34.5	17.2	16.6	17.6
<b>C18:3n-3</b>	1.6	2.2	3.8	17.5
<b>C20:4n-6</b>	nd	nd	nd	nd
<b>C22:6n-3</b>	nd	nd	nd	nd

<sup>1</sup> C18:2n-6:C18:3n-3 of 21.6:1 was obtained by the addition of corn oil to the fat blend.

<sup>2</sup> C18:2n-6:C18:3n-3 of 7.8:1 diet approximates the fatty acid composition used in SMA<sup>1</sup> infant formula. Other diet blends were achieved by mixing corn oil (diet C18:2n-6:C18:3n-3 fatty acid ratio of 21.6:1) or flaxseed oil (diet C18:2n-6:C18:3n-3 fatty acid ratio of 1:1 or 4.4:1) into this basic fat blend.

<sup>3</sup> C18:2n-6:C18:3n-3 of 4.4:1 and 1:1 was obtained by the addition of flaxseed oil.

nd = not detected

### 3. Isolation of Neuronal Cells

Neuronal cells were isolated according to the method described by Sellinger & Azcurra (1974). Briefly, pooled brains were placed in beakers containing 7.5% (wt/vol.) polyvinylpyrrolidone and 10 mmol CaCl<sub>2</sub>/L at pH 4.7 and 25°C. Brain tissue was minced and poured into a 20 mL plastic syringe, fitted with a reusable filter unit (Millipore, Swinnex disc holder, 25mm). The sample was pressed, three times each, through a series of combined nylon mesh filters. The final filtrate volume was adjusted, then layered on a two-step sucrose gradient of 1.0 mol/L and 1.75 mol/L. Gradients were centrifuged in a Beckman SW-28 rotor at 41,000 g for 30 min at 4°C.

Neuronal cell bodies were recovered in the pellet. Aliquots of cells were stained with methylene blue and examined for purity under a light microscope (Zeiss, 1600X:

Appendix 1; Hamberger & Svennerholm, 1971). Gel electrophoresis and immunoblotting were performed to ensure purity of neuronal cell fractions prepared by these procedures (Jumpsen et al., 1997). Proteins isolated from neuronal cells were compared by gel electrophoresis and immunoblotting to neurofilament protein standard (data not shown). Neuronal cells isolated contain only neurofilament proteins.

#### **4. Lipid Analysis**

The neuronal cell lipid was extracted by a modified Folch method (Folch et al., 1957). Separation of individual phospholipids was completed on silica gel thin-layer chromatography (TLC) H-plates (20x20 cm, Analtech, Newark, DE, USA). The plates were developed in a solvent system containing chloroform:methanol:triethylamine:1-propanol:0.25% (wt/vol.) KCl (30:9:18:25:6, by vol.) for approximately 90 min (Touchstone et al., 1980). TLC plates were air dried for 5 min and visualized with 0.1% (wt/vol.) anilino naphthalene sulfonic acid in water.

Phospholipid fractions on the plate corresponding to standards were scraped into culture tubes. Fatty acid methyl esters were prepared with 14% (wt/wt) boron trifluoride in methanol following the method of Morrison & Smith (1964).

#### **5. Fatty Acid Analysis**

Fatty acid methyl esters were separated by automated gas-liquid chromatography. (Varian model 6000 GLC equipped with a Vista 654 data system and a Vista 8000 autosampler; Varian Instruments, Georgetown, ON) using a bonded fused silica BP20 capillary column (25 mm x 0.25 mm inside diameter) and quantitated using a flame ionization detector (Hargreaves & Clandinin, 1987). These conditions are capable of separating methyl esters of saturated, cis-monounsaturated, and cis-PUFA from 14 to 24 carbons in chain length. Quantitation and identification of peaks was based on relative retention times compared to known standards (PUFA 1 and 2, bacterial methyl ester mix-14; Supelco Canada, Mississauga, ON, Canada; Hargreaves & Clandinin, 1987).

## **6. Statistical Analysis**

The effect of diet treatment and sex of rat pups on the fatty acid composition of neuronal cell phospholipid fractions was assessed by two-way analysis of variance (ANOVA) procedures using the SAS package, version 6.11 (SAS Institute Inc., 1988). Significant differences between diet treatments and sex were determined by a Duncan's multiple range test at a significance level of  $p < 0.05$  after a significant ANOVA (Steel & Torrie, 1960). Values are expressed as mean  $\pm$  SEM for  $n=6$ . Two-way ANOVA procedures were performed on six diet treatments (including DHA and AA + DHA), however, in this chapter statistical analysis on four diet treatments were presented for the fatty acid composition of neuronal cell phospholipid fractions in the figures and tables.

## **C. RESULTS**

### **1. Growth Characteristics**

No significant differences were observed between males and females for body weight or total brain weight and the fatty acid composition of the individual phospholipid fractions. Thus, statistical analyses to test subsequent effects of diet treatments were combined for both sexes. Body and brain weight did not differ significantly between rat pups fed the four experimental diets. Final body weights were (mean  $\pm$  SEM):  $35.8 \pm 0.9$  g,  $35.9 \pm 1.0$  g,  $35.3 \pm 0.8$  g, and  $35.6 \pm 1.3$  g for 21.6:1, 7.8:1, 4.4:1, and 1:1 diet treatments, respectively. Final brain weights were (mean  $\pm$  SEM):  $1.2 \pm 0.1$  g,  $1.2 \pm 0.1$  g,  $1.2 \pm 0.1$  g, and  $1.1 \pm 0.1$  g for 21.6:1, 7.8:1, 4.4:1, and 1:1 diet treatments, respectively.

### **2. Purity of Neuronal Cell Preparations**

The neuronal cell preparations contained only minor cross contamination ( $\approx 5\%$ ) from cell membrane fragments and microvessels as determined by microscopic examination. The presence of neurofilament in neuronal samples were previously verified by gel electrophoresis and immunoblotting (Jumpsen et al., 1997). These results indicate that the neuronal cell preparation is primarily neuronal cell bodies with attached extensions.

### 3. Fatty Acid Composition of Stomach Contents

The fatty acid composition of stomach contents of rat pups was analyzed. These analyses relate to the dams' milk composition (Nouvelot et al., 1983; Lien et al., 1994; Jumpsen et al., 1997). The increase in dietary C18:2n-6 or C18:3n-3 fed to the dams altered the stomach contents of the rat pups (Table 3.2) indicating that the range of dietary fat composition fed in the present experiment produced changes in the fat composition of dams' milk.

**Table 3.2 The Content of Fatty Acids in the Stomach of Rat Pups at Two Weeks of Age<sup>1</sup>**

	Diet C18:2n-6 to C18:3n-3 Ratio			
	21.6:1 <sup>2</sup>	7.8:1 <sup>3</sup>	4.4:1 <sup>4</sup>	1:1 <sup>4</sup>
<b>Stomach Content of n-6 and n-3 fatty acid (% wt/wt)</b>				
<b>C10:0</b>	7.9 ± 2.11 <sup>b</sup>	7.2 ± 0.78 <sup>b</sup>	8.9 ± 1.90 <sup>a</sup>	6.9 ± 2.23 <sup>b</sup>
<b>C12:0</b>	10.9 ± 1.12 <sup>b</sup>	15.1 ± 0.36 <sup>a</sup>	16.0 ± 2.32 <sup>a</sup>	10.8 ± 0.58 <sup>c</sup>
<b>C14:0</b>	7.3 ± 0.31 <sup>c</sup>	15.3 ± 0.48 <sup>a</sup>	9.8 ± 0.53 <sup>b</sup>	7.2 ± 0.30 <sup>c</sup>
<b>C16:0</b>	12.6 ± 0.94 <sup>b</sup>	17.7 ± 0.66 <sup>a</sup>	13.9 ± 1.35 <sup>b</sup>	12.9 ± 0.43 <sup>b</sup>
<b>C18:0</b>	4.4 ± 0.35 <sup>a</sup>	3.4 ± 0.13 <sup>b</sup>	4.0 ± 0.19 <sup>b</sup>	4.8 ± 0.21 <sup>a</sup>
<b>C18:1n-7+n-9</b>	28.2 ± 1.5 <sup>a</sup>	24.7 ± 0.69 <sup>a</sup>	28.0 ± 1.5 <sup>a</sup>	26.7 ± 0.99 <sup>a</sup>
<b>C18:2n-6</b>	24.7 ± 0.05 <sup>a</sup>	12.5 ± 0.07 <sup>c</sup>	10.4 ± 0.08 <sup>d</sup>	13.7 ± 0.07 <sup>b</sup>
<b>C18:3n-3</b>	1.1 ± 0.02 <sup>d</sup>	1.6 ± 0.03 <sup>c</sup>	2.1 ± 0.03 <sup>b</sup>	8.8 ± 0.13 <sup>a</sup>
<b>C20:4n-6</b>	1.0 ± 0.07 <sup>a</sup>	0.5 ± 0.04 <sup>b</sup>	0.5 ± 0.02 <sup>b</sup>	0.5 ± 0.08 <sup>b</sup>
<b>C22:6n-3</b>	0.1 ± 0.02 <sup>b</sup>	0.1 ± 0.01 <sup>b</sup>	0.1 ± 0.02 <sup>b</sup>	0.2 ± 0.03 <sup>a</sup>
<b>C18:2n-6:C18:3n-3</b>	22.5	7.8	5.0	1.6

<sup>1</sup>Values are mean ± SEM with n=9 for each experimental diet. For each horizontal set of values, those that have the same superscript letters (a, b, c, or d) are not significantly different. Those that have different letters are statistically significantly different, at p<0.05.

<sup>2</sup> C18:2n-6:C18:3n-3 of 21.6:1 was obtained by the addition of corn oil to the fat blend.


<sup>3</sup> C18:2n-6:C18:3n-3 of 7.8:1 diet approximates the fatty acid composition used in SMA<sup>®</sup> infant formula. Other diet blends were achieved by mixing corn oil (diet C18:2n-6:C18:3n-3 fatty acid ratio of 21.6:1) or flaxseed oil (diet C18:2n-6:C18:3n-3 fatty acid ratio of 1:1 or 4.4:1) into this basic fat blend.

<sup>4</sup> C18:2n-6:C18:3n-3 of 4.4:1 and 1:1 was obtained by the addition of flaxseed oil.

#### 4. Neuronal Cells Phospholipid Fatty Acid Composition

##### a) Phosphatidylcholine and Phosphatidylethanolamine

In brain, PC and PE are quantitatively the two most abundant phospholipids and constitute approximately 90% of total brain phospholipid (Green & Yavin, 1996). The major fatty acids observed in PC were C16:0, C18:0, and C18:1 (47-52%, 13-14%, 15-16% of total fatty acids, respectively). Feeding a maternal diet providing a ratio of C18:2n-6 to C18:3n-3 from 21.6:1 to 1:1 did not significantly alter the content of C20:4n-6 and C22:6n-3 in neuronal cell PC of rat pups ( $p>0.05$ ) (Figure 3.1). In PE, C18:0, C20:4n-6, C22:6n-3, and C16:0 (23-28%, 16-20%, 16-22%, and 13-17% of total fatty acids, respectively) were the predominant fatty acids. Increasing C18:3n-3 in the maternal diet did not significantly alter the C20:4n-6 and C22:6n-3 content in neuronal cell PE of the rat pups ( $p>0.05$ ) (Figure 3.1).



**Figure 3.1** C20:4n-6 and C22:6n-3 Content in Neuronal Cell Phosphatidylcholine and Phosphatidylethanolamine

**b) Phosphatidylserine and Phosphatidylinositol**

Analysis of the fatty acid profile in neuronal cell PS demonstrated that C18:0 and C22:6n-3 (36-40% and 14-28% of the total fatty acid, respectively) were the major fatty acid. The large content of C22:6n-3 in PS of the rat pups was significantly decreased by increasing the maternal dietary levels of C18:3n-3 ( $p < 0.0001$ ). The maternal diet, providing a ratio of C18:2n-6 to C18:3n-3 ratio of 7.8 to 1, resulted in the highest level of C22:6n-3 in the rat pups (Table 3.3). The C16:0 content of PS increased from 7.2-20.1% of the total fatty acids when the C18:2n-6 to C18:3n-3 ratio was lowered from 7.8:1 to 1:1 (Table 3.3).

In neuronal cell PI, the major fatty acids were C18:0 and C20:4n-6 (28-39% and 19-35% of the total fatty acids, respectively). When increasing dietary levels of C18:3n-3 was provided in the maternal diet there was a significant increase in neuronal cell C22:6n-3 content of  $\approx 11\%$  from a dietary C18:2n-6:C18:3n-3 ratio of 7.8:1 to 4.4:1 ( $p < 0.05$ ) with a concomitant decrease in C20:4n-6 of  $\approx 15.5\%$  in PI in the rat pups (Table 3.4).

**Table 3.3 Effect of Varying C18:2n-6 to C18:3n-3 Ratio on the Fatty Acid Composition of Neuronal Phosphatidylserine<sup>1</sup>**

Fatty Acid (% wt/wt)	Diet C18:2n-6 to C18:3n-3 Ratio			
	21.6:1	7.8:1	4.4:1	1:1
<b>C14:0</b>	0.4 ± 0.0 <sup>a</sup>	0.3 ± 0.1 <sup>a</sup>	0.6 ± 0.1 <sup>a</sup>	0.7 ± 0.2 <sup>a</sup>
<b>C16:0</b>	13.4 ± 1.3 <sup>b</sup>	7.2 ± 0.5 <sup>c</sup>	15.0 ± 0.8 <sup>b</sup>	20.1 ± 2.7 <sup>a</sup>
<b>C18:0</b>	39.0 ± 1.3 <sup>a</sup>	36.9 ± 2.8 <sup>a</sup>	36.0 ± 1.7 <sup>a</sup>	38.8 ± 0.3 <sup>a</sup>
<b>C18:1n-9</b>	9.2 ± 0.3 <sup>a</sup>	9.0 ± 3.5 <sup>a</sup>	7.4 ± 1.8 <sup>a</sup>	10.5 ± 0.4 <sup>a</sup>
<b>C18:1n-7</b>	1.4 ± 0.1 <sup>a</sup>	0.5 ± 0.1 <sup>b</sup>	2.9 ± 1.4 <sup>a</sup>	1.8 ± 0.2 <sup>a</sup>
<b>C18:2n-6</b>	0.6 ± 0.0 <sup>b</sup>	0.4 ± 0.0 <sup>c</sup>	0.8 ± 0.0 <sup>a</sup>	0.8 ± 0.0 <sup>a</sup>
<b>C20:4n-6</b>	6.3 ± 0.1 <sup>a</sup>	6.2 ± 0.8 <sup>a</sup>	8.8 ± 1.6 <sup>a</sup>	6.1 ± 0.6 <sup>a</sup>
<b>C22:4n-6</b>	4.4 ± 0.2 <sup>b</sup>	5.4 ± 0.5 <sup>a</sup>	4.1 ± 0.3 <sup>b</sup>	3.0 ± 0.4 <sup>c</sup>
<b>C22:5n-6</b>	3.0 ± 0.1 <sup>ab</sup>	2.8 ± 0.1 <sup>b</sup>	1.7 ± 0.1 <sup>ab</sup>	1.3 ± 0.3 <sup>a</sup>
<b>C18:3n-3</b>	0.0 ± 0.0 <sup>a</sup>	0.0 ± 0.0 <sup>a</sup>	0.0 ± 0.0 <sup>a</sup>	0.1 ± 0.0 <sup>a</sup>
<b>C20:5n-3</b>	0.1 ± 0.0 <sup>b</sup>	0.2 ± 0.1 <sup>a</sup>	0.1 ± 0.1 <sup>b</sup>	0.0 ± 0.0 <sup>c</sup>
<b>C22:5n-3</b>	0.2 ± 0.0 <sup>b</sup>	0.4 ± 0.0 <sup>a</sup>	0.4 ± 0.0 <sup>a</sup>	0.4 ± 0.1 <sup>a</sup>
<b>C22:6n-3</b>	20.0 ± 1.1 <sup>b</sup>	28.0 ± 0.7 <sup>a</sup>	20.1 ± 1.1 <sup>b</sup>	14.1 ± 2.9 <sup>c</sup>

<sup>1</sup>Values are mean ± SEM with n=6 for each experimental diet. For each horizontal set of values, those that have the same superscript letters (a or b) are not significantly different. Those that have different letters are statistically significantly different, at p<0.05.

**Table 3.4 Effect of Varying C18:2n-6 to C18:3n-3 Ratio on the Fatty Acid Composition of Neuronal Phosphatidylinositol<sup>1</sup>**

Fatty Acid (%wt/wt)	Diet C18:2n-6 to C18:3n-3 Ratio			
	21.6:1	7.8:1	4.4:1	1:1
<b>C14:0</b>	0.9 ± 0.1 <sup>a</sup>	0.6 ± 0.1 <sup>a</sup>	0.4 ± 0.0 <sup>a</sup>	0.8 ± 0.1 <sup>a</sup>
<b>C16:0</b>	13.8 ± 1.3 <sup>ab</sup>	7.4 ± 1.7 <sup>b</sup>	12.5 ± 0.5 <sup>ab</sup>	15.2 ± 0.3 <sup>a</sup>
<b>C18:0</b>	28.1 ± 1.3 <sup>c</sup>	34.7 ± 0.5 <sup>ab</sup>	38.6 ± 1.9 <sup>a</sup>	31.0 ± 1.0 <sup>bc</sup>
<b>C18:1n-9</b>	8.1 ± 0.6 <sup>b</sup>	6.1 ± 0.7 <sup>b</sup>	1.8 ± 1.5 <sup>c</sup>	12.3 ± 2.1 <sup>a</sup>
<b>C18:1n-7</b>	1.8 ± 0.1 <sup>ab</sup>	1.4 ± 0.1 <sup>bc</sup>	0.4 ± 0.3 <sup>c</sup>	2.2 ± 0.1 <sup>a</sup>
<b>C18:2n-6</b>	0.8 ± 0.0 <sup>b</sup>	0.7 ± 0.1 <sup>b</sup>	0.8 ± 0.0 <sup>b</sup>	1.0 ± 0.0 <sup>a</sup>
<b>C20:4n-6</b>	26.5 ± 1.6 <sup>b</sup>	35.4 ± 2.3 <sup>a</sup>	19.9 ± 0.2 <sup>c</sup>	19.0 ± 1.4 <sup>c</sup>
<b>C22:4n-6</b>	3.1 ± 0.5 <sup>a</sup>	1.8 ± 0.1 <sup>b</sup>	3.9 ± 0.4 <sup>a</sup>	3.0 ± 0.1 <sup>a</sup>
<b>C22:5n-6</b>	1.3 ± 0.2 <sup>a</sup>	0.5 ± 0.1 <sup>b</sup>	1.0 ± 0.1 <sup>ab</sup>	0.8 ± 0.0 <sup>b</sup>
<b>C18:3n-3</b>	0.3 ± 0.3 <sup>a</sup>	0.1 ± 0.0 <sup>a</sup>	0.1 ± 0.0 <sup>a</sup>	0.1 ± 0.0 <sup>a</sup>
<b>C20:5n-3</b>	0.4 ± 0.3 <sup>a</sup>	0.1 ± 0.0 <sup>a</sup>	0.2 ± 0.1 <sup>a</sup>	0.1 ± 0.0 <sup>b</sup>
<b>C22:5n-3</b>	0.2 ± 0.0 <sup>a</sup>	0.2 ± 0.0 <sup>a</sup>	0.3 ± 0.0 <sup>a</sup>	0.4 ± 0.0 <sup>a</sup>
<b>C22:6n-3</b>	11.1 ± 1.6 <sup>b</sup>	6.2 ± 0.3 <sup>c</sup>	17.5 ± 2.0 <sup>a</sup>	10.7 ± 0.5 <sup>b</sup>

<sup>1</sup>Values are mean ± SEM with n=6 for each experimental diet. For each horizontal set of values, those that have the same superscript letters (a, b, or c) are not significantly different. Those that have different letters are statistically significantly different, at p<0.05.

#### D. DISCUSSION

The present study was initiated to determine the effects of increasing maternal dietary C18:3n-3 content by decreasing the C18:2n-6 to C18:3n-3 ratio from 21.6:1 to 1:1 on the C22:6n-3 content in neuronal cells of rat pups at two weeks of age. The results demonstrate that increasing maternal dietary C18:3n-3 content does not significantly increase the C22:6n-3 content of neuronal cell PC, PE, and PS of rat pups at a stage of

brain development when C22:6n-3 is needed for rapid neural plasma membrane synthesis.

The reason for the similar C20:4n-6 and C22:6n-3 content in PC and PE of neuronal cells between the four experimental diets may be due to the fact that desaturase activity is age-related (Bordoni et al., 1988; Hrelia et al., 1989; Bourre et al., 1990; Ulmann et al., 1991) and that at two-weeks of age activity may be limited. Bourre et al. (1990) demonstrated in rats that delta-6 desaturase activity, a rate-limiting step in C20:4n-6 and C22:6n-3 synthesis (Stoffel, 1961; Holloway et al., 1963; Brenner, 1971) varies during the first 21 days following gestation. Therefore, if delta-6 desaturase activity is low at two-weeks of age, the amount of C18:2n-6 and C18:3n-3 added in the diet would not have any significant effect on increasing the C20:4n-6 and C22:6n-3 content of membrane phospholipids.

The significant decrease in C22:6n-3 content in PS with increasing dietary C18:3n-3 may be attributed to different PS molecular species being produced by deacylation and reacylation processes (Lands, 1960).

PI represents approximately 4% of the total brain phospholipids (Green & Yavin, 1996). The deacylation of C20:4n-6 from PI followed by reacylation of PI with C22:6n-3 from other phospholipids such as PS could account for the decrease in C20:4n-6 and increase in C22:6n-3 content in PI when the C18:2n-6 to C18:3n-3 ratio was decreased from 7.8:1 to 1:1 (Table 3.4).

PS and PI although minor phospholipids in brain membranes are of special interest because both are involved in cellular functions (Berridge, 1984). PS is responsible for the activation of several protein kinase C isoforms (Epanand & Lester, 1990) while PI plays an important role in signal transduction (Hokin, 1985) and in production of eicosanoids (Wood, 1986). Moreover, the fatty acyl composition of PS and PI has been demonstrated to be one of the regulatory functions in enzyme activation (Bolen & Sando, 1991). Therefore, the changes observed in PS in C22:6n-3 content and PI C20:4n-6 and C22:6n-3 content, while small on the basis of total brain content, could have functional implications.

*In vivo* studies have suggested that it is more effective to supply a dietary source of preformed C22:6n-3 to maintain the C22:6n-3 level in membrane phospholipids, rather

than increasing the dietary content of C18:3n-3 (Sinclair, 1975; Anderson et al., 1990). The results from the present study appear to support these findings since increasing the dietary C18:3n-3 content by  $\approx 11$  fold (Table 3.1) did not significantly increase the C22:6n-3 content in neuronal cell PC, PE, and PS (Figure 3.1 and Table 3.3).

The findings of this study may have important implications for neonatal feeding. If the present findings in neonatal rats are extrapolated to infants, it appears that increasing the C18:3n-3 content by decreasing the C18:2n-6 to C18:3n-3 ratio in preterm infant formulas will not stimulate an increase in levels of C22:6n-3 in the early neonatal period.

/

## E. REFERENCES

- Anderson, J., Connor, E., & Corliss, D. (1990). Docosahexaenoic acid is the preferred dietary n-3 fatty acid for the development of the brain and retina. *Pediatr. Res.* 27: 89-97.
- Anderson, R. E., Benolken, R. M., Dudley, P. A., Landis, D. J., & Wheeler, T. G. (1974). Polyunsaturated fatty acids of photoreceptor membranes. *Exp. Eye Res.* 18: 205-213.
- Berridge, M. J. (1984). Inositol triphosphate and diacylglycerol as second messengers. *Biochem. J.* 220: 345-360
- Bolen, E. J. & Sando, J. J. (1991). Effect of phospholipid unsaturation on protein kinase C activation. *Biochemistry* 31: 5945-5951.
- Bordoni, A., Biagi, P. L., Turchetto, E., & Hrelia, S. (1988). Aging influence on  $\Delta 6$  desaturase activity and fatty acid composition of rat liver microsomes. *Biochem. Int.* 17: 1001-1009.
- Bourre, J. M., Piciotti, M., & Dumont, O. (1990).  $\Delta 6$ -desaturase in brain and liver during development and aging. *Lipids* 25: 354-356.
- Brenner, R. R. (1971). The desaturation step in the animal biosynthesis of polyunsaturated fatty acids. *Lipids* 6: 567-576.
- British Nutrition Foundation, The Report of the British Nutrition Foundation's Task Force. (1992). Recommendations for intakes of Unsaturated Fatty Acids. Chapman and Hall, New York, pp. 152-163.
- Clandinin, M. T. & Yamashiro, S. (1980). Effects of basal diet composition on the incidence of dietary fat induced myocardial lesions. *J. Nutr.* 110: 1197-1203.
- Clandinin, M. T., Chappell, J. E., Leong, S., Heim, T., Swyer, P. R., & Chance, G. W. (1980a). Extrauterine fatty acid accretion in infant brain: implications for fatty acid requirements. *Early Hum Dev* 4: 131-138.
- Clandinin, M. T., Chappell, J. E., Swyer, P. R., & Chance, G. W. (1981). Fatty acid utilization in perinatal de novo synthesis of tissues. *Early Hum Dev* 5: 355-366.
- Clandinin, M. T., Chappell, J. E., & Heim, T. (1982). Do low birth weight infants require nutrition with chain elongation-desaturation products of essential fatty acid? *Prog. Lipid Res* 20: 901-904.

Clandinin, M. T., Chappell, J. E., Leong, S., Heim, T., Swyer, P. R., & Chance, G. W. (1986b). Intrauterine fatty acid accretion rates in human brain: implications for fatty acid requirements. *Early Hum Dev* 4: 121-129.

Clandinin, M. T., Garg, M. L., Parrot, A., Van Aerde, J. E., Hervada, A. R., & Lien, E. (1992a). Addition of long-chain polyunsaturated fatty acids to formula for very low birth weight infants. *Lipids* 27: 896-900.

Clandinin, M. T., Parrot, A., Van Aerde, J. E., Hervada, A. R., & Lien, E. (1992b). Feeding preterm infants a formula containing C20 and C22 fatty acids simulates plasma phospholipid fatty acid composition of infants fed human milk. *Early Hum Dev* 31: 41-51.

Dyer, J. R. & Greenwood, C. E. (1991). Neural 22-carbon fatty acids in the weanling rat respond rapidly and specifically to a range of dietary C18:2n-6 to  $\alpha$ -C18:3n-3 fatty acid ratios. *J Neurochem* 56: 1921-1931.

Epad, R. M. & Lester, D. S. (1990). The role of membrane biophysical properties in the regulation of protein kinase C. *Science* 233: 305-312.

European Society of Pediatric Gastroenterology and Nutrition (ESPGAN). (1991) Comment on the content and composition of lipids in infant formulas. ESPGAN committee on nutrition. *Acta Paediatr Scand* 80: 887-896.

Fliesler, S. J. & Anderson, R. E. (1983). Chemistry and metabolism of lipids in the vertebrate retina. *Prog Lipid Res* 22: 79-131.

Folch, J., Lees, M., & Sloane-Stanley, G. G. (1957). A simple method for the isolation and purification of total lipids from animal tissues. *J Biol Chem* 226: 497-509.

Food and Agriculture Organization / World Health Organization (FAO/WHO). (1994). *Fats and Oils in Human Nutrition: report of a joint expert consultation*. FAO/WHO, Rome, pp. 147.

Green, P. & Yavin, E. (1996). Fatty acid composition of late embryonic and early postnatal rat brain. *Lipids* 31: 859-865.

Hamberger, A. & Svennerholm, L. (1971). Composition of gangliosides and phospholipids of neuronal and glial cell enriched fractions. *J. Neurochem* 18: 1821-1829.

Hargreaves, K. M. & Clandinin, M. T. (1987). Phosphatidylethanolamine methyltransferase: evidence for influence of diet fat on selectivity of substrate for methylation in rat brain synaptic plasma membrane. *Biochim Biophys Acta* 918: 97-105.

Hokin, L. E. (1985). Receptors and phosphoinositide-generated second messengers. *Ann Rev Biochem* 54: 205-235.

Holloway, D. W., Peluffo, R., & Walkin, S. J. (1963). On the biosynthesis of dienoic fatty acid by animal tissues. *Biochem Biophys Res Commun* 12: 300-304.

Hrelia, S., Bordoni, A., Celadon, M., Turchetto, E., Biagi, C. A., & Ross, C. A. (1989). Age-related changes in linoleate and  $\alpha$ -linolenate desaturation by rat liver microsomes. *Biochem Biophys Res Commun* 163: 348-355.

International Society for the Study of Fatty Acids and Lipids (ISSFAL). (1994). Recommendations for the essential fatty acid requirements of infant formula. *ISSFAL Newsletter* 1: 4.

Jumpsen, J. A., Lien, E., Goh, Y. K., & Clandinin, M. T. (1997). Diets varying in n-3 and n-6 fatty acid content produce differences in phosphatidylethanolamine and phosphatidylcholine fatty acid composition during development of neuronal and glial cells in rats. *J Nutr* 127: 724-731.

Kinsella, J. E., Shane Broughton, K., & Whelan, J. W. (1990). Dietary unsaturated fatty acids interactions and possible needs in relation to eicosanoid synthesis. *J Nutr Biochem* 1: 123-141.

Lands, W. E. M. (1960). Metabolism of glycerolipids. *J Biol Chem* 235: 2233-2237.

Lien, E. L., Boyle, F. G., Yuhas, R. J., & Kuhlman, C. F. (1994). Effect of maternal dietary arachidonic or C18:2n-6 acid on rat pup fatty acid profiles. *Lipids* 29: 53-59.

Morrison, W. R. & Smith, L. M. (1964). Preparation of fatty acid methyl esters and dimethyl-acetals from lipids with boron fluoride-methanol. *J Lipid Res* 5: 600-608.

Nouvelot, A., Bourre, J. M., Sezille, G., Dewailly, P., & Jaillard, J. (1983). Changes in the fatty acid patterns of brain phospholipids during development of rats fed with peanut or rapeseed oil, taking into account difference between milk and maternal food. *Ann Nutr Metab* 27: 173-181.

Salem, Jr. N., Wegher, B., Mena, P., & Uauy, R. (1996). Arachidonic and docosahexaenoic acids are biosynthesized from their 18-carbon precursors in human infants. *Proc Natl Acad Sci USA* 93: 49-54.

SAS Institute Inc. (1988). *SAS/STAT User's guide*, Release 6.11 Edition. SAS Institute Inc., North Carolina, pp. 125-154.

Sastry, P. S. (1985). Lipids of nervous tissue: composition and metabolism. *Prog Lipid Res* 24: 69-176.

Sellinger, O. Z. & Azcurra, J. M. (1974). Bulk separation of neuronal cell bodies and glial cells in the absence of added digestive enzymes. In: Marks N, Rodnight R (eds) *Research Methods in Neurochemistry*, Plenum Press, New York, pp. 3-38.

Sinclair, A. J. & Crawford, M. A. (1972). The accumulation of arachidonate and docosahexaenote in developing rat brain. *Neurochem* 19: 1753-1758.

Sinclair, A. J. (1975). Incorporation of radioactive polyunsaturated fatty acids into liver and brain of developing rat. *Lipids* 10: 175-184.

Steel, R. G. D. & Torrie, J. H. (1960). *Principles and Procedures of Statistics*. McGraw-Hill, New York.

Stoffel, W. (1961). Biosynthesis of polyenoic fatty acids. *Biochem Biophys Res Commun* 6: 270-273.

Stubbs, C. D. & Smith, A. D. (1984). The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. *Biochim Biophys Acta* 779: 89-137.

Touchstone, J. C., Chen, J. C., & Beaver, K. M. (1980). Improved separation of phospholipids in thin-layer chromatography. *Lipids* 15: 61-62.

Ulmann, L., Blond, J. P., Maniongui, C., Poisson, J. P., Durand, G., Bezard, J., & Pascal, G. (1991). Effects of age and essential fatty acids on desaturase activities and on fatty acid composition of liver microsomal phospholipids of adult rats *Lipids* 26: 127-133.

Wood, J. N. (1986). Essential fatty acids and their metabolites in signal transduction. *Biochem Soc Trans* 18: 755-786.

Woods, J., Ward, G., & Salem, N. (1996). Is docosahexaenoic acid necessary in infant formula? Evaluation of high-linolenate diets in neonatal rat. *Ped Res* 40: 1-7.

## **CHAPTER IV. HIGH DIETARY C18:3N-3 INCREASES THE C18:3N-3 BUT NOT THE C22:6N-3 CONTENT IN THE WHOLE BODY, BRAIN, SKIN, EPIDIDYMAL FAT PADS AND MUSCLES OF SUCKLING RAT PUPS**

### **A. INTRODUCTION**

Research in infant nutrition has demonstrated that during the last trimester of gestation the fetal brain accrues fatty acids of the n-6 and n-3 types (Clandinin et al., 1980b). These fatty acids may be derived from the placenta *in utero* (Clandinin et al., 1980a and 1980b; Clandinin et al., 1981). The hepatic and adipose reserves cannot meet whole body needs for essential fatty acids and total fat if fetal development is interrupted by premature birth early in the third trimester (Clandinin et al., 1981). Mothers' milk provides C20:4n-6 and C22:6n-3 approximating the predicted requirements at day 16 of life at oral intake (Clandinin et al., 1981). Long chain essential fatty acids are synthesized from C18:2n-6 or C18:3n-3; however, the amounts produced *in vivo* may be inadequate to support the accretion rates attained in breast-fed infants (Demmelmair et al., 1995; Carnielli et al., 1996; Salem et al., 1996; Sauerwald et al., 1996; Sauerwald et al., 1997). Deficiencies of dietary C22:6n-3 during perinatal development results in poor C22:6n-3 accretion in brain and retina, subsequently leading to altered neurological and visual function in animals (Bourre et al., 1989; Connor et al., 1990). Thus, it seems prudent to feed the preterm infant human milk or formulas with a fatty acid balance similar to human milk containing long chain polyenoic homologs of C18:2n-6 and C18:3n-3 (Clandinin et al., 1982).

Current infant formulas in North America contain C18:2n-6 and C18:3n-3 but are devoid of C20:4n-6 and C22:6n-3 (Clandinin et al., 1992a and 1992b). Infants fed these formulas must rely on *in vivo* elongation and desaturation of C18:2n-6 and C18:3n-3 to support a similar rate of accretion of C20:4n-6 and C22:6n-3 to that attained in breast-fed infants. Addition of C20:4n-6 and C22:6n-3 to preterm infant formulas to optimize brain development has been recommended (Clandinin et al., 1981; Clandinin et al., 1982; European Society of Pediatric Gastroenterology and Nutrition, 1991; British Nutrition Foundation, 1992; International Society for the Study of Fatty Acids and Lipids, 1994; FAO/WHO, 1994). Infant formulas supplemented with C20:4n-6 and C22:6n-3 produce a

clear dose response in the content of C20:4n-6 and C22:6n-3 in erythrocyte total plasma membrane phospholipids with 0.6% C20:4n-6 and 0.4% C22:6n-3 in the formula fat providing sufficient amounts of these fatty acids to achieve a fatty acid composition of C20:4n-6 and C22:6n-3 similar to that of infants fed human milk (Clandinin et al., 1997). Thus, in the United Kingdom, Europe, South America, Australia, and the Middle East C20:4n-6 and C22:6n-3 have been added to infant formulas.

The question of whether preformed C22:6n-3 is needed or if providing more C18:3n-3 can enable synthesis of C22:6n-3 persists. In human adults that it is more effective to supply a dietary source of preformed C22:6n-3 from fish oil to increase the C22:6n-3 content in plasma phospholipids than C18:3n-3 from flaxseed oil (Layne et al., 1996). Increasing maternal dietary C18:3n-3 by decreasing the diet C18:2n-6:C18:3n-3 from 7.3:1 to 4:1 was not as effective as preformed C22:6n-3 at raising the C22:6n-3 content of neuronal cell phospholipids of weanling rats (Jumpsen et al., 1997a and 1997b). Increasing maternal dietary C18:3n-3 content does not significantly increase the C22:6n-3 content in PC, PE, or PS of neuronal cell phospholipids of rat pups at two-weeks of age (**CHAPTER III**). These observations beg the question if C18:3n-3 does not give rise to significant quantities of C22:6n-3 then what is the metabolic fate of high intakes of C18:3n-3?

The purpose of this study was to determine if the dietary C18:3n-3 consumed could increase the C18:3n-3 and C22:6n-3 content of other whole body tissue lipids. It is hypothesized that increasing maternal dietary C18:3n-3 by decreasing the C18:2n-6:C18:3n-3 ratio will increase the C18:3n-3 and C22:6n-3 content in the whole body, liver, skin (epidermis, dermis, and subcutaneous tissue), epididymal fat pads, and muscles (front and back legs) in two-week-old rat pups.

## **B. MATERIALS AND METHODS**

### **1. Animals and Diets**

Breeding of Sprague-Dawley rats have been described in **Chapter III**. Pups were sacrificed at two weeks of age. One entire litter of rat pups fed the same experimental diet was sexed and weighed prior to decapitation. Rat pups randomly chosen for whole body

lipid analysis were frozen in liquid nitrogen. The brains, livers, skin (epidermis, dermis, and subcutaneous tissue), epididymal fat pads, and muscles (front and back legs) were quickly removed and rinsed with ice-cold physiological saline, blotted dry, weighed, and frozen in liquid nitrogen. Stomach contents of three rats from each litter were also removed and analyzed for fatty acid composition to reflect the composition of maternal milk. All tissue samples were stored under nitrogen and kept in a  $-80^{\circ}\text{C}$  freezer until analysis. Analysis of whole organs was performed on at least three individual rat pups from each of three different litters per diet treatment.

The basal diet fed to the dams contained 20% (wt/wt) fat varying in C18:2n-6 and C18:3n-3 fat composition. Two experimental diets were formulated by addition of various triglycerides from vegetable oils to alter the fatty acid C18:2n-6 : C18:3n-3 ratio (Table 4.1). An C18:2n-6 to C18:3n-3 fatty acid ratio of 24.7 to 1 (low C18:3n-3) was obtained by addition of corn oil to the diet fat blend. The C18:2n-6 to C18:3n-3 fatty acid ratio of 1 to 1 (high C18:3n-3) was obtained by the addition of flaxseed oil. The low and high C18:3n-3 fatty acid diet was nutritionally adequate, providing for all known essential nutrient requirements as described earlier (Clandinin & Yamashiro, 1980). To minimize any changes in sample composition due to fatty acid oxidation, the diets were sealed under nitrogen and stored in a freezer at  $-30^{\circ}\text{C}$  in darkness. Every day the required amount of diet was taken out, mixed, and placed in individual feed cups.

## **2. Lipid Extraction and fatty acid analysis**

Total lipids were extracted from aliquots of tissue homogenate (Folch et al., 1957). The extracted lipids were evaporated under nitrogen and weighed to determine the total fat content of the tissues. The tissue lipids were saponified by a 0.5N KOH in 95% methanol solution and heated at  $100^{\circ}\text{C}$  for 1 hr. Fatty acid methyl esters were prepared using  $\text{BF}_3$  / methanol reagent (Morrison & Smith, 1964).

Fatty acid methyl esters were analyzed by automated gas-liquid chromatography as described in **Chapter III**.

**Table 4.1 Fatty Acid Composition of Experimental Diets Fed to Lactating Dams and Stomach Content of Rat Pups of Two Weeks of Age<sup>a</sup>**

	Diet		Stomach Content	
	Low C18:3n-3	High C18:3n-3	Low C18:3n-3	High C18:3n-3
<b>Fatty Acid (% wt/wt)</b>				
<b>C12:0</b>	15.3	7.90	0.2 ± 0.0 <sup>a</sup>	0.1 ± 0.02 <sup>a</sup>
<b>C14:0</b>	6.8	3.1	20.2 ± 1.5 <sup>a</sup>	16.11 ± 1.4 <sup>a</sup>
<b>C16:0</b>	13.1	9.0	21.1 ± 0.3 <sup>a</sup>	18.5 ± 0.8 <sup>b</sup>
<b>C18:0</b>	4.7	3.7	4.0 ± 0.2 <sup>a</sup>	3.3 ± 0.2 <sup>b</sup>
<b>C18:1n-7+n-9</b>	26.4	27.2	26.7 ± 0.9 <sup>a</sup>	26.2 ± 0.7 <sup>a</sup>
<b>C18:2n-6</b>	27.2	20.4	25.4 ± 0.4 <sup>a</sup>	19.3 ± 0.4 <sup>b</sup>
<b>C18:3n-3</b>	1.1	20.1	1.1 ± 0.2 <sup>b</sup>	14.9 ± 1.1 <sup>a</sup>
<b>C20:4n-6</b>	nd	nd	0.7 ± 0.1 <sup>a</sup>	0.4 ± 0.1 <sup>a</sup>
<b>C22:6n-3</b>	nd	nd	0.04 ± 0.01 <sup>a</sup>	0.12 ± 0.0 <sup>a</sup>
<b>Σ Sat<sup>b</sup></b>	43.4	30.3	46.1 ± 1.3 <sup>a</sup>	38.7 ± 2.1 <sup>b</sup>
<b>Σ Mono<sup>c</sup></b>	28.2	29.2	26.7 ± 0.9 <sup>a</sup>	26.2 ± 0.7 <sup>a</sup>
<b>Σ N-6<sup>d</sup></b>	27.2	20.4	26.1 ± 0.5 <sup>a</sup>	19.7 ± 0.4 <sup>b</sup>
<b>Σ N-3<sup>e</sup></b>	1.3	20.1	1.2 ± 0.2 <sup>b</sup>	15.4 ± 1.2 <sup>a</sup>
<b>C18:2n-6 to C18:3n-3</b>	24.7:1	1.0:1	23.1:1	1.3:1

nd=not detected<sup>a</sup>

Values represent mean ± SEM for n=9 rat pups (5 male and 4 female) for each experimental diet. Values without a common superscript are significantly different at P<0.05.

<sup>b</sup>Σ Sat, sum of saturated fatty acids

<sup>c</sup>Σ Mono, sum of monounsaturated fatty acids

<sup>d</sup>Σ N-6, sum of N-6 fatty acids

<sup>e</sup>Σ N-3, sum of N-3 fatty acids

### 3. Statistical Analysis

The effect of diet treatment and sex of rat pups on the lipid content and fatty acid composition of whole body and tissues lipids was assessed by one-way analysis of variance (ANOVA) procedures using the SAS package, version 6.11 (SAS Institute Inc., 1988). Significant differences between diet treatments and sex were determined by a

Duncan's multiple range test at a significance level of  $p < 0.05$  after a significant ANOVA (Steel & Torrie, 1960). Values are expressed as mean  $\pm$  SEM for  $n=9$  rat pups.

## **C. RESULTS**

### **1. Fatty Acid Composition of Stomach Contents.**

The stomach content of rat pups was analyzed for the fatty acid composition. These analyses reflected dams' milk composition (Nouvelot et al., 1983; Yonekubo et al., 1993; Lien et al., 1994; Jumpsen et al., 1997a and 1997b; Wainwright et al., 1997). The increase in dietary C18:3n-3 fed to the dams increased the C18:3n-3 in the stomach contents of the rat pups (Table 4.1) indicating that the range of dietary fat composition fed in the present experiment produced changes in the fat composition of the dams' milk as predicted.

### **2. Whole Body and Tissue Weights and Lipid Content**

Whole body and tissue weights, lipid content, and fatty acid composition of the tissues were not significantly different for male ( $n=5$ ) and female ( $n=4$ ) rat pups (data not shown), hence in statistical analyses to test subsequent effects of diet treatments were combined for both sexes. The whole body and tissue weights were not significantly different among the two experimental diet treatments (Table 4.2), indicating that the body and tissue growth in the two-week-old rat pups is not different between low and high C18:3n-3 fatty acid diets. The lipid content of whole body and tissues was not significantly different in rat pups fed either the low or high C18:3n-3 fatty acid diet (Table 4.2). Differences in fertility were not observed between dietary treatments.

**Table 4.2 Whole Body, Tissue Weights, and Lipid Content of Rat Pups at Two Weeks of Age<sup>a</sup>**

	Weight (g)		% Lipid	
	Low C18:3n-3	High C18:3n-3	Low C18:3n-3	High C18:3n-3
<b>Whole Body</b>	31.8 ± 1.0 <sup>a</sup>	32.0 ± 1.2 <sup>a</sup>	13.6 ± 1.0 <sup>a</sup>	13.4 ± 0.8 <sup>a</sup>
<b>Brain</b>	1.15 ± 0.0 <sup>a</sup>	1.12 ± 0.1 <sup>a</sup>	4.40 ± 0.4 <sup>a</sup>	4.20 ± 0.3 <sup>a</sup>
<b>Liver</b>	0.66 ± 0.1 <sup>a</sup>	0.67 ± 0.1 <sup>a</sup>	6.90 ± 0.7 <sup>a</sup>	6.90 ± 0.8 <sup>a</sup>
<b>Skin</b>	9.00 ± 1.0 <sup>a</sup>	8.95 ± 1.0 <sup>a</sup>	24.0 ± 1.3 <sup>a</sup>	25.0 ± 1.1 <sup>a</sup>
<b>Epididymal Fat Pads</b>	0.05 ± 0.0 <sup>a</sup>	0.05 ± 0.0 <sup>a</sup>	nd	nd
<b>Muscles</b>	1.00 ± 0.0 <sup>a</sup>	0.91 ± 0.1 <sup>a</sup>	1.70 ± 0.0 <sup>a</sup>	1.60 ± 0.0 <sup>a</sup>

nd = not determined

<sup>a</sup>Values represent mean ± SEM for n=9 rat pups (5 male and 4 female rat pups except for epididymal fat pads in which 9 male rat pups were used) for each experimental diet. Values without a common superscript are significantly different at P<0.05.

#### a) Brain

The brain of two-week-old rat pups contained small amounts of C18:2n-6 and C18:3n-3. The C18:2n-6 content of brain was significantly increased in animals fed the low compared to a high C18:3n-3 fatty acid diet (Table 4.3). The C18:3n-3 content of brain was significantly increased in rat pups fed the high compared to the low C18:3n-3 fatty acid diets (Table 4.3). C20:4n-6 and C22:6n-3 were the predominant n-6 and n-3 fatty acids in brain of rat pups fed low or high C18:3n-3 fatty acid diet, respectively. The C20:4n-6 content of brain was significantly increased in rat pups fed the low vs. high C18:3n-3 fatty acid diet (Table 4.3). The C22:6n-3 content of brain was not significantly different in the animals fed the high compared to the low C18:3n-3 fatty acid diets (Table 4.3). The C20:5n-3 content of brain was not significantly different between rat pups fed low vs. high C18:3n-3 fatty acid diet (Table 4.3). However, the C22:5n-3 content of brain was significantly different between rat pups fed low vs. high C18:3n-3 fatty acid diet (Table 4.3).

**b) Liver**

The partial fatty acid composition of liver from two-week-old rat pups is shown (Table 4.3). High content of C18:2n-6 and C20:4n-6 was observed in the liver of rat pups fed either a low or high C18:3n-3 fatty acid diet. The C18:3n-3 and C22:6n-3 content of liver was considerably lower than the C18:2n-6 and C20:4n-6 content for animals fed either the low or high C18:3n-3 diet. Significant differences were observed in the C18:2n-6 content of liver between rat pups fed low vs. high C18:3n-3 fatty acid diet. The content of C18:3n-3 in liver was approximately 3% in animals fed the high C18:3n-3 fatty acid diet and was significantly different when compared to animals fed the low C18:3n-3 fatty acid diet. The C20:4n-6 content of liver did not differ between rat pups fed low vs. high C18:3n-3 fatty acid diet (Table 4.3) whereas, the C22:6n-3 content of liver was significantly increased in animals fed high vs. low C18:3n-3 fatty acid diet (Table 4.3). The C20:5n-3 and C22:5n-3 content of liver was significantly different between rat pups fed low vs. high C18:3n-3 fatty acid diet (Table 4.3).

**Table 4.3 Effect of Low and High C18:3n-3 Diet on the Essential Fatty Acid Composition of Whole Body and Tissue Lipids <sup>a</sup>**

Fatty Acid (% wt/wt)	Diet C18:3n-3 Content												
	<u>Whole Body</u>		<u>Brain</u>		<u>Liver</u>		<u>Skin</u>		<u>Epididymal Fat Pad</u>		<u>Muscles</u>		
	<u>Low</u>	<u>High</u>	<u>Low</u>	<u>High</u>	<u>Low</u>	<u>High</u>	<u>Low</u>	<u>High</u>	<u>Low</u>	<u>High</u>	<u>Low</u>	<u>High</u>	
<b>Diet 18:3n-3 Content :</b>													
<b>C18:2n-6</b>	24.5 <sup>a</sup> ±0.4	19.3 <sup>b</sup> ±0.3	2.8 <sup>a</sup> ±0.5	1.7 <sup>b</sup> ±0.0	16.3 <sup>a</sup> ±0.2	13.0 <sup>b</sup> ±0.4	21.6 <sup>a</sup> ±1.1	15.5 <sup>b</sup> ±0.5	19.9 <sup>a</sup> ±0.6	18.8 <sup>a</sup> ±0.6	20.8 <sup>a</sup> ±1.8	15.9 <sup>b</sup> ±0.7	
<b>C18:3n-3</b>	0.9 <sup>b</sup> ±0.0	14.7 <sup>a</sup> ±0.4	0.1 <sup>b</sup> ±0.0	0.5 <sup>a</sup> ±0.0	0.2 <sup>b</sup> ±0.1	3.3 <sup>a</sup> ±0.3	0.7 <sup>b</sup> ±0.1	11.6 <sup>a</sup> ±0.4	1.8 <sup>b</sup> ±0.7	13.3 <sup>a</sup> ±0.7	1.6 <sup>b</sup> ±1.0	10.7 <sup>b</sup> ±0.3	
<b>C20:4n-6</b>	1.7 <sup>a</sup> ±0.1	1.0 <sup>b</sup> ±0.1	12.0 <sup>a</sup> ±0.3	10.0 <sup>b</sup> ±0.2	15.0 <sup>a</sup> ±2.1	12.4 <sup>a</sup> ±1.0	0.8 <sup>a</sup> ±0.2	0.6 <sup>a</sup> ±0.1	1.1 <sup>a</sup> ±0.1	0.9 <sup>a</sup> ±0.1	1.7 <sup>a</sup> ±0.3	0.9 <sup>b</sup> ±0.3	
<b>C20:5n-3</b>	0.0 <sup>b</sup> ±0.0	0.7 <sup>a</sup> ±0.0	0.0 <sup>a</sup> ±0.0	0.1 <sup>a</sup> ±0.0	0.1 <sup>b</sup> ±0.0	1.5 <sup>a</sup> ±0.1	0.0 <sup>b</sup> ±0.0	0.5 <sup>a</sup> ±0.0	0.1 <sup>b</sup> ±0.0	0.4 <sup>a</sup> ±0.1	0.1 <sup>b</sup> ±0.1	0.6 <sup>a</sup> ±0.1	
<b>C22:5n-3</b>	0.1 <sup>b</sup> ±0.0	0.7 <sup>a</sup> ±0.0	0.1 <sup>b</sup> ±0.0	0.5 <sup>a</sup> ±0.0	0.4 <sup>b</sup> ±1.3	1.3 <sup>a</sup> ±0.1	0.0 <sup>b</sup> ±0.0	0.4 <sup>a</sup> ±0.0	0.1 <sup>b</sup> ±0.0	0.3 <sup>a</sup> ±0.1	0.0 <sup>a</sup> ±0.0	0.2 <sup>a</sup> ±0.1	
<b>C22:6n-3</b>	0.3 <sup>a</sup> ±0.1	0.5 <sup>a</sup> ±0.1	6.5 <sup>a</sup> ±0.3	7.1 <sup>a</sup> ±0.6	3.5 <sup>b</sup> ±0.8	6.1 <sup>a</sup> ±0.6	0.2 <sup>a</sup> ±0.1	0.4 <sup>a</sup> ±0.0	0.2 <sup>a</sup> ±0.1	0.4 <sup>a</sup> ±0.1	0.2 <sup>a</sup> ±0.1	0.3 <sup>a</sup> ±0.1	

<sup>a</sup>Values represent mean ± SEM for n=9 rat pups (5 male and 4 female rat pups except for epididymal fat pads in which 9 male rat pups were used) for each experimental diet. Values without a common superscript for each fatty acid are significantly different at P<0.05.

**c) Skin (Epidermis, Dermis, and Subcutaneous Tissue)**

The fatty acid composition of skin (epidermis, dermis, and subcutaneous tissue; Table 4.3) shows that C18:2n-6 plus C20:4n-6 were major fatty acids of skin comprising approximately 23 and 17% for animals fed the low and high C18:3n-3 fatty acid diet, respectively. The C18:2n-6 content in skin was significantly higher in rat pups fed low compared to a high C18:3n-3 fatty acid diet. However, there was no significant difference in C20:4n-6 content of skin among the two diet groups. Similar to liver, the C18:3n-3 content of skin was significantly increased by high maternal dietary C18:3n-3 content (Table 4.3). The C22:6n-3 content of skin, however, was not statistically different in animals fed either the low or high C18:3n-3 diet (Table 4.3). The C20:5n-3 and C22:5n-3 content of skin was significantly different between rat pups fed low vs. high C18:3n-3 fatty acid diet (Table 4.3).

**d) Epididymal Fat Pads**

Similar to skin and liver, the C18:2n-6 content of epididymal fat pads from male rat pups was high containing approximately 19-20% of the total fatty acids (Table 4.3). The C18:2n-6 content in epididymal fat pads was not significantly affected by the two dietary fat treatments. However, unlike C18:2n-6, the C18:3n-3 content of this tissue was significantly increased by the dietary C18:3n-3 content (Table 4.3). The content of C18:3n-3 in epididymal fat pads was approximately 1.8 and 13.3% for animals fed either low or high C18:3n-3 fatty acid diet, respectively. C20:4n-6 and C22:6n-3 content in epididymal fat pads was not significantly different between animals fed the two diet groups (Table 4.3). The C20:5n-3 and C22:5n-3 content of epididymal fat pads was significantly different between rat pups fed low vs. high C18:3n-3 diet (Table 4.3).

**e) Muscles (Front and Back Legs)**

The fatty acid composition of muscle (front and back legs) from two-week-old rat pups is shown (Table 4.3). The C18:2n-6 content in muscles was significantly different between rat pups fed low vs. high C18:3n-3 fatty acid diet. The C18:2n-6 content in muscles of rat pups fed low or high C18:3n-3 fatty acid diet was approximately 21 and 16%, respectively. The C18:3n-3 content of muscles was significantly different between

rat pups fed low vs. high C18:3n-3 fatty acid diet (1.6 vs. 10.7%, respectively). The C20:4n-6 content in muscles of rat pups was significantly higher in the low compared to the high C18:3n-3 fatty acid diet (1.7 vs. 0.9%, respectively). No significant differences were observed in the C22:6n-3 content of muscles in the two diet groups. The C20:5n-3 but not the C22:5n-3 content of muscles was significantly different between rat pups fed low vs. high C18:3n-3 fatty acid diet (Table 4.3).

#### **f) Tissue C18:3n-3 Content in Whole Body**

Feeding a low C18:3n-3 fatty acid diet to the dams significantly increased the C18:2n-6 content of whole body lipids of the rat pups compared to the high C18:3n-3 fatty acid diet (Table 4.3). Raising the C18:3n-3 content from a low to a high C18:3n-3 fatty acid diet significantly increased the C18:3n-3 content of whole body lipids (Table 4.3). The C20:4n-6 content of whole body lipids was significantly different between rat pups fed low or high C18:3n-3 fatty acid diet. However, the C22:6n-3 content of whole body lipids was not significantly different between rat pups fed the low vs. high C18:3n-3 fatty acid diet (Table 4.3). The C20:5n-3 and C22:5n-3 content of whole body was significantly different between rat pups fed low vs. high C18:3n-3 fatty acid diet (Table 4.3). Based on the lipid and C18:3n-3, C20:5n-3, C22:5n-3, and C22:6n-3 content, as well as, the weight of the tissues examined in the present study, the C18:3n-3, C20:5n-3, C22:5n-3, and C22:6n-3 content in whole body of rat pups fed either low or high C18:3n-3 fatty acid diet was calculated to be approximately 39 and 630 mg, 0 and 30 mg, 4.3 and 30 mg, 12.9 and 21.4 mg, respectively (data not shown). The other tissues examined in this study including brain, liver, epididymal fat pads, and muscles (front and back legs) from two-week-old rat pups fed either low or high C18:3n-3 fatty acid diet contained small amounts of C18:3n-3, C20:5n-3, and C22:5n-3 (data not shown). Interestingly, the skin (epidermis, dermis, and subcutaneous tissue) of rat pups fed either low or high C18:3n-3 fatty acid diet contained a significant amount of C18:3n-3. The total C18:3n-3 content in skin for the low and high C18:3n-3 fatty acid diet was approximately 15 and 260 mg, respectively (data not shown).

## D. DISCUSSION

The results from the present study demonstrate that increasing maternal dietary C18:3n-3 significantly increases the C18:3n-3 but not the C22:6n-3 content of whole body, brain, skin (epidermis, dermis, and subcutaneous tissue), epididymal fat pads, and muscles (front and back legs) in two-week-old rat pups. Two-week-old rat pups were used in the present study because at this age very active brain growth occurs with rapid accretion of PUFAs, especially C22:6n-3, for brain membrane synthesis (Sinclair & Crawford, 1972; Dobbing & Sands, 1979). Therefore, the demand for C22:6n-3 in two-week-old rat pups for postnatal brain growth and development is high and must be provided by the maternal diet.

It is well known that the fatty acid composition of tissues can be readily modified by dietary fat [reviewed by Clandinin et al. (1985 & 1991)]. The significant differences observed in whole body and tissue C18:2n-6 and C18:3n-3 content between rat pups fed low vs. high C18:3n-3 fatty acid diet were largely a reflection of the dietary fatty acid composition (Field et al., 1985; Bourre et al., 1990; Lin & Connor, 1990; Srinivasarao et al., 1997).

The content of C22:6n-3 was not significantly increased in whole body, brain, skin (epidermis, dermis, and subcutaneous tissue), epididymal fat pads, and muscles (front and back legs) when rat pups were fed the high C18:3n-3 diet. This could be because desaturase activity is age-related and that at two weeks of age desaturase activity may be limited. In this regard, Bourre et al. (1990) demonstrated in rats that delta-6-desaturase activity, a rate-limiting step in C20:4n-6 and C22:6n-3 synthesis varies during the first twenty-one days following gestation. Therefore, if delta-6-desaturase activity is low at two weeks of age, the amount of C18:3n-3 added in the diet would not have any significant effect on increasing the C22:6n-3 content of these tissues. The significant increase in C20:5n-3 (except brain) and C22:5n-3 (except muscles) but not C22:6n-3 content of tissues examined in this study when rat pups were fed the high compared with low C18:3n-3 diet shows that C18:3n-3 is metabolized to long-chain n-3 metabolites but that there is a limit on the conversion of C20:5n-3 and C22:5n-3 to C22:6n-3.

The milk (stomach contents) provided to the rat pups by the dam during the two-week feeding period provide some preformed C22:6n-3 (Table 4.1). It is possible that the preformed C22:6n-3 (0.1%) present in the dams' milk fed the high C18:3n-3 fatty acid diet (Table 4.1) is sufficient to significantly increase the content of C22:6n-3 observed in liver of rat pups fed the high C18:3n-3 fatty acid diet (Table 4.3) without the need for additional synthesis of C22:6n-3 from dietary C18:3n-3. With exception of brain, increasing dietary C18:3n-3 by reducing the C18:2n-6:C18:3n-3 ratio from 24.7:1 to 1.0:1 did not show any competitive effect of reduced C20:4n-6 and increased C22:6n-3 incorporation into whole body or tissue lipids. This would suggest that either desaturase activity is low or that a lower C18:2n-6:C18:3n-3 ratio than that used in the present study may be required to reduce the C20:4n-6 and increase the C22:6n-3 content in the tissues examined (Jumpsen et al., 1997a).

Quantitative analysis of the C18:3n-3 content in rat pup tissues examined in the present study showed that significant amount of C18:3n-3 was incorporated into whole body lipids. The C18:3n-3 content of rat pup whole body lipids was significantly greater in rat pups fed the high compared to the low C18:3n-3 diet (approximately 630 vs. 39 mg, respectively). The skin of rat pups fed low or high C18:3n-3 fatty acid diet contained significant quantities of C18:3n-3 (approximately 39 and 41% of the total C18:3n-3 content in whole body, respectively). The high amounts of C18:3n-3 found in skin was stored as part of the fatty acid component of triglycerides in the subcutaneous fat (data not shown). Thus, it appears that the skin including epidermis, dermis, and subcutaneous tissue, is a major deposition site for C18:3n-3 in two-week-old rat pups.

The saturated fatty acid content in whole body, skin, and epididymal fat pads was significantly decreased ( $p < 0.05$ ) when the pups were fed maternal milk from the dams fed the high C18:3n-3 diet (data not shown). This decrease in the saturated fatty acid content of tissues was due to the substantial increase in the content of C18:3n-3 in these tissues by the high C18:3n-3 diet.

In conclusion, the results from the present study demonstrate that increasing maternal dietary C18:3n-3 content from 1.1 to 20.1% of the total dietary fatty acids significantly increases the C18:3n-3 but not the C22:6n-3 content in most tissues. If the present findings from this study are extrapolated to neonates, it appears that increasing

the dietary C18:3n-3 content of the neonate's feed will significantly increase the C18:3n-3 but not the C22:6n-3 content of neonatal tissues.

/

## E. REFERENCES

- Bourre, J.M., Francis, M., Youyou, A., Dumont, O., Piciotti, M., Pascal, G., & Durand, G. (1989). The Effects of Dietary  $\alpha$ -C18:3n-3 Acid on the Composition of Nerve Membranes, Enzymatic Activity, Amplitude of Electrophysiological Parameters, Resistance to Poisons and Performance of Learning Tasks in Rats, *J. Nutr.* 119: 1880-1892.
- Bourre, J.M., Piciotti, M., & Dumont, O. (1990).  $\Delta$ 6-Desaturase in Brain and Liver During Development and Aging, *Lipids* 25: 354-356.
- Bowen, R.A.R., Wierzbicki, A.A., & Clandinin, M.T. (1999) Does Increasing Dietary C18:3n-3 Acid Content Increase the Docosahexaenoic Acid Content of Phospholipids in Neuronal Cells of Neonatal Rats ? *Pediatr Res.* 45: 815-819.
- British Nutrition Foundation. Unsaturated Fatty Acids (1992) Nutritional and Physiological Significance, pp. 156-163, Chapman and Hall, London.
- Carnielli, V.P., Wattimena, J.L.D., Luijendijk, I.H.T., Boerlage, A., Degenhart, H.J., & Sauer P.J.J. (1996) The Very Low Birth Weight Premature Infant is Capable of Synthesizing C20:4n-6 and Docosahexaenoic Acids from C18:2n-6 and C18:3n-3 Acids, *Pediatr Res* 40: 169-174.
- Clandinin, M.T., & Yamashiro, S. (1980) Effects of Basal Diet Composition on the Incidence of Dietary Fat Induced Myocardial Lesions, *J. Nutr.* 110: 1197-1203.
- Clandinin, M.T., Chappell, J.E., Leong, S., Heim, T., Swyer, P.R., & Chance, G.W. (1980a) Extrauterine Fatty Acid Accretion in Infant Brain: Implications for Fatty Acid Requirements, *Early Human Dev.* 4:131-138.
- Clandinin, M.T., Chappell, J.E., Leong, S., Heim, T., Swyer, P.R., & Chance, G.W. (1980b) Intrauterine Fatty Acid Accretion Rates in Human Brain: Implications for Fatty Acid Requirements, *Early Human Dev.* 4: 121-129.
- Clandinin, M.T., Chappell, J.E., Heim, T., Swyer, P.R., & Chance, G.W. (1981) Fatty Acid Utilization in Perinatal De Novo Synthesis of Tissues, *Early Human Dev.* 5:355-366.
- Clandinin, M.T., Chappell, J.E., & Heim, T. (1982) Do Low Birth Weight Infants Require Nutrition with Chain Elongation-Desaturation Products of Essential Fatty Acids?. *Prog. Lipid Res.* 20: 901-904.

Clandinin, M.T., Field, C.J., Hargreaves, K., Morson, L.A., & Zsigmond, E. (1985) Role of Diet Fat in Subcellular Structure and Function. *Can. J. Physiol. Pharmacol.* 63:546-556.

Clandinin, M.T., Cheema, S., Field, C.J., Garg, M.L., Venkatraman, J., & Clandinin, T.T. (1991) Dietary fat: Exogenous Determination of Membrane Structure and Cell Function. *FASEB J.* 5: 2761-2769.

Clandinin, M.T., Garg, M.L., Parrott, A., Van Aerde, J., Hervada, A., & Lien, E. (1992a) Addition of Long-Chain Polyunsaturated Fatty Acids to Formula for Very Low Birth Weight Infants, *Lipids* 27: 896-900.

Clandinin, M. T., Parrot, A., Van Aerde, J.E., Hervada, A.R., & Lien, E. (1992b) Feeding Preterm Infants a Formula Containing C20 and C22 Fatty Acids Simulates Plasma Phospholipid Fatty Acid Composition of Infants Fed Human Milk, *Early Human Dev.* 31:41-51.

Clandinin, M.T., Van Aerde, J.E., Parrott, A., Field, C.J., Euler, A.R., & Lien, E. (1997) Assessment of the Efficacious Dose of C20:4n-6 and Docosahexaenoic Acids in Preterm Infant Formulas: Fatty Acid Composition of Erythrocyte Membrane Lipids. *Pediatr. Res.* 42:819-825.

Connor, W.E., Neuringer, M., & Lin, D.S. (1990) Dietary Effects on Brain Fatty Acid Composition: the Reversibility of N-3 Fatty Acid Deficiency and Turnover of Docosahexaenoic Acid in the Brain, Erythrocytes, and Plasma of Rhesus Monkeys. *J. Lipid Res.* 31: 237-247.

Demmelair, H., Rinke, U., Behrendt, E., Sauerwald, T., & Koletzko, B. (1995) Estimation of C20:4n-6 Synthesis in Fullterm Neonates Using Natural Variation of <sup>13</sup>C-Abundance. *J. Pediatr. Gastroenterol. Nutr.* 21:31-36.

Dobbing, J. & Sands, J. (1979) Comparative Aspects of the Brain Growth Spurt. *Early Hum. Dev.* 3:79-83.

European Society of Paediatric Gastroenterology and Nutrition: Committee on Nutrition (1991) Comment on the Content and Composition of Lipids in Infant Formula, *Acta Paediatr. Scand.* 80: 887-896.

FAO/WHO. Report of a Joint Expert Consultation (1994) Fats and Oils in Human Nutrition, pp. 49-55, Rome.

Field, C.J., Angel, A. & Clandinin, M.T. (1985) Relationship of Diet to the Fatty Acid Composition of Human Adipose Tissue Structure and Stored Lipids. *Am. J. Clin. Nutr.* 42: 1206-1220.

Folch, J., Lee, M. & Sloane Stanley, G.H. (1957) A Simple Method For the Isolation and Purification of Total Lipids From Animal Tissues, *J. Biol. Chem.* 226: 497-506.

Hargreaves, K.M. & Clandinin, M.T. (1987) Phosphatidylethanolamine Methyltransferase: Evidence for Influence of Diet Fat on Selectivity of Substrate for Methylation in Rat Brain Synaptic Plasma Membrane, *Biochim. Biophys. Acta* 918: 97-105.

International Society for the Study of Fatty Acids and Lipids (1994) Recommendations for the Essential Fatty Acid Requirements of Infant Formula, *ISSFAL Newsletter* 1: 4.

Jumpsen, J. A., Lien, E., Goh, Y. K. & Clandinin, M. T. (1997a) Diets Varying in N-3 and N-6 Fatty Acid Content Produce Differences in Phosphatidylethanolamine and Phosphatidylcholine Fatty Acid Composition During Development of Neuronal and Glial Cells in Rats, *J. Nutr.* 127: 724-731.

Jumpsen, J. A., Lien, E., Goh, Y. K. & Clandinin, M. T. (1997b) During Neuronal and Glial Cell Development Diet N-6 to N-3 Fatty Acid Ratio Alters the Fatty Acid Composition of Phosphatidylinositol and Phosphatidylserine, *Biochim. Biophys. Acta* 1347:40-50.

Layne, K.S., Goh, Y.K., Jumpsen, J.A., Ryan, E.A., Chow, P., & Clandinin, M.T. (1996) Normal Subjects Consuming Physiological Levels of 18:3(n-3) and 20:5(n-3) from Flaxseed or Fish Oils Have Characteristics Differences in Plasma Lipid and Lipoprotein Fatty Acid Levels, *J. Nutr.* 126: 2130-2140.

Lien E. L., Boyle, F. G., Yuhas, R. J. & Kuhlman, C. F. (1994) Effect of Maternal Dietary C20:4n-6 or C18:2n-6 Acid on Rat Pup Fatty Acid Profiles, *Lipids* 29: 53-59.

Lin, D.S. & Connor, W.W. (1990) Are the n-3 Fatty Acids From Dietary Fish Oil Deposited in the Triglyceride Stores of Adipose Tissue?, *Am. J. Clin. Nutr.* 51: 535-539.

Morrison, W.R. & Smith, L.M. (1964) Preparation of Fatty Acid Methyl Esters and Dimethyl-Acetals from Lipids with Boron Fluoride-Methanol, *J. Lipid Res.* 5: 600-608.

Nouvelot, A., Bourre, J.M., Sezille, G., Dewailly, P. & Jaillard, J. (1983) Changes in the Fatty Acid Patterns of Brain Phospholipids During Development of Rats Fed Peanut or Rapeseed Oil, Taking into Account Differences Between Milk and Maternal Food, *Ann. Nutr. Metab.* 27: 173-181.

Salem Jr. N., Wegher, B., Mena, P. & Uauy, R. (1996) C20:4n-6 and Docosahexaenoic Acids are Biosynthesized from Their 18-Carbon Precursors in Human Infants, *Proc. Natl. Acad. Sci. USA* 93: 49-54.

SAS Institute Inc. (1988) SAS/STAT User's Guide, Release 6.11 Edition, SAS Institute Inc. Cary, North Carolina.

Sauerwald, T.U., Hachey, D.L., Jensen, C.L., Chen, H.M., Anderson, R.E. & Heird, W.C. (1996) Effect of Dietary  $\alpha$ -C18:3n-3 Acid Intake on Incorporation of Docosahexaenoic and C20:4n-6 Acids into Plasma Phospholipids of Term Infants. *Lipids* 31: S131-S135.

Sauerwald, T.U., Hachey, D.L., Jensen, C.L., Chen, H.M., Anderson, R.E. & Heird, W.C. (1997) Intermediates in Endogenous Synthesis of C22:6n-3 and CC20:4n-6 by Term and Preterm Infants. *Pediatr. Res.* 41:183-187.

Sinclair, A.J. & Crawford, M.A., (1972) The Accumulation of Arachidonate and Docosahexaenote in the Developing Rat Brain, *J. Neurochem.* 19: 1753-1753.

Srinivasarao, P., Narayanareddy, K., Vajreswari, A., Rupalatha, M., Prakash, P.S. & Rao, P. (1997) Influence of Dietary Fat on the Activities of Subcellular Membrane-Bound Enzymes From Different Regions of Rat Brain. *Neurochem. Int.* 31: 789-94.

Steel, R. G. D. & Torrie, J. H. (1960) *Principles and Procedures of Statistics*. McGraw-Hill, New York.

Wainwright, P.E., Xing, H.C., Mutsaers, L., McCutcheon, D. & Kyle, D. (1997) C20:4n-6 Acid Offsets the Effects on Mouse Brain and Behavior of a Diet with a Low (n-6):(n-3) Ratio and Very High Levels of Docosahexaenoic Acid. *J. Nutr.* 127:184-193.

Yonekubo, A., Honda, S., Okano, M., Takahashi, K. & Yamamoto, Y. (1993) Dietary Fish Oil Alters Rat Milk Composition and Liver and Brain Fatty Acid Composition of Fetal and Neonatal Rats. *J. Nutr.* 123:1703-1708.

## **CHAPTER V. DIETARY C22:6N-3 IS MORE EFFECTIVE THAN LOW OR HIGH LEVELS OF C18:3N-3 IN INCREASING THE C22:6N-3 CONTENT IN PHOSPHOLIPIDS OF NEURONAL AND GLIAL CELLS FROM WHOLE BRAIN IN NEONATAL RAT**

### **A. INTRODUCTION**

C20:4n-6 and C22:6n-3 are the most abundant PUFAs in phospholipids of the central nervous system (O'Brien & Sampson, 1965; Sun & Horrocks, 1968) and can be synthesized in animal tissues by desaturation and elongation of their dietary precursors. C18:2n-6 and C18:3n-3 (Dhopeshwarkar & Subramanian, 1976). C20:4n-6 and C22:6n-3 are found in high concentrations in brain SPM (Cotman et al., 1969; Breckenridge et al., 1972; Sun & Sun, 1974; Foot et al., 1982) and in photoreceptor cells (Anderson et al., 1974). C20:4n-6 plays an important role as a precursor of biologically active molecules like prostanoids, leukotrienes, and other lipoxygenase products (reviewed by Kinsella et al., 1990). C20:4n-6 and C22:6n-3 are involved in providing a specific environment within the phospholipid bilayer that influence important membrane functions, such as ion or solute transport, receptor activity, and adenylate cyclase activity (reviewed by Stubbs & Smith, 1984; Sastry, 1985).

C20:4n-6 and C22:6n-3 accumulate rapidly in the brain during the fetal and early postnatal periods, depending on the species. In rats, C22:6n-3 accumulates during the embryonic period and first three postnatal weeks of life (Kishimoto et al., 1965; Sinclair & Crawford, 1972; Green et al., 1999). In humans, accretion of C20:4n-6 and C22:6n-3 takes place during the last trimester and first 6 – 10 months after birth (Clandinin et al., 1980a & 1980b). The rapid accumulation of C20:4n-6 and C22:6n-3 in rat and human brain suggests that these fatty acids may be essential for neural and visual development. Manipulation of brain C22:6n-3 content by C22:6n-3 deprivation has been attempted to determine some functions of C22:6n-3 in the central nervous system. In this regard, rats fed diets deficient in C18:3n-3 but with adequate C18:2n-6 had lower levels of C22:6n-3 in brain and retina compared to rats fed C18:3n-3 (Bourre et al., 1989) and have delayed electrophysiological responses in the retina (Bourre et al., 1989) together with poorer performance in behavioral tests of learning, memory, and habituation (Lamptey &

Walker, 1976; Yamamoto et al., 1987; Bourre et al., 1989; Enslin et al., 1991; Frances et al., 1996; Belzung et al., 1998; Carrie et al., 1999 & 2000). Activity of Na, K-ATPase has also been shown to be lower in rats fed diets deficient compared to adequate in C18:3n-3 (Gerbi et al., 1994; Tsutsumi et al., 1995). These studies reinforce the essentiality of C22:6n-3 in rat brain. The importance of C22:6n-3 in brain has given rise to the question of whether C18:3n-3 is sufficient to enable synthesis of adequate amounts of C22:6n-3 for optimal brain growth and development?

Studies with isolated brain cells have provided evidence that astrocytes (glial cells) and cerebroendothelial cells but not neuronal cells can synthesize C20:4n-6 and C22:6n-3 from C18:2n-6 and C18:3n-3, respectively (Moore et al., 1991). Further work has also shown that neuronal cells take up C22:6n-3 released by astrocytes and cerebroendothelial cells and incorporate C22:6n-3 into neural plasma membranes (Moore, 1993; Delton-Vandenbroucke et al., 1997). It is not known whether C20:4n-6 and C22:6n-3 are synthesized from precursors by astrocytes and cerebroendothelial cells in amounts that can meet neuronal cell requirements for DHA *in vivo*.

In weanling rats, increasing maternal dietary C18:3n-3 by decreasing the C18:2n-6 to C18:3n-3 fatty acid ratio from 7.3:1 to 4:1 increased the C22:6n-3 content only in neuronal cell PE from the cerebellum during the first two weeks of life. Other phospholipids from frontal or hippocampal regions were not significantly affected (Jumpsen et al., 1997a & 1997b). Recently, it has been shown that increasing maternal dietary C18:3n-3 by lowering the C18:2n-6 to C18:3n-3 fatty acid ratio does not significantly increase the C22:6n-3 content in PC, PE, and PS of neuronal cells from whole brain of two-week-old rat pups (**Chapter III**). Taken together, these studies suggest that astrocytes and cerebroendothelial cells may not synthesize enough C22:6n-3 from C18:3n-3 to provide for maximal levels of C22:6n-3 in plasma membrane phospholipids of neuronal cells in brain.

It is known that diets supplemented with C22:6n-3 fed to dams or directly to suckling animals enrich the C22:6n-3 content of brain phospholipids (Galli et al., 1971; Anderson et al., 1990). It is not known if maternal dietary C18:3n-3 compared to C22:6n-3 can significantly increase the C22:6n-3 content of both neuronal and glial cell phospholipids from whole brain of rats. Therefore, the present study used neonatal rat

brains at two weeks of age, before consumption of solid food, to test the hypothesis that dietary C22:6n-3 but not C18:3n-3 will significantly increase the C22:6n-3 content of both neuronal and glial cell phospholipids of whole brain. The novelty of this study is that it examines: (1) high levels of maternal dietary C18:3n-3 intake and (2) the C22:6n-3 content of both neuronal and glial cells isolated from whole brain.

## **B. MATERIALS AND METHODS**

### **1. Animals and Diets**

Breeding of Sprague-Dawley rats have been described in **Chapter III**. Pups received only maternal milk. Pups were sacrificed at two weeks of age. One entire litter of rat pups fed the same diet was sexed and weighed prior to decapitation. Excised brains were placed in ice-cold 0.32 mol/L sucrose. Six brains from the same sex were pooled per sample. Stomach contents of three rats from each litter were also removed and analyzed for fatty acid composition to represent the composition of maternal milk. Three litters per diet treatment were used.

The basal diet fed to the dams contained 20% (wt/wt) fat (Table 5.1). Diet fats were formulated to approximate the fatty acid composition of an existing infant formula providing an C18:2n-6 to C18:3n-3 fatty acid ratio of 7.3 to 1 (medium LNA) (Jumpsen et al., 1997a and 1997b). This fat blend served as the control fat treatment. An C18:2n-6 to C18:3n-3 fatty acid ratio of 21.6:1 (low LNA) was obtained by addition of corn oil to the medium LNA diet. The diet with a C18:2n-6 to C18:3n-3 fatty acid ratio of 1 to 1 (high LNA) was obtained by the addition of flaxseed oil to the medium LNA diet. The C22:6n-3 (DHA) diet was achieved by the addition of 0.6% (wt/wt) C22:6n-3 to the medium LNA diet. The C20:4n-6 (AA) + 22:6n-3 diet was achieved by the addition of 1% (wt/wt) C20:4n-6 and 0.6% (wt/wt) C22:6n-3 to the medium LNA diet. The AA and DHA triglycerides utilized were obtained from single cell oils (Martek Biosciences, Columbia, MD). The amount C20:4n-6 (1%) and C22:6n-3 (0.6%) used in this study has been shown by Clandinin et al. (1989) to reflect the C20:4n-6 and C22:6n-3 content found in human milk. The five diets were nutritionally adequate, providing for all known essential nutrient requirements as described earlier (Clandinin & Yamashiro, 1980).

To minimize any changes in sample composition due to fatty acid oxidation, the diets were sealed under nitrogen and stored in a freezer at -30°C in darkness. Every day the required amount of diet was taken out, mixed, and placed in individual feed cups.

**Table 5.1 Fatty Acid Composition of Experimental Diets Fed to Lactating Dams at Two-Weeks of Age**

<b>DIET FAT:</b>	<b>Low LNA<sup>1</sup></b>	<b>Medium LNA<sup>2</sup></b>	<b>High LNA<sup>3</sup></b>	<b>DHA<sup>4</sup></b>	<b>AA+DHA<sup>5</sup></b>
<b>Fatty Acid Composition (% wt/wt)</b>					
<b>C12:0</b>	6.4	8.4	6.0	7.5	7.7
<b>C14:0</b>	3.8	5.2	3.6	5.3	5.3
<b>C16:0</b>	12.2	14.0	11.4	14.6	14.5
<b>C18:0</b>	9.8	7.4	6.4	7.3	7.4
<b>C18:1n-7+n-9</b>	29.2	39.9	33.8	38.6	39.4
<b>C18:2n-6</b>	34.5	17.2	17.6	16.2	16.5
<b>C18:3n-3</b>	1.6	2.2	17.5	1.8	1.9
<b>C20:4n-6</b>	nd	nd	nd	nd	1.0
<b>C20:5n-3</b>	nd	nd	nd	nd	nd
<b>C22:6n-3</b>	nd	nd	nd	0.6	0.6

<sup>1</sup> Low LNA diet was obtained by the addition of corn oil to the medium LNA diet.

<sup>2</sup> Medium LNA diet approximates the fatty acid composition used in SMA<sup>2</sup> infant formula.

<sup>3</sup> High LNA diet was obtained by the addition of flaxseed oil to the medium LNA diet.

<sup>4</sup> DHA was obtained by the addition of 0.6% C22:6n-3 triglyceride to the medium LNA diet.

<sup>5</sup> AA + DHA was obtained by addition of 1% C20:4n-6 and 0.6% C22:6n-3 triglyceride to the medium LNA diet.

Nd = not detected.

## **2. Isolation of Neuronal and Glial Cells from Whole Brain**

Neuronal and glial cells were isolated from whole brain (cerebrum and cerebellum) according to the method described by Sellinger & Azcurra (1974). Briefly, pooled brains were placed in beakers containing 7.5% (wt/vol.) polyvinylpyrrolidone and

10 mmol CaCl<sub>2</sub>/L at pH 4.7 and 25°C. Brain tissue was minced and poured into a 20 mL plastic syringe, fitted with a reusable filter unit (Millipore, Swinnex disc holder, 25mm). The sample was pressed, three times each, through a series of combined nylon mesh filters. The final filtrate volume was adjusted, then layered on a two-step sucrose gradient of 1.0 mol/L and 1.75 mol/L. Gradients were centrifuged in a Beckman SW-28 rotor at 41,000 g for 30 min at 4°C.

Neuronal cell bodies were recovered in the pellet. Glial cells were obtained at the interface of 1.0 mol/L and 1.75 mol/L sucrose. Aliquots of each cell type were stained with methylene blue and examined for purity under a light microscope (Zeiss, 1600X; Appendix 1). Gel electrophoresis and immunoblotting were performed to ensure purity of cell fractions prepared by these procedures (Jumpsen et al., 1997a and 1997b). Proteins isolated from neuronal and glial cells were compared by gel electrophoresis and immunoblotting to neurofilament and glial fibrillary acid protein standards. Neuronal and glial cells isolated should only contain neurofilament proteins and glial fibrillary acid proteins, respectively.

### **3. Lipid Extraction and Fatty Acid Analysis**

The neuronal and glial cell lipid was extracted by a modified Folch method (Folch et al., 1957). Individual phospholipids from neuronal and glial cells were separated by thin-layer chromatography (Touchstone et al., 1980) and fatty acid methyl esters were prepared following the method of Morrison and Smith (1964). Fatty acid methyl esters were analyzed by automated gas-liquid chromatography as described in **Chapter III**.

### **4. Statistical Analysis**

The effect of diet treatment and cell type on the C20:4n-6 and C22:6n-3 content of neuronal and glial cell PC, PE, PI, and PS was assessed by a two-way analysis of variance (ANOVA) procedure using the SAS™ package, version 6.11 (SAS™ Institute Inc., 1988). Significant differences between diet treatments and cell type were determined by a Duncan's multiple range test at a significance level of p<0.05 after a significant ANOVA (Steel & Torrie, 1960). Values are expressed as mean ± SEM for n=6. Two-way

ANOVA procedures were performed on six diet treatments (including a C18:2n-6 to C18:3n-3 fatty acid ratio of 4.4:1), however, in this chapter statistical analysis on five diet treatments were presented for the fatty acid composition of neuronal cell phospholipid fractions in the figures and tables.

## **C. RESULTS**

### **1. Whole Body and Brain Weights**

Whole body and brain weights were not significantly different for male and female rat pups (data not shown), hence statistical analyses to test subsequent effects of diet treatments were combined for both sexes. The whole body and brain weights were not significantly different among the three experimental diet treatments, indicating that whole body and tissue growth in the two-week-old rat pups is not different between diets with or without C22:6n-3. Final body weights were (mean  $\pm$  SEM):  $35.8 \pm 1.0$  g,  $35.9 \pm 1.0$  g,  $35.6 \pm 1.3$  g,  $36.1 \pm 0.5$  g, and  $36.1 \pm 0.5$  g for low LNA, medium LNA, high LNA, DHA, and AA + DHA diet treatments, respectively. Final brain weights were (mean  $\pm$  SEM):  $1.2 \pm 0.1$  g,  $1.2 \pm 0.1$  g,  $1.1 \pm 0.1$  g,  $1.2 \pm 0.1$  g,  $1.2 \pm 0.1$  g for low LNA, medium LNA, high LNA, DHA, and AA + DHA diet treatments, respectively. Differences in fertility were not observed between the dietary treatments.

### **2. Purity of Neuronal and Glial Cell Preparations from Whole Brain**

Neuronal and glial cell preparations contained only minor cross contamination ( $\approx 5\%$ ) from cell membrane fragments and microvessels as determined by microscopic examination. The presence of neurofilament in neuronal samples and glial fibrillary acid protein in glial cells samples was previously verified by gel electrophoresis and immunoblotting (Jumpsen et al., 1997a and 1997b). These results indicate that the cell preparations are primarily neuronal and glial cells.

### **3. Fatty Acid Composition of Stomach Contents**

The rat pup stomach contents at day 14 of life contained no particulates indicative of diet consumption and therefore reflected the composition of their dams' milk. The fatty acid composition of stomach contents of rat pups was analyzed. These analyses have been shown to be similar to dams' milk composition (Nouvelot et al., 1983; Yonekubo et al., 1993; Lien et al., 1994; Jumpsen et al., 1997a and 1997b). The dietary C18:3n-3 or C22:6n-3 fed to the dams altered the stomach contents of the rat pups (Table 5.2) indicating that the dietary fat fed in the present experiment produced similar changes in the fat composition of the dams' milk.

/

**Table 5.2 The Content of Fatty Acids in the Stomach of Rat Pups at Two Weeks of Age<sup>1</sup>**

DIET FAT:	Low	Medium	High	DHA <sup>4</sup>	AA+DHA <sup>5</sup>
	LNA <sup>1</sup>	LNA <sup>2</sup>	LNA <sup>3</sup>		
Fatty Acid Composition (% wt/wt)					
C10:0	7.9 ± 2.1 <sup>a</sup>	7.2 ± 0.8 <sup>a</sup>	6.9 ± 2.2 <sup>a</sup>	6.7 ± 0.7 <sup>a</sup>	6.2 ± 0.8 <sup>a</sup>
C12:0	10.9 ± 1.1 <sup>c</sup>	15.1 ± 0.4 <sup>a</sup>	10.8 ± 0.6 <sup>c</sup>	13.8 ± 0.2 <sup>b</sup>	12.2 ± 0.1 <sup>b</sup>
C14:0	7.3 ± 0.3 <sup>c</sup>	15.3 ± 0.5 <sup>a</sup>	7.2 ± 0.3 <sup>c</sup>	9.3 ± 0.1 <sup>b</sup>	9.2 ± 0.1 <sup>b</sup>
C16:0	12.6 ± 0.9 <sup>c</sup>	17.7 ± 0.7 <sup>a</sup>	12.9 ± 0.4 <sup>c</sup>	14.9 ± 0.2 <sup>b</sup>	15.9 ± 0.2 <sup>b</sup>
C18:0	4.4 ± 0.4 <sup>a</sup>	3.4 ± 0.1 <sup>b</sup>	4.8 ± 0.2 <sup>a</sup>	4.6 ± 0.1 <sup>a</sup>	4.8 ± 0.1 <sup>b</sup>
C18:1n-7+n-9	28.2 ± 1.5 <sup>a</sup>	24.7 ± 0.7 <sup>b</sup>	26.7 ± 1.0 <sup>b</sup>	31.5 ± 0.8 <sup>a</sup>	29.2 ± 0.6 <sup>a</sup>
C18:2n-6	24.7 ± 0.1 <sup>a</sup>	12.5 ± 0.1 <sup>b</sup>	13.7 ± 0.1 <sup>a</sup>	13.8 ± 0.2 <sup>a</sup>	13.1 ± 0.1 <sup>b</sup>
C18:3n-3	1.1 ± 0.0 <sup>c</sup>	1.6 ± 0.0 <sup>b</sup>	8.8 ± 0.1 <sup>a</sup>	1.5 ± 0.0 <sup>b</sup>	1.6 ± 0.0 <sup>b</sup>
C20:4n-6	1.0 ± 0.1 <sup>a</sup>	0.5 ± 0.0 <sup>b</sup>	0.5 ± 0.1 <sup>b</sup>	0.5 ± 0.0 <sup>b</sup>	1.1 ± 0.1 <sup>a</sup>
C22:6n-3	0.1 ± 0.0 <sup>c</sup>	0.1 ± 0.0 <sup>c</sup>	0.2 ± 0.0 <sup>b</sup>	0.6 ± 0.0 <sup>a</sup>	0.7 ± 0.0 <sup>a</sup>
C18:2n-6:C18:3n-3	22.5	7.8	1.6	9.2	8.2

<sup>1</sup>Values are mean ± SEM with n=9 for each experimental diet. For each horizontal set of values, those that have the same superscript letters (a, b, or c) are not significantly different. Those that have different letters are significantly different, at p<0.05.

<sup>2</sup>Low LNA diet was obtained by the addition of corn oil to the medium LNA diet.

<sup>3</sup>Medium LNA diet approximates the fatty acid composition used in SMA<sup>®</sup> infant formula.

<sup>4</sup>High LNA diet was obtained by the addition of flaxseed oil to the medium LNA diet.


<sup>5</sup>DHA was obtained by the addition of 0.6% C22:6n-3 triglyceride to the medium LNA diet.

<sup>6</sup>AA + DHA was obtained by addition of 1% C20:4n-6 and 0.6% C22:6n-3 triglyceride to the medium LNA diet.

#### **4. Neuronal and Glial Cells Phospholipid Fatty Acid Composition**

##### **a) Phosphatidylethanolamine**

The analysis of the fatty acid profile in neuronal and glial cell PE from whole brain demonstrated that C16:0, C18:0, C20:4n-6, and C22:6n-3 (11-16%, 24-26%, 16-20%, and 16-29% of the total fatty acids, respectively) were the predominant fatty acids. There was no significant difference in the C20:4n-6 content of PE between neuronal and glial cells (Figure 5.1). However, the C22:6n-3 content of PE was significantly different between neuronal and glial cells ( $p < 0.05$ ) (Figure 5.1). Glial cells contained a significantly greater amount of C22:6n-3 in PE than neuronal cells. The C20:4n-6 content of PE from both cell types was not significantly different between the diet treatments (Figure 5.1). The C22:6n-3 content of PE in neuronal cells was significantly increased by feeding the DHA and AA + DHA diet treatments compared to feeding diets providing low LNA, medium LNA, high LNA (Figure 5.1). The C22:6n-3 content of glial cell PE was significantly increased with animals fed the DHA diet (Figure 5.1). The C22:6n-3 content of neuronal cell PE was (mean  $\pm$  SEM; %wt/wt);  $21.2 \pm 0.6\%$ ,  $17.4 \pm 2.2\%$ ,  $15.7 \pm 1.1\%$ ,  $26.2 \pm 1.6\%$ , and  $26.8 \pm 0.6\%$ , for animals fed the low LNA, medium LNA, high LNA, DHA, and AA + DHA diet treatments, respectively (Figure 5.1). The C22:6n-3 content of glial cell PE was (mean  $\pm$  SEM; %wt/wt);  $17.7 \pm 1.3\%$ ,  $20.9 \pm 2.4\%$ ,  $25.1 \pm 0.3\%$ ,  $31.6 \pm 0.2\%$ , and  $23.8 \pm 0.5\%$ , for animals fed the low LNA, medium LNA, high LNA, DHA, and AA + DHA diet treatments, respectively (Figure 5.1).




**Figure 5.1 Fatty Acid Composition of Neuronal and Glial Cell Phosphatidylethanolamine \* Cell Type Difference at  $p < 0.05$**

**b) Phosphatidylserine**

The major fatty acids in neuronal and glial cells PS from whole brain were C16:0, C18:0, and C22:6n-3 (7-20%, 36-44%, and 14-33% of the total fatty acids, respectively). The C20:4n-6 content of PS between neuronal and glial cells was not significantly different. The C22:6n-3 content of PS was different between neuronal and glial cells with glial cells containing a significantly greater amount of C22:6n-3 than neuronal cells ( $p < 0.05$ ; Figure 5.2). The C20:4n-6 content of PS from both cell types was not significantly different between the diet treatments (Figure 5.2). Feeding the DHA and AA + DHA diet significantly increased the C22:6n-3 content of neuronal PS compared to the diets providing a C18:2n-6 to C18:3n-3 fatty acid ratio of 21.6:1 and 1:1 but not 7.8:1

( $p < 0.0001$ ; Figure 5.2). The C22:6n-3 content of neuronal cell PS was (mean  $\pm$  SEM; %wt/wt):  $20.0 \pm 0.7\%$ ,  $28.0 \pm 0.7\%$ ,  $14.1 \pm 2.9\%$ ,  $29.5 \pm 1.4\%$ , and  $29.5 \pm 0.9\%$ , for animals fed low LNA, medium LNA, and high LNA, DHA, and AA + DHA diet treatments, respectively (Figure 5.2). In glial cells, the C22:6n-3 content of PS was significantly increased with animals fed DHA and AA + DHA diet compared to the animals fed low and high LNA, but not the medium LNA diets ( $p < 0.0001$ ; Figure 5.2). The C22:6n-3 content of glial cell PS was (mean  $\pm$  SEM; %wt/wt):  $23.2 \pm 0.6\%$ ,  $25.5 \pm 3.2\%$ ,  $22.7 \pm 1.5\%$ ,  $34.1 \pm 1.6\%$ , and  $31.3 \pm 0.5\%$ , for animals fed low LNA, medium LNA, high LNA, DHA, and AA + DHA diet treatments, respectively (Figure 5.2).



**Figure 5.2 Fatty Acid Composition of Neuronal and Glial Cell Phosphatidylserine**

\* Cell Type Difference at  $p < 0.05$

**c) Phosphatidylcholine and Phosphatidylinositol**

The predominant fatty acids observed in PC were C16:0, C18:0, and C18:1 (47-52%, 9-16%, 18-22% of the total fatty acids, respectively; Table 5.3). PC C20:4n-6 and C22:6n-3 content was significantly different between neuronal and glial cells. Neuronal cells had greater amounts of C20:4n-6 and C22:6n-3 in PC than glial cells (Table 5.3). Feeding a maternal diet providing a fatty acid ratio of C18:2n-6 to C18:3n-3 from 21.6:1 to 1:1, and DHA and AA + DHA did not significantly increase the C20:4n-6 and C22:6n-3 content of PC in neuronal and glial cells (Table 5.3). In neuronal and glial cell PI, the major fatty acids were C16:0, C18:0, C18:1, and C20:4n-6 (8-15%, 28-37%, 5-12%, and 19-35% of total fatty acids, respectively; Table 5.4). C20:4n-6 but not the C22:6n-3 content was significantly different between neuronal and glial cells with neuronal cells containing significantly more C20:4n-6 in PI than glial cells (Table 5.4).

**Table 5.3 Effect of Low to High Dietary C18:3n-3 Compared to Feeding C22:6n-3 on the Fatty Acid Composition of Neuronal and Glial Cell Phosphatidylcholine<sup>1</sup>**

DIET FAT:	Low LNA <sup>2</sup>		Medium LNA <sup>3</sup>		High LNA <sup>4</sup>		DHA <sup>5</sup>		AA + DHA <sup>6</sup>	
	Neuronal	Glial	Neuronal	Glial	Neuronal	Glial	Neuronal	Glial	Neuronal	Glial
	Fatty Acid (% wt/wt)									
<b>C16:0</b>	50.4±0.6 <sup>a</sup>	46.8±1.6 <sup>a</sup>	46.7±0.9 <sup>a</sup>	51.5±0.4 <sup>a</sup>	50.6±0.0 <sup>a</sup>	48.6±0.4 <sup>a</sup>	50.7±0.3 <sup>a</sup>	50.8±0.5 <sup>a</sup>	48.3±1.2 <sup>a</sup>	52.0±0.9 <sup>a</sup>
<b>C18:0</b>	13.3±0.3 <sup>a</sup>	12.8±1.2 <sup>a</sup>	15.5±0.4 <sup>a</sup>	8.9±0.0 <sup>a</sup>	13.4±0.2 <sup>a</sup>	14.4±0.9 <sup>a</sup>	9.4±0.5 <sup>b</sup>	10.5±1.0 <sup>b</sup>	10.7±1.4 <sup>b</sup>	10.5±0.3 <sup>b</sup>
<b>C18:1n-9</b>	15.3±0.1 <sup>a*</sup>	17.1±0.9 <sup>a</sup>	15.1±0.3 <sup>a*</sup>	16.4±0.0 <sup>a</sup>	15.2±0.0 <sup>a*</sup>	16.6±0.3 <sup>a</sup>	15.9±1.3 <sup>a*</sup>	17.1±0.2 <sup>a</sup>	14.1±3.6 <sup>a*</sup>	16.5±0.3 <sup>a</sup>
<b>C18:2n-6</b>	1.2±0.0 <sup>a</sup>	2.5±0.8 <sup>a</sup>	1.2±0.0 <sup>b</sup>	1.2±0.0 <sup>b</sup>	1.2±0.0 <sup>ab</sup>	1.4±0.1 <sup>ab</sup>	1.5±0.2 <sup>ab</sup>	1.3±0.1 <sup>ab</sup>	1.2±0.1 <sup>b</sup>	0.9±0.1 <sup>a</sup>
<b>C18:3n-3</b>	0.0±0.0 <sup>a</sup>	0.1±0.1 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>
<b>C20:5n-3</b>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.0±0.0 <sup>a</sup>	0.1±0.1 <sup>a</sup>
<b>C22:5n-3</b>	0.1±0.0 <sup>a*</sup>	0.2±0.2 <sup>a</sup>	0.1±0.0 <sup>a*</sup>	0.1±0.0 <sup>a</sup>	0.2±0.0 <sup>a*</sup>	0.1±0.1 <sup>a</sup>	0.1±0.1 <sup>a*</sup>	0.1±0.0 <sup>a</sup>	0.1±0.0 <sup>a*</sup>	0.1±0.0 <sup>a</sup>
<b>C22:6n-3</b>	3.2±0.2 <sup>a*</sup>	3.1±0.5 <sup>a</sup>	3.6±0.2 <sup>a*</sup>	3.3±0.1 <sup>a</sup>	3.1±0.4 <sup>a*</sup>	2.6±0.1 <sup>a</sup>	3.9±0.6 <sup>a*</sup>	3.4±0.4 <sup>a</sup>	4.3±0.5 <sup>a*</sup>	2.9±0.3 <sup>a</sup>
<b>C20:4n-6</b>	7.0±0.1 <sup>a*</sup>	6.6±0.6 <sup>a</sup>	7.2±0.1 <sup>a*</sup>	7.0±0.1 <sup>a</sup>	6.5±0.1 <sup>a*</sup>	6.8±0.3 <sup>a</sup>	7.5±0.6 <sup>a*</sup>	6.5±0.7 <sup>a</sup>	8.5±0.8 <sup>a*</sup>	6.5±0.6 <sup>a</sup>
<b>C22:4n-6</b>	0.9±0.1 <sup>a*</sup>	0.4±0.3 <sup>a</sup>	1.2±0.1 <sup>a*</sup>	0.6±0.1 <sup>a</sup>	0.8±0.0 <sup>a*</sup>	0.6±0.1 <sup>a</sup>	0.8±0.1 <sup>a*</sup>	0.7±0.1 <sup>a</sup>	1.0±0.1 <sup>a*</sup>	0.7±0.1 <sup>a</sup>
<b>C22:5n-6</b>	0.4±0.0 <sup>a</sup>	0.3±0.1 <sup>a</sup>	0.3±0.0 <sup>a</sup>	0.1±0.0 <sup>a</sup>	0.2±0.0 <sup>a</sup>	0.1±0.0 <sup>a</sup>	0.2±0.0 <sup>a</sup>	0.1±0.0 <sup>a</sup>	0.3±0.1 <sup>a</sup>	0.1±0.0 <sup>a</sup>

<sup>1</sup> Values are mean ± SEM with n=6 for each experimental diet. For each horizontal set of values within a cell type, those that have the same superscript letters (a or b) are not significantly different. Those that have different letters are statistically significant different at p<0.05.

<sup>2</sup> Low LNA diet was obtained by mixing safflower oil into the medium LNA diet.

<sup>3</sup> Medium LNA diet approximates the fatty acid composition used in SMA<sup>™</sup> infant formula.

<sup>4</sup> High LNA diet was obtained by the addition of flaxseed oil to the medium LNA diet.

<sup>5</sup> DHA was obtained by the addition of 0.6% C22:6n-3 triglyceride to the medium LNA diet.

<sup>6</sup> AA + DHA was obtained by addition of 1% 20:4n-6 and 0.6% C22:6n-3 triglyceride to the medium LNA diet. \* Cell type difference at p<0.05.

**Table 5.4 Effect of Low to High Dietary C18:3n-3 Compared to Feeding C22:6n-3 on the Fatty Acid Composition of Neuronal and Glial Cell Phosphatidylinositol<sup>1</sup>**

DIET FAT:	Low LNA <sup>2</sup>		Medium LNA <sup>3</sup>		High LNA <sup>4</sup>		DHA <sup>5</sup>		AA + DHA <sup>6</sup>	
	Neuronal	Glial	Neuronal	Glial	Neuronal	Glial	Neuronal	Glial	Neuronal	Glial
<b>C16:0</b>	13.8±1.3 <sup>ab</sup>	13.3±1.3 <sup>ab</sup>	7.4±1.7 <sup>bc</sup>	14.3±2.7 <sup>bc</sup>	15.2±0.3 <sup>a</sup>	15.1±1.0 <sup>a</sup>	10.2±1.6 <sup>c</sup>	8.7±0.6 <sup>c</sup>	11.7±0.7 <sup>bc</sup>	11.5±0.8 <sup>bc</sup>
<b>C18:0</b>	28.1±1.3 <sup>b</sup>	28.1±1.1 <sup>b</sup>	34.7±0.5 <sup>a</sup>	34.8±1.4 <sup>a</sup>	31.0±1.0 <sup>b</sup>	28.4±0.7 <sup>b</sup>	33.6±0.0 <sup>a</sup>	33.8±0.8 <sup>a</sup>	36.7±2.9 <sup>a</sup>	32.4±2.1 <sup>a</sup>
<b>C18:1n-9</b>	8.1±0.6 <sup>b</sup>	9.7±1.9 <sup>b</sup>	6.1±0.7 <sup>b</sup>	6.0±0.5 <sup>b</sup>	12.3±1.0 <sup>a</sup>	11.3±1.5 <sup>a</sup>	6.7±0.8 <sup>b</sup>	5.2±0.4 <sup>b</sup>	5.1±1.5 <sup>b</sup>	6.8±0.8 <sup>b</sup>
<b>C18:2n-6</b>	0.8±0.0 <sup>a</sup>	1.8±0.3 <sup>a</sup>	0.7±0.1 <sup>b</sup>	0.4±0.1 <sup>b</sup>	1.0±0.0 <sup>a</sup>	1.0±0.0 <sup>a</sup>	0.5±0.0 <sup>b</sup>	0.5±0.1 <sup>b</sup>	0.4±0.1 <sup>b</sup>	0.4±0.1 <sup>b</sup>
<b>C18:3n-3</b>	0.3±0.3 <sup>a</sup>	0.3±0.1 <sup>a</sup>	0.1±0.0 <sup>b</sup>	0.0±0.0 <sup>b</sup>	0.1±0.0 <sup>b</sup>	0.0±0.0 <sup>b</sup>	0.0±0.0 <sup>b</sup>	0.2±0.2 <sup>b</sup>	0.0±0.0 <sup>b</sup>	0.0±0.0 <sup>b</sup>
<b>C20:5n-3</b>	0.4±0.3 <sup>ab*</sup>	1.7±0.4 <sup>a</sup>	0.1±0.0 <sup>b*</sup>	0.1±0.0 <sup>b</sup>	0.1±0.0 <sup>b*</sup>	0.2±0.1 <sup>b</sup>	0.2±0.0 <sup>a*</sup>	1.1±0.8 <sup>a</sup>	0.2±0.0 <sup>a*</sup>	0.9±0.7 <sup>a</sup>
<b>C22:5n-3</b>	0.2±0.0 <sup>a*</sup>	0.6±0.3 <sup>a</sup>	0.2±0.0 <sup>a*</sup>	0.4±0.3 <sup>a</sup>	0.4±0.0 <sup>a*</sup>	0.5±0.1 <sup>a</sup>	0.2±0.0 <sup>a*</sup>	0.1±0.0 <sup>a</sup>	0.2±0.0 <sup>a*</sup>	0.7±0.4 <sup>a</sup>
<b>C22:6n-3</b>	11.1±1.6 <sup>a</sup>	8.7±1.9 <sup>a</sup>	6.2±0.3 <sup>b</sup>	7.2±0.9 <sup>b</sup>	10.7±0.5 <sup>a</sup>	13.1±1.5 <sup>a</sup>	6.8±0.7 <sup>a</sup>	13.7±0.6 <sup>a</sup>	9.8±0.7 <sup>ab</sup>	7.9±1.1 <sup>ab</sup>
<b>C20:4n-6</b>	26.5±1.6 <sup>a*</sup>	21.8±1.7 <sup>a</sup>	35.4±2.3 <sup>a*</sup>	27.8±4.0 <sup>a</sup>	19.0±1.4 <sup>a*</sup>	20.1±1.5 <sup>a</sup>	35.1±1.6 <sup>a*</sup>	27.7±1.7 <sup>a</sup>	28.5±1.3 <sup>a*</sup>	30.5±1.8 <sup>a</sup>
<b>C22:4n-6</b>	3.1±0.5 <sup>a</sup>	2.1±0.5 <sup>a</sup>	1.8±0.1 <sup>a</sup>	1.3±0.4 <sup>a</sup>	3.0±0.1 <sup>a</sup>	3.5±0.4 <sup>a</sup>	1.9±0.3 <sup>a</sup>	1.8±0.1 <sup>a</sup>	2.6±0.1 <sup>a</sup>	2.1±0.3 <sup>a</sup>
<b>C22:5n-6</b>	1.3±0.2 <sup>a</sup>	0.8±0.3 <sup>a</sup>	0.5±0.1 <sup>a</sup>	0.8±0.5 <sup>a</sup>	0.8±0.0 <sup>a</sup>	1.0±0.1 <sup>a</sup>	0.3±0.1 <sup>a</sup>	0.4±0.1 <sup>a</sup>	0.7±0.0 <sup>a</sup>	0.6±0.1 <sup>a</sup>

<sup>1</sup> Values are mean ± SEM with n=6 for each experimental diet. For each horizontal set of values within a cell type, those that have the same superscript letters (a or b) are not significantly different. Those that have different letters are statistically significant different at p<0.05.

<sup>2</sup> Low LNA diet was obtained by mixing safflower oil into the medium LNA diet.

<sup>3</sup> Medium LNA diet approximates the fatty acid composition used in SMA<sup>x</sup> infant formula.

<sup>4</sup> High LNA diet was obtained by the addition of flaxseed oil to the medium LNA diet.

<sup>5</sup> DHA was obtained by the addition of 0.6% C22:6n-3 triglyceride to the medium LNA diet.

<sup>6</sup> AA + DHA was obtained by addition of 1% 20:4n-6 and 0.6% C22:6n-3 triglyceride to the medium LNA diet. \* Cell type difference at p<0.05.

## D. DISCUSSION

The present results establish the hypothesis that dietary C22:6n-3 but not increased intake of C18:3n-3 will significantly increase the C22:6n-3 content of both neuronal and glial cell phospholipids from whole brain. These observations extend previous information (Jumpson et al., 1997) by establishing that maternal dietary C22:6n-3 is more effective at increasing the C22:6n-3 content of whole brain neuronal and glial cell membrane phospholipid in two-week-old rat pups than feeding low or high levels of maternal C18:3n-3.

The results from this study are in accordance with other studies showing that rat brain uses C22:6n-3 instead of C18:3n-3 to maintain the C22:6n-3 content of membrane in phospholipids (Sinclair, 1975; Anderson & Connor, 1988; Edmond et al., 1998). This study has shown that C22:6n-3 can be taken up by the brain and used for neuronal and glial cell membrane phospholipids synthesis.

Feeding low or high maternal dietary C18:3n-3 did not significantly increase the C22:6n-3 content in PE, PS, and PC from neuronal and glial cells compared to feeding diets containing C22:6n-3. The lack of significant increase in C22:6n-3 with rat pups fed the high LNA diet may be explained by delta-6 desaturase, the rate-limiting enzyme in the synthesis of C22:6n-3, being not fully active at two weeks of age (Bernhart & Sprecher, 1975). Rodent studies have demonstrated that liver (Nouvelot et al., 1986), astrocytes (Moore et al., 1990 and 1991), choroid plexus (Bourre et al., 1997) and microvessel endothelial cells (Delton-Vandenbroucke et al., 1999) have delta-6 desaturase activity and that C18:3n-3 is converted to C22:6n-3 in these cell types (Ravel et al., 1985; Sanders and Rana, 1987; Bourre et al., 1990). Whether rat pups at two weeks of age are able to convert sufficient amounts of C18:3n-3 into C22:6n-3 to provide for maximal incorporation of C22:6n-3 into neuronal cell membrane phospholipid synthesis is not known. The findings from the present study are in agreement with our previous study showing that low to high maternal C18:3n-3 diets does not significantly increase the C22:6n-3 content of neuronal cell membrane phospholipids (**Chapter III**). In two-week-old rat pups, the metabolic fate of feeding a high maternal C18:3n-3 diet is

deposition of C18:3n-3 in the skin, including subcutaneous fat and adipose tissue, of two-week-old rat pups (**Chapter IV**).

The C20:4n-6 content of neuronal and glial cells PE, PS, PC, and PI was not significantly different among rat pups fed the different diet treatments at two-weeks of age. The reason for the non-significant difference in C20:4n-6 content of individual phospholipids of rats fed the different diet treatments may be explained by the C20:4n-6 present in the stomach contents (Table 2). It is possible that the level of the C20:4n-6 (>0.5%) present in the stomach contents of rat pups may be sufficient to prevent a significant decrease in C20:4n-6 content of PE, PS, PC, and PI from neuronal and glial cells of two-week old rat pups. /

In early postnatal rat brain, PE and PS constitute approximately 30% and 6% of the total phospholipids, respectively (Green and Yavin, 1996). PE and PS in brain are particularly enriched in C22:6n-3 (Breckenridge et al., 1972; Salem et al., 1980; Martinez, 1989) and contain most of the C22:6n-3 (~92%) esterified into the total brain phospholipids by the first week of postnatal life (Green and Yavin, 1996). Therefore, any changes in whole brain neuronal and glial cell C22:6n-3 content caused by dietary fat treatments used in this study should be detected in PE and PS.

Glial cells contained significantly more C22:6n-3 in PE and PS than neuronal cells. Neuronal cells contained greater amounts of C22:6n-3 in PC and C20:4n-6 in PC and PI than glial cells. This difference between neuronal and glial cells C22:6n-3 and C20:4n-6 content is similar to previous findings (Jumpsen et al. 1997a & 1997b) in which differences were observed between C22:6n-3 and C20:4n-6 content in phospholipids of both cell types in the frontal, cerebellum, and hippocampal regions of brain of developing rat pups. Thus, it may be concluded that neuronal and glial cells respond differently to dietary fat treatment.

The functional implications of an increase in C22:6n-3 content of PE and PS of neuronal and glial cells with rat pups fed diets with C22:6n-3 at two-week-old rat pups is not known. Investigations of functional changes associated with an increase in C22:6n-3 content of PE and PS from neuronal and glial cells would be of great interest since modification of the PUFA content of cell membranes has a large impact on membrane properties and the functioning of a variety of membrane-associated proteins such as

transporters, enzymes, and receptors (reviewed by Spector & Yorek, 1985 and Clandinin, 1997). PS is involved in variety of cell functions (Salem & Niebylski, 1995) such as signal transduction via its activation of several protein kinase C isoforms (Bell & Burns, 1991) or Raf-1 kinase to cell membranes (Ghosh et al., 1996), modulation of synaptosomal benzodiazepine receptors (Levi deStein et al., 1989), and increases synaptic efficiency (Borghese et al., 1993). Therefore, it is likely that the diet-induced alterations in neuronal and glial cell C22:6n-3 content observed in PS in the present study may have a physiological impact.

In conclusion, the findings from this study demonstrate that maternal C22:6n-3 is more effective in increasing the C22:6n-3 content of brain PE and PS in neuronal and glial cells in two-week-old rat pups than maternal dietary levels of C18:3n-3. The results of this study in rats suggest that neonates will achieve increased brain C22:6n-3 levels more effectively if preformed C22:6n-3 is fed instead of increased intake of C18:3n-3.

In both two-week-old rat pups and six-month-old human infants, early gliogenesis and macroneurogenesis are completed while microneurogenesis, late gliogenesis, and myelination are continuing in both species during this period (reviewed by Morgane et al., 1993). Rat pups and human infants have a similar metabolic pathway for synthesis of C20:4n-6 and C22:6n-3 via desaturation and elongation of precursors. Rodents have a markedly higher desaturase activity compared to human infants (Cunnane et al., 1984; Horrobin et al., 1984). Thus, it is reasonable to speculate that infants may produce relatively less C22:6n-3 in neuronal and glial cell phospholipids when compared to C22:6n-3 production by rat pups fed the same level of dietary intake of C18:3n-3.

## D. REFERENCES

- Anderson, G. J. & Connor, W. E. (1988) Uptake of fatty acids by the developing rat brain. *Lipids* 23: 286-290.
- Anderson, R. E., Benolken, R. M., Dudley, P. A., Landis, D. J., & Wheeler, T. G. (1974) Polyunsaturated Fatty Acids of Photoreceptor Membranes, *Exp. Eye Res.* 18: 205-213.
- Anderson, J., Connor, E. & Corliss, D., (1990) Docosahexaenoic Acid is the Preferred Dietary n-3 Fatty Acid for the Development of the Brain and Retina. *Pediatr Res* 27:89-97.
- Bell, R.M. & Burns D.J., (1991) Lipid Activation of Protein Kinase C. *J. Biol Chem.* 266: 4661-4664.
- Belzung, C., Leguisquet, AM., Barreau, S., Delion-Vancassel, S., Chalon, S. & Durand, G. (1998) Alpha-linolenic acid deficiency modifies distractibility but not anxiety and locomotion in rats during aging. *J. Nutr* 128:1537-42.
- Bernhart, J.T. & Sprecher, H. (1975) Studies to Determine the Role Rates of Chain Elongation and Desaturation in Regulating the Unsaturated Fatty Acid Composition of Rat Liver Lipids. *Biochim Biophys Acta* 398:354-363.
- Borghese, C.M., Gomez, R.A. & Ramirez, O.A. (1993) Phosphatidylserine Increases Hippocampal Synaptic Efficacy. *Brain Res Bull* 31: 697-700.
- Bourre, J. M., Durand, G., Pascal, G., & Youyou, A. (1989). Brain cell and tissue recovery in rats made deficient in n-3 fatty acids by alteration of dietary fat. *J. Nutr.* 119: 15-22.
- Bourre, J.M., Piciotti, M., & Dumont, O. (1990) Delta-6-desaturase in brain and liver during development and aging. *Lipids* 25: 354-356.
- Bourre, J. M., Dinh, L., Boithias, C., Dumont, O., Piciotti, M., & Cunnane, S. (1997). Possible Role of the Choroid Plexus in the Supply of Brain Tissue with Polyunsaturated Fatty Acids. *Neurosci. Lett.* 224: 1-4.
- Bowen, R.A.R., Wierzbicki, A.A. & Clandinin, M.T. (1999) Does Increasing Dietary C18:3n-3 Acid Content Increase the Docosahexaenoic Acid Content of Phospholipids in Neuronal Cells of Neonatal Rats ? *Pediatr Res.* 45: 815-819.
- Bowen, R.A.R. & Clandinin, M.T. (2000) High Dietary C18:3n-3 Increases the C18:3n-3 but Not the 22:6n-3 Content in the Whole Body, Brain, Skin, Epididymal Fat Pads, and Muscles of Suckling Rat Pups. *Lipids* 35: 389394.

Breckenridge, W.C., Gombos, G., & Morgan, I.G. (1972) The Lipid Composition of Adult Rat Brain Synaptosomal Membranes. *Biochim Biophys Acta* 266: 695-707.

Carrie, I., Clement, M., De Javel, D., Frances, H. & Bourre, JM. (1999) Learning deficits in first generation OF1 mice deficient in (n-3) polyunsaturated fatty acids do not result from visual alteration. *Neurosci Lett* 266:69-72.

Carrie, I., Guesnet, P., Bourre, JM. & Frances, H. (2000) Diets containing long-chain n-3 polyunsaturated fatty acids affect behaviour differently during development than ageing in mice. *British J Nutr* 83:439-47.

Clandinin, M.T., Van Aerde, J.E., Parrott, A., Euler, A.R & Lien, E.L. (1997) Assessment of the efficacious dose of arachidonic and docosahexaenoic acid in preterm infant formulas: fatty acid composition of erythrocyte membrane lipids. *Pediatr. Res.* 42: 819-825.

Clandinin, M. T. (1997). Influence of diet fat on membranes. In: *Membrane and cell signaling. Principles of medical biology.* Vol. 7A. Pp. 93-119. JAI Press Inc.

Clandinin, M.T. & Yamashiro, S. (1980) Effects of Basal Diet Composition on the Incidence of Dietary Fat Induced Myocardial Lesions. *J. Nutr.* 110: 1197-1203.

Clandinin, M.T., Chappell, J.E., Leong, S., Heim, T., Swyer, P.R., & Chance, G.W. (1980a) Extrauterine Fatty Acid Accretion in Infant Brain: Implications for Fatty Acid Requirements. *Early Human Dev.* 4:131-138.

Clandinin, M.T., Chappell, J.E., Leong, S., Heim, T., Swyer, P.R., & Chance, G.W. (1980b) Intrauterine Fatty Acid Accretion Rates in Human Brain: Implications for Fatty Acid Requirements. *Early Human Dev.* 4: 121-129.

Clandinin, M.T (1999) Brain Development and Assessing the supply of Polyunsaturated Fatty Acid. *Lipids* 34:131-137.

Cotman, C., Blank, M.L., Moehl, A, & Snyder F. (1969) Lipid composition of synaptic plasma membranes isolated from rat brain by zonal centrifugation. *Biochemistry* 8: 4606-4612

Cunnane, S. C., Keeling, P. W., Thompson, R. P., & Crawford, M. A. (1984). Linoleic Acid and Arachidonic Acid Metabolism in Human Peripheral Blood Leucocytes: Comparison with the Rat. *Brit. J. Nutr.* 51(2):209-217.

Delton-Vandenbroucke, I., Grammas, P., & Anderson, R. E. (1997). Polyunsaturated fatty acid metabolism in retinal and cerebral microvascular endothelial cells. *J. Lipid Res.* 38: 147-159.

Dhopeswarkar, G. A. & Subramanian, C. (1976). Intracranial conversion of linoleic acid to arachidonic acid: Evidence for lack of delta-8 desaturase in the brain. *J. Neurochem.* 26: 1175-1179.

Edmond, J., Tami, A.H., Rose, A. K., Bergner, E.A., & Lee W.N.P. (1998) Fatty Acid Transport and Utilization for the Developing Brain *J. Neurochem* 70: 1227-1234.

Enslin, M., Milon, H., & Malnoe, A. (1991). Effect of low intake of n-3 fatty acids during development on brain phospholipid fatty acid composition and exploratory behavior in rats. *Lipids* 26: 203-208.

Folch, J., Lee, M., & Sloane-Stanley, G.H. (1957) A simple method for the isolation and purification of total lipids from animal tissues. *J. Biol Chem* 226:497-506.

Foot M., Cruz T. G., & Clandinin M. T. (1982). Influence of dietary fat on the lipid composition of rat brain synaptosomal and microsomal membranes. *Biochem. J.* 208: 631-641.

Frances, H., Coudereau, JP., Sandouk, P., Clement, M., Monier, C. & Bourre, JM. (1996) Influence of a dietary alpha-linolenic acid deficiency on learning in the Morris water maze and on the effects of morphine. *Eur J Pharmacol* 298:217-25

Galli, C., Trzeciak, H. I., & Paoletti, R. (1971). Effects of dietary fatty acids on the fatty acid composition of brain ethanolamine phosphoglyceride: reciprocal replacement of n-6 and n-3 polyunsaturated fatty acids. *Biochim. Biophys. Acta.* 248: 449-454.

Gerbi, A., Zerouga, M., Debray, M., Durand, G., Chanez, C., & Bourre, J. (1994). Effect of Fish Oil Diet on Fatty Acid Composition of Phospholipids of Brain Membranes and on Kinetic Properties of Na, K-ATPase Isoenzymes of Weaned and Adult Rats. *J. Neurochem.* 62: 1560-1569.

Ghosh, S., Strum, J. C., Sciorra, V. A., Daniel, L., & Bell, R. M. (1996). Raf-1 Kinase Possesses Distinct Binding Domains for Phosphatidylserine and Phosphatic Acid. *J. Biol. Chem.* 271: 8472-8480.

Green, P. & Yavin, E. (1996). Natural and Accelerated Docosahexaenoic Acid Accumulation in the Prenatal Rat Brain. *Lipids* 31: S235-S238.

Green, P., Glozman, S., Kamensky, B., & Yavin, E. (1999). Developmental Changes in Rat Brain Membrane Lipids and Fatty Acids: the Preferential Prenatal Accumulation of Docosahexaenoic Acid. *J. Lipid Res.* 40: 960-966.

- Hargreaves, K. M. & Clandinin, M. T. (1987). Phosphatidylethanolamine methyltransferase: evidence for influence of diet fat on selectivity of substrate for methylation in rat brain synaptic plasma membrane. *Biochim Biophys Acta* 918: 97-105.
- Horrobin, D. F., Huang, Y. S., Cunnane, S. C., & Manku, M. S. (1984). Essential Fatty Acid in Plasma, Red Blood Cells and Liver Phospholipids in Common Laboratory Animals as Compared to Humans. *Lipids* 19(10): 806-811.
- Jumpsen, J. A., Lien, E., Goh, Y. K. & Clandinin, M. T. (1997a) Diets Varying in n-3 and n-6 Fatty Acid Content Produce Differences in Phosphatidylethanolamine and Phosphatidylcholine Fatty Acid Composition During Development of Neuronal and Glial Cells in Rats, *J. Nutr.* 127: 724-731.
- Jumpsen, J. A., Lien, E., Goh, Y. K. & Clandinin, M. T. (1997b) During Neuronal and Glial Cell Development Diet n-6 to n-3 Fatty Acid Ratio Alters the Fatty Acid Composition of Phosphatidylinositol and Phosphatidylserine, *Biochim. Biophys. Acta* 1347:40-50.
- Kinsella, J.E., Lokesh, B., Broughton, S. & Whelan, J.W. (1990) Dietary Polyunsaturated Fatty Acids and Eicosanoids: Potential Effects on the Modulation of Inflammatory and Immune Cells: an Overview, *Nutr.* 6: 24-44.
- Kishimoto, Y., Davies, W. E., & Radin, N. S. (1965). Developing rat brain: changes in cholesterol, galactolipids, and the individual fatty acids of gangliosides and glycerophosphatides. *J. Lipid Res.* 6: 532-536.
- Lamprey, M. S. & Walker, B. L. (1976) A possible role for dietary linoleic acid in the development of the young rat. *J. Nutr.* 106: 86-93.
- Levi deStein, M., Medina, J.H. & DeRobertis E.D. (1989) In Vivo and in Vitro Modulation of Central Type of Benzodiazepine Receptors by Phosphatidylserine. *Mol Brain Res* 5: 9-15.
- Lien E. L., Boyle, F. G., Yuhas, R. J. & Kuhlman, C. F. (1994) Effect of Maternal Dietary C20:4n-6 or C18:2n-6 Acid on Rat Pup Fatty Acid Profiles, *Lipids* 29: 53-59.
- Martinez, M. (1989) Polyunsaturated Fatty Acids Changes Suggesting a New Enzymatic Defect in Zellweger Syndrome. *Lipids* 24:261-5.
- Moore, S. A., Yoder, E., Murphy, S., Dutton, G. R., & Spector, A. A. (1991). Astrocytes, not neurons, produce docosahexaenoic acid (22:6n-3) and arachidonic acid (20:4n-6). *J. Neurochem.* 56:518-524.
- Moore, S. A. (1993). Cerebral endothelium and astrocytes cooperate in supplying docosahexaenoic acid to neurons. *Adv. Exp. Med. & Biol.* 331: 229-233.

- Moore, S. A., Yoder, E., & Spector, A. A. (1990). Role of the blood-brain barrier in the formation of long-chain n-3 and n-6 fatty acids from essential fatty acid precursors. *J. Neurochem.* 55: 391-402.
- Moore, S. A., Yoder, E., Murphy, S., Dutton, G. R., & Spector, A. A. (1991). Astrocytes, not neurons, produce docosahexaenoic acid (22:6n-3) and arachidonic acid (20:4n-6). *J. Neurochem.* 56:518-524.
- Morgane, P.J., Austin-LaFrance, R., Bronzino, J., Tonkiss, J., Diaz-Cintra, S., Cintra, L., Kemper, T., & Galler, J.R. (1993) Prenatal Malnutrition and Development of the Brain. *Neurosci Biobehav Rev* 17: 91-128.
- Morrison, W.R. & Smith, L.M. (1964) Preparation of Fatty Acid Methyl Esters and Dimethyl-Acetals from Lipids with Boron Fluoride-Methanol, *J. Lipid Res.* 5:600-608.
- Nouvelot, A., Bourre, J.M., Sezille, G., Dewailly, P. & Jaillard, J. (1983) Changes in the Fatty Acid Patterns of Brain Phospholipids During Development of Rats Fed Peanut or Rapeseed Oil, Taking into Account Differences Between Milk and Maternal Food. *Ann. Nutr. Metab.* 27: 173-181.
- Nouvelot, A., Delbart, C., & Bourre, J. M., (1986). Hepatic metabolism of dietary alpha-linolenic acid in suckling rats, and its possible importance in polyunsaturated fatty acid uptake by the brain. *Ann. Nutr. Metab.* 30: 316-323.
- O'Brien, J. S. & Sampson, E.L. (1965) Fatty acid and fatty aldehyde composition of the major brain lipids in normal human gray matter, white matter and myelin. *J. Lipid Res.* 6: 545-551.
- Ravel, D., Chambaz, J., Pepin, D., Manier, MC., Bereziat, G. (1985) Essential fatty acid interconversion during gestation in the rat. *Biochim Biophys Acta.* 833:161-4
- Salem, Jr. N. & Niebylski, C. D. (1995). The Nervous System has an Absolute Molecular Species Requirement for Proper Function. *Mol. Membr. Biol.* 12: 131-134.
- Salem Jr. N., Wegher, B., Mena, P. & Uauy, R. (1996) C20:4n-6 and Docosahexaenoic Acids are Biosynthesized from Their 18-Carbon Precursors in Human Infants. *Proc. Natl. Acad. Sci. USA* 93:49-54.
- Sanders, TA. & Rana, SK. (1987) Comparison of the metabolism of linoleic and linolenic acids in the fetal rat. *Annals Nutr & Metab* 31:349-53.
- SAS Institute Inc. (1988) SAS/STAT User's Guide, Release 6.11 Edition, SAS Institute Inc. Cary, North Carolina.
- Sastry, P.S. (1985) Lipids of Nervous Tissue: Composition and Metabolism. *Prog Lipid Res* 24: 69-176.

Sellinger, O.Z. & Azcurra, J.M. (1974) Bulk Separation of Neuronal Cell Bodies and Glial Cells in the Absence of Added Digestive Enzymes, in Research Methods in Neurochemistry (Marks, N., and Rodnight, R., eds.) pp 3-38. Plenum Press, New York

Sinclair, A. J. (1975) Incorporation of radioactive polyunsaturated fatty acids into liver and brain of developing rat. *Lipids*, 10: 175-184.

Sinclair, A.J & Crawford, M.A. (1972) The Accumulation of Arachidonate and Docosahexaenoate in Developing Rat Brain, *J. Neurochem.* 19: 1753-1758.

Spector, A.A. & Yorek, M.A. (1985) Membrane Lipid Composition and Cellular Function. *J. Lipid Res* 26: 1015-1035.

Steel, R. G. D. & Torrie, J. H. (1960) Principles and Procedures of Statistics. McGraw-Hill, New York.

Stubbs C.D. & Smith, A.D. (1984) The Modification of Mammalian Membrane Polyunsaturated Fatty Acid Composition in Relation to Membrane Fluidity and Function.. *Biochim Biophys Acta* 779: 89-137.

Sun, G. Y. & Horrocks, L. A. (1970). The acyl and alk-1-enyl groups of the major phosphoglycerides from ox brain myelin and mouse brain microsomal, mitochondrial and myelin fractions. *Lipids* 5: 1006-1012.

Sun, G. Y. & Sun, A. Y. (1974). Synaptosomal plasma membranes: acyl group composition of phosphoglycerides and (Na<sup>+</sup> + K<sup>+</sup>)-ATPase activity during essential fatty acid deficiency. *J. Neurochem.* 22: 15-18.

Touchstone, J.C., Chen, J.C. & Beaver, K.M. (1980) Improved Separation of Phospholipids in Thin-Layer Chromatography. *Lipids* 15: 61-62.

Tsutsumi, T., Yamauchi, E., Suzuki, E., Watanabe, S., Kobayashi, T., & Okuyama, H. (1995) Effect of a high alpha-linolenate and high linoleate diet on membrane-associated enzyme activities in rat brain--modulation of Na<sup>+</sup>, K<sup>+</sup>-ATPase activity at suboptimal concentrations of ATP. *Biol Pharm Bull* 18:664-70

Yamamoto, N., Saitoh, M., Moriuchi, A., Nomura, M. & Okuyama, H. (1987) Effect of dietary linolenate/linoleate balance on brain lipid compositions and learning ability of rats. *J. Lipid Res.* 28: 144-151.

Yonekubo, A., Honda, S., Okano, M., Takahashi, K. & Yamamoto, Y. (1993) Dietary Fish Oil Alters Rat Milk Composition and Liver and Brain Fatty Acid Composition of Fetal and Neonatal Rats. *J. Nutr.* 123: 1703-1708.

## **CHAPTER VI. DIETARY LINOLENIC AND DOCOSAHEXAENOIC ACID ALTER SYNAPTIC PLASMA MEMBRANE PHOSPHOLIPID FATTY ACID COMPOSITION AND SODIUM-POTASSIUM ADENOSINE TRIPHOSPHATASE KINETICS IN DEVELOPING RATS**

### **A. INTRODUCTION**

The SPM is comprised of phospholipids with high levels of PUFAs, particularly, C22:6n-3 (Cotman et al., 1969; Breckenridge et al., 1972; Sun & Sun, 1972; Foot et al., 1982; Hargreaves et al., 1989). Histological (Mashanskii et al., 1969) as well as biochemical studies have shown that Na, K-ATPase (EC 3.6.1.37) is associated with brain SPM (Kurokawa et al., 1965; Cotman et al., 1969). Na, K-ATPase in SPM has a specific and distinct function in maintenance of cation gradients across neuronal membrane, impulse propagation, release and uptake of neurotransmitters (Skou, 1957; Schwartz et al., 1975, Gloor, 1997; da Silva et al., 1999). Past research has shown that activity of SPM Na, K-ATPase can be modulated by phospholipids and cholesterol (Goldman & Albers, 1973) as well as by the fatty acyl groups of the SPM phospholipids (Sun & Sun, 1974; Kimelberg & Papahadjopoulos, 1974; Srivivasarao et al., 1997; Gerbi & Maxient, 1999). Alterations in diet fat have been shown to induce changes in the phospholipid content (Foot et al., 1982; Hargreaves and Clandinin, 1987) and fatty acyl composition of SPM (Foot et al., 1982), accompanied by alterations in activity of membrane-associated enzymes (Sun & Sun, 1974; Foot et al., 1983; Bourre et al., 1989; Tsutsumi et al., 1995; Gerbi & Maxient, 1999), and regulation of neurotransmitters (Delion et al., 1994; Zimmer et al., 1998). Feeding rats and their offspring diets deficient in C18:3n-3 (LNA) dramatically alters the fatty acid composition of SPM phospholipids by decreasing n-3 PUFA and increasing n-6 PUFA, particularly, C22:4n-6 and C22:5n-6 (Salem et al., 1986; Bourre et al., 1984, 1989, & 1993; Gazzah et al., 1993). Long term n-3 deficiency affects membrane-bound enzymes activities (Salem et al., 1986; Bourre et al., 1989; Tsutsumi et al., 1995) decreasing Na, K-ATPase activity at optimal (Bourre et al., 1984) and suboptimal (Tsutsumi et al., 1995) ATP concentrations.

Increasing maternal dietary C18:3n-3 from 1.6% to 17.5% of total fatty acids, by lowering the C18:2n-6 to C18:3n-3 fatty acid ratio from 22:1 to 1:1, does not

significantly increase the C22:6n-3 content in PC, PE, and PS of neuronal cells from whole brain of two-week-old rat pups (**Chapter III**). The metabolic fate of feeding a high C18:3n-3 diet is deposition of C18:3n-3 in tissues, particularly, skin (epidermis, dermis, and subcutaneous tissue) (**Chapter IV**). Human and animal studies have shown that feeding preformed C22:6n-3 from fish or single-cell oils can significantly increase the C22:6n-3 content of brain (Jumpson et al., 1997), erythrocytes, and plasma phospholipids (Makrides et al, 1994; Clandinin et al. 1997). Since C22:6n-3 is enriched in SPM phospholipids, it would be of interest to determine whether change in SPM phospholipid C22:6n-3 content occurring in rats fed diets containing C18:3n-3 or C22:6n-3 has functional consequences. /

Thus, the objective of the present study was to investigate if maternal dietary C20:4n-6 (AA) and C22:6n-3 compared to feeding adequate or low levels of C18:3n-3 (LNA) increases SPM cholesterol and phospholipid content, phospholipid C20:4n-6 and C22:6n-3 content, and Na, K-ATPase kinetics in rat pups at two and five weeks of age.

## **B. MATERIALS AND METHODS**

### **1. Animal Care**

Breeding of Sprague-Dawley rats have been described in **Chapter III**. All litters were culled to twelve rat pups following parturition. Rats sacrificed at two weeks of age received only maternal milk. Rats sacrificed at five weeks of age were weaned at three weeks of age to the same diet received by their respective dams.

One entire litter of rat pups fed the same diet was sexed and weighed before decapitation. Birth and weaning weights were not determined. Excised brains were placed in ice-cold 0.32 M sucrose. Six brains from the same sex were pooled per sample for isolation of SPM. Stomach contents of three rats from each litter were also removed and analyzed for fatty acid composition to reflect the composition of maternal milk and diet. Three litters per diet treatment and age were used.

## 2. Diets

Three semi-synthetic 20% (wt/wt) fat diets were fed (Clandinin & Yamashiro, 1982). The diets differed by the amount or nature of n-6 and n-3 fatty acids (Table 6.1). The control fat diet was formulated to approximate the fatty acid composition of an existing infant formula providing an C18:2n-6 to C18:3n-3 ratio of 7.1:1 (Table 6.1). The low LNA diet was obtained by addition of safflower oil as the diet fat blend. The AA+DHA diet was obtained by addition of C20:4n-6 (ARASCO™) and C22:6n-3 (DHASCO™) triglycerides from single cell oils (Martek Biosciences, Columbia, MD, USA) to the control diet fat blend. These diets were nutritionally adequate, with exception of the low LNA diet (0.04% of energy as C18:3n-3), providing for all known essential nutrient requirements as described in **Chapter III**. To minimize fatty acid peroxidation, the diets were sealed under nitrogen and stored in a freezer at -30°C in darkness. Each day the required amount of diet was mixed thoroughly and placed in individual feed cups.

## 3. Isolation of Synaptic Plasma Membrane

Rat brains in 0.32 M sucrose were homogenized in 10 volumes of 0.32 M sucrose with 1 mM EDTA, pepstatin A (20 µg/mL), aprotinin (20 µg/mL), trypsin inhibitor (20 µg/mL), phenylmethylsulfonyl fluoride (5 µg/mL), and leupeptin (20 µg/mL), pH 7.4 homogenizing buffer (Nikolova-Karakashian & Merrill, 2000; Cotman, 1974). The homogenate was centrifuged at 3,000 g for 5 min to remove the nuclear fraction (Cotman, 1974). Supernatant was then centrifuged at 10,500 g for 20 min to obtain the crude mitochondrial pellet (Cotman, 1974). The pellet obtained was resuspended in 3 mL of homogenizing buffer, layered over a preformed discontinuous sucrose gradient of 0.8 M and 1.2 M and centrifuged in a swinging-bucket rotor (Beckman SW-28) at 97,000 g for 2 hr (Appendix 2; Cotman, 1974). The band at the interface of 0.8 M and 1.2 M sucrose was diluted and lysed in ice-cold distilled water for 1 hr at 4°C (Cotman, 1974). The SPM was recovered by centrifugation in a fixed angle rotor (Beckman JA-20 rotor) at 19,000 g for 30 min. This pellet was resuspended in homogenizing buffer and used for subsequent analysis of lipid, protein, and Na, K-ATPase (Esmann, 1988). The SPM

purity was tested by measuring the RNA content for microsomes (Fleck & Begg, 1965) and succinic dehydrogenase for mitochondrial contamination (Pennington, 1961).

**Table 6.1 Fatty Acid Composition of Experimental Diets<sup>a</sup>**

<b>Diet Treatment :</b>	<b>Low LNA<sup>†</sup></b>	<b>Control<sup>†</sup></b>	<b>AA + DHA<sup>‡</sup></b>
<b>Fatty acid (% wt/wt)</b>			
<b>C10:0</b>	nd	1.23	1.92
<b>C12:0</b>	nd	11.7	13.1
<b>C14:0</b>	0.11	5.70	6.39
<b>C16:0</b>	6.66	12.5	12.7
<b>C18:0</b>	2.52	6.13	7.27
<b>C18:1n-9</b>	13.6	40.3	37.2
<b>C18:1n-7</b>	0.40	3.21	2.57
<b>C18:2n-6</b>	75.2	17.9	16.5
<b>C18:3n-3</b>	0.09	2.51	2.54
<b>C20:4n-6</b>	nd	nd	1.11
<b>C22:6n-3</b>	nd	nd	0.64
<b>Σ Sat</b>	9.29	37.3	41.3
<b>Σ Mufa</b>	14.0	43.5	39.8
<b>Σ N-6</b>	75.2	17.9	17.6
<b>Σ N-3</b>	0.09	2.51	3.18
<b>C18:2n-6 to C18:3n-3 ratio</b>	835	7.13	6.50

<sup>a</sup> nd = not detected; Σ sat, sum of saturated fatty acids; Σ mufa, sum of monounsaturated fatty acids; Σ n-6, sum of n-6 fatty acids; and Σ n-3, sum of n-3 fatty acids.

<sup>†</sup> Low LNA diet (0.04% of energy) was obtained by the addition of safflower oil as the fat blend.

<sup>†</sup> The control fat diet of C18:2n-6 to C18:3n-3 fatty acid ratio of 7.1:1 approximates the fatty acid composition used in SMA<sup>®</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO<sup>™</sup> and DHASCO<sup>™</sup> oil to the control diet fat blend.

#### **4. Lipid Analysis**

Total lipids within the SPM fraction were extracted as described by Folch et al. (1957). The lower chloroform phase of the lipid extract was evaporated to dryness under a stream of nitrogen. The residue was resuspended in 2 mL chloroform : methanol (2:1,

by vol.) and aliquots were taken for determination of total and individual phospholipid and cholesterol content and fatty acid analysis. Total phospholipid from aliquots of lower phase chloroform : methanol (2:1, by vol.) were determined by spotting the samples on a prewashed silica gel "G" thin-layer chromatography (TLC) plate (20 x 20 cm, Analtech, Newark, DE) and developing the plate in a solvent system containing petroleum ether : diethyl ether : acetic acid (80:20:1, by vol.) for approximately 1 hr (Suh et al., 1996). The total phospholipid band was visualized with 0.1% (wt/vol.) aniline naphthalene sulfonic acid (ANSA) in water. Separation of individual phospholipids was completed on prewashed silica gel, "H" TLC plates (20 x 20 cm, Analtech, Newark, DE). TLC plates were developed in a solvent system containing chloroform : methanol : triethylamine : 1-propanol : 0.25% (wt/vol.) KCl (30:9:18:25:6, by vol.) for approximately 90 min. (Touchstone et al., 1980). TLC plates were air-dried for 5 min. and visualized with 0.1% ANSA.

Total and individual phospholipid content of SPM was determined in triplicate by inorganic phosphorous assay after digestion with 72% perchloric acid at 180 °C for 1 hr (Chen et al., 1956). Cholesterol was measured according to the procedure of Zlatkis & Zak (1969). Individual SPM phospholipid fatty acid methyl esters were prepared with 14% (wt/wt) boron trifluoride in methanol following the method of Morrison & Smith (1964).

## **5. Fatty Acid Analysis**

Fatty acid methyl esters were analyzed by automated gas-liquid chromatography as described in **Chapter III**.

## **6. Na, K-ATPase Assay**

The Na, K-ATPase activity was measured following the method described by Esmann (1988) and Tsutsumi et al. (1995). An aliquot (100µL) of the SPM fraction was incubated at 37 °C for 15 min. with reaction buffer containing 100 mM NaCl, 20mM KCl, 5 mM MgCl<sub>2</sub>, various concentrations of ATP from 0.5 to 6 mM, and 30 mM histidine buffer, pH 7.4 in the presence and absence of 1 mM ouabain, a specific inhibitor

of Na, K-ATPase (Kawamura et al., 1999) in a total volume of 1 mL. The reaction was terminated by adding 0.5 mL 10% (wt/vol.) trichloroacetic acid. After a 10 min centrifugation, 100 $\mu$ L of supernatant was removed and assayed for inorganic phosphate content (Pi). Inorganic phosphate liberated was determined spectrophotometrically (Chen et al., 1956) using  $K_2HPO_4$  as standard. Na, K-ATPase activity was obtained by the difference between total ATPase and  $Mg^{2+}$ -ATPase (ouabain-insensitive) activity (Esmann, 1988).

Na, K-ATPase activity is expressed as  $\mu$ mol Pi / mg / hr. The protein concentration in the SPM was estimated by the method of Lowry et al. (1951) using crystalline bovine serum albumin as a standard. Six different membrane preparations were assayed in triplicate for each diet treatment and age. Data for kinetic analysis was plotted as an Eadie-Hofstee plot and analyzed by a linear regression program (Caspers et al., 1993). The slope ( $K_m$ ) and y-intercepts ( $V_{max}$ ) were determined.

#### **7. Synaptic Plasma Membrane PAGE and Immunoblotting**

For analysis of Na, K-ATPase  $\beta$ 1-subunit, six different membrane preparations for each diet treatment and age were pooled. SPM protein (20  $\mu$ g) samples from rats fed either the low LNA, control, or AA + DHA diets at two and five weeks of age were separated by 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Laemmli, 1970) and then transferred to nitrocellulose paper by electroblotting (Towbin et al., 1979). The quantity of protein in each lane as well as the efficiency of transfer was confirmed by staining with Ponceau S. Western blots were probed with an anti- $\beta$ 1 antibody (dilution 1:1000) (Upstate Biotechnology, Lake Placid, NY, USA). The  $\beta$ 1-subunit was detected by chemiluminescence (Pierce, Rockfort, Illinois, USA) and visualized on x-ray film (X-OMAT AR<sup>TM</sup>). The protein bands corresponding to the  $\beta$ 1-subunit of Na, K-ATPase were quantitated by transmittance densitometry using a Bio-Rad imaging densitometer (Life Science Group, Cleveland, Ohio, USA).

## **8. Statistical Analysis**

The effect of diet treatment and age on body weight, brain weight, SPM lipid content, SPM fatty acid composition, and Na, K-ATPase kinetics was assessed by two-way analysis of variance (ANOVA) procedures using an SAS™ package, version 6.11 (SAS™ Institute, 1988). Significant differences between diet treatments and age were determined by Duncan's multiple range test at a significance level of  $p < 0.05$  after a significant ANOVA (Steel & Torrie, 1960). Values are expressed as mean  $\pm$  SEM for  $n=6$ .

## **C. RESULTS**

### **1. Growth Characteristics**

Body and brain weights were significantly different for male and female rat pups at two and five weeks of age. Male rats had significantly greater body and brain weights compared to female rats at two and five weeks of age. Body weights for male and female rats at two and five weeks of age were (mean  $\pm$  SEM):  $34.4 \pm 0.51$  g and  $33.0 \pm 0.40$  g ( $p < 0.002$ ) and  $140 \pm 2.0$  g and  $134 \pm 1.5$  g ( $p < 0.003$ ), respectively. Brain weights for male and female rats at two and five weeks of age were (mean  $\pm$  SEM):  $1.24 \pm 0.00$  g and  $1.21 \pm 0.01$  g ( $p < 0.02$ ) and  $1.73 \pm 0.01$  g and  $1.69 \pm 0.01$  g ( $p = 0.05$ ), respectively. Body and brain weights and brain to body weight ratio, however, were not significantly different among diet groups at two and five weeks of age (data not shown), indicating that body and brain growth in rats are not affected by adequate or low LNA or AA + DHA in the maternal diet at two and five weeks of age. No gross differences in fertility were observed among diet groups at both ages.

### **2. Fatty Acid Composition of Stomach Contents**

The rat pup stomach contents at day 14 of life contained no particulates indicative of diet consumption, and therefore reflected the composition of their dams' milk. The fatty acid composition of stomach contents of rats at two and five weeks of age was analyzed. This analysis reflected dams' milk fatty acid composition (Nouvelot et al.,

1983; Lien et al., 1994; Jumpsen et al., 1997a & 1997b) and indicated that the range of dietary fat composition fed in the present experiment produced similar changes in the fat composition of the dams' milk. The major fatty acids in the stomach contents of rats fed either the low LNA, control, or AA + DHA diet treatments at two and five weeks of age were C12:0, C14:0, C16:0, C18:0, C18:1n-7+n-9, and C18:2n-6 (Table 6.2). The C14:0 content of the stomach contents was higher at two compared to five weeks of age (Table 6.2).

Feeding mothers a low LNA compared with the control or AA + DHA diet produced a significant increase in C18:2n-6 and C22:5n-6 content and a decrease in C18:3n-3 content in the stomach at two weeks of age (Table 6.2). Feeding mothers AA + DHA versus control or low LNA diets increased the C22:6n-3 content in the stomach of the rat pups at two weeks of age (Table 6.2). Rat pups fed the low LNA diet showed negligible levels of C22:6n-3 in the stomach at two weeks of age (Table 6.2).

At five weeks of age, feeding rats a low LNA diet also resulted in significantly increased C18:2n-6 content in the stomach compared to animals fed the control or AA + DHA diet (Table 6.2). The C18:3n-3 content in the stomach was lower in animals fed the low LNA diet versus animals fed the control or AA + DHA diet at five weeks of age. The C20:4n-6 and C22:6n-3 content was significantly increased in the stomach of animals fed AA + DHA compared to feeding the control or low LNA diet at five weeks of age. Feeding rats a low LNA compared to feeding rats a control or AA + DHA diet increased the C22:5n-6 content of the rat pups stomach at five weeks of age.

31

**Table 6.2 Content of Fatty Acids in the Stomach of Rats at Two and Five Weeks of Age\***

Diet Treatment:	2 Weeks			5 Weeks		
	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>
<b>Fatty acid (% wt/wt)</b>						
<b>C12:0</b>	1.74±0.4 <sup>b</sup>	14.7±0.7 <sup>a</sup>	16.1±1.1 <sup>a</sup>	1.59±0.4 <sup>c</sup>	18.1±3.1 <sup>a</sup>	11.9±0.4 <sup>b</sup>
<b>C14:0</b>	6.52±0.1 <sup>bv</sup>	9.27±0.4 <sup>av</sup>	9.54±0.7 <sup>av</sup>	1.20±0.1 <sup>c</sup>	8.26±0.6 <sup>a</sup>	6.71±0.1 <sup>b</sup>
<b>C16:0</b>	9.12±0.0 <sup>b</sup>	17.1±0.4 <sup>a</sup>	17.2±0.1 <sup>a</sup>	11.5±0.1 <sup>b</sup>	19.7±1.9 <sup>b</sup>	14.8±0.2 <sup>a</sup>
<b>C18:0</b>	2.20±0.0 <sup>b</sup>	4.28±0.5 <sup>a</sup>	4.41±0.2 <sup>a</sup>	2.04±0.1 <sup>c</sup>	3.08±0.7 <sup>b</sup>	6.72±0.1 <sup>a</sup>
<b>C18:1n-7 + n-9</b>	11.9±0.1 <sup>c</sup>	35.8±1.3 <sup>a</sup>	34.1±1.5 <sup>a</sup>	10.9±0.3 <sup>c</sup>	32.8±1.1 <sup>b</sup>	36.1±0.7 <sup>a</sup>
<b>C18:2n-6</b>	66.9±0.3 <sup>a</sup>	16.2±0.3 <sup>b</sup>	15.3±0.2 <sup>b</sup>	71.0±1.0 <sup>a</sup>	15.7±0.5 <sup>b</sup>	17.8±0.2 <sup>b</sup>
<b>C18:3n-3</b>	0.04±0.0 <sup>b</sup>	1.76±0.0 <sup>a</sup>	1.50±0.2 <sup>a</sup>	0.26±0.0 <sup>c</sup>	1.89±0.2 <sup>b</sup>	2.36±0.0 <sup>a</sup>
<b>C20:4n-6</b>	0.66±0.1 <sup>b</sup>	0.70±0.1 <sup>b</sup>	1.29±0.0 <sup>a</sup>	0.14±0.0 <sup>c</sup>	0.39±0.1 <sup>b</sup>	1.14±0.0 <sup>a</sup>
<b>C20:5n-3</b>	<0.10 <sup>a</sup>	0.01±0.0 <sup>a</sup>	0.02±0.0 <sup>a</sup>	0.01±0.0 <sup>a</sup>	<0.10 <sup>a</sup>	<0.10 <sup>a</sup>
<b>C22:4n-6</b>	<0.10 <sup>a</sup>	0.01±0.0 <sup>a</sup>	0.01±0.0 <sup>a</sup>	0.02±0.0 <sup>b</sup>	<0.10 <sup>b</sup>	0.87±0.3 <sup>a</sup>
<b>C22:5n-6</b>	1.06±0.0 <sup>a</sup>	0.01±0.0 <sup>b</sup>	0.01±0.0 <sup>b</sup>	1.27±0.7 <sup>a</sup>	<0.10 <sup>b</sup>	0.91±0.4 <sup>a</sup>
<b>C22:5n-3</b>	<0.10 <sup>a</sup>	<0.10 <sup>a</sup>	<0.10 <sup>a</sup>	<0.10 <sup>a</sup>	<0.10 <sup>a</sup>	<0.10 <sup>a</sup>
<b>C22:6n-3</b>	<0.10 <sup>b</sup>	0.14±0.0 <sup>b</sup>	0.60±0.0 <sup>a</sup>	0.08±0.0 <sup>b</sup>	0.17±0.1 <sup>b</sup>	0.63±0.0 <sup>a</sup>

\* Values are mean ± SEM with n=9 for each experimental diet. For each horizontal set of values within an age group that have the same superscript letters (a, b, or c) are not significantly different. Those that have different letters are statistically significantly different, at p<0.05.

<sup>†</sup> Low LNA was obtained by the addition of safflower oil as the fat blend.

<sup>†</sup> The control fat diet of C18:2n-6 to C18:3n-3 fatty acid ratio of 7.3:1 approximates the fatty acid composition used in SMA<sup>®</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO™ and DHASCO™ oil to the control diet fat blend.

<sup>∧</sup> Age difference at p<0.05.

### **3. Purity of Synaptic Plasma Membrane Preparations**

The purity of the SPM preparation has been described previously (Hargreaves & Clandinin, 1987). The SPM preparation contained only minor cross-contamination (<5%) from microsomes and mitochondria as determined by RNA (SPM,  $0.01 \pm 0.0$   $\mu\text{g} / \text{mg}$ ; microsomes,  $19.3 \pm 0.8$   $\mu\text{g} / \text{mg}$ ) and succinate dehydrogenase (p-iodonitrotetrazolium violet; INT) (SPM,  $30.5 \pm 7.3$  nmol INT reduced / mg / hr; microsomes,  $234.3 \pm 54.4$  nmol INT reduced / mg / hr) analysis, respectively. The SPM marker, Na, K-ATPase, was approximately 8-fold greater in the SPM ( $35.8 \pm 3.1$   $\mu\text{mol Pi} / \text{mg} / \text{hr}$ ) compared to the brain homogenate ( $4.53 \pm 1.4$   $\mu\text{mol Pi} / \text{mg} / \text{hr}$ ).

### **4. Synaptic Plasma Membrane Protein Electrophoresis and Immunoblotting**

Immunoblots of pooled SPM protein were probed with the anti- $\beta 1$  antibody: a band at 55 kDa was identified (Appendix 3). No significant differences in relative abundance of  $\beta 1$ -subunit protein were found between rat pups at two and five weeks of age (data not shown). The diet treatments had no significant effect on SPM  $\beta 1$ -subunit Na, K-ATPase protein abundance at two and five weeks of age (Appendix 3). The relative abundance of  $\beta 1$ -subunit protein for rats fed either the low LNA, control, or AA+DHA diet was 34.6, 31.9, 34.5% for two-week-old and 32.0, 35.2, and 32.8% for five-week-old rat pups, respectively (Appendix 3).

### **5. Synaptic Plasma Membrane Phospholipid and Cholesterol Content**

The total and individual phospholipid and cholesterol content, as well as, the fatty acid composition of SPM phospholipids did not differ between male and female rats at two or five weeks of age (data not shown). Thus, statistical analysis to test subsequent effects of diet treatments combined results from both sexes at each age. The amount of total and individual phospholipids and cholesterol content in SPM of rats fed different diets at each age group are similar to that of Breckenridge et al. (1972) and Foot et al. (1982).

The relative distribution of SPM phospholipids from two to five week-old rats is shown (Table 6.3). At all ages and diet treatments examined, the major SPM

phospholipids were PC and EPG (Table 6.3). Other investigators have also found that the major phospholipids in rodent SPM were the PC and EPG (Breckenridge et al., 1972; Sun & Sun, 1974; Foot et al., 1982; Hrboticky et al., 1989). There was no significant change in total and individual phospholipids and cholesterol to phospholipid ratio between diet treatments at two and five weeks of age (Table 6.3).

**Table 6.3 Total and Individual Phospholipids and Cholesterol Content in Synaptic Plasma Membranes from Rats Fed Different Fat Diets at Two and Five Weeks of Age\***

Diet Treatment:	2 Weeks			5 Weeks		
	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>
Total PLs <sup>†</sup>	0.65±0.06	0.87±0.21	0.73±0.07	0.66±0.08	0.62±0.09	1.01±0.27
SM <sup>†</sup>	0.13±0.04	0.10±0.02	0.08±0.02	0.06±0.03	0.06±0.02	0.08±0.02
PC <sup>†</sup>	0.19±0.04	0.38±0.08	0.39±0.05	0.25±0.044	0.25±0.03	0.29±0.19
PS <sup>†</sup>	0.13±0.03	0.14±0.03	0.16±0.04	0.14±0.03	0.10±0.02	0.13±0.02
PI <sup>†</sup>	0.10±0.03	0.19±0.06	0.10±0.03	0.10±0.03	0.05±0.02	0.10±0.05
EPG <sup>†</sup>	0.27±0.10	0.37±0.07	0.32±0.05	0.33±0.12	0.25±0.03	0.31±0.02
Cholesterol / PL <sup>‡</sup>	0.37±0.08	0.61±0.26	0.69±0.18	0.39±0.4	0.61±0.09	0.73±0.18

EPG, ethanolamine glycerophospholipid (PE + ethanolamine plasmalogen); PL, phospholipids; SM, sphingomyelin; PC, phosphatidylcholine; PS, phosphatidylserine; PI, phosphatidylinositol; PE, phosphatidylinositol

\* Values are mean ± SEM with n=6 for each experimental diet. <sup>†</sup> μmol/mg protein

<sup>‡</sup> μmol/μmol

<sup>†</sup> Low LNA was obtained by the addition of safflower oil as the fat blend.

<sup>†</sup> The control fat diet of C18:2n-6 to C18:3n-3 fatty acid ratio of 7.3:1 approximates the fatty acid composition used in SMA<sup>®</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO<sup>™</sup> and DHASCO<sup>™</sup> oil to the control diet fat blend.

## **6. Fatty Acid Composition of Synaptic Plasma Membrane Phospholipids**

### **a) Total Phospholipids**

Consideration of age- and diet-related changes in this study will be given to the C20:4n-6, C22:5n-6, and C22:6n-3 content of rat SPM phospholipids at two and five weeks of age.

SPM total phospholipids were comprised of mostly saturated (C16:0 and C18:0), C18:1n-9, C20:4n-6, and C22:6n-3 (Table 6.4). Age-related changes occurred in C16:0 and C18:1n-7 content of total phospholipids from two to five weeks of age (Table 6.4). No age-related changes were detected in C20:4n-6 and C22:5n-6, and C22:6n-3 content of total phospholipids from two to five weeks of age (Table 6.4). The C20:4n-6 content of total phospholipids was higher in rat pups fed the AA+DHA diet compared to the control or low LNA diet at five but not two weeks of age (Table 6.4). Generally, diet-specific increase in C22:5n-6 and decrease in C22:6n-3 content was observed in the total phospholipids of rat pups fed the low LNA versus control or AA+DHA diets at two and five weeks of age (Table 6.4).

**Table 6.4 Fatty Acid Composition of Total Phospholipids in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet\***

Diet Treatment:	2 Weeks			5 Weeks		
	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>
<b>Fatty acid (% wt/wt)</b>						
<b>C14:0</b>	0.85±0.8 <sup>a</sup>	0.17±0.0 <sup>a</sup>	0.82±0.7 <sup>a</sup>	1.00±0.6 <sup>a</sup>	1.34±1.3 <sup>a</sup>	0.78±0.3 <sup>a</sup>
<b>C16:0</b>	45.2±6.4 <sup>a∨</sup>	31.7±0.5 <sup>a∨</sup>	28.5±3.4 <sup>a∨</sup>	29.6±1.6 <sup>a</sup>	31.4±0.5 <sup>a</sup>	25.2±3.1 <sup>a</sup>
<b>C18:0</b>	23.3±1.3 <sup>a</sup>	20.7±0.2 <sup>a</sup>	18.6±0.7 <sup>a</sup>	22.3±1.4 <sup>a</sup>	24.2±2.1 <sup>a</sup>	24.7±0.9 <sup>a</sup>
<b>C18:1n-9</b>	9.66±1.1 <sup>a</sup>	11.4±0.0 <sup>a</sup>	11.3±0.3 <sup>a</sup>	12.2±0.4 <sup>a</sup>	11.9±0.2 <sup>a</sup>	10.8±2.8 <sup>a</sup>
<b>C18:1n-7</b>	2.20±0.6 <sup>a∨</sup>	2.73±0.1 <sup>a∨</sup>	2.65±0.1 <sup>a∨</sup>	3.45±0.2 <sup>a</sup>	3.49±0.2 <sup>a</sup>	2.84±0.6 <sup>a</sup>
<b>C18:2n-6</b>	1.10±0.1 <sup>a</sup>	0.80±0.0 <sup>ab</sup>	0.44±0.2 <sup>b</sup>	1.13±0.2 <sup>a</sup>	0.51±0.0 <sup>b</sup>	0.76±0.2 <sup>ab</sup>
<b>C18:3n-3</b>	0.34±0.2 <sup>a</sup>	0.01±0.0 <sup>a</sup>	0.01±0.0 <sup>a</sup>	0.04±0.0 <sup>a</sup>	0.07±0.1 <sup>a</sup>	0.07±0.1 <sup>a</sup>
<b>C20:4n-6</b>	6.72±0.7 <sup>b</sup>	12.7±0.1 <sup>a</sup>	15.0±1.7 <sup>a</sup>	9.39±0.7 <sup>a</sup>	8.68±0.4 <sup>a</sup>	11.6±2.5 <sup>a</sup>
<b>C20:5n-3</b>	0.03±0.0 <sup>a</sup>	<0.10 <sup>a</sup>	<0.10 <sup>a</sup>	<0.10 <sup>a</sup>	0.03±0.0 <sup>a</sup>	0.01±0.0 <sup>a</sup>
<b>C22:4n-6</b>	1.24±0.7 <sup>a</sup>	3.05±0.1 <sup>a</sup>	2.36±1.3 <sup>a</sup>	3.42±0.7 <sup>a</sup>	2.72±0.3 <sup>a</sup>	0.81±0.8 <sup>a</sup>
<b>C22:5n-6</b>	3.05±1.2 <sup>a</sup>	1.71±0.1 <sup>a</sup>	2.52±1.2 <sup>a</sup>	6.13±0.6 <sup>a</sup>	1.15±0.2 <sup>b</sup>	2.72±0.9 <sup>b</sup>
<b>C22:5n-3</b>	0.83±0.8 <sup>a</sup>	0.03±0.0 <sup>a</sup>	0.55±0.4 <sup>a</sup>	<0.10 <sup>a</sup>	0.05±0.0 <sup>a</sup>	0.45±0.4 <sup>a</sup>
<b>C22:6n-3</b>	5.46±1.8 <sup>b</sup>	15.0±0.4 <sup>a</sup>	17.2±1.8 <sup>a</sup>	11.4±1.3 <sup>b</sup>	14.5±0.3 <sup>ab</sup>	19.2±2.2 <sup>a</sup>

\* Values are mean ± SEM with n=6 for each experimental diet. For each horizontal set of values within an age group that have the same superscript letters (a or b) are not significantly different. Values that have different letters are statistically significantly different, at p<0.05.

<sup>†</sup> Low LNA was obtained by the addition of safflower oil as the fat blend.

<sup>†</sup> The control fat diet of C18:2n-6 to C18:3n-3 fatty acid ratio of 7.3:1 approximates the fatty acid composition used in SMA<sup>®</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO<sup>™</sup> and DHASCO<sup>™</sup> oil to the control diet fat blend.

<sup>∨</sup> Age difference at p< 0.05.

**b) Phosphatidylcholine**

The effect of feeding low LNA, control, or AA+DHA diet on the fatty acid composition of rat SPM PC is shown (Table 6.5). C16:0, C18:0, C18:1n-9, and C20:4n-6 were the major fatty acids present in PC (Table 6.5). Decrease in C14:0, C16:0, C18:2n-6, C18:3n-3, and C20:4n-6 content and increase in C18:0 and C22:6n-3 content occurred in PC from two to five weeks of age (Table 6.5). A diet-related decrease was found in C20:4n-6 and C22:6n-3 content in rat pups fed the low LNA compared to the control or AA+DHA diet at five but not two weeks of age (Table 6.5).

**c) Ethanolamine Glycerophospholipid**

EPG constituted the most highly unsaturated phospholipid class in SPM (Table 6.6). The predominant fatty acids in EPG were C16:0, C18:0, C20:4n-6, and C22:6n-3 (Table 6.6). C18:1n-9 and C18:1n-7 content increased and C18:2n-6, C18:3n-3, C20:4n-6, C20:5n-3 content decreased in EPG from two to five weeks of age (Table 6.6). Decrease in the C22:6n-3 content of EPG was observed in rat pups fed the low LNA compared to control or AA+DHA diet at two and five weeks of age (Table 6.6). Feeding rat pups AA+DHA or the control diet increased the C20:4n-6 content in EPG compared to feeding the low LNA diet at two and five weeks of age (Table 6.6).

**Table 6.5 Fatty Acid Composition of Phosphatidylcholine in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet\***

Diet Treatment:	2 Weeks			5 Weeks		
	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>
<b>Fatty acid (% wt/wt)</b>						
<b>C14:0</b>	0.77±0.4 <sup>av</sup>	0.45±0.1 <sup>av</sup>	0.67±0.2 <sup>av</sup>	0.47±0.3 <sup>a</sup>	0.04±0.0 <sup>a</sup>	0.14±0.0 <sup>a</sup>
<b>C16:0</b>	55.0±1.4 <sup>av</sup>	50.5±0.7 <sup>bv</sup>	53.9±0.9 <sup>av</sup>	52.6±1.4 <sup>a</sup>	43.9±2.1 <sup>b</sup>	47.0±1.3 <sup>b</sup>
<b>C18:0</b>	9.61±0.5 <sup>av</sup>	10.3±1.0 <sup>av</sup>	8.95±0.3 <sup>av</sup>	12.4±0.3 <sup>a</sup>	13.6±0.5 <sup>a</sup>	12.6±0.4 <sup>a</sup>
<b>C18:1n-9</b>	14.7±0.5 <sup>bv</sup>	17.4±0.4 <sup>av</sup>	17.7±0.3 <sup>av</sup>	16.1±0.7 <sup>b</sup>	18.9±0.6 <sup>a</sup>	18.7±0.5 <sup>a</sup>
<b>C18:1n-7</b>	3.18±0.2 <sup>av</sup>	3.59±0.3 <sup>av</sup>	3.97±0.1 <sup>av</sup>	4.92±0.5 <sup>b</sup>	5.91±0.2 <sup>a</sup>	4.98±0.1 <sup>b</sup>
<b>C18:2n-6</b>	2.03±0.3 <sup>av</sup>	1.25±0.1 <sup>bv</sup>	0.86±0.2 <sup>bv</sup>	1.51±0.2 <sup>a</sup>	0.66±0.0 <sup>b</sup>	0.75±0.0 <sup>b</sup>
<b>C18:3n-3</b>	0.67±0.3 <sup>av</sup>	0.24±0.1 <sup>ahv</sup>	<0.10 <sup>bv</sup>	0.04±0.0 <sup>a</sup>	0.02±0.0 <sup>a</sup>	<0.1 <sup>a</sup>
<b>C20:4n-6</b>	8.45±0.6 <sup>bv</sup>	10.6±0.4 <sup>av</sup>	9.22±0.3 <sup>bv</sup>	6.71±0.3 <sup>b</sup>	7.79±0.4 <sup>a</sup>	8.63±0.2 <sup>a</sup>
<b>C20:5n-3</b>	0.19±0.1 <sup>b</sup>	0.47±0.2 <sup>a</sup>	<0.10 <sup>b</sup>	0.15±0.1 <sup>b</sup>	0.50±0.2 <sup>a</sup>	<0.10 <sup>b</sup>
<b>C22:4n-6</b>	0.75±0.2 <sup>a</sup>	0.42±0.2 <sup>a</sup>	0.19±0.2 <sup>a</sup>	0.26±0.2 <sup>a</sup>	0.51±0.2 <sup>a</sup>	0.17±0.1 <sup>b</sup>
<b>C22:5n-6</b>	0.69±0.1 <sup>a</sup>	0.63±0.1 <sup>a</sup>	0.67±0.1 <sup>a</sup>	1.11±0.2 <sup>a</sup>	1.06±0.4 <sup>a</sup>	0.83±0.1 <sup>a</sup>
<b>C22:5n-3</b>	0.41±0.2 <sup>a</sup>	0.13±0.0 <sup>b</sup>	0.08±0.0 <sup>b</sup>	0.96±0.5 <sup>a</sup>	0.16±0.1 <sup>ab</sup>	0.04±0.0 <sup>b</sup>
<b>C22:6n-3</b>	3.25±0.3 <sup>bv</sup>	4.31±0.3 <sup>av</sup>	3.85±0.3 <sup>ahv</sup>	2.85±0.2 <sup>b</sup>	7.06±0.4 <sup>a</sup>	6.21±0.2 <sup>a</sup>

\* Values are mean ± SEM with n=6 for each experimental diet. For each horizontal set of values within an age group that have the same superscript letters (a or b) are not significantly different. Values that have different letters are statistically significantly different, at p<0.05.

<sup>†</sup> Low LNA was obtained by the addition of safflower oil as the fat blend.

<sup>†</sup> The control fat diet of C18:2n-6 to C18:3n-3 fatty acid ratio of 7.3:1 approximates the fatty acid composition used in SMA<sup>®</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO<sup>™</sup> and DHASCO<sup>™</sup> oil to the control diet fat blend.

<sup>∧</sup> Age difference at p<0.05

**Table 6.6 Fatty Acid Composition of Ethanolamine Glycerophospholipid in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet\***

<b>Diet Treatment:</b>	<b>Low LNA<sup>†</sup></b>	<b>2 Weeks Control<sup>†</sup></b>	<b>AA+DHA<sup>‡</sup></b>	<b>Low LNA<sup>†</sup></b>	<b>5 Weeks Control<sup>†</sup></b>	<b>AA+DHA<sup>‡</sup></b>
<b>Fatty acid (% wt/wt)</b>						
<b>C14:0</b>	1.04±0.2 <sup>a</sup>	0.01±0.0 <sup>a</sup>	0.77±0.7 <sup>a</sup>	0.78±0.2 <sup>a</sup>	0.67±0.6 <sup>a</sup>	0.94±0.8 <sup>a</sup>
<b>C16:0</b>	22.5±1.6 <sup>a</sup>	7.47±0.3 <sup>a</sup>	7.32±0.6 <sup>a</sup>	14.0±0.7 <sup>a</sup>	8.89±0.5 <sup>a</sup>	17.1±8.6 <sup>a</sup>
<b>C18:0</b>	29.7±1.7 <sup>a</sup>	29.5±0.6 <sup>a</sup>	28.7±1.3 <sup>a</sup>	30.5±1.2 <sup>b</sup>	37.0±2.3 <sup>a</sup>	25.3±3.0 <sup>b</sup>
<b>C18:1n-9</b>	5.88±0.4 <sup>av</sup>	6.73±0.3 <sup>av</sup>	6.55±0.2 <sup>av</sup>	6.57±0.3 <sup>b</sup>	8.89±0.6 <sup>a</sup>	6.38±0.7 <sup>b</sup>
<b>C18:1n-7</b>	0.48±0.2 <sup>av</sup>	0.80±0.0 <sup>av</sup>	0.86±0.0 <sup>av</sup>	1.04±0.1 <sup>a</sup>	1.23±0.1 <sup>a</sup>	0.88±0.1 <sup>a</sup>
<b>C18:2n-6</b>	2.36±0.5 <sup>av</sup>	0.53±0.1 <sup>bv</sup>	0.30±0.1 <sup>bv</sup>	0.83±0.1 <sup>a</sup>	0.32±0.0 <sup>b</sup>	0.19±0.0 <sup>b</sup>
<b>C18:3n-3</b>	0.53±0.1 <sup>av</sup>	0.33±0.1 <sup>av</sup>	<0.10 <sup>bv</sup>	0.08±0.1 <sup>a</sup>	<0.10 <sup>a</sup>	<0.10 <sup>a</sup>
<b>C20:4n-6</b>	15.3±1.3 <sup>bv</sup>	24.1±0.4 <sup>av</sup>	24.0±0.6 <sup>av</sup>	14.2±0.9 <sup>a</sup>	16.9±0.2 <sup>a</sup>	15.3±1.7 <sup>a</sup>
<b>C20:5n-3</b>	1.45±0.3 <sup>av</sup>	0.05±0.0 <sup>bv</sup>	<0.10 <sup>bv</sup>	0.27±0.1 <sup>a</sup>	<0.10 <sup>b</sup>	<0.10 <sup>b</sup>
<b>C22:4n-6</b>	0.89±0.3 <sup>a</sup>	0.03±0.0 <sup>a</sup>	2.59±1.3 <sup>a</sup>	1.43±1.4 <sup>a</sup>	1.68±1.1 <sup>a</sup>	0.91±0.9 <sup>a</sup>
<b>C22:5n-6</b>	4.27±0.4 <sup>a</sup>	6.14±0.1 <sup>a</sup>	3.71±1.1 <sup>a</sup>	7.89±0.4 <sup>a</sup>	2.58±0.5 <sup>a</sup>	3.35±1.0 <sup>a</sup>
<b>C22:5n-3</b>	2.80±0.3 <sup>a</sup>	1.56±0.0 <sup>b</sup>	1.06±0.3 <sup>b</sup>	4.74±0.3 <sup>a</sup>	0.34±0.1 <sup>b</sup>	0.98±0.2 <sup>b</sup>
<b>C22:6n-3</b>	12.8±1.4 <sup>b</sup>	22.7±0.4 <sup>a</sup>	24.2±1.0 <sup>a</sup>	17.7±1.0 <sup>b</sup>	21.5±1.9 <sup>b</sup>	28.7±3.1 <sup>a</sup>

\* Values are mean ± SEM with n=6 for each experimental diet. For each horizontal set of values within an age group that have the same superscript letters (a or b) are not significantly different. Values that have different letters are statistically significantly different, at p<0.05.

<sup>†</sup> Low LNA was obtained by the addition of safflower oil as the fat blend.

<sup>†</sup> The control fat diet of C18:2n-6 to C18:3n-3 fatty acid ratio of 7.3:1 approximates the fatty acid composition used in SMA<sup>™</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO<sup>™</sup> and DHASCO<sup>™</sup> oil to the control diet fat blend.

<sup>^</sup> Age difference at p<0.05

**d) Phosphatidylserine**

The major fatty acids of SPM PS were C16:0, C18:0, C18:1n-9, C20:4n-6, C22:4n-6, C22:5n-6, and C22:6n-3 (Table 6.7). PS contained high levels of C22:6n-3 (Table 6.7). C18:0 and C18:3n-3 content of PS was higher at two compared to five weeks of age (Table 6.7). The C18:1n-9, C22:5n-6, and C22:6n-3 content of PS was generally higher at five compared to two weeks of age. A diet-associated decrease in C22:6n-3 along with increase in C22:5n-6 occurred in rats fed the low LNA versus rats fed the control or AA+ DHA diet at two and five weeks of age (Table 6.7). Rat pups fed the AA+DHA diet at five weeks of age contained a significantly higher C20:4n-6 content in PS compared to animals fed the low LNA or control diet (Table 6.7).

**e) Phosphatidylinositol**

The PI fraction from SPM contained a large amount of saturated fatty acids, particularly, C16:0 and C18:0 (Table 6.8). C20:4n-6 and C22:6n-3 present in PI were the predominant n-6 and n-3 fatty acids, respectively. Increase in C20:4n-6 content of PI occurred in rat pups from two to five weeks of age (Table 6.8). The C20:4n-6 and C22:6n-3 content of PI was lower in rats fed the low LNA compared to rats fed the control or AA + DHA diet at five weeks of age (Table 6.8).

**Table 6.7 Fatty Acid Composition of Phosphatidylserine in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet\***

Diet Treatment:	2 Weeks			5 Weeks		
	Low LNA <sup>†</sup>	Control <sup>‡</sup>	AA+DHA <sup>‡</sup>	Low LNA <sup>†</sup>	Control <sup>‡</sup>	AA+DHA <sup>‡</sup>
<b>Fatty acid (% wt/wt)</b>						
<b>C14:0</b>	0.57±0.2 <sup>a</sup>	0.16±0.1 <sup>a</sup>	0.18±0.1 <sup>a</sup>	0.54±0.2 <sup>a</sup>	0.05±0.0 <sup>b</sup>	0.05±0.0 <sup>b</sup>
<b>C16:0</b>	12.9±2.0 <sup>a</sup>	8.01±1.3 <sup>a</sup>	12.6±2.2 <sup>a</sup>	15.6±1.0 <sup>a</sup>	3.94±0.3 <sup>c</sup>	6.21±0.5 <sup>b</sup>
<b>C18:0</b>	30.0±2.6 <sup>av</sup>	37.9±1.9 <sup>av</sup>	34.0±2.6 <sup>av</sup>	32.7±2.1 <sup>b</sup>	37.7±0.3 <sup>a</sup>	15.1±0.3 <sup>c</sup>
<b>C18:1n-9</b>	6.46±0.7 <sup>bv</sup>	8.62±1.0 <sup>av</sup>	8.28±0.6 <sup>abhv</sup>	9.37±0.4 <sup>b</sup>	8.98±0.2 <sup>b</sup>	11.4±0.1 <sup>a</sup>
<b>C18:1n-7</b>	1.02±0.3 <sup>a</sup>	0.71±0.1 <sup>a</sup>	1.29±0.3 <sup>a</sup>	0.95±0.3 <sup>a</sup>	0.53±0.0 <sup>a</sup>	0.99±0.1 <sup>a</sup>
<b>C18:2n-6</b>	1.85±0.6 <sup>a</sup>	0.90±0.7 <sup>a</sup>	0.38±0.0 <sup>a</sup>	0.88±0.2 <sup>a</sup>	0.23±0.1 <sup>a</sup>	0.31±0.1 <sup>a</sup>
<b>C18:3n-3</b>	4.33±1.4 <sup>av</sup>	1.79±1.1 <sup>abhv</sup>	0.42±0.4 <sup>bv</sup>	0.03±0.0 <sup>a</sup>	<0.10 <sup>a</sup>	0.08±0.0 <sup>a</sup>
<b>C20:4n-6</b>	8.16±1.4 <sup>a</sup>	9.28±1.4 <sup>a</sup>	10.0±0.4 <sup>a</sup>	3.81±0.7 <sup>b</sup>	2.81±0.4 <sup>b</sup>	16.7±0.2 <sup>a</sup>
<b>C20:5n-3</b>	4.14±1.1 <sup>av</sup>	0.04±0.0 <sup>bv</sup>	0.14±0.1 <sup>bv</sup>	0.39±0.1 <sup>a</sup>	0.15±0.0 <sup>b</sup>	<0.10 <sup>b</sup>
<b>C22:4n-6</b>	6.12±1.1 <sup>a</sup>	5.15±0.9 <sup>a</sup>	5.78±0.3 <sup>a</sup>	5.13±0.2 <sup>b</sup>	0.11±0.0 <sup>c</sup>	8.71±0.1 <sup>a</sup>
<b>C22:5n-6</b>	4.60±0.3 <sup>av</sup>	1.89±0.3 <sup>bv</sup>	1.34±0.4 <sup>bv</sup>	10.0±0.5 <sup>a</sup>	4.70±0.2 <sup>b</sup>	0.86±0.1 <sup>c</sup>
<b>C22:5n-3</b>	2.21±0.7 <sup>a</sup>	1.54±1.2 <sup>a</sup>	0.30±0.1 <sup>a</sup>	<0.10 <sup>c</sup>	2.25±0.1 <sup>a</sup>	0.33±0.0 <sup>b</sup>
<b>C22:6n-3</b>	17.7±2.1 <sup>bv</sup>	24.0±2.5 <sup>iv</sup>	25.2±0.9 <sup>av</sup>	20.6±1.0 <sup>b</sup>	38.6±0.6 <sup>a</sup>	39.2±0.4 <sup>a</sup>

\* Values are mean ± SEM with n=6 for each experimental diet. For each horizontal set of values within an age group that have the same superscript letters (a or b) are not significantly different. Values that have different letters are statistically significantly different, at p<0.05.

<sup>†</sup> Low LNA was obtained by the addition of safflower oil as the fat blend.

<sup>‡</sup> The control fat diet of C18:2n-6 to C18:3n-3 fatty acid ratio of 7.3:1 approximates the fatty acid composition used in SMA<sup>®</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO<sup>™</sup> and DHASCO<sup>™</sup> oil to the control diet fat blend.

<sup>∧</sup> Age difference at p<0.05

**Table 6.8 Fatty Acid Composition of Phosphatidylinositol in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet\***

<b>Diet Treatment:</b>	<b>Low LNA<sup>†</sup></b>	<b>2 Weeks Control<sup>†</sup></b>	<b>AA+DHA<sup>‡</sup></b>	<b>Low LNA<sup>†</sup></b>	<b>5 Weeks Control<sup>†</sup></b>	<b>AA+DHA<sup>‡</sup></b>
<b>Fatty acid (% wt/wt)</b>						
<b>C14:0</b>	1.74±0.5 <sup>a</sup>	0.35±0.1 <sup>b</sup>	0.98±0.4 <sup>ab</sup>	2.36±0.6 <sup>a</sup>	0.30±0.2 <sup>b</sup>	0.88±0.6 <sup>ab</sup>
<b>C16:0</b>	29.3±5.6 <sup>a</sup>	14.4±6.8 <sup>b</sup>	18.4±2.3 <sup>b</sup>	24.8±3.3 <sup>a</sup>	14.5±2.6 <sup>b</sup>	12.8±2.3 <sup>b</sup>
<b>C18:0</b>	27.9±1.7 <sup>b</sup>	34.6±1.7 <sup>a</sup>	36.5±1.8 <sup>a</sup>	30.1±2.7 <sup>a</sup>	31.3±2.5 <sup>a</sup>	33.0±1.1 <sup>a</sup>
<b>C18:1n-9</b>	6.85±1.0 <sup>a</sup>	8.42±0.5 <sup>a</sup>	5.26±1.5 <sup>a</sup>	7.64±1.8 <sup>a</sup>	7.65±1.5 <sup>a</sup>	7.45±1.2 <sup>a</sup>
<b>C18:1n-7</b>	0.61±0.3 <sup>a</sup>	1.51±0.2 <sup>a</sup>	2.18±0.2 <sup>a</sup>	1.46±0.5 <sup>a</sup>	1.72±0.2 <sup>a</sup>	1.49±0.2 <sup>a</sup>
<b>C18:2n-6</b>	2.47±0.9 <sup>a</sup>	0.69±1.6 <sup>b</sup>	0.54±0.0 <sup>b</sup>	1.75±0.4 <sup>a</sup>	0.59±0.1 <sup>b</sup>	0.68±0.1 <sup>b</sup>
<b>C18:3n-3</b>	1.26±0.4 <sup>a</sup>	1.69±0.5 <sup>a</sup>	4.01±1.7 <sup>a</sup>	2.87±1.8 <sup>a</sup>	0.11±0.5 <sup>a</sup>	0.33±0.3 <sup>a</sup>
<b>C20:4n-6</b>	21.2±4.4 <sup>uv</sup>	23.5±3.1 <sup>uv</sup>	22.8±2.2 <sup>uv</sup>	20.8±1.9 <sup>b</sup>	33.1±3.0 <sup>a</sup>	31.6±4.2 <sup>a</sup>
<b>C20:5n-3</b>	0.75±0.3 <sup>a</sup>	0.87±0.3 <sup>a</sup>	0.70±0.6 <sup>a</sup>	0.97±0.4 <sup>a</sup>	0.85±0.8 <sup>a</sup>	0.67±0.6 <sup>a</sup>
<b>C22:4n-6</b>	2.19±0.9 <sup>a</sup>	2.39±0.6 <sup>a</sup>	2.18±0.7 <sup>a</sup>	1.80±0.6 <sup>a</sup>	1.65±1.0 <sup>a</sup>	1.95±0.9 <sup>a</sup>
<b>C22:5n-6</b>	1.39±0.6 <sup>a</sup>	0.74±0.2 <sup>a</sup>	0.23±0.1 <sup>a</sup>	1.44±0.5 <sup>a</sup>	0.70±0.2 <sup>a</sup>	0.65±0.1 <sup>a</sup>
<b>C22:5n-3</b>	0.13±0.1 <sup>a</sup>	0.31±0.1 <sup>a</sup>	0.38±0.2 <sup>a</sup>	0.26±0.1 <sup>a</sup>	<0.10 <sup>a</sup>	0.01±0.0 <sup>a</sup>
<b>C22:6n-3</b>	4.20±0.8 <sup>b</sup>	10.6±1.4 <sup>a</sup>	5.87±0.5 <sup>b</sup>	3.71±0.7 <sup>b</sup>	7.55±1.4 <sup>a</sup>	8.49±1.5 <sup>a</sup>

\* Values are mean ± SEM with n=6 for each experimental diet. For each horizontal set of values within an age group that have the same superscript letters (a or b) are not significantly different. Values that have different letters are statistically significantly different, at p<0.05.

<sup>†</sup> Low LNA was obtained by the addition of safflower oil as the fat blend.

<sup>†</sup> The control fat diet of C18:2n-6 to C18:3n-3 fatty acid ratio of 7.3:1 approximates the fatty acid composition used in SMA<sup>™</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO<sup>™</sup> and DHASCO<sup>™</sup> oil to the control diet fat blend.

<sup>∧</sup> Age difference at p<0.05


## 7. Na, K-ATPase Kinetics

Kinetic parameters of Na, K-ATPase, obtained from SPM of two and five week-old rats, were examined and the results are presented as Eadie-Hofstee plots (Figure 6.1). Among the three diet treatments, rat pups at two weeks of age showed a low activity ( $V_{max} = 7.85 - 21.8 \mu\text{mol Pi/ mg / hr}$ ) and high affinity ( $K_m = 0.49 - 1.04 \text{ mM}$ ) compared to rat pups at five weeks of age which showed a high activity ( $V_{max} = 24.92 - 45.33 \mu\text{mol Pi/ mg / hr}$ ) and low affinity ( $K_m = 1.56 - 2.44 \text{ mM}$ ) (Table 6.9).


The Na, K-ATPase kinetics in the SPM of rats fed either the low LNA, control, or AA+DHA diets are shown (Figure 6.1). Rat pups fed the low LNA diet showed a decrease in  $V_{max}$  compared to pups consuming the control or AA+DHA diet at two weeks of age (Figure 6.1). The  $V_{max}$  of Na, K-ATPase at two weeks of age in low LNA rats was 7.85 compared to 21.6 and 21.8  $\mu\text{mol Pi/ mg / hr}$  for control or AA + DHA diet, respectively (Table 6.9). The  $V_{max}$  of Na, K-ATPase at five weeks of age in rats fed low LNA was 24.9 compared to 45.3 and 39.7  $\mu\text{mol Pi/ mg / hr}$  for rats fed control or AA + DHA diet, respectively.

The  $K_m$  of Na, K-ATPase in SPM of rat pups at both ages also showed differences among diet treatments. The  $K_m$  of Na, K-ATPase in SPM of rat pups fed the low LNA or control diet was lower compared to the rats fed AA+DHA diet at two weeks of age. The  $K_m$  of Na, K-ATPase at two weeks of age was 0.57, 0.49, and 1.04 mM for rats fed the low LNA, control, or AA+DHA diet, respectively. Rat pups fed the low LNA diet had a higher  $K_m$  compared to the rats fed the control or AA+DHA diet at five weeks of age. The  $K_m$  of the SPM Na, K-ATPase of rats fed the low LNA was 2.44 mM compared to 1.56 and 1.67 mM for the rats fed control or AA+DHA diet, respectively.

a)



b)



**Figure 6.1** Synaptic Plasma Membrane Na, K-ATPase Kinetics of Rats Fed Low LNA, Control, or AA + DHA Diet at Two and Five Weeks of Age. Specific activity was determined by subtracting the activity observed in the presence of 1 mM ouabain from total activity. a) a Michaelis-Menten plot of Na, K-ATPase activity ( $\mu\text{mol Pi / mg / hr}$ ;  $V$ ) vs. ATP (mM). Each point represents mean  $\pm$  SEM of six experiments performed in triplicates. Values without a common letter among diet treatments at each ATP concentration (mM) differ significantly ( $p < 0.05$ ). \*Age differences at each ATP concentration (mM) at  $p < 0.05$ ; b) an Eadie-Hofstee plot of Na, K-ATPase activity ( $V$ ) vs. Na, K-ATPase ( $V$ ) / ATP (mM) [S]. The correlation coefficient ( $r$ ) for straight line in the graph are indicated ( $df=4$ ). Values are mean with  $n=6$  for each experimental diet.

## **D. DISCUSSION**

The present study was conducted to compare the effects of feeding rat pups diets with C18:3n-3 vs. C22:6n-3 on the SPM lipid composition and kinetic properties of Na, K-ATPase at two and five weeks of age. The results of this study revealed that rat pups fed a low LNA compared to animals fed the control or C22:6n-3 diet have increased SPM phospholipid C22:5n-6 content, decreased SPM phospholipid C22:6n-3 and C20:4n-6 content and decreased SPM Na, K-ATPase activity at two and five weeks of age.

### **Age- and Diet-Related Changes in Synaptic Plasma Membrane Phospholipid and Cholesterol Content**

The developmental changes in rat SPM lipid composition during the first five weeks of life were small (Table 6.3). The lack of developmental change in rat SPM total and individual phospholipid and cholesterol to phospholipid ratio during the first five weeks of life is similar to that of weanling rats (Foot et al., 1982; Hofteig et al., 1985) and piglets (Hrboticky et al., 1989).

Dietary fat had a non-significant effect on SPM PC content (Table 6.3). The reason for the higher PC content in rats fed control or AA + DHA diet compared to the low LNA diet at two weeks of age is unknown. However, Hitzemann (1982) found that PEMT activity was highest in rat synaptosomes at two weeks of age. It is possible that the higher PC content in rats fed control or AA + DHA diet compared to feeding rats a low LNA diet may be due to the increased PEMT activity at two-weeks of age.

The content of PS in SPM of rats was not significantly affected by the diet fat treatments used in this study (Table 6.3). Ikemoto et al (2000) which showed that dietary C18:3n-3 deficiency does not affect PS synthesis in rat synaptosomes.

The rats fed the control or AA + DHA diet showed a higher cholesterol to phospholipid ratio compared to rats fed the low LNA diet at two and five weeks of age. The higher cholesterol to phospholipid ratio in SPM of rats fed control or AA + DHA diet at two and five weeks of age may compensate for the higher n-3 fatty acids, particularly, the C22:6n-3 content in total phospholipids (Table 6.4).

### **Age- and Diet-Related Changes in Synaptic Plasma Membrane Phospholipid Fatty Acid Composition**

The high levels of C20:4n-6 and C22:6n-3 in rat SPM phospholipids in this study are similar to data published by Breckenridge et al. (1972), Sun & Sun (1974), Foot et al. (1982), and Hargreaves et al. (1989). The developmental changes observed in rat SPM phospholipids C16:0 and C18:0 and the general increase in C22:6n-3 and decrease in C20:4n-6 fatty acid, which were observed in total phospholipids, PC, PS, and EPG are similar to data from other rodent SPM (Foot et al., 1982).

The major effect of feeding the low LNA compared to control or AA + DHA diet on the rat SPM was depletion of C22:6n-3 and a reciprocal enrichment of C22:5n-6. Similar changes have been reported for SPM in rodents fed diets containing high C18:2n-6:C18:3n-3 fatty acid ratio (Foot et al., 1982; Bourre et al., 1984). Conceivably, this effect may be explained by competition of n-6 and n-3 fatty acids for microsomal desaturation (Brenner & Peluffo, 1966; Cook, 1978; Sanders & Rana, 1987). Therefore, the significantly lower C22:6n-3 content in SPM phospholipids of rats fed the low LNA diet was compensated by a significantly higher level of docosapentaenoic acid (C22:5n-6), indicating that polyunsaturation of membrane phospholipids was preserved in agreement with previous reports (Youyou et al., 1986; Connor et al., 1990).

The higher C20:4n-6 and C22:6n-3 content in SPM phospholipids of rats fed the AA + DHA diet compared to control or low LNA diet is similar to data by Anderson et al. (1990) and Jumpsen et al. (1997) which demonstrated that preformed C20:4n-6 and C22:6n-3 are more readily incorporated into brain phospholipids. Both delta-6- and delta-5 desaturases are present in liver and brain of the newborn rodents (Ravel et al., 1985; Sanders & Rana, 1987; Bourre et al., 1990) and some C18:2n-6 and C18:3n-3 can be converted to C20:4n-6 and C22:6n-3, respectively, in the suckling rat (Nouvelot et al., 1983). The data from this study demonstrates that the newborn rat is able to convert C18:2n-6 and C18:3n-3 into C20:4n-6 and C22:6n-3, respectively, but it is not as effective as preformed C20:4n-6 and C22:6n-3 at raising the SPM phospholipid C20:4n-6 and C22:6n-3 content.

### **Age- and Diet-Related Changes in Synaptic Plasma Membrane Na, K-ATPase Kinetics**

The kinetic parameters of Na, K-ATPase obtained from the present study shows that two-week-old relative to five-week-old rat pups possess high affinity ATP binding sites and low activity of SPM Na, K-ATPase. Conversely, the five-week-old relative to two-week-old rat pups have low affinity ATP binding sites and high activity SPM Na, K-ATPase. The results of this study are in agreement with those of Samson & Quin (1967), Mishra & Shankar (1980), and Tsutsumi et al. (1995), showing enhanced Na, K-ATPase activity with age. These findings of increased SPM Na, K-ATPase activity with age differ from those reported by Calderini et al. (1983) who showed a decrease ( $\approx 35\%$ ) in SPM Na, K-ATPase with age. The reason for this discrepancy between studies may be due to the time periods in which Na, K-ATPase activity was measured (weeks vs. months). The reason for this shift in Na, K-ATPase kinetics may be due to a mechanism essential for maintenance of ionic gradients at very low concentration of ATP (Tsutsumi et al., 1995). Expression of different molecular forms of Na, K-ATPase could account for the altered Na, K-ATPase kinetics with age (Tsutsumi et al., 1995). Thus, a high Na, K-ATPase affinity at a young age permits a greater tolerance of low levels of ATP (Tsutsumi et al., 1995).

The results of the present study show no significant changes in the total and individual change in the total and individual SPM phospholipid content between age and diet treatments. This finding is important because it has been shown that membrane phospholipids, such as PC (Tanaka & Strickland, 1965), PS (Tsakris & Deliconstantinos, 1984), and PE (Goldman & Albers, 1973) have a significant effect on Na, K-ATPase activity. Therefore, the lower  $V_{max}$  of SPM Na, K-ATPase of rats fed low LNA compared to rats fed control or AA + DHA diet is not attributed to altered phospholipid content.

It is well known that alterations in the lipid environment of membrane-bound enzymes may be associated with changes in kinetics parameters such as  $V_{max}$  and  $K_m$  for substrate (reviewed by Lenaz, 1979). The low  $V_{max}$  of Na, K-ATPase in SPM of rats fed low LNA compared to rats fed control or AA + DHA diet is similar to that reported by Bourre et al. (1989) and Tsutsumi et al. (1995). The increased C22:5n-6 and decreased

C22:6n-3 in the low LNA compared to control or AA + DHA fed rats may account for the low V<sub>max</sub> in low LNA compared to control or AA + DHA fed rats at two and five weeks of age. Recently, Swarts et al. (1990) showed a decrease in the dephosphorylation rate of the phosphorylated intermediate of Na, K-ATPase in the presence of unsaturated fatty acids, particularly n-6 fatty acids. Therefore the increase in C22:5n-6 content in SPM phospholipids of rats fed the low LNA diet could result in lower levels of the dephosphorylated form of Na, K-ATPase which may decrease Na, K-ATPase activity because dephosphorylated form of Na, K-ATPase is needed to bind potassium.

A role of dietary fat on Na, K-ATPase gene or protein expression could potentially be responsible for the differences in Na, K-ATPase V<sub>max</sub> for rat pups fed either the low LNA, control, or AA + DHA diet (Takeuchi et al., 1995; Clarke & Jump, 1996). Western blot analysis of the  $\beta$ 1-subunit of SPM Na, K-ATPase did not show any significant difference in amount of Na, K-ATPase  $\beta$ 1-subunit protein among diet groups at two and five weeks of age (data stated in results section). This finding is in agreement with Sato et al. (1999) which showed that long-term C18:3n-3 deficiency induces no substantial change in the rate of protein synthesis in rat brain. Therefore, the significant increase in Na, K-ATPase V<sub>max</sub> for rat pups fed either control or AA + DHA compared to the pups fed the low LNA diet is attributed to alterations in the SPM lipid environment.

The physiological significance of a lower Na, K-ATPase activity in animals fed the low LNA compared to the control or AA + DHA diet is unknown. Inhibition of SPM Na, K-ATPase activity may result in decreased reuptake as well as increased release of neurotransmitters (Benzi et al., 1993). Conceivably, the altered learning and memory abilities in rats and mice fed the low LNA diet may be due to lower Na, K-ATPase activity which may be a biochemical basis for the altered brain functions (Lamprey & Walker, 1976; Yamamoto et al., 1987; Bourre et al., 1989; Yonekubo et al., 1994; Frances et al., 1996; Belzung et al., 1998; Carrie et al., 1999 & 2000).

In summary, this study demonstrates that developmental changes in rat SPM lipids from two to five weeks of age are not significantly altered by the diet fat treatments used in this study. Feeding rats diets with either C18:3n-3 or C22:6n-3 alters the SPM

phospholipid fatty acid content, particularly, C20:4n-6, C22:5n-6, and C22:6n-3. The subsequent alterations in SPM Na, K-ATPase kinetic properties suggests that SPM phospholipid C20:4n-6, C22:5n-6, and C22:6n-3 content plays an important role in modulating Na, K-ATPase activity. Thus, the findings from the present study may have important implications for infant formulas that are devoid of C22:6n-3.

/

## E. REFERENCES

- Anderson .GJ., Connor. WE., & Corliss, JD. (1990) Docosahexaenoic acid is the preferred dietary n-3 fatty acid for the development of the brain and retina. *Pediatr Res* 27:89-97.
- Belzung. C., Leguisquet, AM., Barreau, S., Delion-Vancassel, S., Chalon, S. & Durand, G. (1998) Alpha-linolenic acid deficiency modifies distractibility but not anxiety and locomotion in rats during aging. *J. Nutr* 128:1537-42.
- Benzi, G., Gorini, A., Ghigini, B., Arnaboldi, R., Villa, RF. (1993) Synaptosomal non-mitochondrial ATPase activities and drug treatment. *Neurochem Res* 18: 719-26
- Bourre, J. M., Pascal , G., Durand, G., Masson, M., Dumont, O., & Piciotti, M. (1984). Alterations in the fatty acid composition of rat brain cells (neurons, astrocytes and oligodendrocytes) and of subcellular fractions (myelin and synaptosomes) induced by a diet devoid of n-3 fatty acids. *J. Neurochem.* 43: 342-348.
- Bourre, J. M., Durand, G., Pascal, G., & Youyou, A. (1989). Brain cell and tissue recovery in rats made deficient in n-3 fatty acids by alteration of dietary fat. *J. Nutr.* 119: 15-22.
- Bourre, J.M., Piciotti, M., & Dumont, O. (1990a) Delta-6-desaturase in brain and liver during development and aging. *Lipids* 25: 354-356.
- Bourre, JM, Dumont, O., & Durand, G. (1993) Brain phospholipids as dietary source of (n-3) polyunsaturated fatty acids for nervous tissue in the rat. *J. Neurochem* 60:2018-28.
- Breckenridge, WC., Gombos, G., & Morgan, IG., (1972) The lipid composition of adult rat brain synaptosomal plasma membranes. *Biochim Biophys Acta* 266:695-707
- Brenner RR. & Peluffo RO. (1966) Effect of saturated and unsaturated fatty acids on the desaturation in vitro of palmitic, stearic, oleic, linoleic, and linolenic acids. *J.Biol. Chem* 241:5213-9
- Calderini, G., Bonetti, AC., Battistella, A., Crews, FT., & Toffano, G. (1983) Biochemical changes of rat brain membranes with aging. *Neurochem Res* 8: 483-92
- Carrie, I., Clement, M., De Javel, D., Frances, H. & Bourre, JM. (1999) Learning deficits in first generation OF1 mice deficient in (n-3) polyunsaturated fatty acids do not result from visual alteration. *Neurosci Lett* 266:69-72.
- Carrie, I., Guesnet, P., Bourre, JM. & Frances, H. (2000) Diets containing long-chain n-3 polyunsaturated fatty acids affect behaviour differently during development than ageing in mice. *British J Nutr* 83:439-47.

Caspers, M.L., Bussone, M., Dow, M.J., Ulanski, L.J. & Grammas, P. (1993) Alterations of cerebrovascular Na, K-ATPase activity due to fatty acids and acute hypertension. *Brain Res* 602: 215-220.

Chen, P.S., Toribara, T.Y., & Warner (1956). Microdetermination of phosphorus. *Anal.Chem.* 28: 1756-1758.

Clandinin, M.T., & Yamashiro, S. (1982) Dietary factors affecting the incidence of dietary fat-induced myocardial lesions. *J. Nutr* 112 :825-8

Clandinin, M. T. (1997). Influence of diet fat on membranes. In: *Membrane and cell signaling. Principles of medical biology.* Vol. 7A. Pp. 93-119. JAI Press Inc.

Clarke, S.D. & Jump, D.B. (1996) Polyunsaturated fatty acid regulation of hepatic gene transcription. *J. Nutr* 126:1105S-9S.

Connor, W.E., Neuringer, M., & Lin, D.S. (1990) Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. *J. Lipid Res* 31:237-47

Cook, H.W. (1978) In vitro formation of polyunsaturated fatty acids by desaturation in rat brain :some properties of the enzymes in developing brain and comparisons with liver. *J. Neurochem.* 30:1327-34

Cotman, C., Blank, M.L., Moehl, A., & Snyder F. (1969) Lipid composition of synaptic plasma membranes isolated from rat brain by zonal centrifugation. *Biochemistry* 8: 4606-12

Cotman, C.W. (1974) Isolation of synaptosomal and synaptic plasma membrane fractions. *Meth in Enzymol* 31: 445-452.

da Silva, G.C., Parolo, E., Streck, E.L., Wajner, M., Wannmacher, C.M. & Wyse AT. (1999) In vitro inhibition of Na<sup>+</sup>,K<sup>+</sup>-ATPase activity from rat cerebral cortex by guanidino compounds accumulating in hyperargininemia. *Brain Res* 838:78-84

Delion, S., Chalon, S., Herault, J., Guilloteau, D., Besnard, J.C., & Durand, G. (1994) Chronic Dietary  $\alpha$ -linolenic acid deficiency alters dopaminergic and serotonergic neurotransmission in rats. *J. Nutr* 124: 2466-2476.

Esmann, M. (1988) ATPase and phosphatase activity of Na, K-ATPase: molar and specific activity, protein determination. *Methods in Enzymol* 156:105-15.

Fleck, A. & Begg, D (1965) The estimation of ribonucleic acid using ultraviolet absorption measurements. *Biochim Biophys Acta.* 108:333-9.

Folch, J., Lee, M., & Sloane-Stanley, G.H. (1957) A simple method for the isolation and purification of total lipids from animal tissues. *J. Biol Chem* 226:497-506.

Foot, M., Cruz, TF, & Clandinin MT (1983) Effect of dietary lipid on synaptosomal acetylcholinesterase activity. *Biochem J.* 211: 507-509.

Foot, M., Cruz, TF, & Clandinin MT (1982) Influence of dietary fat on the lipid composition of rat brain synaptosomal and microsomal membranes. *Biochem J* 208:631-40

Frances, H., Coudereau, JP., Sandouk, P., Clement, M., Monier, C. & Bourre, JM. (1996) Influence of a dietary alpha-linolenic acid deficiency on learning in the Morris water maze and on the effects of morphine. *Eur J Pharmacol* 298:217-25

Garcia, MC., Ward, G., Ma, YC., Salem, N Jr., & Kim HY. (1998) Effect of docosahexaenoic acid on the synthesis of phosphatidylserine in rat brain in microsomes and C6 glioma cells. *J. Neurochem* 70:24-30.

Gazzah, N., Gharib, A., Delton, I., Moliere, P., Durand, G., Christon, R., Lagarde, M., & Sarda, N., (1993) Effect of an n-3 fatty acid-deficient diet on the adenosine-dependent melatonin release in cultured rat pineal. *J. Neurochem* 61:1057-63

Gerbi, A. & Maixent, JM. (1999) Fatty acid-induced modulation of ouabain responsiveness of rat Na, K-ATPase isoforms. *J. Membr Biol* 168:19-27.

Gloor, SM. (1997) Relevance of Na,K-ATPase to local extracellular potassium homeostasis and modulation of synaptic transmission. *FEBS Lett* 412:1-4.

Goldman, SS. & Albers, RW. (1973) Sodium-potassium-activated adenosine triphosphatase. The role of phospholipids. *J. Biol. Chem* 248:867-74

Hargreaves, KM.& Clandinin, MT. (1987) Phosphatidylethanolamine methyltransferase: evidence for influence of diet fat on selectivity of substrate for methylation in rat brain synaptic plasma membranes. *Biochim et Biophys Acta.* 918:97-105

Hargreaves, KM., Pehowich, DJ., & Clandinin, MT. (1989). Effect of dietary lipid composition on rat liver microsomal phosphatidylcholine synthesis. *J. Nutr* 119:344-8

Hitzemann, R (1982) Developmental regulation of phospholipid methylation in rat brain synaptosomes. *Life Sci* 30:1297-303.

Hofteig, JH., Noronha, AB., Druse, MJ., & Keresztes-Nagy, C. (1985) Synaptic membrane phospholipids: effects of maternal ethanol consumption. *Exp Neurol* 87:165-71

Hrboticky, N., MacKinnon, MJ., Puterman, ML., & Innis SM. (1989) Effect of linoleic acid-rich infant formula feeding on brain synaptosomal lipid accretion and enzyme thermotropic behavior in the piglet. *J. Lipid Res* 30:1173-84

Ikemoto, A., Ohishi, M., Hata, N., Misawa, Y., Fujii, Y. & Okuyama, H. (2000). Effect of n-3 fatty deficiency on fatty acid composition and metabolism of aminophospholipids in rat brain synaptosomes. *Lipids* 35:1107-1115.

Jumpsen, JA., Lien, EL., Goh, YK. & Clandinin, MT. (1997) During neuronal and glial cell development diet n - 6 to n - 3 fatty acid ratio alters the fatty acid composition of phosphatidylinositol and phosphatidylserine. *Biochim Biophys Acta* 1347:40-50

Jumpsen, J., Lien, EL., Goh, YK. & Clandinin, MT. (1997) Small changes of dietary (n-6) and (n-3)/fatty acid content ratio on alter phosphatidylethanolamine and phosphatidylcholine fatty acid composition during development of neuronal and glial cells in rats. *J. Nutr* 127:724-31

Kawamura, A., Guo, J., Itagaki, Y., Bell, C., Wang, Y., Hauptert, GT Jr., Magil, S., Gallagher, RT., Berova, N. & Nakanishi, K. (1999) On the structure of endogenous ouabain. *Proc Natl Acad Sci USA*. 96:6654-9.

Kimelberg HK. Papahadjopoulos D. (1974) Effects of phospholipid acyl chain fluidity, phase transitions, and cholesterol on (Na<sup>+</sup> + K<sup>+</sup>)-stimulated adenosine triphosphatase. *J. Biol Chem* 249:1071-80

Kurokawa, M., Kato, M., & Sakamoto, T. (1965) Distribution of sodium-plus-potassium-stimulated adenosine-triphosphatase activity in isolated nerve-ending particles. *Biochem J*. 97:833-44

Laemmli, UK. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*. 227:680-5.

Lamprey, MS. & Walker, BL. (1976) A possible essential role for dietary linolenic acid in the development of the young rat. *J. Nutr* 106:86-93.

Lenaz, G. (1979) The role of lipids in the structure and function of membranes. *Sub-Cellular Biochemistry*. 6:233-343

Lien, EL., Boyle, FG., Yuhas, RJ. & Kuhlman, CF. (1994) Effect of maternal dietary arachidonic or linoleic acid on rat pup fatty acid profiles. *Lipids*. 29:53-9.

Loh, HH., & Law, PY. (1980) The role of membrane lipids in receptor mechanisms. *Ann Rev Pharm & Toxicol* 20:201-34

Lowry, O.H., Rosebrough, N.J., Farr, A.L., & Randall, R.J. (1951). Protein measurement with the Folin Phenol reagent. *J. Biol Chem*. 193:265-275.

Makrides, M., Neumann, M.A., Byard, R.W., Simmer, K. & Gibson, R. (1994). Fatty acid composition of brain, retina, and erythrocytes in breast and formula-fed infants. *Am J Clin. Nutr.* 60:189-194.

Mashanskii, V.F., Mirkin, A.S., & Vinnichenko, L.N. (1969) Effect of vibrational stimulation on the ultrastructure of the mechanoreceptor--the pacinian corpuscle *Tsitologiya*. 11:1572-5

Mishra OP & Shankar R. (1980) Na<sup>+</sup>,K<sup>+</sup>-ATPase in developing rat brain during undernutrition. *Nutrition & Metabolism*. 24:114-21

Morrison, W.R. & Smith, L.M. (1964) Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol. *J. Lipid Res* 5: 600-608.

Nikolova-Karakashian, M. & Merrill, A.H., Jr. (2000) Ceramidases. *Meth in Enzymol* 311:194-201

Nouvelot, A., Bourre, J.M., Sezille, G., Dewailly, P. & Jaillard, J. (1983) Changes in the fatty acid patterns of brain phospholipids during development of rats fed peanut or rapeseed oil, taking into account differences between milk and maternal food. *Ann Nutr & Metab* 27:173-81

Ravel, D., Chambaz, J., Pepin, D., Manier, M.C., Bereziat, G. (1985) Essential fatty acid interconversion during gestation in the rat. *Biochim Biophys Acta*. 833:161-4

Robinson, D., Lovenberg, W., & Sjoerdsma, A. (1968) Subcellular distribution and properties of rat brain stem tryptophan hydroxylase. *Arch Biochem Biophys* 123:419-21.

Salem, N. Jr., Kim, H-Y., & Yergey, J.A. (1986) Docosahexaenoic acid:membrane function and metabolism. In: *Health Effects of Polyunsaturated Fatty Acids in Seafoods*. Simopoulos, A., Martin, R., & Kifer, R., eds, pp. 263-317. Academic Press, New York.

Samson, F.E., Jr., & Quinn D.J. (1967) Na<sup>+</sup>-K<sup>+</sup>-activated ATPase in rat brain development. *J. Neurochem* 14:421-7

Sanders, T.A. & Rana, S.K. (1987) Comparison of the metabolism of linoleic and linolenic acids in the fetal rat. *Annals Nutr & Metab* 31:349-53.

Schwartz, J.H., Eisenstadt, M.L., & Cedar, H (1975) Metabolism of acetylcholine in the nervous system of *Aplysia californica*. I. Source of choline and its uptake by intact nervous tissue. *J. Gen Physiol*. 65:255-73

Skou, J. C. (1957). The influence of some cations on an adenosine triphosphatase from peripheral nerves. *Biochim Biophys Acta* 23: 394-401.

Srinivasarao, P., Narayanareddy, K., Vajreswari, A., Rupalatha, M., Prakash, PS. & Rao, P. (1997) Influence of dietary fat on the activities of subcellular membrane-bound enzymes from different regions of rat brain. *Neurochem Int* 3:789-94

Steel, R.G.D. & Torrie, J.H. (1960) *Principles and Procedures of Statistics*, 2<sup>nd</sup> edn., McGraw-Hill, New York.

Sun GY & Sun Y. (1972) Phospholipids and acyl groups of synaptosomal and myelin membranes isolated from the cerebral cortex of squirrel monkey (*Saimiri sciureus*). *Biochim Biophys Acta* 280:306-15

Sun, GY. & Sun, AY. (1974) Synaptosomal plasma membranes: acyl group composition of phosphoglycerides and (Na<sup>+</sup> plus K<sup>+</sup>)-ATPase activity during fatty acid deficiency. *J. Neurochem.* 22:15-8

Suh, M. Wierzbicki, AA., Lien E., & Clandinin, MT. (1996) Relationship between dietary supply of long-chain fatty acids and membrane composition of long- and very long chain essential fatty acids in developing rat photoreceptors. *Lipids.* 31:61-4

Swarts, HG., Schuurmans-Stekhoven, FM. . & De Pont, JJ. (1990) Binding of unsaturated fatty acids to Na<sup>+</sup>, K<sup>+</sup>-ATPase leading to inhibition and inactivation. *Biochim Biophys Acta* 1024:32-40.

Takeuchi, H., Matsuo, T., Tokuyama, K. & Suzuki, M. (1995) Serum triiodothyronine concentration and Na<sup>+</sup>,K<sup>(+)</sup>-ATPase activity in liver and skeletal muscle are influenced by dietary fat type in rats. *J. Nutr* 125:2364-9.

Tanaka, R. & Strickland, KP. (1965) Role of phospholipid in the activation of Na<sup>+</sup>, K<sup>+</sup>-activated adenosine triphosphatase of beef brain. *Arch Biochem Biophys* 111:583-92.

Touchstone, J. C., Chen, J. C., & Beaver, K. M. (1980). Improved separation of phospholipids in thin-layer chromatography. *Lipids* 15: 61-62.

Towbin, H., Staehelin, T. & Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets:procedure and some applications. *Proc Natl Acad Sci USA.* 76:4350-4

Tsakiris, S.& Deliconstantinos, G. (1984) Influence of phosphatidylserine on (Na<sup>+</sup> + K<sup>+</sup>)-stimulated ATPase and acetylcholinesterase activities of dog brain synaptosomal plasma membranes. *Biochem J.* 220:301-7.

Tsutsumi, T., Yamauchi, E., Suzuki, E. ,Watanabe, S., Kobayashi, T., & Okuyama, H. (1995) Effect of a high alpha-linolenate and high linoleate diet on membrane-associated enzyme activities in rat brain--modulation of Na<sup>+</sup>, K<sup>+</sup>- ATPase activity at suboptimal concentrations of ATP. *Biol Pharm Bull* 18:664-70

Yamamoto, N., Saitoh, M., Moriuchi, A., Nomura, M. & Okuyama, H.. (1987) Effect of dietary alpha-linolenate/linoleate balance on brain lipid compositions and learning ability of rats. *J. Lipid Res* 28:144-51.

Yonekubo, A., Honda, S., Okano, M., Takahashi, K., & Yamamoto, Y. (1993) Dietary fish oil alters rat milk composition and liver and brain fatty acid composition of fetal and neonatal rats. *J. Nutr* 123:1703-8.

Youyou, A., Durand, G., Pascal, G., Piciotti, M., Dumont, O. & Bourre, JM. (1986) Recovery of altered fatty acid composition induced by a diet devoid of n-3 fatty acids in myelin, synaptosomes, mitochondria, and microsomes of developing rat brain. *J. Neurochem* 46:224-8.

Zimmer, L., Hembert, S., Durand, G., Breton, P., Guilloteau, D., Besnard, JC, & Chalon, S. (1998) Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. *Neurosci Lett* 240:177-81.

Zlatkis A & Zak B. (1969) Study of a new cholesterol reagent. *Anal Biochem* 29:143-8.

## **CHAPTER VII. DIETARY N-6 AND N-3 FATTY ACIDS ALTERS SYNAPTIC PLASMA MEMBRANE GANGLIOSIDE FATTY ACID COMPOSITION OF RATS AT TWO WEEKS OF AGE**

### **A. INTRODUCTION**

Gangliosides (sialic acid containing glycosphingolipids) are plasma membrane constituents, which are especially abundant in neuronal tissues (Panzetta & Allende, 2000). Although their precise function has not been clearly defined, gangliosides do play an important role in cell-cell interaction (Cheresh et al., 1986; Baker, 1988; Yang et al., 1996), recognition and signaling (Bremer et al., 1986; Hakomori, 1990; Nagai, 1995; Meillet et al., 1996), neuritogenesis (Wu et al., 1995), and cellular immunity (Massa, 1993; Lu & Sharom, 1995). It has been shown using artificial (Palestini et al., 1994; Stewart & Boggs, 1993) and intact biological membranes (Palestini et al., 1991) that the hydrophobic portion (ceramide) of glycosphingolipids is involved in controlling the availability of gangliosides to interact with external ligands and enzymes as well as governing the aggregative and lateral phase separation properties (Masserini & Freire, 1986; Masserini et al., 1989; Palestini et al., 1991).

Previous studies have shown that ganglioside pattern and ceramide composition can undergo substantial changes with age (Merat & Dickerson, 1973; Ohsawa, 1989; Palestini et al., 1990 & 1991). In this regard, in rat brain, it was shown that the long-chain base component of ceramides containing 18 and 20 carbon atoms and one double bond (C18:1 and C20:1) constitute up to 97% of total long-chain base content at all ages (Palestini et al., 1990 & 1991). The C20:1 long-chain base occurs only in postnatal life and increases with age in all gangliosides with a maximal content in aged animals (Palestini et al., 1990 & 1991). The fatty acid composition of the ceramide moiety from the brain gangliosides tends to remain constant with age with stearic acid (C18:0) being the predominant fatty acid species (Palestini et al., 1990 & 1991).

Although there are extensive studies of developmental changes of brain gangliosides, studies concerning the effect of dietary fat on brain ganglioside fatty acid composition during development are limited. Berra et al. (1976) examined the effects of diets with different fatty acid composition on whole brain gangliosides of rats from birth to 100 days of age. The authors reported that the fatty acid composition of whole brain

ganglioside was unaffected by the diet treatments. However, the authors did not show any data on the fatty acid composition of the gangliosides and the fat content of the diet treatments was different. Recently, Saito & Saito (1991) reported that C22:0 and C24:1 added to cell culture media can be incorporated into the fatty acyl moiety of SM and gangliosides of cultured neuronal cells. Studies with neurotumor cell lines have shown incorporation of  $^3\text{H}$ -C20:4n-6 into globosides and gangliosides (Dawson & Vartanian, 1988). Taken together, these studies demonstrate that the fatty acid composition of gangliosides can be altered and that PUFAs can be detected as part of the fatty acyl moiety of gangliosides. It is well established that C20:4n-6 and C22:6n-3 are present in membrane phospholipids, however, it is not known if C20:4n-6 and C22:6n-3 are present in SPM gangliosides.

Since gangliosides are enriched in SPM and modulation of some membrane functions may depend on the ceramide moiety of gangliosides, it is conceivable that dietary fat induced changes in the fatty acid composition of the ceramide moiety of brain gangliosides may affect membrane function similar to that shown with membrane phospholipids (reviewed by Stubbs & Smith, 1984 and Clandinin et al., 1997). Therefore, the objectives of this study were to determine if C20:4n-6 and C22:6n-3 are present in rat SPM gangliosides and to investigate whether dietary fat can alter the C20:4n-6 and C22:6n-3 content of rat SPM gangliosides.

## **B. MATERIALS AND METHODS**

### **1. Animal Care**

Breeding of Sprague-Dawley rats have been described in **Chapter III**. All litters were culled to twelve rat pups following parturition. Rats sacrificed at two weeks of age received only maternal milk. One entire litter of rat pups fed the same diet was sexed and weighed before decapitation. Excised brains were placed in ice-cold 0.32 M sucrose with 1mM EDTA, pepstatin A (20 $\mu\text{g}/\text{mL}$ ), aprotinin (20  $\mu\text{g}/\text{mL}$ ), trypsin inhibitor (20  $\mu\text{g}/\text{mL}$ ), phenylmethylsulfonyl fluoride (5  $\mu\text{g}/\text{mL}$ ), and leupeptin (20 $\mu\text{g}/\text{mL}$ ), pH 7.4. Thirty-six brains were pooled per sample for isolation of SPM. Thirty-six brains were determined to be the minimum amount needed to detect the fatty acid composition of SPM

gangliosides. Stomach contents of three rats from each litter were also removed and analyzed to determine the fatty acid composition of maternal milk. Three litters per diet treatment were used.

## **2. Diets**

Three semi-synthetic diets were used as described in **Chapter VI** (Table 6.1). To minimize fatty acid peroxidation, the diets were sealed under nitrogen and stored in a freezer at -30°C in darkness. Each day the required amount of diet was taken out, mixed thoroughly, and placed in individual feed cups.

## **3. Isolation of Synaptic Plasma Membrane**

SPMs from rat pups at two of age were isolated as described in **Chapter VI**.

## **4. Lipid Analysis**

Total gangliosides were extracted from rat SPM according to the method of Folch (1957), which involves SPM extraction with chloroform:methanol (2:1, by vol.). Partitioning of gangliosides was carried out using 0.1 M KCl. The ganglioside containing aqueous phase was hydrolyzed with 5 mL of 0.5 M potassium hydroxide in methanol:water (1:1, by vol.) at room temperature overnight to remove any glycerophospholipids present (Mansson et al. 1978). The pH of the solution was adjusted to 5-6 with HCl and methanol was removed from the solution by a rotary evaporator (Mansson et al. 1978). The remaining aqueous solution was lyophilized and resuspended in 10 mL 0.1 M KCl. This solution was applied three times to a Sep-Pak™ reverse-phase C18 cartridge (Waters Associates) and gangliosides were eluted with chloroform : methanol (2:1, by vol.) and methanol (Williams & McCluer, 1980). Fractions containing gangliosides were evaporated to dryness under nitrogen. The dry residue was dissolved in chloroform : methanol (2:1, by vol.) and stored at -30°C until analysis.

Identification of individual gangliosides was performed by high-performance thin-layer chromatography (HPTLC) using 10 x 10 cm silica gel 60 HPTLC plates (Whatman, Clifton, NJ). After spotting the sample on the HPTLC plate, the plate was developed with chloroform : methanol (85:15, by vol.) to remove interfering neutral

lipids and phospholipids (Yu et al., 1988). When the plates were completely air-dried, the individual gangliosides were separated by developing the HPTLC plate in chloroform : methanol : 0.02% (wt/vol.)  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$  (55:45:10, by vol.; Ando et al., 1978; Appendix 3).

To confirm the presence of gangliosides in the SPM, some SPM ganglioside samples were visualized on the HPTLC plate with resorcinol reagent spray (Svennerholm et al., 1957) and characterized by comparison with standard bovine brain gangliosides (GM1, GD1a, GD1b, and GT1b; Sigma Chemical Co., St. Louis, MO). For fatty acid analysis of SPM gangliosides, the separated gangliosides on the HPTLC plate were sprayed with 0.01% (wt/vol.) primulin in water and visualized under UV light. Ganglioside fractions on the HPTLC plate corresponding to standards were scraped into culture tubes. Fatty acid methyl esters were prepared with 1.0 M hydrochloric acid in methanol for 26 hr at 80°C (Mansson et al., 1978).

#### **5. Fatty Acid Analysis**

Fatty acid methyl esters were analyzed by automated gas-liquid chromatography as described in **Chapter III**.

#### **6. Gas-Chromatography Mass Spectrometry**

For final identification of fatty acids in SPM gangliosides, a Hewlett Packard 5890 GLC equipped with a flame ionization detector MS ChemStation (HP-UX series) data system was used. Mass spectra of individual saturated, monounsaturated, and polyunsaturated fatty acid in SPM gangliosides were compared with mass spectra of the corresponding standards.

### **C. RESULTS**

#### **1. Growth Characteristics**

The body and brain weights of rat pups at two weeks of age are similar to that shown in **Chapter VI**.

## 2. Fatty Acid Composition of Stomach Content


The rat pup stomach contents at day 14 of life contained no particulates indicative of diet consumption, and therefore reflected the composition of their dams' milk. The fatty acid composition of the stomach contents of rat pups fed low LNA, control, or AA+DHA diet at two weeks of age was similar to that shown in **Chapter VI** (Table 6.2).

## 3. Purity of SPM Preparations

The SPM purity was tested as described in **Chapter VI**.

## 4. Gas-Chromatography Mass Spectrometry Analysis

Mass spectra of C20:4n-6 and C22:6n-3 from SPM gangliosides were identical with mass spectra of corresponding standards. These data appear to be the first evidence to show the presence of C20:4n-6 and C22:6n-3 in rat SPM gangliosides (Figure 7.1).



**Figure 7.1 Total Ion Chromatogram of C20:4n-6 and C22:6n-3 methyl esters from GM1a in Synaptic Plasma Membrane of Rats at Two Weeks of Age**

## 5. Dietary Fat Changes in SPM Ganglioside Fatty Acid Content

Fatty acid composition of GM1a, GD1a, GD1b, and GT1b from the rat SPM at two-weeks of age are shown in Table 7.1, Table 7.2, Table 7.3, and Table 7.4, respectively. The most abundant molecular species present in the SPM individual

ganglioside fractions were C16:0 and C18:0, a feature already reported for gangliosides from whole brain (Palestini et al., 1990). The diet treatments used in this study appeared to alter the fatty acid composition of the individual gangliosides differently. The proportion of C16:0 was higher and C18:0 lower in GM1a and GD1a (Table 7.1 and 7.2) compared to GD1b and GT1b (Table 7.3 and 7.4) with the three diet treatments. The C20:4n-6 and C22:6n-3 content of rat SPM gangliosides was also altered by the diet treatments at two weeks of age (Table 7.1, 7.2, 7.3, and 7.4).

/

**Table 7.1 Fatty Acid Composition of GM1a in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet at Two Weeks of Age\***

	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>
<b>Fatty acid (% wt/wt)</b>			
<b>C12:0</b>	1.04	0.14	0.42
<b>C14:0</b>	4.42	2.48	4.10
<b>C16:0</b>	52.2	43.9	44.9
<b>C18:0</b>	18.7	14.4	24.2
<b>C20:0</b>	2.75	0.69	0.86
<b>C22:0</b>	0.50	0.35	0.39
<b>C24:0</b>	0.97	0.67	0.73
<b>C18:1n-9</b>	5.94	11.5	5.14
<b>C18:1n-7</b>	1.20	2.64	1.13
<b>C20:1n-9</b>	0.72	0.13	0.04
<b>C22:1n-9</b>	0.35	0.09	0.10
<b>C24:1n-9</b>	0.29	0.02	2.12
<b>C18:2n-6</b>	0.22	10.5	9.77
<b>C20:4n-6</b>	6.82	6.47	2.48
<b>C18:3n-3</b>	0.87	0.95	0.94
<b>C22:6n-3</b>	2.97	5.12	2.65
<b>Σ Sat</b>	80.6	62.5	75.6
<b>Σ Mono</b>	8.49	14.41	8.53
<b>Σ N-6</b>	7.04	17.0	12.3
<b>Σ N-3</b>	3.84	6.08	3.59

\* n=1 (36 pooled brains) for each experimental diet.

<sup>†</sup> Low LNA was obtained by the addition of safflower oil as the fat blend.

<sup>†</sup> The control fat diet of LA to LNA of 7.1:1 approximates the fatty acid composition used in SMA<sup>®</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO<sup>™</sup> and DHASCO<sup>™</sup> oil to the control diet fat blend.

nd, not detected.

**Table 7.2 Fatty Acid Composition of GD1a in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet at Two Weeks of Age\***

	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>
<b>Fatty acid (% wt/wt)</b>			
<b>C12:0</b>	1.10	0.17	4.21
<b>C14:0</b>	5.07	2.34	4.15
<b>C16:0</b>	54.0	42.6	39.5
<b>C18:0</b>	13.5	17.6	23.1
<b>C20:0</b>	2.68	1.19	0.62
<b>C22:0</b>	0.51	0.36	0.31
<b>C24:0</b>	nd	0.54	0.30
<b>C18:1n-9</b>	7.80	9.57	8.73
<b>C18:1n-7</b>	1.52	2.07	1.71
<b>C20:1n-9</b>	0.49	0.20	0.36
<b>C22:1n-9</b>	0.21	0.37	nd
<b>C24:1n-9</b>	nd	0.16	nd
<b>C18:2n-6</b>	6.78	9.29	8.83
<b>C20:4n-6</b>	4.54	7.77	5.01
<b>C18:3n-3</b>	0.43	0.93	0.73
<b>C22:6n-3</b>	1.38	4.89	2.42
<b>Σ Sat</b>	76.8	64.8	72.2
<b>Σ Mono</b>	10.0	12.4	10.8
<b>Σ N-6</b>	11.3	17.1	13.8
<b>Σ N-3</b>	1.81	5.82	3.15

\* n=1 (36 pooled brains) for each experimental diet.

<sup>†</sup> Low LNA was obtained by the addition of safflower oil as the fat blend.

<sup>†</sup> The control fat diet of LA to LNA of 7.1:1 approximates the fatty acid composition used in SMA<sup>®</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO<sup>™</sup> and DHASCO<sup>™</sup> oil to the control diet fat blend.

nd, not detected.

**Table 7.3 Fatty Acid Composition of GD1b in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet at Two Weeks of Age\***

	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>
<b>Fatty acid (% wt/wt)</b>			
<b>C12:0</b>	0.65	11.0	0.61
<b>C14:0</b>	3.31	12.0	2.37
<b>C16:0</b>	34.0	33.8	14.1
<b>C18:0</b>	36.2	27.3	65.1
<b>C20:0</b>	4.38	1.34	2.11
<b>C22:0</b>	1.11	0.25	0.22
<b>C24:0</b>	1.55	1.62	0.57
<b>C18:1n-9</b>	6.20	3.87	2.95
<b>C18:1n-7</b>	1.10	0.54	0.52
<b>C20:1n-9</b>	2.55	0.26	0.39
<b>C22:1n-9</b>	0.77	0.61	0.39
<b>C24:1n-9</b>	0.14	2.86	5.01
<b>C18:2n-6</b>	4.02	2.27	3.03
<b>C20:4n-6</b>	1.97	0.59	0.42
<b>C18:3n-3</b>	0.28	0.94	1.85
<b>C22:6n-3</b>	1.79	0.77	0.34
<b>Σ Sat</b>	81.2	87.3	85.1
<b>Σ Mono</b>	10.8	8.14	9.26
<b>Σ N-6</b>	5.99	2.86	3.45
<b>Σ N-3</b>	2.07	1.71	2.19

\* n=1 (36 pooled brains) for each experimental diet.

<sup>†</sup> Low LNA was obtained by the addition of safflower oil as the fat blend.

<sup>†</sup> The control fat diet of LA to LNA of 7.1:1 approximates the fatty acid composition used in SMA<sup>®</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO<sup>™</sup> and DHASCO<sup>™</sup> oil to the control diet fat blend.

nd, not detected.

**Table 7.4 Fatty Acid Composition of GT1b in the SPM of Rats Fed Low LNA, Control, or AA + DHA Diet at Two Weeks of Age\***

	Low LNA <sup>†</sup>	Control <sup>†</sup>	AA+DHA <sup>‡</sup>
<b>Fatty acid (% wt/wt)</b>			
<b>C12:0</b>	0.85	0.46	0.56
<b>C14:0</b>	3.26	2.61	2.45
<b>C16:0</b>	41.9	27.4	14.2
<b>C18:0</b>	34.9	49.4	70.5
<b>C20:0</b>	3.81	1.39	2.39
<b>C22:0</b>	0.49	0.47	nd
<b>C24:0</b>	nd	0.43	nd
<b>C18:1n-9</b>	6.17	5.07	2.82
<b>C18:1n-7</b>	0.97	0.81	nd
<b>C20:1n-9</b>	0.90	0.50	0.69
<b>C22:1n-9</b>	0.68	1.27	nd
<b>C24:1n-9</b>	nd	0.26	nd
<b>C18:2n-6</b>	3.89	6.16	5.24
<b>C20:4n-6</b>	1.52	2.11	0.64
<b>C18:3n-3</b>	0.71	0.64	0.51
<b>C22:6n-3</b>	nd	1.02	nd
<b>Σ Sat</b>	85.2	82.2	90.1
<b>Σ Mono</b>	8.71	7.91	3.51
<b>Σ N-6</b>	5.41	8.27	5.88
<b>Σ N-3</b>	0.71	1.65	0.51

\* n=1 (36 pooled brains) for each experimental diet.

<sup>†</sup> Low LNA was obtained by the addition of safflower oil as the fat blend.

<sup>†</sup> The control fat diet of LA to LNA of 7.1:1 approximates the fatty acid composition used in SMA<sup>†</sup> infant formula.

<sup>‡</sup> The AA + DHA diet was obtained by the addition of ARASCO<sup>™</sup> and DHASCO<sup>™</sup> oil to the control diet fat blend.

nd, not detected.

## A. DISCUSSION

The results obtained from this study demonstrate that C20:4n-6 and C22:6n-3 are present in SPM gangliosides and dietary fat can alter the C20:4n-6 and C22:6n-3 content of SPM gangliosides.

The SPM gangliosides studied had one characteristic in common: the predominant fatty acid was C16:0 and C18:0. This finding is in agreement with other studies which showed that saturated fatty acids, particularly, C16:0 and C18:0 are abundant in gangliosides (Berra & Galli, 1971; Vanier et al., 1973; Svennerholm et al., 1991 & 1994). Analysis of the fatty acid composition of SPM gangliosides by GC-MS revealed that C20:4n-6 and C22:6n-3 were present. The presence of C20:4n-6 and C22:6n-3 in SPM gangliosides was unexpected since previous studies on the fatty acid composition of rat SPM gangliosides did not detect PUFAs. Avrova (1986) has also shown that C20:4n-6 and C22:6n-3 are present as the fatty acyl moiety of brain gangliosides in some species of fish. It was found in fish that C20:4n-6 and C22:6n-3 constituted up to 5 and 25 % of the total brain ganglioside fatty acids, respectively. This is the first study, to the author's knowledge, that has shown the presence of C20:4n-6 and C22:6n-3 in the fatty acyl moiety of rat SPM gangliosides.

The data suggests that the C20:4n-6 and C22:6n-3 content of rat SPM gangliosides may be altered by dietary fat. However, a previous study by Berra et al. (1976) showed in whole brain of rats from birth to 100 days of age that alterations in diet fat altered the amount but not the fatty acid composition of individual gangliosides. The reason for the differences between the two studies could be due to the diet treatments, amount of diet fat, or SPM vs. whole brain studied. The mechanism for the diet effect on the C20:4n-6 and C22:6n-3 of SPM gangliosides may be due to the activity and specificity deacylation-reacylation enzymes for fatty acids of gangliosides similar to that observed with phospholipids (Saito & Saito, 1991). Moreover, there may be a common pool of fatty-acyl CoA or ceramides that are altered by diet fat and used for synthesis of sphingolipids (Saito & Saito, 1991).

The presence of C20:4n-6 and C22:6n-3 in SPM gangliosides and the effect of diet fat on their fatty acid composition could effect the fluidity of SPM and the calcium

flux involved in synaptic transmission. It has been proposed that the reversible binding of calcium to the sialic acid residue of gangliosides at the SPM is involved in the mechanism of synaptic transmission (reviewed by Rahmann et al., 1982 and Wu & Ledeen, 1994). The release of calcium from the ganglioside-calcium complexes may locally change the fluidity of SPM leading to neurotransmitter release. Thus, dietary fat induced alterations in the SPM C20:4n-6 and C22:6n-3 content of ganglioside could alter the binding of calcium to the sialic acid residues of gangliosides, and therefore modulate synaptic transmission.

In conclusion, the data from this study in rats at two weeks of age show the presence of C20:4n-6 and C22:6n-3 in SPM ganglioside and suggest that dietary fat may induce changes in the C20:4n-6 and C22:6n-3 content of SPM gangliosides.

**B. REFERENCES**

- Ando, S., Chang, N. C., Yu, R. K. (1978). High-performance thin-layer chromatography and densitometric determination of brain ganglioside compositions of several species *Anal Biochem* 89: 437-450
- Avrova, N. F., Ghidoni, R., Karpova, O. B., Nalivayeva, N. N., Malesci, A., & Tettamanti, G. (1986). Systematic position of fish species and ganglioside composition and content. *Comp Biochem & Physiol - B: Comp Biochem.* 83: 669-676
- Baker, R. E. (1988). Gangliosides as cell adhesion factors in the formation of selective connections within the nervous system. *Prog Brain Res* 73: 491-508
- Berra, B. & Galli, C. (1971). Abnormal fatty acid pattern in brain gangliosides in a case of Kufs' disease. *Life Sci* 10: 213-216
- Berra, B., Ciampa, M., Debernardi, G., Manto, M., & Zambotti, V. (1976). Gangliosides and Glycoproteins in Brain of Rats Fed on Different Fats. *Lipids* 1: 227-235
- Bremer, E. G., Schlessinger, J., & Hakomori, S. (1986). Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor. *J. Biol Chem* 261: 2434-2440
- Cheresh, D. A. & Klier, F. G. (1986). Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin. *J Cell Biol* 102: 1887-1897
- Dawson, G. & Vartanian, T. (1988). Glycolipids as the source and modulator of receptor-mediated second messengers. *New Trends in Ganglioside Research* (pp 219-228). Ledeen, R.W., Hogan, E.L., Tettamanti, G., Yates, A.J. & Yu, R.K. Liviana Press. Berlin
- Folch, J., Lees, M., & Sloane-Stanley, G. G. (1957). A simple method for the isolation and purification of total lipids from animal tissues. *J Biol Chem* 226: 497-509.
- Hakomori, S. (1990). Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling and mediators for cellular interactions. *J. Biol. Chem* 265: 18713-18716
- Lu, P. & Sharom, F. J. (1995). Gangliosides are potent immunosuppressors of IL-2-mediated T-cell proliferation in a low protein environment. *Immunology.* 86: 356-363
- Mansson, J.E., Vanier, M.T. & Svennerholm, L. (1978) Changes in the fatty acid and sphingosine composition of the major gangliosides of human brain with age. *J. Neurochem.* 30:273-275.

Massa, P. T. (1993). Specific suppression of major histocompatibility complex class I and class II genes in astrocytes by brain-enriched gangliosides. *J Exp Med* 178: 1357-1363

Masserini, M. & Freire, E. (1986) Thermotropic characterization of phosphatidylcholine vesicles containing ganglioside GM1 with homogeneous ceramide chain length. *Biochemistry*. 25: 1043-1049

Masserini, M., Palestini, P. & Freire, E. (1989). Influence of glycolipid oligosaccharide and long-chain base composition on the thermotropic properties of dipalmitoylphosphatidylcholine large unilamellar vesicles containing gangliosides. *Biochemistry* 28: 5029-5034

Merat, A., & Dickerson, J. W. (1973). The effect of development on the gangliosides of rat and pig brain. *J. Neurochem* 20: 873-880

Nagai, Y. (1995). Functional roles of gangliosides in bio-signaling. *Behav Brain Res* 66: 99-104

Meuillet, E., Cremel, G., Dreyfus, H., & Hicks, D. (1996). Differential modulation of basic fibroblast and epidermal growth factor receptor activation by ganglioside GM3 in cultured retinal Muller glia. *Glia*. 17: 206-216

Ohsawa, T. (1989). Changes of mouse brain gangliosides during aging from young adult until senescence. *Mech Ageing & Dev* 50: 169-177

Palestini, P., Masserini, M., Sonnino, S., Giuliani, A., & Tettamanti, G. (1990). Changes in the ceramide composition of rat forebrain gangliosides with age. *J. Neurochem* 54: 230-235

Palestini, P., Sonnino, S., & Tettamanti, G. (1991). Lack of the ganglioside molecular species containing the C20-long-chain bases in human, rat, mouse, rabbit, cat, dog, and chicken brains during prenatal life. *J. Neurochem* 56: 2048-2050.

Palestini, P., Masserini, M., Fiorilli, A., Calappi, E., & Tettamanti, G. (1993). Age-related changes in the ceramide composition of the major gangliosides present in rat brain subcellular fractions enriched in plasma membranes of neuronal and myelin origin. *J Neurochem* 61: 955-960

Palestini, P., Masserini, M., & Tettamanti, G. (1994). Exposure to galactose oxidase of GM1 ganglioside molecular species embedded into phospholipid vesicles. *FEBS Lett* 350: 219-222

Panzetta, P. & Allende, M. L. (2000). Ganglioside expression during differentiation of chick retinal cells in vitro. *Neurochem Res* 25: 163-169

- Rahmann, H., Probst, W., & Muhleisen, M. (1982). Gangliosides and synaptic transmission. *Jap J. Exp Med* 52: 275-286
- Saito, M., & Saito, M. (1991) Incorporation of very-long-chain fatty acids into sphingolipids of cultured neural cells. *J. Neurochem* 57: 465-469
- Stewart, R. J. & Boggs, J. M. (1993). Exposure of galactosylceramide to galactose oxidase in liposomes: dependence on lipid environment and ceramide composition. *Biochemistry* 32: 5605-5614
- Stubbs, CD. & Smith, A. D. (1984). The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. *Biochim Biophys Acta.* 779: 89-137
- Svennerholm, L., Bostrom, K., Helander, C. G., & Jungbjer, B. (1991). Membrane lipids in the aging human brain. *J. Neurochem* 56: 2051-2059
- Svennerholm, L., Bostrom, K., Jungbjer, B., & Olsson, L. (1994). Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. *J Neurochem.* 63: 1802-1811
- Vanier, MT., Holm, M., Mansson, JE., & Svennerholm, L. (1973). The distribution of lipids in the human nervous system--V. Gangliosides and allied neutral glycolipids of infant brain. *J. Neurochem* 21: 1375-1384
- Williams, M. A., & McCluer, R. H. (1980). The use of Sep-Pak C18 cartridges during the isolation of gangliosides. *J. Neurochem* 35: 266-269
- Wu, G. & Ledeen, R.W. (1994) Gangliosides as modulators of neuronal calcium. *Prog Brain Res* 101: 101-112
- Wu, G., Lu, Z. H., & Ledeen, R. W. (1995). Induced and spontaneous neuritogenesis are associated with enhanced expression of ganglioside GM1 in the nuclear membrane. *J Neurosci* 15: 3739-3746
- Yang, L. J., Zeller, C. B., Shaper, N. L., Kiso, M., Hasegawa, A., Shapiro, R. E., & Schnaar, R. L., (1996). Gangliosides are neuronal ligands for myelin-associated glycoprotein. *Proc Natl Acad Sci USA* 93: 814-818
- Yu, R. K., Macala, L. J., Taki, T., Weinfield, H. M., & Yu, F. S. (1988). Developmental changes in ganglioside composition and synthesis in embryonic rat brain. *J. Neurochem* 50: 1825-1829

## **CHAPTER VIII. THE PRESENCE OF ALKALINE CERAMIDASE IN THE SYNAPTIC PLASMA MEMBRANE OF TWO-WEEK-OLD RAT PUPS**

### **A. INTRODUCTION**

Sphingolipids are complex lipids that play a structural role in cell membranes (Coroneos, 1995). Sphingolipids consist of a long-chain base (sphingosine), an amide-linked fatty acyl groups, usually saturated, and a polar or glycosidic head group (Hannun, 1996). Recently, derivatives of sphingolipid metabolism have been identified as membrane signal transduction molecules (Hannun, 1996; Hannun & Obeid, 1997). SM, the major membrane sphingolipid, can be hydrolyzed by SMase to form ceramide, a secondary messenger which stimulates cell differentiation, inhibits proliferation and has been associated with apoptosis (Jarvis et al., 1994; Jayadev et al., 1995). CDase (EC 3.5.1.23) is widely distributed in animal tissues such as brain and catalyzes hydrolysis of ceramide to yield sphingosine and a fatty acid (reviewed by Hassler & Bell, 1993). CDase is important to animal tissues because it is the only known mechanism for ceramide catabolism (Tani et al., 2000). Sphingosine is also known to affect a variety of biological functions (Ballou, 1992). There are three distinct isoforms of CDase (acidic, neutral, and alkaline) that have different pH optima, 4.0, 7.6, and 9.0, respectively. The acidic lysosomal CDase has been purified to apparent homogeneity (Bernardo et al., 1995) and characterized (Li et al., 1998). Neutral CDase activity were found in porcine intestine (Nilsson, 1969; Nilsson & Duan, 1999), guinea pig skin (Yada et al., 1995) and human fibroblasts (Morell & Braun, 1972) and recently purified and cloned from mouse liver (Tani et al., 2000). The alkaline CDase was described in human cerebellum (Sugita et al., 1972), fibroblasts (Momoi et al., 1982) and in many rat tissues (Spence et al., 1985). A non-lysosomal CDase from rat brain was recently purified and characterized (El Bawab et al., 1999). However, to date, no study has determined the presence of alkaline CDase in SPM. Based on the evidence that ceramide and sphingosine play an important role in biological processes and ceramide constitutes the core structure of several sphingolipids which are highly abundant in SPM, it would be of interest to determine whether alkaline CDase activity is present in the SPM. The aim of the present study was to determine if the SPM of rat pups at two-weeks of age has alkaline CDase.

## **B. MATERIALS AND METHODS**

### **1. Animal Care**

Breeding of Sprague-Dawley rats have been described in **Chapter III**. Rats sacrificed at two weeks of age received only maternal milk. One entire litter of rat pups fed the same diet was sexed and weighed before decapitation. Excised brains were placed in ice-cold 0.32 M sucrose. Six brains from the same sex were pooled per sample for isolation of SPM. Three litters per diet were used.

### **2. Diets**

The diet contained 20% (wt/wt) fat and met all essential nutrient requirements (Clandinin & Yamashiro, 1980). The control fat treatment was formulated to approximate the fatty acid composition of an existing infant formula providing an C18:2n-6 to C18:3n-3 fatty acid ratio of 7.8:1 (Table 3.1; **Chapter III**).

### **1. Synaptic Plasma Membrane Isolation**

SPMs from rat pups at two-weeks of age were isolated as described in **Chapter VI**. The SPM purity was tested as described in **Chapter VI**.

### **2. Ceramide Synthesis**

The  $^3\text{H}$ -palmitoyl ceramide was prepared as follows (Kishimoto, 1975): to a mixture of 34  $\mu\text{mol}$  cold palmitic acid, 75  $\mu\text{Ci}$  (9, 10- $^3\text{H}$ ) palmitic acid (30 – 60 Ci/mmol; New England Nuclear-DuPont, Boston, MA), 102  $\mu\text{mol}$  triphenylphosphine (Sigma Chemical Co., St. Louis, MO), and 102  $\mu\text{mol}$  2,2'-dipyridyldisulfide (Sigma Chemical Co., St. Louis, MO) was added 0.4 mL of methylene chloride (Sigma Chemical Co., St. Louis, MO) solution containing 34  $\mu\text{mol}$  sphingosine (free base; Sigma Chemical Co., St. Louis, MO). This mixture was stirred at room temperature for 5 hr. The mixture became yellow immediately after mixing. Solvent was removed from the reaction mixture by evaporation under nitrogen and the residue was resuspended in 500  $\mu\text{L}$  of chloroform : methanol (2:1, by vol.). The ceramides synthesized were isolated and purified on a silica gel "G" plate (20 x 20 cm; Analtech, Newark, DE, USA) developed in

a solvent system of chloroform : methanol : acetic acid (90:2:8, by vol.). The plate was sprayed with 0.01% (wt/vol.) primulin in water. Purified ceramide was located under ultraviolet light by comparison with ceramide standard (Sigma Chemical Co., St. Louis, MO), and eluted with chloroform : methanol (2:1, by vol.). An aliquot of the chloroform : methanol solution was added to a liquid scintillation cocktail (ScintiSafe™, Fisher Scientific, Fair-Lawn, NJ, USA) and taken for liquid scintillation counting (Beckman LS 5801). Counting efficiency was approximately 97% and all counts were corrected for counting efficiency. The ceramides were stable to alkaline hydrolysis (0.5 N KOH in methanol at 25 °C for 12 hr) under conditions where all fatty acid esters were released from total phospholipids.

## 5. Ceramidase Assay

Alkaline CDase was assayed by measuring the amount of radioactive palmitic acid released from <sup>3</sup>H-palmitoyl ceramide as described by Nikolova-Karakashian & Merrill (1999). The ceramide suspension was prepared by adding 10 mg of Triton X-100 (Sigma Chemical Co., St. Louis, MO) and 16 mg of sodium cholate (Sigma Chemical Co., St. Louis, MO) in chloroform : methanol (2:1, by vol.) to 1 mL of labeled <sup>3</sup>H-palmitoyl ceramide in chloroform : methanol (2:1). The mixture was vortexed and evaporated to dryness under nitrogen. The residue was suspended in 1 mL of 0.25 M sucrose – 1mM EDTA and the tubes were placed in a sonifying water bath at 37°C for 10 min. The final suspension was free of particulates and was opalescent. This suspension containing 0.25 mg Triton X-100, 0.40 mg sodium cholate, and 50 μmol of <sup>3</sup>H-palmitoyl ceramide in 25 μL solution was stored at 4 °C.

The reaction mixture consisted of 50 μmol <sup>3</sup>H-palmitoyl ceramide (20 μCi/μmol) solution, 250 – 500 μg of SPM protein, and Hepes buffer (pH 8.0) in a final volume of 200 μL. After incubation in a shaking water bath at 37 °C for 1 hr, the reaction was stopped by adding 1 mL of chloroform : methanol (2:1, by vol.) containing 50 μg of carrier palmitic acid. Tubes were vigorously mixed and centrifuged at 2000 g for 15 min. The lower phase was spotted on a silica gel “G” plate (20 x 20 cm) and developed in a solvent system of chloroform : methanol : acetic acid (94:1:5, by vol.). The free fatty acid band was located by using iodine vapor, and the corresponding areas were scraped from

the plate into a scintillation vial with liquid scintillation cocktail (Scintisafe™, Fisher Scientific). The radioactivity of the free fatty acid released was counted in a liquid scintillation counter (Beckman LS 5801). CDase activity after correction for blank value (boiled SPM protein in incubation mixture) was expressed as  $\mu\text{mol } ^3\text{H-palmitic acid/mg}\cdot\text{hr}$ .


## **C. RESULTS**

### **1. Purity of Synaptic Plasma Membrane Preparation**

The purity of the SPM preparation has been described previously (Hargreaves & Clandinin, 1987). The SPM preparations contained only minor cross-contamination (<5%) from mitochondria as determined by RNA and succinate dehydrogenase analysis (data not shown). The SPM marker, Na, K-ATPase, was approximately 8-fold greater in the SPM ( $33.8 \pm 3.0 \mu\text{mol Pi/mg/hr}$ ) compared to the brain homogenate ( $4.1 \pm 1.2 \mu\text{mol Pi/mg/hr}$ ).

### **2. Purity of $^3\text{H}$ -Palmitoyl Ceramide**

$^3\text{H}$ -Palmitoyl ceramide was synthesized after 5 hr at room temperature as indicated by thin-layer chromatography analysis of the reaction mixture (Figure 8.1). The  $^3\text{H}$ -palmitoyl ceramide product was isolated with an overall yield of approximately 70%, which is similar to that shown by Kishimoto (1975).



- Lane 1: Test sample (<sup>3</sup>H-palmitoyl-ceramide synthesized in vitro)
- Lane 2: Ceramide standard (C16:0 and C24:1 ceramide)
- Lane 3: Palmitic Acid
- Lane 4: Triphenylphosphine
- Lane 5: 2',2-Dipyridyldisulfide
- Lane 6: Sphingosine (free base)
- Lane 7: Blank (no sample)

**Figure 8.1 Separation of Synthesized <sup>3</sup>H-Palmitoyl Ceramide on Thin-Layer Chromatography Plate.**

**Table 8.1 Alkaline CDase Activity of Rat Pups on a Control Diet at Two Weeks of Age\***

Brain homogenate alkaline CDase activity:  $49.6 \pm 11.7$  pmol  $^3\text{H}$ -palmitic acid / mg / hr  
 SPM alkaline CDase activity:  $745 \pm 160$  pmol  $^3\text{H}$ -palmitic acid / mg / hr

Enrichment:  $\frac{\text{SPM alkaline CDase activity}}{\text{Brain homogenate alkaline CDase activity}} = 15.0$

\* Values are mean  $\pm$  SEM for n=6.

#### **D. DISCUSSION**

In the present study, alkaline CDase activity was detected in the SPM of two-week-old rat pups. The CDase activity in SPM was 15-fold greater than in the brain homogenate (Table 8.1). The activity of CDase in the SPM was lower than that reported by Spence et al. (1986) in rat cerebrum, cerebellum, and brain stem. The reason for the lower alkaline CDase in SPM in the present study compared to brain cerebrum, cerebellum, and brain stem homogenates may be due to the different age, strain, or diet treatment of the rats studied. In the study by Spence et al. (1986), the age and diet treatment is unknown. Although neutral and alkaline CDase has been detected in microsomes of rat liver (Stoffel & Melzner, 1980), there is no contamination of microsomes in the SPM since the membrane preparation was devoid of RNA.

$^3\text{H}$ -Palmitoyl ceramide was used to assay alkaline CDase activity in the SPM because palmitic, as well as, stearic acid are the predominant fatty acids associated with the ceramide moiety of sphingolipids. Also, comparison of brain alkaline CDase activities from the present study could be made to Spence et al. (1986) study.

Ceramide is involved as structural and functional components of sphingolipids (Hannun, 1996). Ceramide plays an important role as an intracellular signaling molecule (reviewed by Hannun et al., 1993; Mathias & Kolesnick, 1993) and enzymes, such as, CDase can regulate the metabolism of ceramide and consequently ceramide mediated functions (Mao et al., 2000; Tani et al., 2000).

In conclusion, the present study is the first to identify alkaline CDase activity in the SPM of two-week-old rat pups. CDase is thought to be rate limiting enzyme in the production of sphingosine and sphingosine-1-phosphate because sphingosine is only generated from ceramide by the action of CDase and not by de novo synthesis (Tani et al., 2000). Hence, alkaline CDase could play a critical role in signal transduction mediated by sphingosine and sphingosine-1-phosphate.

## E. REFERENCES

- Ballou, L. R. (1992). Sphingolipids and cell function. *Immunology Today* 13: 339-341.
- Bernardo, K., Hurwitz, R., Zenk, T., Desnick, R. J., Ferlinz, K., Schuchman, E. H., & Sandhoff, K. (1995). Purification, characterization, and biosynthesis of human acid ceramidase. *Journal of Biological Chemistry* 270: 11098-11102.
- Coroneos, E., Martinez, M., McKenna, S., & Kester, M. (1995). Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. Implications for cellular proliferation and differentiation. *Journal of Biological Chemistry* 270: 23305-23309.
- El Bawab, S., Bielawska, A., & Hannun, Y. A. (1999). Purification and characterization of a membrane-bound nonlysosomal ceramidase from rat brain. *Journal of Biological Chemistry* 274: 27948-27955.
- Hannun, Y. A. (1996). Functions of ceramide in coordinating cellular responses to stress. *Science* 274: 1855-1859.
- Hannun, Y. A. & Obeid, L. M. (1997). Ceramide and the eukaryotic stress response. *Biochemical Society Transactions* 25:1171-1175.
- Hassler, D. F. & Bell, R. M. (1993). Ceramidases: enzymology and metabolic roles. *Advances in Lipid Research* 26: 49-57.
- Jarvis, W. D., Fornari, F. A. Jr., Browning, J. L., Gewirtz, D. A., Kolesnick, R. N., & Grant, S. (1994). Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. *Journal of Biological Chemistry* 269: 31685-31692.
- Jayadev, S., Liu, B., Bielawska, A. E., Lee, J. Y., Nazaire, F., Pushkareva, M., Obeid, L. M., & Hannun, Y. A. (1995). Role for ceramide in cell cycle arrest. *Journal of Biological Chemistry* 270: 2047-2052.
- Li, C. M., Hong, S. B., Kopal, G., He, X., Linke, T., Hou, W. S., Koch, J., Gatt, S., Sandhoff, K., & Schuchman, E. H. (1998). Cloning and characterization of the full-length cDNA and genomic sequences encoding murine acid ceramidase. *Genomics* 50: 267-274.
- Mao, C., Xu, R., Bielawska, A., & Obeid, L. M. (2000). Cloning of an alkaline ceramidase from *Saccharomyces cerevisiae*. An enzyme with reverse (CoA-independent) ceramide synthase activity. *Journal of Biological Chemistry* 275: 6876-6884.
- Mathias, S. & Kolesnick, R. (1993). Ceramide: a novel second messenger. *Adv. Lipid Res.* 25: 65-90.

Momoi, T., Ben-Yoseph, Y., & Nadler, H. L. (1982). Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls. *Biochem. J.* 205: 419-425.

Morell, P. & Braun, P. (1972). Biosynthesis and metabolic degradation of sphingolipids not containing sialic acid. *J. Lipid Res.* 13: 293-310.

Nilsson, A. & Duan, R. D. (1999). Alkaline sphingomyelinases and ceramidases of the gastrointestinal tract. *Chem. Phys. Lipids.* 102: 97-105.

Spence, M. W., Beed, S., & Cook, H. W. (1986). Acid and alkaline ceramidases of rat tissues. *Biochem. Cell Biol.* 64: 400-404.

Stoffel, W., Kruger, E., & Melzner, I. (1980). Studies on the biosynthesis of ceramide. Does the reversed ceramidase reaction yield ceramides?. *Hoppe-Seylers Zeitschrift fur Physiologische Chemie* 361: 773-779.

Sugita, M., Dulaney, J. T., & Moser, H. W. (1972). Ceramidase deficiency in Farber's disease (lipogranulomatosis). *Science* 178: 1100-1102.

Tani, M., Okino, N., Mori, K., Tanigawa, T., Izu, H., & Ito, M. (2000). Molecular cloning of the full-length cDNA encoding mouse neutral ceramidase. A novel but highly conserved gene family of neutral/alkaline ceramidases. *J. Biol. Chem.* 275: 11229-11234.

Yada, Y., Higuchi, K., & Imokawa, G. (1995). Purification and biochemical characterization of membrane-bound epidermal ceramidases from guinea pig skin. *J. Biol. Chem.* 270: 12677-12684.

## **CHAPTER IX. GENERAL SUMMARY, CONCLUSIONS, LIMITATIONS, IMPLICATIONS, AND FUTURE RESEARCH**

### **A. GENERAL SUMMARY**

The hypotheses (**Chapter II**) tested in this thesis have been verified as follows:

#### **Hypothesis 1.**

It was hypothesized that feeding a high C18:3n-3 diet will not increase the C22:6n-3 content in neuronal cell phospholipids from whole brain of rats at two weeks of age. The results obtained suggest that raising the dietary C18:3n-3 content is inadequate to increase the C22:6n-3 content of neuronal cell phospholipids of two-week-old rat pups.

#### **Hypothesis 2.**

It was hypothesized that feeding a high C18:3n-3 diet will increase the C18:3n-3 content in whole body and tissue lipids of rats at two weeks of age. The results obtained suggest that the metabolic fate of high C18:3n-3 diet is deposition of C18:3n-3 in adipose tissue and skin (epidermis, dermis, and subcutaneous tissue) of two-week-old rat pups.

#### **Hypothesis 3.**

It was hypothesized that feeding diets with preformed C22:6n-3 will increase the content of C22:6n-3 in neuronal and glial cell membrane phospholipids from whole brain of rats at two weeks of age. The results obtained suggest that preformed C22:6n-3 significantly increases the C22:6n-3 content in PE and PS of neuronal and glial cell phospholipids from two-week-old rat pups.

#### **Hypothesis 4.**

It was hypothesized that feeding a diet with C20:4n-6 and C22:6n-3 will increase the total and individual phospholipids and cholesterol content of the SPM of rats at two and five weeks of age. The results obtained suggest that diets with C20:4n-6 and C22:6n-3 does not alter the SPM total and individual phospholipid content and cholesterol content of rats at two and five weeks of age.

**Hypothesis 5.**

It was hypothesized that feeding a diet with C20:4n-6 and C22:6n-3 will increase the C20:4n-6 and C22:6n-3 content in total and individual phospholipids of the SPM of rats at two and five weeks of age. The results obtained suggest that dietary C20:4n-6 and C22:6n-3 increases the C20:4n-6 and C22:6n-3 content of SPM total and individual phospholipids of rats at two and five weeks of age.

**Hypothesis 6.**

It was hypothesized that the  $K_m$  and  $V_{max}$  of Na, K-ATPase in the SPM of rats will increase from two to five weeks of age. The results obtained suggest that Na, K-ATPase  $K_m$  is decreased and  $V_{max}$  is increased from two to five weeks of age.

**Hypothesis 7.**

It was hypothesized that feeding diet with C20:4n-6 and C22:6n-3 will not alter the  $K_m$  but increase the  $V_{max}$  of Na, K-ATPase in the SPM of rats at two and five weeks of age. The results obtained suggest that dietary C20:4n-6 and C22:6n-3 does not alter the  $K_m$  but increases the  $V_{max}$  of SPM Na, K-ATPase of rat pups of two and five weeks of age.

**Hypothesis 8.**

It was hypothesized that C20:4n-6 and C22:6n-3 were present in SPM gangliosides and feeding a dietary fat will alter the C20:4n-6 and C22:6n-3 content of individual gangliosides in the SPM of rats at two weeks of age. The results obtained demonstrate that C20:4n-6 and C22:6n-3 are present in SPM ganglioside and dietary fat may alter the C20:4n-6 and C22:6n-3 content of individual gangliosides in the SPM of two-week-old rat pups.

**Hypothesis 9.**

It was hypothesized that alkaline CDase is present in the SPM of rat pups at two weeks of age. The results obtained demonstrate that alkaline CDase is present in SPM of rat pups at two weeks of age.

## **B. CONCLUSIONS**

The data presented in this thesis expands on existing knowledge of the effects of dietary fat on membrane lipid composition and function in brain. Feeding diets with or without C18:3n-3 or C20:4n-6 and C22:6n-3 has been shown in this thesis to play an important role in brain structure and function. The important concepts that this thesis has contributed are as follows:

1. High dietary C18:3n-3 content does not significantly increase the C22:6n-3 content in neuronal cells from whole brains of rats at two weeks of age.
2. High dietary C18:3n-3 significantly increases the C18:3n-3 but not the C22:6n-3 content of whole body and tissue lipids with the major deposition site being the skin including the subcutaneous fat of rats at two weeks of age.
3. Dietary C22:6n-3 is more effective than high levels of C18:3n-3 at significantly increasing the C22:6n-3 content in neuronal and glial cell phospholipids, particularly, PE and PS of rats at two weeks of age.
4. Dietary C20:4n-6 and C22:6n-3 does not increase the cholesterol, total and individual phospholipid content of SPM of rats at two and five weeks of age.
5. Dietary C20:4n-6 and C22:6n-3 increases the C20:4n-6 and C22:6n-3 content of rat total and individual phospholipids at two and five weeks of age.
6. The  $V_{max}$  and  $K_m$  of Na, K-ATPase in the rat SPM significantly increases during development from two to five weeks of age.
7. Dietary C20:4n-6 and C22:6n-3 compared to low C18:3n-3 diet significantly increases the  $V_{max}$  but does not alter the  $K_m$  of Na, K-ATPase in the rat SPM at two and five weeks of age.
8. C20:4n-6 and C22:6n-3 are present and feeding a dietary fat may alter the C20:4n-6 and C22:6n-3 content of individual gangliosides in the rat SPM at two weeks of age.
9. Alkaline CDase is present in the SPM of rat pups at two weeks of age.

### **C. LIMITATIONS**

The studies presented in this thesis employed maternal dietary fat alterations as a method of delivering various fatty acid compositions to rapidly growing rat pups. A limitation of this maternal feeding model is that it hinders the ability to directly manipulate the fatty acid composition of the nutrient supply to the rat pups during which most of the brain growth spurt is occurring in the first three postnatal weeks of life (Dobbing and Sands, 1979). Therefore, in this model there is the confounding influence of LCPUFAs, such as C20:4n-6 and C22:6n-3, present in the stomach contents (dams' milk) of rat pups. In addition, the maternal milk composition in this model can have changes that are secondary to the changes in dietary n-6 and / or n-3 fatty acids (i.e. hormones, cytokines, and growth factors) (Ward et al., 1996).

The artificial rearing (AR) model in the rat pups would have been ideal to use in the studies presented in this thesis. In this model, rat pups are removed from their dams and fed, via gastrostomy tube, a rat milk substitute which closely resembles the composition of rat milk, and whereby the fatty acid composition can be altered experimentally (Patel and Hiremagalar, 1992). This AR model permits the evaluation of dietary fat treatments on brain development without the confounding influence of C20:4n-6 and C22:6n-3 present in the maternal diet and mammary processes (Patel and Hiremagalar, 1992). Furthermore, the AR model approximates the extremely premature infant who is exposed to the stress of maternal separation, nasogastric formula feeding, testing, and surgical procedures (Ward et al., 1996). However, this model is very labor intensive and expensive.

### **D. IMPLICATIONS OF THESIS**

The findings from this thesis in rats have important implications for neonatal feeding. Infant formulas currently marketed in North America are devoid of C20:4n-6 and C22:6n-3. The only n-3 fatty acid present in these formulas is C18:3n-3. It has been questioned whether C18:3n-3 in infant formulas can meet the C22:6n-3 requirements for brain growth and development. The findings from this thesis demonstrate in rats that

raising the dietary C18:3n-3 content does not significantly raise the C22:6n-3 content of brain phospholipids. In fact, this thesis has shown that the metabolic fate of high dietary C18:3n-3 is deposition of C18:3n-3 in rat adipose and subcutaneous tissues especially skin. Furthermore, dietary C22:6n-3 was shown to be more effective than low or high levels of C18:3n-3 at increasing the C22:6n-3 content of rat brain phospholipids. Therefore, these results suggest that formulas providing only C18:3n-3 may not meet the C22:6n-3 requirements of neonatal brain.

The functional importance of C22:6n-3 in rat brain was demonstrated by showing that the low SPM C22:6n-3 phospholipid content is associated with low SPM Na, K-ATPase activity. Therefore, these findings suggest that infants with lower levels of C22:6n-3 in SPM phospholipids may have low SPM Na, K-ATPase activity that will ultimately affect synaptic transmission in infant brain.

The findings from this thesis indicated that rat SPM gangliosides contain C20:4n-6 and C22:6n-3 and the content of C20:4n-6 and C22:6n-3 in SPM gangliosides may be altered by dietary fat. These results if extrapolated to human neonates would suggest that infants fed formulas containing C20:4n-6 and C22:6n-3 incorporate these fatty acids into the fatty acyl moiety of SPM gangliosides.

The presence of alkaline CDase activity in rat SPM is novel. This finding implies that neonates possess SPM alkaline CDase activity. The presence of alkaline CDase in neonatal SPM may be significant since sphingolipids are involved in mediating biological responses. Hence, it is conceivable that SPM alkaline CDase in infants may play an important role in brain functions.

## **E. FUTURE RESEARCH**

Progress has been made over the last decade in understanding the desaturation and chain elongation of essential fatty acids and the influence of these fatty acids and their long-chain homologues on membrane fatty acid composition and function. However, as new information is gathered on the mechanism, regulation, and function of fatty acid desaturation and elongation reactions in mostly animal models, the extent to which this information applies to human infants needs to be fully elucidated. The application of

cloning techniques and molecular probe technologies to desaturation and elongation enzymes are beginning to be used but much more work is needed. Specific probes for the delta-6 desaturase will be beneficial for determining whether this rate-limiting enzyme(s) acting on C18:2n-6, C18:3n-3, C24:4n-6, and C24:5n-3 are identical. Specific studies on the modulation of the desaturase enzymes should provide insight into regulation at the genomic level. The extent to which desaturase and elongase are regulated and if the sequence of reactions catalyzed by these enzymes are physically associated to provide "channeled" conversion to their major end products awaits further research. The subcellular location of these enzymes to other compartments beside the endoplasmic reticulum like peroxisomes or nuclear and plasma membrane needs further work.

The role and function of C18:3n-3 in the skin of rats needs to be understood. Further studies need to determine if C18:3n-3 present in the skin may be synthesized to other fatty acids, such as, C16:0, C18:0, and C18:1n-9, or cholesterol as observed in brain of suckling rats. Studies are also needed to determine whether the C18:3n-3 in skin is preferentially  $\beta$ -oxidized and used as a source of energy rather than for synthesis of n-3 long-chain polyenes like C20:5n-3 and C22:6n-3. The relevance of C18:3n-3 in skin of rats to human infants remains to be determined.

Future studies to determine the mechanism for the increased activity of Na, K-ATPase observed with the control and AA + DHA compared to the low LNA diet are needed. It is conceivable that the increased activity of Na, K-ATPase with the control or AA+ DHA diet may be due to decreased degradation rate, or increased synthesis rate, or both processes working in concert. Hence, molecular biology techniques examining Na, K-ATPase protein and gene expression will be insightful.

Future research is needed to determine the exact role of diet fat on cholesterol and PUFA content in modulating the SPM Na, K-ATPase kinetics. It is possible that dietary fat affects the distribution of cholesterol in the exofacial and cytofacial leaflet thereby altering the fluidity of the two leaflets and thus Na, K-ATPase activity.

C20:4n-6 and C22:6n-3 in SPM may directly affect Na, K-ATPase kinetics by its presence as the fatty acid moiety by its presence as the fatty acid moiety of annular membrane phospholipids or indirectly via modulation of eicosanoids that can affect Na,

K-ATPase activity. Further investigations should clarify or provide further information to the exact mechanism of C20:4n-6 and C22:6n-3 on Na, K-ATPase kinetics.

Despite the tremendous progress over the last decade in understanding the cellular function of sphingolipids, this area is still in its infancy. The exact physiological roles which gangliosides play in biological processes must be studied further. Why are there so many different molecular species of gangliosides? What role does C20:4n-6 and C22:6n-3 play in gangliosides? Is the subtle changes induced by diet fat in the ceramide moiety of gangliosides to optimize its physical properties or to achieve a greater specificity in ganglioside-protein interaction; or are gangliosides synthesized for other reasons, such as, signal transduction? Future work should provide answers to these questions. /

The precise metabolic and biological roles of alkaline CDase are not entirely understood. *In vitro* catalytic activity and metabolic studies suggest that ceramide catabolism is their primary biological role. The alkaline CDase may be responsible for the recycling of sphingosine from the cell sphingolipids. Moreover, alkaline CDase could be used to salvage unused ceramides synthesized for sphingolipids. Conceivably, alkaline CDase may also perform the task of regulating the cellular levels of sphingosine or ceramide that can be used as cellular effectors. Finally, alkaline CDases in the SPM may function to regulate the types and levels of particular fatty acids, possibly PUFAs, incorporated into ceramides, and consequently its overall sphingolipid structure and function. The potential importance of alkaline CDase in producing sphingosine for a regulatory purpose within cells makes them prime candidates for future study. Some future research should be to characterize alkaline CDase activity with respect to dietary fat alterations and biological functions.

The studies in this thesis were performed on Sprague-Dawley rats. It would be of interest to study the effects of dietary fat on brain C20:4n-6 and C22:6n-3 content in an animal model of PKU. Recently, a true mouse model of PKU with a deficiency of phenylalanine hydroxylase (PAH) and a similar pathology to human PKU has been developed (Shedlovsky et al., 1993). This mouse strain generated through mutagenesis of chromosome 10, the PAH gene, by ethylnitrosurea, closely simulates human PKU phenotype (McDonald, 1994). In this disease, there are low levels of brain C20:4n-6 and C22:6n-3 partly due to the absence C20:4n-6 and C22:6n-3 in PKU formulas and the low

C20:4n-6 and C22:6n-3 content in the diet of individuals with PKU (Agostoni et al., 1995; Poge et al., 1998). PKU formulas are used in place of or in addition to human milk for infants born with PKU (Greve et al., 1994). Most of the commercial PKU formulas contain casein hydrolysate to which some vegetable oils like soy, coconut, palm, peanut, or corn oil are added as the only fat component. These formulas contain only vegetable oils with C18:2n-6 and C18:3n-3 as the only source of n-6 and n-3 fatty acids, respectively. None of the PKU formulas on the market contain preformed C20:4n-6 and C22:6n-3. The PKU diet is devoid of meat and fish, which contain large amounts of C20:4n-6 and C22:6n-3 (Agostoni et al., 1995; Poge et al., 1998). Therefore, it is conceivable that diet fat with C20:4n-6 and C22:6n-3 may normalize brain C20:4n-6 and C22:6n-3 levels in brain of individuals with PKU. It is also of interest to study if these changes in C20:4n-6 and C22:6n-3 content of PKU brain phospholipids could have some functional effects, such as alterations in the kinetics of SPM Na, K-ATPase. Therefore, dietary C20:4n-6 and C22:6n-3 may have a profound effect on brain phospholipid fatty acid composition and function, and hence alleviating some of the brain dysfunction in PKU individuals.

The outcome for preterm infants have steadily improved over the past three decades. Advances in neonatal care have resulted in improved survival of infants born as early as 25 weeks of gestation. The provision of effective nutritional support for this vulnerable group has become an area of increasing importance. Optimum nutrition should lead to more normal growth and development with fewer infections or metabolic disturbances. Infant formulas for preterm infants are continuously being refined and the ideal composition is unknown. The studies presented in this thesis show that dietary fat is a strong determinant of brain fatty acid composition and function. The data support the rationale for supplementing infant formulas with preformed C20:4n-6 and C22:6n-3.

## **F. REFERENCES**

Agostoni, C. , Riva, E , Biasucci, G., Luotti, D., Bruzzese M.G., Marangoni, F. & Giovannini M. (1995). The effects of n-3 and n-6 polyunsaturated fatty acids on plasma lipids and fatty acids of treated phenylketonuric children. *Prog Leuko Ess FA*, 53: 401-404.

Bourre, J.M., Piciotti, M., & Dumont, O. (1990) Delta-6-desaturase in brain and liver during development and aging. *Lipids* 25: 354-356.

Dobbing, J., & Sands, J. (1979) Comparative aspects of brain growth spurt. *Early Hum. Dev.* 3: 79-83.

Greve, L. C., Wheeler, M. D., Green-Burgeson, D. K., & Zorn, E. M. (1994). Breast-feeding in the management of the newborn with phenylketonuria: a practical approach to dietary therapy. *J. Am. Diet. Assoc.* 94: 305-309.


McDonald, J.D. (1994) The PKU mouse project: its history, potential and implications. *Acta Paediatr* 407: 122-123.

Patel, M.S. & Hiremagalar, B.K. (1992) Artificial-rearing technique: Its usefulness in nutrition research. *J. Nutr.* 122: 412-419.


Poge, A.P., Baumann, K., Muller, E., Leichsenring, M., Schmidt, H. & Bremer, H. J. (1998). Long-chain polyunsaturated fatty acids in plasma and erythrocyte membrane lipids of children with phenylketonuria after controlled linoleic acid intake. *J. Inher. Metab. Dis.* 21: 373-381.

Shedlovsky, A., McDonald, J. D., Smyula, D., & Dove, W. F. (1993). Mouse models of human phenylketonuria. *Genetics* 134: 1205-1210.

Ward, G., Woods, J., Reyzer, M. & Salem, N., Jr. (1996) Artificial rearing of infant rats on milk formula deficient in n-3 essential fatty acids: A rapid method for the production of experimental n-3 deficiency. *Lipids* 31: 71-77.




Neuronal Cells



Glial Cells


**APPENDIX 1.** Neuronal and glial cells isolated from whole brain of rat pups at two weeks of age (1600x)  
(adapted from Hamberger & Svennerholm, 1971)



**APPENDIX 2.** Isolation of synaptosomes on sucrose density gradient from whole brain of rat pups at two and five weeks of age.


a)

2 Weeks




b)

5 Weeks



**APPENDIX 3.** SDS-PAGE of synaptic plasma membrane Na, K-ATPase  $\beta$ 1-subunit of rats fed either low LNA, control, or AA+ DHA diet at a) 2 weeks and b) 5 weeks of age. Gels were probed with monoclonal antibodies specific for  $\beta$ 1-subunit of Na, K-ATPase. Each lane contains 20  $\mu$ g of SPM protein.



**APPENDIX 4.** Separation of gangliosides from SPM of rats at two and five weeks of age on high performance thin-layer chromatography plates: a) lower and upper phase of Folch extraction of sample sprayed with 0.01% ANSA under ultraviolet light; b) ganglioside standards and upper phase of Folch extraction from samples sprayed with 0.01% ANSA under ultraviolet light; c) ganglioside standards and upper phase of Folch extraction from samples sprayed with resorcinol-HCl.